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Process chromatography proves to be a continual bottleneck in bioprocessing, especially when 
considered against constraints such as rocketing product titres, complexity and size of emerging 
bio-products and a drive to reduce cost of goods and waste generation. Incremental changes in 
mono-functional chromatography media do not appear to be sufficient in coping with these 
increased demands and opens the door for novel ‘multifunctional’ beaded media, designed from 
the ground up, to posit a solution.  
This work will, in part, demonstrate the creation of bi-layered chromatography resins with size-
exclusion and anion exchange functionality and subsequently assess their performance against 
benchmarked commercial beads of similar structure. Three size exclusion chromatography 
matrices, differing in agarose content, cross-linker chemistry, particle and pore size distributions, 
were transformed into bi-layered supports featuring anion exchange functionalised cores and 
exterior size excluding shells.  
The media were evaluated with respect to loss of surface and core binding, utilising finite bath 
studies allied with confocal scanning laser microscopic imaging. Plasmid DNA, bovine serum 
albumin and bovine serum albumin nanoparticles were utilised as surface and core binding probes, 
and the binding selectivities of different bi-layered support materials were compared by means of 
a simple selectivity ratio (μg of pDNA (or NP) bound per mg of BSA bound); the lower the 
number the more selective the support. The best performing bi-layered matrix was Superose 6 
Prep Grade, when challenged with both plasmid DNA and BSA nanoparticles. Results for other 
base matrices was dependent on the nanoplex challenge as well as the bi-layering technique 
employed.  
A second challenge addressed in this thesis was the acquisition of representative virus feedstock 
to road-test chromatography media, which can pose several practical issues with respect to 
requirements of particle concentration, volume and methods for tracking the species through 
chromatography media. A major focus has been developing a reliable platform in characterising 
commercial and in-house manufactured mono-functional and multi-functional chromatography 
resins, especially in the context of purifying large nanoplexes.  
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Against this backdrop, this work details a method for the reproducible manufacture of protein 
nanoparticles using a modified desolvation method; the nanoparticles function as surrogate mimics 
of virus products with a view to characterising viral chromatographic media.  
Initially, BSA nanoparticles were explored and their manufacture optimised to develop a robust 
and reproducible system for creating defined nanoparticles within a defined size range. The 
nanoparticles were subsequently characterised for efficiency of manufacture, their morphological 
appearance, and secondary protein structure composition as well as how well they represented a 
bona fide viral species, namely adenovirus type V. The approach was then translated to other readily 
available proteins (e.g. lysozyme, bovine haemoglobin and ovalbumin) to determine the flexibility 
of the desolvation/coacervation approach and to target a wider range of viral species in terms of 
their physiochemical properties. The concept here was to develop a “toolbox approach” to 
develop custom-made nanoparticles to target a variety of viral species. Similar characterisation 
techniques were applied to the newly formed nanoparticles, as well as novel strategies applied to 
develop “second-generation nanoparticles” using alternative cross-linking mechanisms to produce 
multi-component nanoparticles.   
The final chapter brings the work full-circle and looks to road-test the chromatography materials 
manufactured in Chapter II, with a range of sizes of BSA nanoparticles described in Chapter III. 
The nanoparticles are qualitatively assessed using confocal microscopy alongside quantitative 
assessment to determine bead performance. As in Chapter II, BSA protein is utilised as a core-
binding probe. The nanoparticles are also applied to commercial resins, Q-Sepharose Fast Flow 
and Capto™ Core 700, both in batch and column scenarios. Of the bi-layered materials, Superose 
6 Prep Grade generally outperformed both Sepharose 6 Fast Flow and Superose 12 Prep Grade, 
revealing differences between the media not shown by the plasmid DNA binding studies. This was 
generally supported by the complimentary confocal data, which provided an insight into the spatial 
location and binding kinetics when challenged onto the beads.   
It is envisioned that the chromatographic supports manufactured here may be utilised in large scale 
nanoplex purification, exploiting their utility derived from their bi-functional modality. 
Furthermore, it is hoped that the protein nanoparticle-viral mimic methodology may be employed 
in the characterisation of a wider range of purification materials, taking advantage of their low cost 
and rapid manufacture, as well as their ability to provide valuable purification data which may 
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1.1 Project Overview  
The bioprocessing landscape is continually evolving in an effort to meet the growing and ever 
more complex demands of global patient requirements. Biological therapeutics are at the forefront 
of a  capricious battle to treat the ailments and issues of an ageing population; their utility stems 
from their inherent diversity, high specificity and the ability to produce large volumes of bulk 
product in a tightly-controlled fashion.  There is therefore a persistent need to innovate and 
improve our approaches to developing and manufacturing therapeutics such that effective 
treatments can reach patients faster and are produced in an efficient and sustainable manner.  
This doctoral research project is supported by the Engineering and Physical Sciences Research 
Council’s Centre for Doctoral Training in Emergent Macromolecular Therapies who aim to 
“deliver new scientific advances into safely produced, more selective therapies for currently 
intractable conditions at affordable costs.” 
Chapter I sets the scene for the thesis through a literature review of gene therapy and its current 
applications. The literature then transitions to the need of vectors for delivery of gene therapy and 
how these vectors can be purified. The chapter ends with some literature on similar work in the 
field which this thesis falls within and highlights the need for a robust method for chromatography 
development and methods for characterisation.  
The primary objective of this work is to develop novel chromatography strategies for the 
purification of macromolecular nanoplex products and focusses on the creation of a unique bi-
layered bead architecture. The methodology looks to modify commercially available 
chromatographic base supports (un-functionalised agarose size-exclusion media) through an allyl 
glycidal ether / partial bromination route to create an inert shell around the bead.  
Chapter II describes the manufacture and characterise a set of bi-layered chromatography 
matrices from a variety of starting base resin materials. The bi-layering is carried out through a 
partial bromination strategy, which is tightly controlled through temperature and viscosity 
mediated techniques. The materials are then road-tested using biological species, namely Bovine 
Serum Albumin to test core binding and plasmid DNA to assess residual shell binding.  
The properties of the shell (i.e. its thickness and robustness) are strongly dependent on the 
manufacturing technique and the research looks at fine-tuning the viscosity and temperature 
conditions of the partial bromination step to enhance the characteristics of the shell that forms, 
playing on a reaction-diffusion balancing paradigm governed by the Stokes-Einstein principle. The 
characteristics of the base supports also play a role here, with different particle diameters and pore 
sizes impacting the success of manufacture and also the chromatographic performance of the 
modified resins.  
Once manufactured, the resins are rigorously characterised to determine key performance metrics 
including binding capacity and chromatographic resolution (selectivity). Initially, Bovine Serum 
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Albumin and plasmid DNA were used to assess core and shell binding, respectively, whilst also 
coupled with orthogonal fluorescence studies to compliment the quantitative data.  
In characterising these bi-layered materials, it is important to assess their performance when 
challenged with the separation of a variety of clinically applicable feed-streams. Given the 
renaissance of gene therapy, strategies to improve the purification of viral vectors become 
increasingly more relevant. However, the acquisition of sufficient viral material (as well as the 
techniques to assay them) to assess and optimise analytical scale chromatography materials is both 
financially and practically unfeasible in most downstream processing laboratory environments. As 
such, a secondary objective of the project arises; the development of a novel characterisation 
platform that utilises protein nanoparticles as surrogate analogues of viruses. 
Consequently, Chapter III moves away from chromatographic materials and transitions into the 
manufacture of protein nanoparticles, namely from Bovine Serum Albumin, to mimic viral species, 
specifically the adenovirus type V. The protein nanoparticles mimic the physiochemical properties 
of bona fide viral particles such that they interact with chromatography species in a similar way; 
therefore affording an alternative approach to viral chromatography optimisation screening and 
optimisation.  
The research details the ability to produce nanoparticles within a tightly controlled size range as 
well assessing a number of factors during the desolvation, coacervation and cross-linking process 
which can affect the quality of the final nanoparticle preparation. The nanoparticles are also 
characterised with respect to their size, shape, surface properties and composition and finally 
compared to the true adenoviral species to determine suitability as a mimic.  
The platform is advantageous in that the nanoparticles can be produced safely and rapidly, using 
un-sophisticated manufacturing equipment at low cost and utilising commonly available reagents. 
Furthermore, the manufacturing conditions can be modified to tailor the mimic to a variety of 
viral physiochemical properties, including size and surface charge.  
Chapter IV expands on the work of Chapter III, utilising a wider range of proteins as “building 
blocks” with the aim of creating nanoparticulates with adjustable properties; thus facilitating the 
production of a range of viral mimics. Ovalbumin, Bovine Haemoglobin and Lysozyme are tested 
for their suitability in the coacervation reaction and the final nanoparticles undergo similar 
characterisation. The work in the chapter develops further into the manufacture of “second 
generation nanoparticles” which look to produce multi-component protein nanoparticles using 
different cross-linking strategies which target various functional groups on the proteins. Two 
approaches emerge here, blended and core-shell nanoparticles, each with varying degrees of 
success.  
Chapter V looks to tie up both sides of the thesis by applying a range of nanoparticles described 
in Chapter III with the chromatographic materials manufactured in Chapter II. The nanoparticles 
are also applied to commercial chromatography media, highlighting their utility as a tool for 
screening the purification potential of various chromatography resins. It is also interesting to see 
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how the bi-layered materials from Chapter II respond to a different nanoplex challenge aside from 
plasmid DNA.  
Finally, Chapter VI highlights the conclusions from the work and any further recommendations 
for future work, both from the perspective of the chromatography media and the nanoparticle 
manufacture.  
In summary, the research detailed herein aims to address one of the fundamental steps in purifying 
biological therapeutics; to ensure that product purity and yield are preserved and that patient safety 
is not compromised. This work looks at re-modelling the purification of an emergent type of 
therapeutic molecule, the nanoplex, adapting and tailoring its chromatographic separation strategy 
to suit its physiochemical characteristics and ultimately achieve higher yields, purity and 
bioprocessing throughput as a result. The thesis will address the development of new types of bi-
layered chromatographic materials and subsequently assaying their performance using a novel 




The literature review begins with gene therapy; the general literature detailing the general field of 
bioprocessing can be found in the appendices (Chapter VII, 7.1).  
1.2 Gene Therapy 
Gene therapy is defined as a treatment which “involves the insertion of a functioning gene into 
cells to correct a cellular dysfunction or to provide new cellular function” (Culver, 1994). The 
methodology relies upon the successful transfer of nucleic acids to the nucleus of patient’s cells, 
usually with the aid of a vector.  
There are two classifications for gene therapy; 1. Germ line gene therapy:  The integration of 
functional genes into the chromosomes of gametes to facilitate treatment of genetic diseases and 
counteract hereditary disorders. 2. Somatic gene therapy: In this case, functionality is restored 
in somatic cells of the patient and as such no hereditary implications can result from such a 
treatment. The focus of gene therapy has been on somatic treatment, due to both ethical and 
practical implications of treating human germ cells (Razi Soofiyani et al., 2013).  
The ethical implications of germ line gene therapy have become a topic of contentious debate in 
recent times as a consequence of the work by He Jiankui of the Southern University of Science & 
Technology, Shenzen, China. He claims to have successfully edited the genetic make-up of two 
twin girls by knocking out the CCR5 gene, thus protecting the girls (and their future inheritance 
lineage) against HIV infection. His announcement was met with a great deal of controversy given 
its un-regulated approach and questionable ethics (Cyranoski and Ledford, 2018). The 
fundamental routes of gene therapy are described in Figure 1.1. 
Two administration routes are possible with gene therapy, either ex vivo, an autologous therapy 
where patient cells are harvested and transfected and usually amplified prior to re-administering 
into the patient’s body, or in vivo where transfection is targeted to post-mitotic cells in the patient. 
Both rely on the use of a vector for targeted gene transfer, through either viral or non-viral carriers 
(Mulligan, 1993; Kumar et al., 2016).  
The concept of gene therapy dates back, somewhat surprisingly, to the early 1960s where the 
geneticist Joshua Ledberg developed work on the bacterial transfer of genetic material and the 
method of transduction. He predicted “…the direct control of nucleotide sequences in human 
chromosomes…it will only be a matter of time…before polynucleotide sequences can be grafted 
by chemical procedures onto viral DNA” (Cotrim and Baum, 2008). Fast forward to 1989, where 
the first approved gene therapy clinical study was reported; the use of autologous human tumour 
infiltrating lymphocytes (TIL) plus interleukin-2, which had undergone retroviral-mediated gene 
transfer to facilitate neomycin resistance (essentially a genetic marker), to expedite metastatic 
melanoma regression in five patients. This proof of concept study demonstrated that retroviral 
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gene transduction of human cells (and re-introduction into patients) in gene therapy was both 
feasible and safe (Rosenberg et al., 1990; Ginn et al., 2018a).1 
On the back of this, in 1990 a successful gene therapy treatment was reported; a four year old 
infant by the name of Ashanti De Silva, born of a Sri Lankan migrant family (much like myself, in 
fact), was treated for severe combined immunodeficiency (SCID), more specifically adenosine 
deaminase (ADA) deficiency.  The treatment comprised of 11 infusions of T Lymphocyte cells, 
transduced (by engineered oncoretroviral vectors) with the ADA gene in vitro, over the course of 
two years to the point of 20-25% circulation level of gene-corrected T cells, with2 evidence of 
transduced T cell persistence up to 20 years later (Blaese et al., 1995; Mullen et al., 1996; Anderson, 
2000; Fischer, Hacein-Bey-Abina and Cavazzana-Calvo, 2010).  
It should be noted here that two important breakthroughs precluded this ground-breaking work 
and without them gene therapy would simply not be possible. The first was the work by Waclaw 
Syzbalski, who demonstrated the ability to carry out DNA-mediated gene transfer in mammalian 
cell lines (Szybalska and Szybalski, 1962), whilst the second was the proof-of-concept work by 
Rogers and Pfuderer, who were the first to mediate gene transfer using a viral vector (Rogers and 
Pfuderer, 1968).  
 
Fig. 1.1 The fundamental concepts behind gene therapy defining both allogeneic and autologous treatment routes 
(Collins and Thrasher, 2015).   





There was consequently a great deal of enthusiasm surrounding gene therapy in the 1990s; a review 
in Nature in 1992 opened with “the treatment of human disease by gene transfer has now moved 
the theoretical to the practical realm” (Miller, 1992) – the TIL-neomycin marker research was 
heralded as a “landmark study” which evidenced the potential of gene therapy as a viable treatment 
option for a range of clinical applications including tissue damage, autoimmune, neurodegenerative 
and haematological diseases, protein deficiencies and a number of cancers. In many ways this work 
was the advent of gene therapy and paved the way for a number of gene therapy-based studies and 
clinical trials, which continue even today (Cotrim and Baum, 2008; Hanna et al., 2017; Ginn et al., 
2018a).  
Similar ADA-SCID trials were run in the same year in Italy and showed similar promising results 
in two patients with evidence of ADA gene expression after two years (Bordignon et al., 1995). In 
1998, a group in Finland then demonstrated successful transfer of the β-galactosidase gene in 
treating malignant brain tumours (Puumalainen et al., 1998). However, it was not always plain 
sailing for gene therapy; there was fierce debate as to the efficacy of the gene therapy treatment 
given to Ashanti De Silva, as she was simultaneously receiving enzyme replacement therapy (PEG-
ADA). On top of this, a second child in the same trial had a significantly reduced response to the 
treatment and naturally the trial, and gene therapy, was subject to some scrutiny (Wirth, Parker 
and Ylä-Herttuala, 2013). In 1995, the National Institute of Health (NIH) panel  advised that a 
deeper understanding of the biology behind viral transfection, the target cells and the diseases that 
the therapy aimed to treat (Orkin, Motulsky and Varmus, 1995).  
The main event which tarnished the reputation of gene therapy was the untimely death of teenager 
Jesse Gelsinger as a result of a trial in 1999. In an attempt to treat an ornithine transcarbamylase 
deficiency of the liver, an adenoviral vector was used to introduce corrective genes. Tragically, 
however, his immune system responded heavily to the high adenoviral dose and he unfortunately 
died four days later due to multi-organ failure (Stolberg, 1999; Jenks, 2000).  
As a result, the late 1990s and early 2000s saw a gradual decline in optimism in gene therapy and 
although trials were carried out, early indications were disappointing with little to no clinical benefit 
observed. As per advice from the NIH, research was ongoing, however was hampered by worrying 
evidence of therapy-related toxicities, derived from unmodulated high gene transfer efficacy 
resulting in high immune responses (similar to that of the Gelsinger case), insertional genotoxicity 
and a compromising of the target cells immune response (Jenks, 2000; Nienhuis, Dunbar and 
Sorrentino, 2006; Mingozzi and High, 2011).  
However the last decade has seen somewhat of a renaissance in gene therapy, fuelled by significant 
breakthroughs in vector development, genetic engineering and gene editing, geared towards 
improving the safety and efficacy of gene therapy (Kumar et al., 2016; Dunbar et al., 2018). One of 
the main driving forces was the continual improvement in retroviral technology (Mann, Mulligan 
and Baltimore, 1983; Watanabe and Temin, 1983), facilitating the production of vectors which 
could carry out reverse transcription coupled with DNA integration whilst also being replication-
deficient (Danos and Mulligan, 1988; Miller et al., 1991). The design of self-inactivating retroviral 
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vectors was also a step forward in the fight to reduce genotoxicity and drive gene therapy towards 
regular clinical application (Yu et al., 1986; Baum et al., 2011).  
Table 1.1 Gene therapy products which have attained market approval to date (adapted from Dunbar et al. 
2018).  
Abbreviations: FDA: U.S. Food & Drug Administration, EMA: European Medicines Agency, 
γRV: murine-γ-retrovirus, LV: lentivirus, HSPC: haematopoietic stem and progenitor cells, X-
SCID: X-linked severe combined immunodeficiency, BCMA: B cell maturation antigen, ARSA: 
arylsulfatase A, ABCD1: transporter gene mutated in adrenoleukodystrophy, CNS: Central 
Nervous System, AAV: Adeno-associated virus, AADC: amino acid decarboxylase, IDA: 
iduronate-2-sulfotase.     
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Fig. 1.2 The progress of gene therapy from the late 1980s to date; a) The number of gene therapy clinical trials to 
November 2017. b) Proportion of target indications addressed by gene therapy clinical trials. c) Types of therapeutic 
genes transferred in clinical trials. (Data sourced from Ginn et al. 2018).    
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The mid-1990s saw progress in the engineering of lentiviral (Naldini et al., 1996)and spumaviral 
(Russell and Miller, 1996) vectors as well, offering advantages such as the incorporation of larger 
and highly complex gene cassettes as well as preferential integration into the coding regions of 
target genes, thus reducing the propensity of oncogenic insertional mutagenesis (Montini et al., 
2009). Adeno-associated viruses (AAVs) also slowly came to prominence, first in murine models 
(Kessler et al., 1996; Xiao, Li and Samulski, 1996) and later in humans (Kay et al., 2000; Manno et 
al., 2006). Whilst having a relatively smaller packaging capacity compared to retroviral vectors, 
AAVs have the advantage of being non-integrating with the t-DNA packaged and stabilised within 
an episome within the host cell (Dunbar et al., 2018). 
Amidst global developments in genetic and vector engineering, gene therapy products were slowly 
gaining regulatory approval and emerging onto the market. The first regulatory approved gene 
therapy product arrived in China in 2004; Gendicine®, developed by Shenzhen SiBiono GeneTech 
Co. Ltd., is a treatment for head and neck squamous cell carcinoma which functions on the basis 
of a recombinant human adenovirus type V vector, engineered to carry a wild-type p53 gene 
responsible for tumour suppression (Peng, 2005). Designed to work in-tandem with radio/chemo 
therapy, Gendicine® has been administered to over 30,000 cancer patients in over 30 published 
clinical trials (Liu, Pestka and Shi, 2012; Zhang et al., 2018). This has led to a plethora of gene 
therapy products entering the market, as summarised in Table 1.1 and Fig. 1.2.  
Advances in genome editing have also complimented the resurgence of gene therapy in recent 
times. For more detail on genome editing, refer to the appendices (Chapter VII, 7.2). The early 
2000s saw the birth of site-specific endonucleases; the first of these was the engineering of zinc 
finger nucleases (ZFN) which carry out DNA alteration through nuclease-induced double-
stranded breaks followed by corrective host repair mediated by homing endonucleases 
(meganucleases) initiating homologous recombination using an introduced template (Urnov et al., 
2010; Collins and Thrasher, 2014). This was followed by significant developments in the alteration 
of transcription activator-like effectors (TALEs) on bacterial proteins to produce TALE nucleases 
(or TALENs) (Christian et al., 2010; Li et al., 2011); enzymes which have a broad applicability in 
specific cleaving of theoretically any DNA sequence (Reyon et al., 2012) thus making it highly 
amenable for gene therapy.  
A pivotal milestone occurred in 2012, when Charpentier demonstrated the efficacy of using closely 
clustered regularly interspaced short palindromic repeat (CRISPR) nucleases, guided by a 
complimentary gRNA sequence (to the target site), to specifically cleave DNA. This, coupled with 
a CRISPR-associated 9 (Cas 9) protein, was demonstrated in mammalian cell lines for efficient and 
adaptable gene editing, whereby the nucleases can be programmed to theoretically cleave any 
specific DNA sequence, opening the door to a wide range of applications, including gene therapy 
(Jinek et al., 2012; Mali et al., 2013).  This technique was a major stepping stone, providing a solution 
to simple viral vector-mediated gene transfer, such as reduced genotoxicity and better gene 
expression regulation as a result of high specificity and control using an endogenous promoter 
(Eyquem et al., 2017; Dunbar et al., 2018).  
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1.3 Gene & Cell Therapy  
Recent developments have seen a marriage between gene and cell therapy for therapeutic 
application spurred by significant progress in genetic editing techniques to date; ZFNs have been 
used to develop HIV resistance in both T and haematopoietic stem cells through disruption of the 
C-C motif chemokine receptor type V (Perez et al., 2008; Li et al., 2013; Tebas et al., 2014). One of 
the most promising ventures has stemmed from the treatment of B cell acute lymphoblastic 
leukaemia through use of TALENs to modify lentiviral-induced anti-CD19 chimeric antigen 
receptor T (CAR-T) cells by selective gene disruption of T cell receptor α-chain and CD52 gene 
loci. This methodology represented a transition away from autologous therapy to an “off-the-
shelf” allogeneic approach, whereby a theoretical “universal T cell bank” can be developed (Qasim 
et al., 2017).  
The CAR-T approach offers simpler manufacture of T cells, increases the availability of the 
treatment to a wider patient base and avoids harvesting cells from the patient prior to gene editing, 
which can be tricky, especially in infant cases. As such, two CAR-T cell products, Yescarta (Kite 
Pharma) and Kymriah (Novartis), received FDA approval in 2017 (Salmikangas, Kinsella and 
Chamberlain, 2018), the latter gaining EMA approval earlier this year (August 2018) and an 
agreement between Novartis and the NHS in England to treat children with acute lymphoblastic 
leukaemia using the promising gene therapy product (Hawkes, 2018). 
Recent advances have seen the CAR-T approach being applied to a number of indications, with 
pre- and clinical trials currently being run on haematological diseases such as multiple myeloma, 
targeting the B cell maturation antigen (BCMA) in B and plasma cells (de Larrea et al., 2019). CAR-
T cell therapies continue to make headway in treating many B cell malignancies, with 19 clinical 
trials currently under way (as of March 2019) for treating non-Hodgkin lymphoma, with early 
reports suggesting complete remission rates of between 40-60% (Hill, Lulla and Heslop, 2019).  
Exciting animal studies have demonstrated the power of stem cell and gene therapy in other disease 
states too; one such example was the utilisation of neural progenitor cells (NPCs) in a transgenic 
mural model to treat Huntington’s disease (HD). In this study, NPCs were isolated from rhesus 
monkeys prior to genetic modification to allow for stable expression of small hairpin RNA and 
subsequent grafting back into HD mice. Immunohistochemistry illustrated both integration and 
differentiation of the grafted, engineered cells and the mice displayed both improved motor 
functions as well as prolonged lifespans (Cho et al., 2019).  
Another interesting clinical trial looked at the treatment of Wiskott-Aldrich syndrome (WAS) using 
genetically modified haemopoietic stem cells, mediated by lentiviral transduction of a corrected 
WAS gene, with favourable outcomes reported for all eight patients in the trial. Four of the patients 
were able to move away from a protected environment into normal society with no adverse effects 
reported after a follow up 3 years after the treatment (Ferrua et al., 2019).  
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1.4 Gene Delivery Vectors 
Naturally, developments in gene therapy have simultaneously seen a complimentary rise in interest 
in the use and development of suitable delivery vectors. It has now reached a stage where there is 
a diverse arsenal of gene delivery vehicle at the disposal of gene therapy clinicians, depending on 
the specific application. Therapeutic genes can be delivered in a number of different ways and can 
generally be classed into either viral or non-viral mediated delivery mechanisms; the relative 
popularity of each delivery mechanism is summarised in Chapter IV, Fig.4.1.  
1.4.1 Viral Vectors  
1.4.1.1 Adenovirus 
Adenoviral vectors are ds linear DNA viruses which have a high delivery capacity of ~ 36 kb. 
There are over 100 serotypes of adenovirus and their popularity in gene therapy application 
originates from their broad tissue tropism and their ability to transfect both dividing and non-
dividing cells. This wide ranging tropism stems from an adaptable viral fibre protein – cell surface 
interaction which can be enhanced with an integrin co-receptor (Kay, Glorioso and Naldini, 2001).  
The vector fibre proteins are amenable to modification; the attachment of seven lysine residues to 
the fibre facilitates binding to the heparin sulphate moieties on the cell surface whilst the 
attachment of small binding epitopes has improved specific cell targeting. Even antibodies against 
specific proteins have been conjugated to fibre proteins to mediate better targeting properties with 
higher affinity to receptors (Nayerossadat, Maedeh and Ali, 2012).  
 
Fig. 1.3 Adenovirus-meditated gene transfer into the host cell (from Lee et al. 2017).     
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There are significant disadvantages to adenoviral-based gene therapy; a significant one is low levels 
of transient gene expression, which can limit its applicability in treating genetic disorders, which 
require long expression times. This is because a defective adenovirus is needed for gene therapy 
and as such, the E1 gene is removed, which limits both expression and replication. There is also a 
great deal of concern as to the safety of adenoviral vectors, which, at high infusion concentrations, 
can illicit both cell-mediated and humoral immune responses, leading to devastating effects, as in 
the case of Jesse Gelsinger.  
There have been attempts to construct “second-generation, gutless vectors” through deletion of 
specific open reading frames of the E4 and E2 genes to reduce antigenicity,. though this has further 
compounded the issue of low gene expression and as such, compromises the therapeutic modality 
of the vector. Research continues into adenoviral vector mediated gene therapy mainly due to their 
wide applicability to a range of tissue tropisms (Robbins and Ghivizzani, 1998). 
1.4.1.2 Adeno-associated Virus 
Adeno-associated viruses (AAVs) are small (~20-25 nm) non-enveloped, ssDNA viruses which 
are a member of the Parvoviridae family. AAVs require a helper virus to initiate gene expression 
and replication and as such are part of the Dependovirus genus; these ancillary viruses can range 
from adenovirus, herpes simplex, vaccinia, cytomegalo- and human papilloma viruses. These 
helper viruses allow the AAV ssDNA to be converted to replicative dsDNA to facilitate gene 
expression and replication (Merten and Al-Rubeai, 2011).  
 
 
Fig. 1.4 Adeno-associated viral replication and infection with the aid of a helper virus (from Daya & Berns 
2008).     
Like adenovirus, wild-type AAVs are able to transfect non-dividing cells, however crucially they 
facilitate stable gene expression rather than transient; they are able to integrate specifically to a 
locus on chromosome 19 and as such avoid issues such as random insertional mutagenesis. 
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Recombinant AAV does not integrate into the host genome and remains episomal after gene 
transfer.  
One of the main disadvantages of AAVs is their relatively small packaging capacity (~5.2 kb), as 
well as low production yields. However recent advances in scalable production methods have 
helped to mitigated this issue and opened the door for high dose-applications in in vivo gene therapy 
clinical trials (Robbins and Ghivizzani, 1998; Merten and Al-Rubeai, 2011).  
1.4.1.3 Herpes Simplex Virus 
The herpes simplex virus (HSV) is a large (~ 200 nm), enveloped human pathogenic virus. It is 
structured with four concentric layers, with its linear dsDNA encased in a icosahedral shaped 
capsid, which is further enshrouded by a tegument, a layer containing twenty viral proteins. The 
tegument is contained within a lipid envelope containing viral glycoproteins (Laine et al., 2015).  
Glycoprotein D, H, L and B mediate host cellular entry by envelope fusion initiated by interaction 
with a surface receptor on the cell membrane.   
Gene regulation is determined by first recognition of viral protein 16, which instigates an enhancer 
to express immediate early (IE) genes which are responsible for producing infected cell proteins 
(ICP); the IE gene also controls early (E) and late (L) genes which are responsible for controlling 
viral replication and producing virion structural proteins(Artusi et al., 2018).  
A relatively new entrant to the arena of gene therapy, HSV vectors have curried favour due to their 
significantly high delivery capacity (~150 kb), partially due to the size of the viral vector but also 
as there are ~ 40 non-essential genes which can be deleted from its genome while still preserving 
its replication capacity. This genome complexity can also be exploited to derive oncolytic potential, 
selectively targeting cancer cells for instance.   
Like adenovirus and AAVs, HSV has a broad tissue tropism; importantly this includes neurons, 
which open this vector up to interesting applications. Further advantages include its lack of 
integration into host genomes, which lowers the risk of insertional mutagenesis (Fink et al., 1996; 
Nayerossadat, Maedeh and Ali, 2012; Kanda et al., 2017).  
A significant risk of HSV vectors is the potential for recombination with latent HSV infected cells 
and thus reactivate and potentially spread to other individuals. Additionally, HSV transfection is 
mitigated by pre-existing immunity in ~ 70% of people and as such HSV vectors and transfected 
cells which present HSV cell surface markers are  inactivated by a specific immune response  





Fig. 1.5 The structure, life-cycle and replication pathway for HSV-1 viral vectors (from Artusi et al. 2018).      
Another limitation of HSV is its potential cytotoxicity and high inflammatory risk, partially due to 
a trade-off concerning it ICP0 gene, which is required for both infection and sustained transgene 
expression. As such, gene expression tends to be transient, though recent work into activating a 
HSV-1 protein whilst deleting ICP0 has overcome issues of low expression levels (Thomas et al., 
2002; Thomas, Ehrhardt and Kay, 2003).   
1.4.1.4 Retrovirus 
One of the most popular choices for gene therapy delivery vectors during the advent of gene 
therapy (e.g. in X-SCID clinical trials), most retroviral vectors are based on the Moloney murine 
leukaemia virus (MMLV) which encodes three polyprotein genes, gag (which forms the viral core 
structure), env and pol. Retroviruses are RNA viruses which use a DNA intermediate to achieve 
replication and are spherical particles of ~ 80-100 nm, enveloped by a lipid bi-layer.  
Transfection occurs through a specific interaction between a viral envelope protein (env) and a cell 
surface receptor. Once internalised, the retrovirus, mediated by its pol reverse transcriptase, is 
uncoated followed by reverse-transcription of its RNA into dsDNA. The dsDNA is then 
integrated into the host cell genome via an integrase enzyme, allowing for stable expression, 




Fig. 1.6 The life cycle of a generic retrovirus including the use of reverse transcriptase prior to transport to the host 
genome (adapted from Power 2001).       
As the provirus is maintained during mitotic division, the transduced cell population can be 
expanded through cloning. Retroviral vectors also have a limited impact on the growth properties 
of the cell, facilitating sustained viral production through stable producer lines, with titres of 107 
cfu/ml now possible. As many of the source viral genes have been removed, the packaging capacity 
of retroviral vectors are also moderately high, ~ 8 kb (Nayerossadat, Maedeh and Ali, 2012).  
The main drawback of retroviral vectors is that they require mitosis to instigate breakdown of the 
nuclear envelope to integrate the viral genome into the host and thus can only infect dividing cells. 
There are a few exceptions, for instance lentivirus (e.g. HIV), which have both cis- (viral genome 
sequences localised to the same DNA molecule) and trans- (viral elements which can achieve gene 
regulation in isolation) acting factors, which can mediate active transport of DNA to the nucleus 
of non-mitotic cells. Consequently, this feature allows for in vivo gene therapy and broadens the 
range of treatment of non-dividing cells (Robbins and Ghivizzani, 1998). 
1.4.1.5 Lentivirus 
Lentiviral vectors are classed a genus of the Retroviridae family and are spherical, enveloped viruses 
with a diameter of ~ 80 – 100 nm. As is common within the retroviral family, the lentiviral genome 
contains the 5’-gag-pol-env-3’ viral proteins, though lentiviruses also have tat and rev regulatory 
genes, as well as regulatory genes, depending on the strain (e.g. for HIV-1 they are vif, vpr, vpu and 




Fig. 1.7 Lentiviral vector cellular entry, reverse transcription and formation of the PIC complex prior to integration 
into the host nucleus (from Nienhuis 2008). 
One of the fundamental discrepancies between conventional c-type retroviruses and lentiviral 
vectors is that the latter viral cDNA forms a pre-initiation complex (PIC) with other viral factors. 
This facilitates translocation across the nuclear membrane, mediated by a central polypurine tract 
within the cDNA and a valine residue at position 165 in the PIC. Crucially, this means that, unlike 
other retroviruses, lentiviral vectors can transfect non-dividing cells, with a broad tissue tropism 
including neurons, hematopoietic precursor and lymphoid cells, which makes them amenable to 
treating  a wide range of indications, including neurological diseases (Thomas, Ehrhardt and Kay, 
2003; Anson, 2004).  
Packaging capacity is usually the same as with other retroviruses (~ 8 kb) and as the vector genome 
is integrated gene expression is stable and persistent, which makes the vector suitable for long-
term treatments. Despite integration, there is low risk of insertional mutagenesis or oncogenesis 
as genome integration occurs away from cellular promoters (Vannucci et al., 2013).  
One disadvantage of lentiviral vectors is their relative complexity in engineering and manufacture, 
relative to other retroviruses, and this stems from a higher proportion of regulatory genes required 
for replication and function. These genes need to be provided within the vector or separate 
construct such as in a DNA plasmid (Vannucci et al., 2013). A second disadvantage is concern over 
biosafety, particularly in the case of HIV, when one considers the pathogenic nature of the parental 
virus. A major worry is the creation of replication-competent recombinant viruses; however 
sequential generations of new viral vector construct engineering have aimed to mitigate this. 
Initial work looked to delete virulence-linked genes (Vpr, Vif, Vpu, Nef and Tat), leaving only gag, 
pol and rev genes from the original parental virus. More recently, self-inactivating vectors have been 
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engineered by deletion of part of the U3 region of the 3’-long terminal repeat of the DNA prior 
to transcription to viral RNA. Both these measures improve the safety implications in using 
lentiviral vectors as they significantly reduce the risk of a replication-competent virus will form in 
the target cells also limiting the potential for  recombination with wild-type virus in the host system 
(Zufferey et al., 1998).  
1.4.1.6 Pox Virus / Vaccinia Virus 
Poxvirus or Vaccinia virus is part of the Poxviridae family and are large (~ 200 nm), enveloped 
viruses containing liner dsDNA. Poxviruses are characterised by their large and complex genome, 
with approximately 250 genes and replication that occurs completely within the cytoplasm. The 
genetic delivery capacity is significantly large (30 kb) as many of these genes are non-essential and 
therefore can be deleted (Moroziewicz & Kaufman 2005).  
 




Poxvirus also differs in that transgene insertion is achieved through homologous recombination 
or in vitro ligation and as such are characterised as recombinant viral vectors. Expression of the 
transgene is high but transient and thus poxvirus is commonly used for vaccination, cancer 
therapies and recombinant protein production; a recent example of this was the use of 
Orthopoxvirus modified vaccinia ankara (MVA) which was used en masse as a smallpox 
vaccination (Nayerossadat et al. 2012).  
Poxvirus has a number of advantages as a gene therapy vector as it is flexible in offering numerous 
potential sites for insertion of the transgene, as well as having low levels of pre-existing immunity 
in patient populations. There are however issues; the complexity of engineering the recombinant 
viruses and the attenuated nature of the virus compromising the replication efficiency has limited 
the use of poxvirus. Further research is required to address issues of cytotoxicity and safety in 
order to justify their clinical use and utilise their high genetic transfection capacity (Nayerossadat 
et al. 2012; Vannucci et al. 2013). 
1.4.2 Non-Viral Vectors  
1.4.2.1 Chemical  
1.4.2.1.1 Lipofection 
The process of lipofection employs the use of a lipid-DNA complex to achieve effective gene 
transfer. A liposome forms around the therapeutic DNA, by way of a nucleic acid-poly-cationic 
complex, prior to delivery and enters the host cell by endocytosis or fusion with the plasma 
membrane. Liposomes are particularly useful as they circumvent the safety issues associated with 
viral vectors, with little to no immunogenic or pathogenic associated implications. Their 
manufacture is also significantly simpler and quicker to produce than a typical viral vector and can 
be scaled to large scale manufacture (Carter et al., 2015).  
A major issue with lipofection is its low efficiency, partially due to host endonucleases degrading 
the introduced DNA via the host reticuloendothelial system. This being said, recent developments 
in engineered, stimuli-sensitive liposomes have drastically increased the transfection efficiency 
from a miserly 1% to some reports of 60-70%. One possible rationale for this is the resistance to 
lysosomal DNA degradation through the enzymatic disruption of endosomes, as well as directed 
fusion between the DNA/liposome complex with the cell membrane, both of which either 
regresses or limits the endosome-mediate lysosomal pathway which leads to DNA degradation 
and ultimately loss of transfection efficiency (Young et al., 2002).  
In addition, the use of polycations such as polyethylenimine (PEI) in the liposome complex can 
serve two functions; the first is the high cationic charge increases its DNA complexing capacity 
and secondly the molecule instigates what is known as a “proton sponge” effect. Here, PEI exploits 
its high buffer capacity and “absorbs” the protons released by lysosomes, which consequently leads 
to an influx of chloride ions and water. This leads to lysosomal membrane disruption as a result 
of osmotic swelling and cationic charge repulsion, further limiting DNA degradation and 
improving transfection efficiency (Benjaminsen et al., 2013).   
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Further improvements have been instigated through surface modification of the liposomes with 
hydrophilic polymers (e.g. PEG) or by modulating the pH and ionic strength of the formulation 
buffer to optimise gene transfection. Research into liposome-based delivery systems for gene 
therapy continues, driven by their ability to target a broad range of tissue tropisms, largely due to 
their modification potential with signal peptides, antibodies, carbohydrates etc., all of which aid in 
achieving directed genetic transfer to target cells  (Son, Tkach and Hall, 2000; Nayerossadat, 
Maedeh and Ali, 2012).  
1.4.2.1.2 Calcium Phosphate Precipitation 
Therapeutic DNA can also be complexed with calcium phosphate precipitates, prior to cellular 
transfection. The methodology is relatively simple: DNA is mixed with a solution of calcium 
chloride, prior to addition of a source of phosphate ions, usually 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffered saline. A precipitate complex is formed between 
the calcium and phosphate ions, consequently causing a co-precipitating effect on the DNA in 
solution. These precipitates can then transfect cells through endocytosis and as such presents a 
relatively inexpensive, quick method of manufacturing a vector for gene therapy (Khan et al., 2016).  
 
Fig. 1.9 Gene delivery achieved by a) Lipofection (from Koirala et al. 2013) and b) Calcium phosphate 
precipitation (from Carter et al. 2015). 
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Calcium phosphate precipitation shares many of the advantages as that of lipofection, being a 
rapid, relatively inexpensive method for achieving transfection. The vectors are biodegradable and 
as such there are few issues with cytotoxicity or advocating an adverse host immune response. As 
with liposomes, transfection efficiency is strongly dependent on the operating parameters and 
heavily influenced by ion and DNA concentration, pH, temperature, aeration, mixing and time 
between precipitation and transfection (due to precipitate aggregation). 
Whilst these factors can be modulated to optimise transfection efficiency, they are also the cause 
of a high degree of variability and low reproducibility in the technique. Whilst some transfection 
efficiencies can be as high as 90%, others can be as low as 1% (Carter et al., 2015); this is strongly 
dependent on cell type and requires a high level of front-end methodology optimisation to improve 
DNA incorporation in each individual case.  
As with lipofection, calcium phosphate precipitation is also amenable to modification to improve 
transfection and vector stability. Examples include a multi-shell approach of repeating coats of 
DNA and calcium phosphate to improve colloid stability and act as a protective barrier against 
lysosomal degradation (Sokolova et al., 2006). Via a similar thought process, the introduction of a 
lipid (Li et al. 2010), protein (Chowdhury et al., 2005; Liu et al., 2005) , ionic additives (Khan et al., 
2016) or block co-polymer (PEG-PAA) (Kakizawa and Kataoka, 2002) coat to the precipitate 
showed improvements in therapeutic effect through better release kinetics, stability and mitigated 
vector aggregation. Host cell targeting can also be modulated by studding the surface of the 
precipitates with cellular membrane entry peptides to improve delivery and transfection (Liu et al., 
2011). 
1.4.2.2 Physical  
1.4.2.2.1 Electroporation 
Gene transfer into a host cell can also be achieved by exposing the cell membrane to an electric 
field, thus polarising the phospholipid bilayer and lowering the energy barrier for water 
penetration. This leads to the reversible formation of nanopores in the membrane and thus an 
entrance route for DNA in to the cell; this process is termed “electroporation”(Nayerossadat, 
Maedeh and Ali, 2012; Carter et al., 2015).  
Electroporation has a number of advantages in that it is applicable to a wide range of tissue 
tropisms and can be applied at all stages of the cell life cycle whilst also having applicability for in 
vivo treatments. Unlike viral vector-based therapies, electroporation does not have cytotoxic risks, 
whilst also being particularly amenable to vaccine therapies; this is due to an enhanced adjuvant-
based activation of the host immune response mediated by higher levels of antigen expression and 
cytokine release at the site of treatment, as a result of moderate tissue damage at the treatment site. 
In addition, parameters such as electrode placement and timing of the pulses can be controlled to 
influence specific spatial and temporal responses and expression levels in vivo.  
There are, however, concerns with the feasibility of electrode placement within certain tissue 
groups as well as the risk of significant localised tissue damage or DNA modification as a 
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consequence of excessive voltage conditions. In addition, mass transport across the membrane is 
non-specific and as such, intra-cellular ionic environments could be adversely affected. These 
issues require rigorous optimisation of the treatment parameters to modulate appropriate 
transfection and gene expression whilst also limiting any host tissue damage (Lambricht et al., 
2016).  
1.4.2.2.2 Gene Gun 
The concept of the “gene gun” falls within the remit of biolistics (biological ballistics) and 
functions by electrostatically coating the transfer DNA onto the surface of heavy metal particles, 
usually either tungsten or gold.   
 
Fig. 1.10 Mechanism of the “gene gun” as a technique to deliver therapeutic DNA to host tissue (from Carter et 
al. 2015). 
Transfection occurs through a build of helium gas pressure which eventually breaks a rupture disk, 
causing a plastic bullet (tipped with the DNA-coated metallic microparticles) to travel at high 
velocity down the shaft of the gun. The bullet is halted at the end of the shaft by a filter screen; 
however the excessive force built up by the gas pressure causes the microparticles to fire past the 
screen and through the cell membrane of the target cells (Carter et al., 2015).  
Advantages of using the “gene gun” include its in vivo applicability (currently in both skin and liver 
cells) and broad tissue application (including neurons) as it is cell-receptor independent (Thomas, 
Ehrhardt and Kay, 2003). As with all the non-viral methods, there are little immunogenic or 
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toxicity considerations, when compared to viral-mediated treatments. It is a relatively simplistic 
technique and does not require modification by ligands, liposomes or polymers to achieve cellular 
entry and can deliver large volumes of therapeutic DNA, depending on the surface area of the 
microparticles used (Lin et al., 2000).  Furthermore, the gene gun can achieve transfection deep 
into a tissue and the transfection pattern can be well dispersed, targeting specific cells within a 
tissue amongst a background of un-touched cells.  
The main disadvantages of the technique are the risk of high shear damage to cells due to high 
projectile velocity and as such the pressure and geometric parameters need to be optimised prior 
to treatment. Expression is also transient and therefore repeat treatments are required for sustained 
gene therapy to be achieved (Lin et al., 2000; Nayerossadat, Maedeh and Ali, 2012; Carter et al., 
2015).  
1.4.2.2.3 Naked / Plasmid DNA  
“Vector-less” or naked DNA can be injected via micro-injection directly into a cell by puncturing 
the cell membrane with a needle. Often packaged into a plasmid, therapeutic DNA can 
theoretically be transfected into any cell type at relatively high delivery capacity (2 – 19 kb), with 
some cases of long term expression of over a year (Nayerossadat, Maedeh and Ali, 2012). It is a 
particularly efficient technique, as the amount of therapeutic DNA in each dose is entirely injected 
into the cell and little is lost via a transduction process, as is the case with other vector systems. As 
with other physical methods, the tissue tropism is not entry-mediated and there are little 
safety/immunological concerns given the lack of viral components.  
The fundamental disadvantage of this technique is the degree of manual labour involved, as each 
cell needs to be treated individually using micromanipulation techniques and a skilled operator. 
This can be both time consuming and have low reproducibility, given human factors such as 
fatigue and microscope image interpretation. There are also issues in treating certain cell types, 
particularly neurons given their morphology and cellular sensitivity (Carter et al., 2015).  
Whilst having applicability in germ line gene therapy in creating transgenic animals, a somatic gene 
therapy using microinjection is still too slow and not scalable, though there have been efforts to 
improve microinjection techniques, using automated platforms for microinjection to speed up 
throughput (Chow et al., 2016).  
Plasmid DNA can also be utilised in DNA vaccines, whereby an intravenous injection of naked 
DNA, encoding for a specific antigen, can transfect host cells and elicit a cellular and humoral 
immune response. This is advantageous as it is possible to generate a broad immune response and 
develop host immunity without the need for a replicating viral vector, whilst also being relatively 
simple and non-toxic. However, there have been issues with low immunogenicity with first 
generation DNA vaccines with little to no activation of T-cells, likely due to DNA degradation by 
host endonucleases and issues with cellular integration due to the physical size and strong negative 
charge of plasmid DNA (Ferraro et al., 2011).  
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Significant work has gone into developing the immunogenicity of DNA vaccines by increasing 
antigen expression and activation of CD8+ T-cell responses. DNA vaccines have also seen 
improvements in promoters, enhancers and introns, whilst also utilising adjuvants to stimulate 
host responses and engineering better formulation and delivery methods, including those listed 
here (e.g. the gene gun). The use of a number of additions, including transferrin, solvents, 
surfactant, polymers and endonuclease-inhibitors have demonstrated improvements in the 
transfection efficiency of naked and plasmid DNA (Karnchanasri, 2012).  
This has opened the door for a number of DNA vaccines, including those against malaria (Doolan 
and Hoffman, 2001), AIDS (Chen, Wang and Lu, 2014), Ebola (Sridhar, 2015), Influenza 
(Stachyra, Góra-Sochacka and Sirko, 2014) and certain cancer indications, such as cervical 
carcinoma (Bharadwaj et al., 2009; Khan, 2013).  
1.4.2.2.4 Ultrasound 
Ultrasound can also be an effective tool for achieving gene transfer through a technique known as 
“sonoporation.” Here, pores are created in the cellular membrane through sonication, which 
creates microbubbles in solution that oscillate in size in response to the frequency of the ultrasonic 
source applied through the solution. Acoustic cavitation of the membrane occurs as the ultrasound 
mediated acoustic pressure increases and the microbubble burst, creating nanopores (~ 100 nm) 
which allow therapeutic DNA to enter the cells (Newman and Bettinger, 2007).   
Whilst having the benefits of other non-viral, physical gene transfer techniques, there are some 
drawbacks to the method; expression is often transient and the efficiency of transfection is usually 
low as the cavitation mechanism is short lived. Localised increased temperature and pressure can 
lead to cell death and as such operating parameters such as duration, intensity and frequency of 
ultrasound pulses need to be optimised to balance transfection efficiency and host cell damage 
(Kim et al., 1996; Liang et al., 2004; Newman and Bettinger, 2007).  
1.4.2.2.5 Magnetofection  
Gene delivery can also be mediated through the use of cationic superparamagnetic iron oxide 
nanoparticles as part of a DNA complex to deliver therapeutic genetic material to host cells under 
a magnetic field. The concept relies on a magnetic field facilitating a high localised concentration 
of the nanoparticle-DNA complex around the host cells, improving the rate of endocytosis and 
thus transfection of DNA (Prosen et al., 2013). 
Importantly, the nanoparticles are biodegradable and will dissociate with DNA in the host 
cytoplasm and have demonstrated the potential to increase transfection efficiency several hundred-
fold, whilst also dramatically increasing the rate of transfection to increase treatment throughput 
time (Scherer et al., 2002).  
The main advantage of magnetofection is the rapid rate (as fast as 15 minutes) at which the DNA-
nanoparticle complexes sediment onto the surface of target cells, under a magnetic field. This 
coupled with transfection efficiencies as high as 73% make the technique an attractive option. As 
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with other techniques detailed here, operating parameters need to be optimised and tailored to 
specific cell types, including the strength of the magnetic field, morphology of the nanoparticles 
and DNA conjugation chemistry (e.g. mediated by PEI) to optimise the transfection efficiency 
(Plank et al., 2003). 
To summarise, both viral and non-viral methods of gene therapy offer viable means for achieving 
efficient therapeutic nucleic acid delivery for gene therapy. Viral vectors have a number of 
advantages in that they can target specific cell types, can achieve long term, stable transgene 
expression as well as having high transfection efficiencies. Of the viruses, adenovirus and herpes 
virus offer promise due to their high insert capacities, though retrovirus vectors have gained 
popularity due to their stable transgene expression, with lentiviral vectors also able to infect non-
dividing cells. The four viral vector groups represent ~ 50% of all vectors used in gene therapy up 
to 2017 (Hanna et al., 2017).   
Non-viral vectors have also showed a great deal of promise; they avoid the complexity of viral 
vector manufacture with respect to lengthy and expensive cloning and propagation methods as 
well as the safety implications of using viral vectors.  Vectors can be produced rapidly and at scale, 
with little cell type dependency, high throughput and in some cases high gene transfer efficiency.  
The main issue is the lack of stable and pro-longed gene expression, though this could be overcome 
through hybrid nonviral-viral plasmid vector engineering; including replication signals sourced 
from HPV and Epstein-Barr Virus in the plasmid which encode both cis- and trans- elements could 
aid in mediating episomal replication and allow for stable long term gene expression using non-
viral vectors (Robbins and Ghivizzani, 1998).  Further research is needed to overcome some 
associated issues such as localised tissue damage, expensive specialised equipment and lengthy 
manual handling techniques to improve in vivo applications.  
1.5 Nanoplex Purification 
An important facet of using plasmid DNA and viral vectors in clinical gene therapy is their 
purification strategy. The regulatory authorities, whether it be the Food and Drug Administration 
(FDA), European Medicines Agency (EMA) or  Medicines and Healthcare products Regulatory 
Agency (MHRA) will require adherence to strict ICH (International Council for Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use) guidelines on vector 
quality characteristics, including their identity, potency, purity, infectivity and stability as well as 
stringent upper limits on process and product impurities that require removal prior to formulation 
(White et al., 2017).   
Exemplary cases for impurity removal for a therapeutic plasmid DNA and AAV vector product 
are provided in Table in Table 1.3. It should be noted that there are a multitude of critical quality 
attributes (CQA) requirements that need to be fulfilled, depending on the product type and 
regulatory body. Theses CQAs relate not only to purity, but also to product quality and safety and 
will involve the reporting of a number of other parameters (e.g. final pH, osmolality, visual 
appearance, protein concentration, viral titre, potency and seal integrity). 
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Purification strategies are designed based on the characteristics of the feedstock and the target 
product of interest. Each vector has its own set of unique characteristics which need to be 
considered when optimising its purification train, including its hydrodynamic radius, net charge, 
isoelectric point, hydrophobicity, ligand affinity, density, intra-/extra- cellular release fraction, 
stability, lability etc. 
Each unit operation and the sequence they are run in are designed with the aim of meeting product 
quality and safety requirements as stipulated by the regulatory agency, whilst also being robust, 
cost efficient, productive and scalable (Morenweiser, 2005; Carvalho, Sepodes and Martins, 2017).  
Table 1.2 Clinical testing parameters and specifications for the manufacture of an example plasmid vector and 
adeno-associated vector (Diogo et al., 2000; Stadler, Lemmens and Nyhammar, 2004; Allay et al., 2011; 
Lloyd-Evans, 2017; Penaud-Budloo et al., 2018) . 
Product 
Type 
Parameter Assay Acceptability Range 
Plasmid 
Vector 
Genomic DNA TaqMan-PCR < 10 ng gDNA / µg pDNA 
Host Cell Proteins Bicinchoninic Acid 
Assay or Silver 
Staining Gel 
Undetectable 
RNA 0.8% Agarose Gel 
or Analytical HPLC 
Not visible or < 0.2 µg / mg 
pDNA 
Endotoxins Limulus Amebocyte 
Lysate 
< 0.1 EU / µg pDNA 
Circular Closed 
Covalent over 




> 97 % 
DNA Purity Optical Density 
A260/A280 
1.7 – 2.0 
Sterility - Bacteria / 
Fungi Static Activity 

















Serial Infection / rep 
or cap qPCR 
< 1 rcAAV per 1 x 108 vector 
genomes (vg) 
Residual BSA ELISA < 50 ng / ml 
Residual Host 
DNA 
qPCR ≤ 10 ng / dose 
Protein Purity SDS-PAGE ≥ 80 % 
Endotoxins Limulus Amebocyte 
Lysate 






HPLC, MS, ELISA 
etc. 
Quantitative results should be 
reported 
Sterility - Bacteria / 
Fungi Static Activity 







Empty Capsids / 
Intermediate Viral 
Particles 
vg (qPCR) / vp 
(ELISA), EM or 
AUC 
Quantitative results should be 
reported 
Aggregation Dynamic Light 
Scattering 






Table 1.3 Characteristics pertinent to the purification of common gene therapy viral vectors (adapted from Kieff et 
al. 1971; Francis & Bradford 1976; Lankinen et al. 1991; Baxby 1996; Müller et al. 2000; Gray et al. 2010; 
Michen & Graule 2010; Segura et al. 2011a; Venkatakrishnan et al. 2013). Important to note here is that the 















Genome dsDNA ssDNA ssRNA dsDNA dsDNA 
Envelope      
Fraction Lysate Lysate Supernatan
t 
Supernatant Lysate or 
Supernatant 
Stability ↑ ↑ ↓ ↓ Moderate 
Density (g/cm3) 1.34 1.39 1.16 1.73 1.27 
Hydrodynamic 
Size (nm) 
80 – 100 20 – 30 100 100 140 – 450 
Net charge (at pH 
7) 
Negative Neutral – 
Positive 
Positive Positive Negative 
Isoelectric Point 4.5 6.3-6.8 6.8-7.9 5.3 – 7.28 6.56 
Plasmid DNA, for example, is characterised by its large hydrodynamic size (100 – 250 nm), with a 
strong net negative charge resulting from the negatively charged phosphate groups on the nucleic 
acid backbone of the plasmid molecule, thus the overall charge increases with increasing number 
of bases (Ferreira et al., 2000).  Viral vectors vary in their morphology and characteristics; Table 
1.4 summarises some of the key features of some of the salient viruses used in gene therapy which 
become useful when considering their purification strategy.  
Given low transfection efficiencies (approximately 1 in 1000 pDNA molecules in a dose 
successfully transfects a target cell and is expressed) (Varley et al., 1999) and high dosage 
requirements (sometimes as high as mg levels of pDNA), as well as the growing popularity of gene 
therapy and DNA vaccine therapies, large volumes of plasmid DNA and viral vectors need to be 
produced. Large scale manufacture of plasmid DNA and viral vectors usually involves 
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fermentation-based cell culture, usually followed by a cell lysis step (depending on if the vector is 
located intracellularly or is released into the culture supernatant) to release product into the bulk 
feedstock (Ferreira et al., 2000; Levy et al., 2000; Segura, Kamen and Garnier, 2011b). 
When required, cell lysis can be achieved by thermal, mechanical or chemical means; thermal lysis 
is less favoured due to the complexity and lengthy of the heat-shock method (repeated cycles of 
freeze thaw -80 ⁰C/ 37 ⁰C), as well the lack of feasible scale up options due to the requirement for 
efficient and controlled heat transfer equipment to treat large feedstock volumes (Florencio et al., 
2015). Mechanical disruption, including ultrasonication, microfluidisation and bead milling, offers 
a scalable alternative with recoveries of up to 74% for plasmid DNA (Ferreira et al. 2000) and  
successful application also demonstrated with viral vectors too (Burova and Ioffe, 2005; Wright, 
2008a; Allay et al., 2011; Segura, Kamen and Garnier, 2011b; Potter et al., 2014). Viral vectors can 
also be liberated from the host cell through hypotonic shock or small pressure changes e.g. via a 
cross-flow filtration system (Segura, Kamen and Garnier, 2011b).  
However, optimisation is required to achieve an appropriate trade-off between cell disruption and 
vector recovery, as well as to limit the micronisation of cell debris through prolonged mechanical 
cell disruption which can complicate higher resolution purification steps further downstream 
(Balasundaram, Harrison and Bracewell, 2009); plasmid DNA (and its polynucleotide 
components) is particularly shear sensitive and mechanical stress can cause a break/relaxation of 
the supercoiled structure of pDNA to form open circular DNA, which ultimately leads to a 
reduction in the transfection efficiency of the genetic material (Levy et al., 2000; Schmidt, Friehs 
and Flaschel, 2007), whilst high shear forces can cause a shedding effect on the envelope of viruses, 
leading to a loss of infectivity (Morenweiser, 2005).  
Alkaline lysis appears to be the most favourable approach for large scale cell disruption for plasmid 
DNA (Ferreira et al., 2000; Urthaler, Buchinger and Necina, 2004) and is based on the method first 
described by Birnboim and Doly (Birnboim and Doly, 1979). Cells are separated from the broth 
by an initial centrifugation or microfiltration step and then re-suspended in a lysis buffer (0.2 M 
NaOH, 1% SDS), designed to disrupt the lipid-protein hydrogen and ionic bonds within the 
bacterial outer and plasma membranes.  
The buffer will often also contain ethylene diamine tetra-acetic acid (EDTA) as a chelating agent 
for Ca2+ -and Mg2+ cations, which facilitates a reduction in membrane integrity whilst also reducing 
the efficacy of Mg2+ dependent endonucleases, preserving the quality of the released plasmid DNA 











Fig. 1.11 Purification strategies for generic a) plasmid DNA and b) viral vector products (adapted from Prazeres 
et al. 1999; Ferreira et al. 2000; Fuerstenau-Sharp et al. 2003; Shi et al. 2009; Allay et al. 2011; Merten et 
al. 2014; Florencio et al. 2015; van der Loo & Wright 2016; Lloyd-Evans 2017; Terova et al. 2018).  
Mixing is a key parameter here which needs to be carefully monitored as the released genomic 
DNA greatly increases the viscosity of the lysate and consequently the P/V (power input per unit 
volume) increases (Marquet et al., 1997). Mixing is complicated as the lysate displays non-
Newtonian rheological characteristics and thus the geometrical design of the mixing vessel, 
impellers and flow properties of the material need to be carefully considered to preserve the quality 
of the plasmid DNA (Stephenson, Norman and Cumming, 1992; Ciccolini et al., 1999; Levy et al., 
2000).  
Whilst rapid mixing is required to achieve homogenous distribution of the buffer, consistent cell 
disruption and the avoidance of localised high pH regions in the lysis tank (which can lead to 
significant plasmid denaturation (Rush and Warner, 1970; Prazeres, Schluep and Cooney, 1998a)), 
a balance must be struck to avoid agitation-related shear damage of the released plasmid DNA and 
fragmentation of host chromosomal DNA which pose difficulties further downstream in 
separating from target plasmid DNA (Ciccolini et al., 1999; Urthaler, Buchinger and Necina, 2004). 
Often additives such as glucose and sucrose are included in the lysis buffer as a shear-protectant 
to mitigate this issue (Prazeres et al., 1999).  
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In the case of viral vectors, cell disruption can be achieved by addition of non-ionic detergents, 
such as Triton X-100 or Tween-80, which can disrupt both the viral envelope and the cell 
membrane whilst leaving the viral nucleocapsid intact. The cell disruption step does, however, 
often lead to nucleic acid-protein and viral particle aggregation in the cell lysate. This can be offset 
by addition of either 150 mM NaCl or a non-ionic surfactant which prevents electrostatic 
interaction between cell debris and host cell proteins, whilst use of a divalent salt buffer such as 
citrate or 200 mM MgSO4 can also mediate better viral particle dispersion in future processing 
steps and storage (Merten et al., 2014; Penaud-Budloo et al., 2018).  
Cell disruption is not 100% selective and consequently a high percentage of the cell lysate or cell 
supernatant consists of product-related impurities. In the case of bacterial production of plasmid 
DNA the percentage of plasmid DNA can be as low as 3%, with impurities including RNA, host 
genomic DNA, endotoxins (lipopolysaccharides), cell debris and host cell proteins (Stadler, 
Lemmens and Nyhammar, 2004). In the case of viral vectors, impurities can also include empty or 
intermediate capsids, cell membrane vesicles, as well as helper viruses used to facilitate vector 
production; these will also need to be purified away from the fully formed viral vector (Merten 
and Al-Rubeai, 2011).  
As many of these impurities exhibit a negative charge (nucleic acids, endotoxins) and have similar 
physiochemical properties such as hydrophobicity (endotoxins) and size (empty capsids, 
membrane vesicles) to the target plasmid or viral vector, multiple sequential purification steps are 
required to recover the target species at sufficiently high levels of purity (Stadler, Lemmens and 
Nyhammar, 2004; Segura, Kamen and Garnier, 2011b). Endotoxin removal is particularly critical; 
they are lipopolysaccharides derived from bacterial cell walls and can cause toxic shock syndrome 
in vivo and thus should be stringently monitored (de Azavedo et al., 1985).  
Prior to these impurities being removed, a chilled high-salt neutralisation buffer is added the 
alkaline lysate which facilitates the formation of genomic DNA aggregates and proteins complexed 
by SDS, creating a precipitate/floc (Ciccolini et al., 1999; Prazeres et al., 1999). Whilst the potassium 
acetate buffer causes irreversible denaturation of chromosomal DNA which form part of the floc, 
plasmid DNA is able to renature into its supercoiled conformation and are re-solubilised, given 
the pH conditions are not excessive (Levy et al., 2000).  The floc is separated either by a 
centrifugation or filtration step prior to plasmid precipitation using sequential isopropanol and 
ethanol wash steps (Prazeres et al., 1999).  
Primary clarification of the cell lysate or supernatant is then required to remove cellular debris and 
any low molecular weight impurities, whilst also concentrating the feedstock volume for 
subsequent lower capacity, high resolution purification steps.  This initial clarification step tends 
to be low resolution, though must have a high volumetric capacity to handle the large volumes of 
a cell lysate / supernatant direct from fermentation harvest (Ferreira et al., 2000).  
Further intermediate purification and concentration steps are also required to exclude product-
related impurities, including enzymatic endonuclease degradation of host RNA and DNA, though 
issues arise due to the animal source of the enzyme, which makes process validation and regulatory 
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approval trickier and thus tends to be avoided during commercial, large-scale manufacture 
(Ferreira et al., 2000; Gustavsson et al., 2004a; Stadler, Lemmens and Nyhammar, 2004). This can 
be remedied through endogenous endonucleases; incubation of the cell lysate at 37 ⁰C can reduce 
RNA levels by 40%, including problematic high molecular weight RNA (Monteiro et al., 1999). 
Removal of other host impurities (at large scale) can be achieved by a series of precipitation 
reactions; a wide range of host cell proteins and high molecular weight RNA can be salted out 
using chaotropic salts such as lithium chloride and ammonium or potassium acetate or co-
precipitated with high molecular weight polymers such as PEG, which aids in removing smaller 
nucleic acid impurities (Ferreira et al., 2000).  
Aqueous-two phase extraction (ATPS) is another scalable technique which can be utilised on 
cleared lysates and have showed high removal of impurities such as RNA (98%) and endotoxins 
(68%), whilst achieving high levels of plasmid recovery (91%) in systems such as PEG 600 and 
sodium citrate / ammonium sulphate.  
The technique is particularly useful preceding a hydrophobic interaction chromatography step as 
no buffer exchange is required saving both cost and time, thus improving process efficiency 
(Gomes et al., 2009). In a similar vein, AAV vectors have shown to be successfully purified using 
a PEG 8000 / ammonium sulphate ATPS system as faster alternative to density gradient 
ultracentrifugation (Guo et al., 2013).  
Higher resolution purification of plasmid DNA and viral vectors tend to be carried out by either 
density gradient ultracentrifugation or by column chromatography.  Whilst both have the ability 
to achieve the high levels of recovery and purity demanded by regulatory agencies (Garger, Griffith 
and Grill, 1983; Sambrook and Russell, 2006; Merten and Al-Rubeai, 2011; Segura, Kamen and 
Garnier, 2011b; Blom et al., 2014; Florencio et al., 2015), gradient ultracentrifugation is plagued by 
a lack of scalability, expensive capital costs, long processing times which can induce product 
aggregation as well as the use of difficult to remove, toxic reagents such as ethidium bromide, 
caesium chloride and iodixanol (Ferreira et al., 2000; Burova and Ioffe, 2005; Merten et al., 2014; 
Kramberger, Urbas and Štrancar, 2015a; Terova et al., 2018). 
Given the nature of this research project, we will now look at the variety of chromatography 
options available in downstream processing to understand the versatility and wide scope of the 







1.6 Chromatographic Purification 
Chromatography has been the work-horse of the bioprocessing field since the early 1940s (Martin 
and Synge, 1941), providing a robust and flexible platform for the isolation and purification of 
high value compounds with a variety of applications. Chromatography appears to be the most 
favourable downstream processing technique having the highest resolution, whilst also being 
scalable, robust and well characterised (Urthaler, Buchinger and Necina, 2004; Przybylowski et al., 
2007).  Indeed, chromatography is an over-arching term and there are a multitude of variations to 
the technique that achieve separation through various physical and chemical principles. 
1.6.1 Ion Exchange Chromatography  
Ion-exchange chromatography has been widely employed in the intermediate, conditioning stages 
as well as the capture and polishing steps of nanoplexes. The purification strategy relies on the 
high negative surface charge of the target species; for plasmid DNA and most viral vectors, the ζ-
potential in typical aqueous buffers and neutral pH is between -30 to -50 mV(Ledley 1996; Michen 
& Graule 2010) and as such, anion-exchange chromatography is favoured for both vector types 
(Prazeres, Schluep and Cooney, 1998b; Steppert et al., 2016).  
Plasmid DNA binding and elution behaviour on ion-exchangers are also mediated by their 
hydrodynamic size and shape, which will determine their overall net charge and charge density. 
For plasmid DNA, these physiochemical characteristics are a function of their nucleic acid 
composition; nucleic acids in general exhibit a negative charge stemming from their sugar-
phosphate backbone, whilst for supercoiled plasmid DNA (> 1000 bp) regions of charge 
compression can occur in “bend” regions, as a consequence of poly-adenine sequences leading to 
localised dipole and electrostatic interactions with chromatographic supports (Huber, 1998).  
Anion-exchange chromatography offers a number of benefits over other competitive techniques, 
including scalability across preparative and analytical scales and robust media with facile sanitation 
options (as with most chromatographic unit operations), high throughput purification of plasmids 
from low charge density impurities (and in some cases other plasmid DNA isoforms) and a wide 
range of tailored media options, including strong and weak ion-exchangers (Eon-Duval and Burke, 
2004).  
Some of the fundamental drawbacks of anion-exchange chromatography are its low-resolution 
and selectivity, particularly in instances of high concentrations of polyanionic molecules such as 
endotoxins, genomic DNA and RNA3 in the feed stream which can lead to co-elution and 
diminished purity levels of the eluent (Prazeres, Schluep and Cooney, 1998b; Eon-Duval and 
Burke, 2004).  
                                                 
3 A RNA-depleting conditioning step often precedes anion-exchange runs and involves treatment of the feedstock 
with ribonuclease A to degrade the RNA impurities. This does, however, have both cost and regulatory implications 
due to the enzyme being sourced from the bovine pancreas (Hines et al., 1992; Prazeres, Schluep and Cooney, 1998b; 




Fig. 1.12 Theoretical schematic of the electrostatic interaction between a positively charged anion-exchange stationary 
phase (in this case a weak AEX matrix, DEAE) and the negatively charged phosphodiester functional groups of 
double stranded DNA (sourced from Huber 1998).  
In the case of viral vectors, their net surface charge (and thus interaction behaviour with ion-
exchange supports) is derived from their surface composition; this includes the proteins which 
make up their capsid or the overall composition of their envelope (Segura, Kamen and Garnier, 
2011b). Compared to smaller protein therapeutics, viral vectors exhibit stronger binding 
interactions and elute at higher ionic strengths (Trilisky and Lenhoff, 2007). This is likely due to 
an energetics scaling effect, as stronger colloidal interactions will occur with increasing particle size 
(Oberholzer and Lenhoff, 1999) as well as multiple sites for electrostatic interaction on virion 
surfaces due to their complexity and multi-protein composition.  
This enhanced binding capacity allows a wide-range of viral vectors to be purified using anion-
exchange chromatography4 and allows for high ionic loading conditions and salt elution gradients 
to facilitate isolation and fractionation of the target species away from impurities such as host cell 
proteins. However, as with plasmid DNA, viral vectors also suffer from low resolution anion-
exchange runs due to co-elution of similarly densely charged nucleic acids and endotoxins, which 
compete for binding sites on the stationary support (Segura, Kamen and Garnier, 2011b).  
                                                 
4 Table 1 from Segura et al. 2011 provides an apt summary of the applications of AEX chromatography for a variety 
of viral vectors.  
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Interestingly, the ability of AAVs to tolerate substantial pH changes without impacting vector 
functionality (Gruntman et al., 2015) can aid in its purification by ion-exchange chromatography. 
It has been demonstrated that “charge-switching” of the vector surface by pH modulation of the 
viral feedstock (below the vector’s isoelectric point) of AAV serotypes 2, 5 and 8 can result in 
better selectivity and elevated vector yields (Gao et al., 2000; Brument et al., 2002; Davidoff et al., 
2004; Qu et al., 2007). It should be noted that this does not apply to the majority of viral vectors, 
given their high sensitivity to pH changes (Kramberger, Urbas and Štrancar, 2015a).  
One of the major stumbling blocks of ion-exchange purification of both plasmid DNA and viral 
vectors is the low capacity of the resins due to a lack of pore-penetration; indeed this is one of the 
issues this research project aims to address. As a result, anion-exchange chromatography is often 
coupled with sequential chromatographic in a downstream processing train, using alternative 
separation principles including those discussed throughout Section 1.6.  
1.6.2 Affinity Chromatography  
Affinity chromatography offers a more selective and higher resolution approach to the purification 
of nanoplexes. The technique relies on the reversible, specific interaction between a target 
biomolecule and a ligand coupled to a stationary phase. Affinity chromatography utilises the 
nanoplex’s unique biological function or chemical structure and purification is based on highly 
specific molecular recognition between a natural or synthetic ligand and the target species. Elution 
can subsequently be achieved by modification of the ligand-target interaction, through modulation 
of the pH, polarity or ionic strength, or by competitive inhibition by introduction of a second 
ligand (Cuatrecasas, 1970; Platonova and Tennikova, 2005; Janson, 2011).  
1.6.2.1 Triple Helix Affinity Chromatography  
There are a number of variations to affinity chromatography, with applicability across protein, 
plasmid DNA and viral vector purification. In the case of plasmid DNA, Triple-Helix affinity 
chromatography (THAC) has been one of the more prevalent purification techniques; it relies on 
a specific recognition between a triple helix-forming stationary phase-immobilised oligonucleotide 
sequence and a sequence on the double stranded target plasmid. The ligand is usually a single 
stranded homo-pyrimidine oligonucleotide sequence which binds to an inserted, complimentary 
homo-purine sequence on the major groove of the duplex DNA. Molecular recognition between 
thymine on the third strand thymine (T) and adenine-thymine (A.T) base pairs on the plasmid 
facilitate the formation of (T.A.T) triplexes, whilst the complex is stabilised by protonated cytosine 
(C+) interacting with guanine-cytosine (G.C) base pairs to form C+.G.C triplexes. The interaction 
relies on Hoogsteen hydrogen bonding and requires cytosine protonation, thus loading should be 
at mildly acidic pH, followed by dissociation in alkaline buffer (Wils et al., 1997).    
Whilst offering a promising, economical, single-step chromatography step for significantly 
reducing the levels of contaminants such as genomic DNA, RNA and endotoxins two fold, THAC 
is hampered by a number of issues. Triple helix formation kinetics are slow and consequently 
binding steps require ≥ 60 minutes, which limits process throughput. In addition, support binding 
capacity is low (28 µg / ml support) and as such plasmid recovery is low (32% - 62%), whilst some 
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reports also suggest plasmid denaturation and loss of plasmid during wash stages, perhaps due to 
long processing times. To combat this, new resin designs have been employed for THAC, 
including wide-pored resins (Schluep and Cooney, 1998) and thermo-responsive affinity macro-
ligands, which have seen yields jump to 70 – 90% (Costioli et al., 2003).  
1.6.2.2 Protein / Amino Acid – DNA Affinity Chromatography  
An alternative to THAC is the use of protein-DNA affinity chromatography, which facilitates the 
isolation of plasmids from a crude alkaline lysate. The principle is based on a zinc finger (ZF) 
DNA binding protein coupled with a glutathione S-transferase (GST), creating an affinity ligand 
with bi-functionality; here the GST links to a glutathione Sepharose media, whilst the ZF domain 
recognises a 5’-GGGGCGGCT-3’ sequence motif on the target plasmid (Woodgate et al., 2002). 
Elution is achieved by competitive inhibition with the addition of reduced glutathione, resulting 
in high resolution plasmids but with modest yields (23-27%) (Ghose, Forde and Slater, 2004).  
Via a less specific, yet more robust approach, amino acid-DNA affinity chromatography has been 
applied to plasmid DNA purification, facilitated by the use of histidine (Sousa et al., 2006) ligands 
coupled to a stationary support. Histidine affinity chromatography has been demonstrated to 
resolve supercoiled plasmid DNA from host impurities as well as open circular DNA. The 
histidine-base recognition is based on a number of potential interactions, including hydrogen 
bonding, hydrophobic interaction and ring stacking (Luscombe, Laskowski and Thornton, 2001).  
The interaction is particularly specific to supercoiled DNA, likely due to the higher exposure and 
availability of bases (particularly high percentage adenine or guanidine sequences) for interaction, 
relative to the open circular form of DNA (Sousa, Prazeres and Queiroz, 2007). Despite strong 
endotoxin column retention, it is possible to isolate plasmid DNA via an ammonium sulphate 
elution gradient (Sousa et al., 2005, 2006).  
Despite high purities (up to 100%, with removal of gDNA, endotoxins, RNA and host cell 
proteins to acceptable limits) and dynamic binding capacities in the range of 500 µg/ ml support, 
one of the fundamental issues of the technique is the relatively low yield and high salt conditions 
required for elution (Sousa et al. 2008). Studies have suggested that the use of arginine may 
overcome this issue, with better specificity for supercoiled plasmid DNA (stemming from more 
stable, multiple contact point-interactions between arginine and the nucleic acid chains, particularly 
guanine rich sequences) and an option to elute by competitive inhibition with arginine-spiked 
buffer (Sousa et al. 2008).  
1.6.2.3 Thiophilic Aromatic Chromatography 
Thiophilic Aromatic Chromatography (TAC) utilises chromatographic resins functionalised with 
aromatic thioether ligands which are capable of separating plasmid DNA from other DNA 
isoforms. The recognition is suggested to be two-fold; an intercalating π-π hydrophobic interaction 
between the aromatic ring of the thioether ligand and the double helix plasmid DNA. The second 
is possibly the ligand’s sulphur residue behaving as an electron donor to specific nucleotides on 
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the plasmid, allowing a hydrophilic interaction with the highly available phosphate backbone of 
the supercoiled DNA isoform (Sandberg et al., 2004).   
The main drawbacks of the technique are the requirement for high concentrations of ammonium 
sulphate (or other lyotropic salt) to facilitate conformational compression of the nucleic acid 
moieties to enhance separation. Furthermore, elution kinetics can be slow and maximum yields of 
~ 70% are reported; in all, this technique may have application as a polishing step after a series of 
group separation unit operations (Lemmens et al., 2003; Sandberg et al., 2004).  
1.6.2.4 Immobilised Metal Affinity Chromatography  
Immobilised metal affinity chromatography (IMAC) matrices are supports coupled with chelating 
agents, usually nitrilotriacetic acid (NTA) or iminodiacetic acid (IDA) which coordinate transition 
metal ions, such as Co, Zn, Ca, Mg, Ni or Cu in a 2+ oxidation state. Their separation principle 
relies on the relative affinity of target species to the immobilised transition ions; the interaction is 
reversible and can be eluted under gentle conditions using a competitive inhibitor such as 
imidazole or glycine, or by modifying the pH (Chaga, 2001; Murphy et al., 2003; Nastasijevic et al., 
2008).    
IMAC can be utilised in the purification of both plasmid DNA and viral vectors, though by 
different principles. For viral vectors, IMAC has been demonstrated to be a successful bind-and-
elute purification strategy for a number of vectors, including HSV-1 (Jiang et al., 2004), Adenovirus 
(Huyghe et al., 1995), AAV (Koerber et al., 2007), baculovirus  (His-tagged) (Hu et al., 2003) and γ-
retrovirus (McNally et al., 2014), with yields of ~ 50 – 90 % and purities comparable to gradient 
ultracentrifugation. A significant advantage of IMAC is its tolerance to high salt conditions and as 
such, an eluate from a preceding ion-exchange run can be loaded directly onto the column, without 
the need for buffer exchange (Burova and Ioffe, 2005). 
With respect to plasmids, the step aims to remove single stranded nucleic acids and endotoxins 
from the feedstream and thus increase the purity of plasmid DNA in the flow through. The 
technique relies on both endotoxins and RNA having a higher avidity for the chelated metal ion 
(relative to the plasmid DNA) because of a higher availability of aromatic nitrogen (purine – 
adenine and guanine) bases available for interaction (Murphy et al., 2003; Tan et al., 2007). The 
main drawback of the technique is co-elution of genomic DNA, unless a conditioning step 
precedes IMAC to disrupt the gDNA, exposing the aromatic bases for metal affinity interactions 
(Cano et al., 2005).  
1.6.2.5 Viral Affinity Chromatography  
There are a variety of options for affinity chromatography of viral vectors which rely on 
recognition between antigens on the viral capsid or envelope and an immobilised receptor. One 
such example of this is the use of immune-affinity including monoclonal antibodies, such as A20, 
which has a high affinity for AAV-2 capsids (Grimm et al., 1998) or antibody fragments, such as 
the Camelid or Llama single domain heavy chain ligands which make up the commercially available 
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CaptureSelect™ (Thermo Fischer) and AVB Sepharose HP(GE Healthcare) resins, respectively 
and provide high affinity for the capsid proteins of a range of AAV serotypes (Terova et al. 2018). 
An alternative to immune-affinity is the use of either cellufine or heparin sulphate affinity columns, 
exploiting the biological function of the heparin sulphate proteoglycan on viral vector surfaces 
which mediates cellular entry. Recoveries of ~ 70% have been reported on the POROS HE/M 
(PerSeptive Biosystems) heparin affinity column for the AAV-2 vector (Clark et al., 1999), whilst 
applicability has also been demonstrated for retrovirus, HSV and vaccinia viruses (Segura, Kamen 
and Garnier, 2011b). Mucin has also been utilised as an immobilised ligand in the purification of 
AAV type 5 vectors, based on its high 2-3, linked sialic acid content and the fact that, similar to 
heparin, its requirement for cellular entry of AAV-5 (Walters et al., 2001); studies have 
demonstrated higher viral vector yield with mucin conjugated-Sepharose media, than that of 
conventional gradient ultracentrifugation (Auricchio et al., 2001).   
1.6.2.6 Immobilised Metal Affinity Viral Chromatography 
Viruses can also be engineered to display markers which aid in affinity-based capture. Examples 
of this approach include the use of hexahistdine tags displayed on AAV-2 and AAV-8 (yields > 
90%), which have high affinity for Ni-IMAC columns (Koerber et al., 2007), as well as HSV-1 
engineered to present the histidine affinity tag (HAT) peptide which has high avidity in Co-IMAC 
purification columns (Jiang et al., 2004), whilst adenoviruses naturally bind to Zn-IMAC columns 
without genetic modification. In a similar vein, the commonly used biotin-avidin interaction can 
be exploited for viral purification, with vectors biotinylated via metabolic engineering or chemical 
conjugation reactions, the latter achieved through fusion of a viral structural protein to a biotin 
acceptor peptide, though this comes at the risk of compromising viral transduction efficiency 
(Segura, Kamen and Garnier, 2011b).   
In general, affinity chromatography techniques offer highly selective and often significantly high 
resolution separation compared to alternative chromatographic unit operations. They are 
particularly attractive as they present a one-step solution to target purification, which can increase 
product yield, process throughput and is economically favourable.  
The main setbacks of the approach tend to be the fragility of the ligands, their biological source, 
high cost of manufacture and functionalisation, low binding capacities and their occasional 
propensity to leak into the product stream (Gribnau and Tesser, 1974; Lowe, Lowe and Gupta, 
2001; Jozala et al., 2016). Research continues into the development of synthetic ligands to offset 
these limitations and though the manufacture of artificial, biomimetic ligands can be resource-
intensive, this work is justified given the potential long-term economic benefits of robust, one-
step affinity chromatography (Sousa, Prazeres and Queiroz, 2008).  
1.6.3 Hydrophobic Interaction Chromatography  
Hydrophobic interaction chromatography (HIC) exploits differences in the hydrophobicity of 
solutes to achieve efficient separation. Non-polar groups on the biological species interact with 
hydrophobic alkyl or aryl ligands on the stationary phase; loading occurs at high ionic 
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concentrations to displace ordered water molecules which shield both the solute species in the 
mobile phase and the ligands functionalised on the stationary phase, whilst elution is achieved by 
either decreasing the salt concentration or by introduction of an organic solvent to modify the 
polarity of the mobile phase (Queiroz, Tomaz and Cabral, 2001).   
The technique is particularly amenable to the purification of plasmid DNA given the differences 
in hydrophobicity of the plasmid DNA and its other isoforms, as well as other process impurities 
such as endotoxins, with some reporting yields as high as 98% (Bo et al., 2013). Denatured nucleic 
acids from the alkaline lysis step, as well as single stranded nucleic acids, exhibit higher non-polar 
character, whilst lipid A on endotoxins provides a moiety for hydrophobic interaction (Diogo et 
al., 2000; Diogo, Queiroz and Prazeres, 2001).  
The technique has been applied with less success for viral vectors, with low recoveries (5 – 30%) 
reported, likely due to either viral degradation or aggregation resulting from high salt 
concentrations (Burova and Ioffe, 2005; Segura, Kamen and Garnier, 2011b). The high salt 
requirement means the operation is associated with high economical cost as well as adding an 
additional step to re-buffer the product for further purification / formulation, which can further 
reduce yield (Sousa, Prazeres and Queiroz, 2008).   
1.6.4 Reverse Phase Chromatography  
Similar to HIC, reverse phase chromatography (RPC) is dependent on hydrophobic interactions 
between solute species and the stationary phase. The key difference is the higher concentration of 
non-polar ligands on the stationary phase (commonly silica, polystyrene or linear hydrocarbons, 
e.g. C8-C18 are used) and consequently the need for highly non-polar solvents for elution. In order 
to improve separation, ion pairing molecules such as triethylamine or trifluoroacetic acid are used 
to supress charges for ionic interaction and thus enhance hydrophobic interaction with the 
stationary phase (Neville, 1996). 
Due to its particularly high resolution, RPC is mainly used as an analytical tool for assessing the 
quality of purified plasmid or viral vector , though can be run in flow-through mode for preparative 
purification of adenoviral vectors (Green et al., 2002) as well for plasmid DNA, with nearly 100% 
recovery for the latter (Colote, Ferraz and Liautard, 1986).  
One of the main disadvantages of RPC is the requirement for organic solvents, which can be 
costly, volatile and mutagenic, which have process, environmental and regulatory safety 
implications (Yabré et al., 2018). Furthermore, the solvents can denature the biological product 




Fig. 1.13  A schematic detailing the principles of reverse-phase chromatography, whereby it is possible to elute 
species based by modulating the polarity of the mobile phase (from Salvato et al. 2012) .   
1.6.5 Size Exclusion Chromatography  
Size Exclusion Chromatography (SEC), also known as gel filtration, relies on the principle of 
differences in species’ size to achieve separation and given the comparatively large sizes of both 
plasmid DNA and viral vectors compared to other feedstock impurities, the technique serves as a 
useful tool for purification.  
Species will elute from the column in order of size, with smaller and lower molecular weight 
feedstock components such as RNA and endotoxins retained for longer in the column, whilst 
larger targets will elute earlier or even in the earliest void volume of the column, being completely 
excluded from entering the pores of the matrix (Varley et al., 1999). An appropriate media should 
be selected based on the exclusion limit, fractionation range and porosity of the beads, as well as 
the composition of the feedstream and product characteristics, in order to achieve optimum 
separation; for instance, large pored resins such as Sephacryl S-1000 SF (GE Healthcare), which 
has exclusion limits of 1 x 108 Da and 20 kb for globular proteins and linear DNA, respectively, 
can achieve better resolution of target plasmid against similar high molecular weight impurities 
such as genomic DNA (Ferreira et al., 2000), plasmid DNA isoforms (Latulippe and Zydney, 2009), 
proteoglycans and  empty viral capsids (Qu et al., 2015).  
However, to achieve high resolution, there are limitations to loading capacity (usually < 10% of 
the column volume) and linear flow rates (< 15 cm/hr); as such concentration of the feedstock is 
required prior to SEC, which may lead to loss of yield through particle aggregation (Kamen and 
Henry, 2004). Low flow rates lead to long processing times and potential product degradation as 
well as hampering process productivity (Segura, Kamen and Garnier, 2011b).  
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In all, the technique offers a gentle method of purification; there is no media-target chemical 
interaction and as SEC is usually run isocratically, no harsh elution conditions are required. High 
recoveries are regularly achieved and the step also has the additional benefit of being able to buffer 
exchange / de-salt (ideal for post-IEX elution or HIC chromatography) the target species for either 
pre-conditioning for the next unit operation or for formulation. As such, SEC is often used as a 
polishing step towards the end of the downstream processing train, when feed volumes and 
process impurity concentrations are low and re-constitution of the product to its final fill buffer is 
required (Varley et al., 1999; Urthaler, Buchinger and Necina, 2004; Segura, Kamen and Garnier, 
2011b).  
1.7 Developments in Chromatographic Separation  
In order to meet the challenge of purifying higher titre, diverse and more problematic feedstocks 
composed of larger, sensitive and more complex bio-products,  purification platforms such as 
chromatography have had to adapt and evolve. As product titre increases, upstream capacity can 
facilitate this without impacting cost, whilst process bottlenecks and costs shift to downstream 
processing, as its “capacity scales at least linearly with costs due to its physical principles of 
separation” (Gronemeyer, Ditz and Strube, 2014). 
Chromatographic separation accounts for approximately 50% of the total bioprocess cost and 
product yield falls with each additional unit operation added to the bioprocess train (Ladisch, 
2001). Conventional chromatography matrices were custom built for the purification of small 
protein complexes at low concentrations and consequently have to be retro-fitted to purify large 
vectors such as viruses or plasmid DNA (Lyddiatt and O’Sullivan, 1998). This is somewhat of an 
inefficient approach as the diffusivity of a nanoplex such as plasmid DNA is 10-fold lower than a 
typical therapeutic protein (Subramanian, 2012) and given the small pore sizes of conventional 
chromatography beads, large target molecules can only interact with the bead’s surface, 
representing a dramatic loss in binding capacity (Stadler, Lemmens and Nyhammar, 2004).  
This has driven research into new types of chromatography media for the purification of large 
nanoplexes, innovating conventional methodologies and techniques to handle more complex, 
concentrated feed streams, whilst maintaining an economically feasible bioprocess. 
1.7.1 Mixed Mode Chromatography 
One such example of innovative chromatography is the relatively novel mixed-mode (MMC) 
approach. As the name suggests, the stationary phase is composed of ligands which can interact 
with at least two or more interaction types, which often leads to higher selectivity, better retention 
and more favourable yields. The technique grants better flexibility whereby the mobile phase can 
be modulated to promote and tailor specific solute interactions with the stationary phase (Zhang 
and Liu, 2016).   
GE Healthcare’s Capto Adhere MMC resin utilises an N-Benzyl-N-Methyl ethanol amine ligand 
to interact with target species by ionic, hydrogen bonding and hydrophobic interaction. Whilst 
developed for the purification of mAbs, it has also been successfully applied to the purification of 
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plasmid DNA, with dynamic binding capacities of 60 µg/ml of resin reported (Matos, Queiroz 
and Bülow, 2014).  
The technique is particularly amenable to viral purification, as certain viral populations can bind 
to both anion and cation exchange resins at neutral pH; this mixed binding character is due to the 
complex and non-uniform charge distribution of the viral surface, with multiple capsid proteins 
exhibiting both positive and negative charge surface charges. This subsequently aids the removal 
of impurities as a cation-exchanger and anion exchanger will successfully deplete chromosomal 
DNA and host cell proteins, respectively (Gagnon, 1996; Carta and Jungbauer, 2010).  
Hydroxyapatite chromatography (HAC) is another good example of MMC whereby viruses are 
able to bind to both the positively charged calcium ions as well as the negatively charged phosphate 
groups, even at high salt concentrations, with subsequent elution using a phosphate gradient 
(Segura, Kamen and Garnier, 2011b). HAC has been demonstrated for the successful purification 
of HPV-like particles, with yields of 59% reported (Baek et al., 2011).    
One of the main disadvantages of MMC is its time consuming method development and front end 
optimisation requirements. Particularly in the case of pH-sensitive viral vectors, loading and 
elution conditions need to be carefully optimised to avoid compromising product integrity in an 
effort to strive for higher recoveries (Segura, Kamen and Garnier, 2011b; Kramberger, Urbas and 
Štrancar, 2015).  
1.7.2 Membrane & Monolithic Chromatography  
Next generation chromatography materials such as membrane and monolithic systems aim to 
move away from the traditional, beaded chromatography supports, towards macroporous (700 – 
1000 nm) stationary phases with elevated porosities which facilitate better mass transfer 
characteristics through convection and so separation is not limited by diffusion. This also creates 
lower pressure drops across the column, which allows for rapid flow rates and all of this ultimately 
leads to higher binding capacities (Urthaler et al., 2005; McNally et al., 2014).  
The membrane adsorber Mustang Q (Pall Life Sciences), which utilises the same quaternary amine 
as many beaded media, has demonstrated significantly higher binding capacities for both plasmid 
DNA (10 mg/ml resin) (Teeters et al., 2003) and lentiviral vectors (140 fold concentration factor) 
(Kutner et al., 2009). In a similar fashion, monolithic columns, such as BIA’s DEAE Convective 
Interaction Media (CIM), have been used successfully for the purification of nanoplexes, with 
improvements in binding capacity up to 13 mg/ml media for plasmid DNA (Tarmann and 
Jungbauer, 2008) and recoveries of up to 80% for a range of viral particles, including lentivirus 
(Bandeira et al., 2012) and bacteriophages (Kramberger, Urbas and Štrancar, 2015).  
1.7.3 Tentacular Supports 
In an effort to improve the overall surface area for interaction between stationary phases and the 
target solutes, long poly-electrolyte “tentacles”, with elongated spacer arms, have been 
functionalised into supports, aiming to combat the issue of low pore penetration of nanoplexes 
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(Müller, 1990; Merten and Al-Rubeai, 2011). For canine adenoviral vectors, yields of up to 88% 
have been achieved using Merck’s Fractogel propyl-tentacle resins (Segura et al., 2012). Fractogel 
EMD and Sepharose Q XL also have tentacle structures extending from their exterior which could 
facilitate plasmid DNA clustering onto the surface of the beads (Theodossiou, Søndergaard and 
Thomas, 2001).  
1.7.4 Wide-Pore Matrices  
To maximise the interior surface area of beaded media, wide-pored media have also been employed 
to improve the separation and recovery of large nanoplexes. These include Celbeads DEAE and 
PL SAX 4000 Å resins, with pores larger than 500 nm to support better convective mass transfer 
of target species. Celbeads and PL SAX were demonstrated to have static binding capacities of 
1.76 and 5.03 mg/ml resin of plasmid DNA, respectively and correlate well with the available 
surface area for anion-exchange interactions on each media (Tarmann and Jungbauer, 2008).  One 
of the main drawbacks of wide-pored matrices is the risk of comprising the bead’s physical integrity 
and compressibility under packed-bed conditions (Lyddiatt, 2002). 
 
Fig. 1.14  A cartoon depiction of Fractogel’s tentacular arms interaction with target solute species in the mobile 
phase (courtesy of Aldridge 2009).    
1.7.5 Multi-Layer Chromatography Beads 
At the focal point of this research is the employment of multi-layer chromatography matrices 
which aims to isolate nanoplexes using a purification-by-flow-through strategy. Here, a bi-layered 
media is created, whereby large particulates, such as plasmid DNA and viral vectors, are excluded 
from the porous support, whilst smaller impurities are “hoovered” into the core. The first example 
of this methodology was reported by Gustavsson and co-workers, who utilised a multi-column 
approach to achieve 89% recovery of plasmid DNA and 99.5% and 96% removal of RNA and 
proteins, respectively (Gustavsson et al., 2004).   
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Two commercial resins from GE Healthcare, Capto™ Core 700 and 400, were released in 2012 
and 2018, respectively, with the former shown to be effective at purifying H3N2 A influenza from 
egg allantoic fluid, achieving recoveries of 69% and an ovalbumin binding capacity of 14.1 mg /ml 
resin, using a multimodal octylamine ligand functionalised within the core (Blom et al., 2014). An 
alternative approach is that of laminating or coating ion-exchange resins with non-reactive polymer 
such as agarose to create a bi-layered media with an inert shell; whilst this has proven to be 
somewhat effective, there are challenges in achieving a sufficiently thin pellicle around the bead to 
avoid compromising mass transfer of smaller impurities into the core of the bead (Zhang et al., 
2001; Jahanshahi, Zhang and Lyddiatt, 2005; Jahanshahi, Partida-Martinez and Hajizadeh, 2008).  
This approach is particularly effective as it combines the capture and resolution potential of both 
ion-exchange and size-exclusion chromatography, whilst overcoming capacity and volume 
limitations of the unit operations if run in isolation. This allows the bi-layered-based separation to 
be run higher up the downstream processing train and simultaneously cuts down on the number 
of subsequent steps which will help in dramatically improving process efficiency through lowering 
overall cost and increasing process throughput.  
1.8 Virus Mimics 
As research continues into new types of chromatography media to meet the ever increasing 
demands of gene therapy and DNA vaccines, as well as the continual battle to drive down 
bioprocess costs, a key issue is the availability and cost of nanoplex material to optimise with. 
Plasmid DNA and live viral vectors can take days to produce in conventional cell culture systems 
and the cost of manufacture and subsequent purification of sufficient material to test novel 
chromatography systems often becomes an inhibitory factor (Lyddiatt and O’Sullivan, 1998). As 
such there is a niche to create a cheap and readily available nanoplex mimic which can provide 
valuable process data on new chromatographic supports, at a fraction of the price whilst also 
circumventing some of the associated safety concerns of using live viral vectors.  
1.8.1 Inclusion Bodies  
One of the first accounts of surrogate virus mimics was the use of nanoparticulate inclusion bodies 
(IBs) for the optimisation of aqueous two phase systems. The inclusion bodies were harvested 
from E. coli culture producing yeast α-glucosidase, expressed as IBs in the cytoplasm. The IBs were 
found to have similar physiochemical properties to that of adeno- and retro- viruses, in terms of 
hydrodynamic size and buoyant density, with concentration in the order of ~5 x 1014 particles/ml 
produced (Braas et al., 2000; Braas, Walker and Lyddiatt, 2000).  
The main disadvantage of using IBs as viral mimics is the lengthy production time and cost of 
equipment and materials associated with E. coli culture and subsequent cell disruption steps, as well 
as a lack of process control in terms of quantity or physiochemical characteristics of the 




1.8.2 Silica Nanoparticles 
Silica nanoparticles have been utilised as mimics of viruses for a range of applications, including 
as surrogates for rotavirus in characterising filtration media (Pang et al., 2014) and mimicking the 
surface topography of enveloped viruses such as HSV, influenza and HIV to monitor 
nanoparticulate uptake into cells (Niu et al., 2013). Some examples are particularly sophisticated, 
mimicking the protruding capsid proteins of non-enveloped viruses using grafted silica nanotubes 
onto the surface of silica nanoparticles (Wang et al., 2017).  
Silica nanoparticles are advantageous as they can be functionalised with protein and/or DNA 
(Farkas, Varsani and Pang, 2015), in part due to the high density of silanol groups available on 
their surface (Wu, Hung and Mou, 2011). They are also mesoporous and can be “loaded” with 
therapeutic agents such as doxorubicin for drug delivery, particularly in cancer applications 
(Watermann and Brieger, 2017). One of the major drawbacks is the complexity involved in the 
synthesis of silica nanoparticles; the precursor  tetraethyl orthosilicate requires the use of organic 
solvent due to its poor aqueous solubility and the formation of nanoparticles requires toxic 
reagents such as tetramethylammonium hydroxide and concentrated sodium hydroxide solutions 
(Bharti et al., 2015).   
1.8.3 Gold Nanoparticles  
Metallic nanoparticles such as gold have also been extensively characterised for their use as drug 
delivery vehicles (Ghosh et al., 2008; Schäffler et al., 2014), in part due to their high amenability for 
surface functionalisation with protein and DNA (Giljohann et al., 2010; Patel et al., 2010; Tiwari et 
al., 2011; Singh et al., 2012). Gold nanoparticles have also been demonstrated as useful surrogate 
mimics in the characterisation of ion-exchange filtration membranes and are particularly useful 
due to their ease of assaying given their signature surface plasmon resonance band at 520 nm 
(Matsushita et al., 2006).  
Whilst gold nanoparticles are useful mimics of most viral species owing to their strong negative 
surface charge (Giljohann et al., 2010),  the nanoparticles are tricky to synthesise and require boiling 
steps, reflux condensers, as well as reducing agents and expensive hydrogen tetrachloroaurate 
precursor material (Frens, 1973; Zhou et al., 2009; Yeh, Creran and Rotello, 2012). Gold 
nanoparticles are also particularly dense (~19 g/cm3) (Akbulut et al., 2012) and experimental 
observations have found nanoparticles of similar hydrodynamic radius to some viral vectors (~ 
100 nm) readily collapse out of suspension.  
1.8.4 Polymeric Nanoparticles 
Nanoparticles formed using polymeric sub-units have also been successfully applied as mimics of 
a variety of viruses, including bacteriophage (Patel, 2017) and enveloped viruses such as HIV and 
influenza (Lou et al., 2019) using cationic polymers such as azide or cross-linked ε-poly-lysine 
conjugated to 1,2-epoxytetradecane polymers. As with silica nanoparticles, there have been 
demonstrations of conjugated viral “spikes” to the surface of the nanoparticles using a zinc 
coordinate ligand to aid in cell surface recognition and entry for drug delivery (Liu et al., 2018). 
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Much of the focus on polymeric nanoparticles has been their utility as drug delivery vehicles, using 
biocompatible polymers such as polyhydroxyalkanoates (PHA) and poly-(lactic-co-glycolic) acid 
(PGLA) as starting materials for nanoparticle formation (Masood, 2016). As with many synthetic 
nanoparticles, polymer-based nanoparticles are often manufactured using complex emulsion or 
emulsification techniques, including difficult to control polymerisation reactions. Furthermore, 
toxic impurities can accumulate within or in proximity to the nanoparticles, including organic 
solvents, cross-linkers, initiators and monomeric components, which need to be extensively 
dialysed to ensure high levels of nanoparticle purity (Crucho and Barros, 2017).  
1.8.5 Virus-Like Particles 
The gold standard of viral mimics is that of virus-like particles (VLPs), i.e. viral structure proteins 
which form into nanoparticulate structures during expression and can often very closely resemble 
the parent virus, making ideal surrogates. As with most viral vectors, VLPs can also be utilised for 
drug delivery; one example of this is the use of HPV-VLPs utilised as vectors for the delivery of 
pDNA in a murine model, with successful antigen presentation recorded (Malboeuf et al., 2007).   
VLPs can also be modified to aid in targeted drug delivery; a good example of this is where a 
model green fluorescent protein was fused to an SV40 VP2/3 minor protein of a VLP, with 
successful cellular delivery observed (Inoue et al., 2008). Despite their significant advantages and 
close resemblance to bona fide virus species, VLPs do not circumvent some of the key issues of 
using live viral material which justify the need for viral mimics. VLPs, like live viral material, still 
require proper containment and have similar safety concerns to live or attenuated viral material, 
whilst their use is hampered by the same cost and resource requirements given their production in 
cell culture and purification requirements (Lai et al., 2010; Somiya, Liu and Kuroda, 2017).  
1.8.6 Protein Nanoparticles  
One promising approach for the development of appropriate viral vector mimics is the use of 
cross-linked protein nanoparticles. These particles offer a cheap, readily available and easy to 
manufacture mimic and logically fit well given that non-enveloped viruses are encased by a 
composite of proteins and it is this capsid which is responsible for its interaction with purification 
media. 
Much of the work into the formation of protein nanoparticles concerns their use as drug delivery 
vehicles (Mehravar, Jahanshahi and Saghatoleslami, 2009; Lohcharoenkal et al., 2014) and relies 
upon the coacervation/cross-linking method first detailed by Marty et al. in 1978. The focus has 
generally been on albumin-based nanoparticles, due to the high availability of lysine residues 
available for cross-linking  (Habeeb and Hiramoto, 1968), though there have also been accounts 
of the use of self-associating viral protein nanoparticles which have been utilised in vaccine 
applications (López-Sagaseta et al., 2016).  
Work by Langer and co-workers has looked at optimising the desolvation procedure to tailor 
specific sizes of albumin nanoparticles, including organic solvent, protein and cross-linker ratios, 
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as well as experimental conditions such as pH, temperature and ionic strength (Weber et al., 2000; 
Langer et al., 2003, 2008; von Storp et al., 2012). 
Some initial research was carried out by Lyddiatt et al. on characterising chromatography media 
and aqueous two phase systems using both inclusion bodies and BSA nanoparticles as surrogate 
mimics of viruses. The intent was to utilise these mimics in lieu of difficult to attain gene therapy 
vectors to test the chromatography of polymer-coated resins. Here a weak anion-exchange matrix 
(Streamline DEAE, GE Healthcare) was coated with polymer to form a “subtractive adsorbent” 
and subsequently incubated with BSA nanoparticles of 95 nm average size to observe binding 
kinetics (Lyddiatt and O’Sullivan, 1998; Braas, Walker and Lyddiatt, 2000; Zhang et al., 2001; 
Jahanshahi et al., 2004; Jahanshahi, Zhang and Lyddiatt, 2005).  
The research detailed here looks to refine this approach; particularly in the production of viral 
mimics, with more stringent characterisation and systematic variance of processing conditions, to 
tailor nanoparticles to specific virus species and utilise the manufactured surrogates in informing 
the chromatographic performance of a range of novel bi-layered matrices manufactured in house.   
1.9 Nanoplex Market Analysis 
A market appraisal demonstrating the dosage requirement and patient population of an exemplary 
disease state treatable by gene therapy was carried out in order to estimate the requirement of scale 
of manufacture of viral vectors (and thus viral mimics required to characterise chromatography 
media).  
The example disease used in this analysis is Epidermolysis Bullosa (EB), referring to the Phase I 
clinical trial carried out by Siprashvili et al. in 2016. In this study, autologous recessive dystrophic 
epidermolysis bullosa (RDEB) keratinocytes were subjected to retroviral-mediated transduction of 
a COL17A1 gene, contained within an epidermal sheet graft. A 70% transduction efficiency with 
was reported with graft longevity of more than 5 years (Siprashvili et al., 2016). Similar work 
transfecting HEK 293T cells with COL17A1 via retroviral vectors demonstrated high titres of 
2.1 x 106 infectious particles per ml with transduction efficiencies of ~ 60% (Titeux et al., 2010).  
To provide context, a similar study for the treatment of EB employed lentiviral vectors transducing 
human keratinocytes, demonstrating the successful transduction of 107 infectious particles per graft 
and used a green fluorescent protein (GFP) marker to illustrate ~ 50% transduction efficiency 
(Kuhn et al., 2002).  
The estimated prevalence of EB in the United States and Europe is 1 per 100,000 people though 
this continues to grow as it is estimated inherited EB incidence is 8 per 1 million new births (Fine, 
2016; Maldonado-Colin et al., 2017). Estimating the population of the US and Europe at ~ 1 
billion, as per the latest ONS figures, the EB patient population can be approximated to be 
1 x 10^7.  
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If we optimistically assume each patient requires one successful graft once per lifetime, i.e. one 
dose (assuming a 50% transduction efficiency) would be ~ 2 x 107 infectious particles, then 
effectively the total patient population demand for potent, infectious viral particles would be 
~ 2 x 1014, not considering the difficulties and costs of acquiring sufficient skin graft material as 
well as the complications of dose administration, including host-graft rejection. Nonetheless, a 
requirement in the order of 1014 particles for just one disease state is a huge demand in the context 
of bio-processing; particularly when manufacturing a product at such a large scale.  
The associated costs of producing infectious viral particles can be huge; cell culture, clarification, 
viral particle isolation, concentration and purification as well as final formulation and filling and 
also product quality testing and validation (all this even before the transfection stage) are all 
extremely costly; an example from GE Healthcare for producing adenovirus particles for 
therapeutic use estimates a cost per batch of ~ $500,000 to produce a batch in the order of ~ 1013  
viral particles per litre (GE Healthcare, 2019).  
When considering such high costs of manufacture, decisions at each stage of the process design 
are vital and small scale optimisation studies to determine optimum purification trains are crucial. 
Consequently, using protein nanoparticles as a proxy for bona fide viral particles can provide, both 
cheaply and rapidly, informative bioprocess data (e.g. by screening various chromatography media 
and other processing steps for purification performance prior to scale up) to inform important 
decisions with respect to maintaining product integrity, purity and yield and can aid in saving time 
and driving down product costs, as well as improving process throughput to deliver gene and cell 
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MANUFACTURE & CHARACTERISATION OF 




The manufacture of bi-layered chromatography materials intended for the purification of nanoplex 
products for gene therapy and vaccine applications is described. Three size exclusion 
chromatography matrices (Sepharose 6 Fast Flow, Superose 6 Prep Grade, and Superose 12 Prep 
Grade) differing with respect to agarose content, cross-linker chemistry, particle and pore size 
distributions, were transformed into bi-layered supports featuring anion exchange functionalised 
cores and exterior size excluding shells in five sequential steps (i.e. allyl glycidyl ether activation, 
partial bromination, hydrolysis, full bromination, ligand coupling). 
In the second ‘key’ step two different approaches were employed to balance bromine’s reaction 
with immobilised allyl functions against its depth of diffusion into the porous allylated matrices, 
namely the inclusion of the viscosity enhancing agents (sucrose or Carbopol® 934) in the reaction 
cocktail, and single mode microwave heating immediately prior to adding the reactant.  
The resulting media were evaluated with respect to loss of surface and core binding, cf. control Q-
coupled anion exchangers constructed from the same base matrices in finite bath studies allied 
with confocal scanning laser microscopic imaging. Plasmid DNA and bovine serum albumin in 
native and fluorescently tagged forms were respectively as surface and core binding probes, and 
the binding selectivities of different bi-layered support materials were compared by means of a 
simple selectivity ratio (μg of pDNA bound per mg of BSA bound); the lower the number the 
more selective the support. 
Whilst all media received 10% bromination to achieve a thin, inert shell, the best performing bi-
layered matrix was Superose 6 Prep Grade manufactured using the viscosity enhanced 64% sucrose 
route, which displayed a similar core binding capacity to the control, with nearly 100% reduction 
in surface plasmid DNA binding, recording an overall SI of 0.04. Sepharose 6 Fast Flow bi-layered 
resins manufactured using the microwave 60% ethylene glycol route displayed strong plasmid 
binding and only a 50% reduction compared to the control, with confocal images suggesting 
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Table 2.6 Langmuir fitting parameters for each of the control samples for the plasmid DNA 
probe.  
Table 2.7 Quantitation of allyl group generation and partial bromination achieved accompanied 






2.1 Introduction   
2.1.1 Gene Therapy & Vaccines 
In recent times, the landscape of bioprocessing has seen a gradual transition to manufacturing 
more complex bio-products. Traditionally, a bioprocess train would be challenged with a simple, 
small protein to purify from a typical bacterial cell culture (Jozala, Geraldes, Tundisi, Feitosa, 
Breyer, Cardoso, Mazzola, Oliveira-Nascimento, Rangel-Yagui, Magalhães, Oliveira, Pessoa, et al., 
2016). The modern bioprocess is now challenged with being more flexible, as well as having to 
handle more convoluted feed streams from a variety of cell lines, with the task of removing 
problematic contaminants and impurities, as well as isolating larger, more sensitive and ultimately 
more complex products (Morenweiser, 2005; Tran, 2011; Kramberger, Urbas and Štrancar, 2015b).  
The industry has also found itself having to adapt to meet new demands, responding to global 
epidemics and new diseases, having to be flexible whilst generating product at large scale and at 
high throughput. An example of this was the 2009 influenza A (H1N1) pandemic, which prompted 
the World Health Organisation to lead a revolution in vaccine-based therapeutic production 
platforms (Li and Qiu, 2013).  
The advent of gene therapy and novel, more effective vaccine treatments has seen a rise in the 
development of large, complex and fragile therapeutic products (Collins and Thrasher, 2014). This 
grouping will often include macromolecular drug delivery vehicles such as viral vectors, virus-like 
particles, as well as non-viral vectors such as supercoiled plasmid DNA. Whilst boasting huge 
potential, especially in the field of cancer treatment, these nanoplex products pose a number of 
similar challenges in the context of a bioprocess purification chain (Wold and Toth, 2013).  
The burden of separating a complex and large bio-product runs throughout the bioprocess, from 
fermentation harvest to primary clarification, intermediate purification, capture and finally 
polishing. The large size of the macromolecules,  their shear sensitive nature, the existence of 
similarly sized and charged non-functional vectors as well as the need to maintain potency (or 
virulence in the case of viral vectors) all require thought when designing an efficient separation 
train for gene therapy vectors. Isolation and capture methods for these molecules require 
continuous development to maintain standards of purity, efficacy and safety (Segura, Kamen and 
Garnier, 2011b).  
2.1.2 Downstream Processing   
Whilst the entire bioprocess requires adaptation to gene therapy considerations, this work will 
focus primarily downstream of a cell harvest, as this tends to be the main cost driver for most 
conventional bioprocesses, as well as the bottleneck in terms of process throughput (Chon and 
Zarbis-Papastoitsis, 2011; Gronemeyer, Ditz and Strube, 2014; Kelley, 2016).  
Downstream processing unit operations have traditionally been optimised for the purification and 
isolation of small protein targets. They therefore require re-engineering and re-thinking to cope 
with the challenges presented by novel gene therapy products. As Levy et al. 2000 put it; “By 
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acknowledging these challenges and using bio-process design information based on fundamental 
studies of the system’s properties, it will be possible to create efficient and consistent processes 
for these materials.”  
Whilst there are a number of downstream operations that could be considered, including initial 
disruption by centrifugation, homogenisation or cell lysis, and primary clarification steps such as 
filtration, the focus of this thesis chapter is on re-thinking the chromatographic-based steps. This 
particular unit is considered the most expensive (in terms of capital and consumables) and in many 
scenarios suffers from low productivity and high amounts of waste generation and thus directing 
optimisation will likely have a large impact on the overall process efficiency (Przybycien et al., 
2004). 
2.1.3 Chromatographic Separation 
In order to achieve high resolution separation of gene therapy vectors, at least one or usually 
multiple chromatography steps are an essential requirement especially for clinical application 
(Horn et al., 1995). 
In the case of viral vectors and plasmid DNA, mis-folded and non-functional structures (usually 
of a similar size to the target product) require removal from the feed-stream. Therapeutic 
formulations for plasmid DNA should also be free of host genomic DNA (<0.05 µg/ µg plasmid 
DNA), host proteins, endotoxins (<0.1 EU/ µg plasmid DNA) as well as being over 90% super-
coiled to be considered  an effective gene therapy product (Prazeres et al., 2001; Diogo, Queiroz 
and Prazeres, 2005). 
In the case of viral vectors, removal of host cell proteins and host DNA (<10 ng/dose), cell debris 
(product dependent) and product-related impurities, such as empty capsids (non-detectable) and 
viral DNA (100 pg / 109 vectors) require removal from a cell lysate feedstock (Wright, 2008b). In 
addition, due consideration to infectivity and potency is needed when assessing the bulk drug 
substance prior to clinical application.  
In the context of industrial downstream processing, chromatographic methods employing 
orthogonal separation principles of size, charge, hydrophobicity and specific interaction are utilised 
in complementary manner to separate and purify target species free of impurities. For instance, 
size exclusion chromatography (SEC) utilises differences in molecular size or hydrodynamic radius, 
whereas  adsorptive techniques such as ion exchange adsorption chromatography (IEC), 
hydrophobic interaction chromatography (HIC) and affinity chromatography (AC) respectively 
exploit differences in electrostatic charge, hydrophobicity and molecular recognition to achieve 
separation of targets and impurities. 
2.1.4 Novel Chromatography Designs  
In an effort to meet ever-changing demands in downstream processing, recent years have seen a 
plethora of advancements in chromatography systems directed towards new media designs, 
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column and ligand designs and operational modes, all aimed at improving product yields, purity 
and process economics (Lowe, Lowe and Gupta, 2001; Orr et al., 2013).  
Expanded Bed Adsorption (EBA) was a novel development in the ‘90s which was an innovative 
method of operating a column, effectively as a fluidised bed where the beads are suspended in a 
stable manner under up-flow. EBA, due to its larger void volumes, allow for applications much 
earlier in the purification chain and handling of solid-containing feedstocks (Arpanaei et al., 2010; 
Tran, 2011).  
Monolith columns and membrane adsorbers aim to move away from the traditional beaded 
column towards a macro-porous support design which facilitate larger surface areas and better 
mass transfer mechanistics, improving binding capacity and flow rates (Segura, Kamen and 
Garnier, 2011b). There has also been work done on expanding the surface area of beads through 
designs with surface pellicular/tentacular ligands; aiming to improve resolution, throughput and 
recovery (Janzen et al., 1990), as well as the development of environmentally responsive polymer 
brushes to aid elution, cleaning and column lifetimes (Cao et al., 2015; Müller et al., 2013; Willett, 
2009).  
2.1.5 Multi-Layer Chromatography Designs  
A major challenge of a crude virus feedstock is that many of the impurities bear similar physical 
and chemical characteristics to the target vector and therefore multiple columns of different 
functionality are required in succession to achieve target purity and acceptable yields. Generally, 
SEC and IEC chromatography are the most prevalent and arguably most successful techniques at 
accommodating the issues associated with nanoplex purification. Their popularity stems from their 
ability to their scalability options, as well as being able to resolve target vectors away from similarly 
sized, mis-folded vectors and smaller feed impurities based on both molecular weight and charge 
variations (Gustavsson et al., 2004b; Burova and Ioffe, 2005; Kramberger, Urbas and Štrancar, 
2015b).  
IEC, on its own, affords poor binding capacities for large viral vectors, mainly due to intra-particle 
mass transfer issues, lack of pore penetration and weak binding. SEC, though good for separating 
molecules of disparate molecular size is unable to separate similarly sized yet misfolded and non-
functioning vectors from one another, nor resolve different charge isoforms of DNA from target 
plasmid species (Latulippe and Zydney, 2009).  
One major innovation built on by the work described in this chapter is the development of 
chromatography media that combine two different separation principles, namely SEC and IEC, 
spatially separated from one another within the same chromatographic bead (Arpanaei et al., 2010; 
Daniak et al., 2002; Gustavsson et al., 2004a,b; Jahanshahi et al., 2008; Karnchanasri, 2013; 
Olszewski et al., 2013; Viloria-Cols et al., 2004) In this fashion, it should be possible to 
synergistically exploit the benefits of both technologies, namely high capacities (for small, charged 
molecules), throughput and scalability options achievable through ion-exchange, whilst also 
achieving separation of  large vectors from smaller impurities by size exclusion (the former species 
eluting in the void volume), whilst eliminating the inherent disadvantages of employing IEC 
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followed by SEC, i.e. low target binding capacities of ion exchangers, and, limited sample volume 
and throughput of SEC (Gustavsson et al., 2004a; Karnchanasri, 2013).   
 
Fig. 2.1 Purification of a virus feed-stream using beads with a bi-layered architecture (Courtesy of Dr. E. 
Theodosiou). 
If successful, such bi-layered SEC-IEC matrices would enable efficient and gentle separation of 
nanoplex products from smaller chemically similar contaminants in a ‘one column-one bead’ based 
process (Fig. 2.1), that promises overall improvements in process performance, costs (capital and 
consumables) and sustainability without compromising on purity or yield. 
In 2012, GE Healthcare released its first multi-modal chromatography core/shell media, Capto™ 
Core 700, designed specifically for intermediate purification and polishing of viruses and other 
large biomolecules, and recently introduced its second, Capto™ Core 400. Both of these media5 
feature bi-layered architectures with t thin ‘inert’ shells with 700 kDa or 400 kDa size-exclusion 
cut off, too small for large therapeutic viruses to penetrate and bind (i.e. 700 kDa for Capto™ 
Core 700 and 400 kDa for Capto™ Core 400). The cores of both media are functionalised with 
octylamine, a hydrophobic and positively charged mixed-mode ligand that binds protein impurities 
small enough to pass through the shell strongly over a broad pH and ionic strength range. In this 
way, the target virus is isolated in the flow through fraction, whilst the smaller impurities are 
“hoovered” into the core, as illustrated in Fig. 2.1.  
This “negative mode” chromatography (Jahanshahi, Partida-Martinez and Hajizadeh, 2008b) is 
particularly useful for large nanoplex vectors due to limited interaction with the functionalised 
matrix, allowing for a “gentler” form of purification and limited impact on the structure and 
activity of the final vector product (Burova and Ioffe, 2005). There a number of routes to achieve 
a “negative mode” beaded bi-layered architecture featuring a “non-stick” surface and 
functionalised core.  
The earliest reports employed coating strategies. For example, Daniak and co-workers (2002) 
grafted a small pored Amberlite anion exchange adsorbent with  an oppositely charged ‘cell 
                                                 
5 GE Healthcare claims for these multimodal chromatography media include: significant improvements in productivity 
cf. SEC through the use of 100 fold higher sample loads and significantly higher flow rates; and straightforward 

























































































repelling’ layer of poly(acrylic acid) physically adsorbed and subsequently cross-linked in situ, 
whereas others (Viloria-Cols, Hatti-Kaul and Mattiasson, 2004; Jahanshahi, Partida-Martinez and 
Hajizadeh, 2008b) simply laminated adsorbent particles with  thick underivatised layers of agarose. 
Lamination is the more promising approach for eradicating surface binding of large species to 
meso-macroporous chromatography media appropriate for unhindered binding of protein. 
However, a major stumbling block is the difficulty in casting sufficiently thin, uniform and 
mechanically sound shells; failure to do so will result in reduced protein mass transfer and binding 
capacity, compromised inertness and performance life span (Arpanaei et al., 2010).  
An alternative approach is to modify the surface of the chromatography matrix using plasma6 
irradiation. Arpanaei and co-workers (2010) modified the exterior surfaces of the rigid ‘gel-in-a-
shell’ expanded bed adsorbent Q HyperZ with low temperature low pressure plasmas in a purpose 
built reactor. The authors detailed two different approaches namely ‘plasma etching and oxidation’ 
and ‘plasma polymerization coating’. The former approach involved shaving anion exchange 
ligands away from the exterior surface and replacing with polar oxygen containing functions using 
an air plasma, whilst the latter involved using various monomers in an argon carrier gas to coat 
exterior surface bound ligands beneath an anti-fouling polymer layer.  
Whilst showing much promise, the broad application of low temperature low pressure plasma for 
the modification of chromatography media seems unlikely, as it requires base matrices that can 
tolerate gross removal of water without suffering major changes to their physical dimensions7.  
Though eminently suitable for rigid ‘gel-in-a shell’ or ‘controlled pore glass’ media it is not 
appropriate for softer porous hydrogels (90+% water), which represent the bulk of 
chromatography materials used for macromolecule separation today. In recognition of this, 
Olszewski et al. (2013)  turned to cold atmospheric plasma and devised a means to modify 
chromatography adsorbents in their wet state (Fig. 2.2). In their work reactive oxygen species 
(ROS) transported to aqueous slurries of anion exchange media (Q Sepharose Fast Flow, DEAE 
Sepharose Fast Flow and EMD Fractogel DEAE) by ignited He-O2 plasma gas bubbles in an 
underwater fluidised bed reactor (Fig. 2c and 2d), reduced the ‘surface’ binding of large plasmid 
DNA molecules threefold at the expense of a ~10% drop in core protein binding.  
                                                 
6 Fisher (2002) defines plasma is defined as a partially or wholly ionized medium consisting of electrons, ions and 
possibly neutrals and photons. 
7 Low pressure plasma treatment requires application of a vacuum which draws out all of the water. In the case of soft 
hydrogel based matrices this will lead to (i) support collapse; and (ii) on rehydration post treatment to deep 




Fig. 2.2 Schematics illustrating: a) plasma surface etching of a chromatography adsorbent bead to form a bi-layered bi-
functional support; b) sectioning of through the resulting support to highlight the ‘ligand free’ exterior and ligand functionalised 
core; and c) the underwater fluidized bed plasma treatment reactor operating with He-O2 at an input power of 3.7 W. Also 
shown d) is a photograph of the plasma reactor in operation (Taken from Olszewski et al., 2013).  
Various chemical methods to manufacture bilayered chromatography media, exploiting fast 
reactions of anchored groups with limiting amounts of soluble reactant,  have been described 
(Bergstrom et al.,1998; Gustavsson et al.,2004; Berg et al., 2005; Karnchanasri, 2013).  Gustavsson 
and coworkers (2004) and Karnchanasri (2013) created a bi-layered SEC-AEC matrices from 
Sephacryl S500 HR and Sepharose CL6B base matrices respectively using broadly similar five step 
processes. Briefly, these involved activation of un-functionalised base matrix with allyl glycidyl 
ether (AGE) to introduce allyl groups throughout the matrix (step 1). In the next crucial step (step 
2) a calculated amount of bromine sufficient to react with a small percentage (typically <30%) of 
the AGE activated support’s allyl groups is added.  
 
The electrophilic addition reaction of bromine with the carbon-carbon double bonds of the 
anchored allyl functions as it diffuses into the porous support gives rise to a bilayered support 
intermediate featuring an allylated core and brominated shell. As the reaction of allyl groups with 
bromine is carried out in aqueous solution the brominated reaction product is a likely a mixture of 
bromoalcohol (bromohydrin) and dibromo adducts, the precise balance of these is dependent both 
on the rate of addition and the additives present (Zabicky, 1986). In the subsequent steps bromo-
alkyl groups in the outer layer are hydrolysed to render it inert (step 3), the allylated core is then 
reacted with excess bromine (step 4), before finally coupling the strong anion exchange quaternary 
amine ligand, tri-methylamine chloride, Q (step 5).  
 
In her work, Karnchansri (2013) employed two different reaction-diffusion balancing approaches 
to reduce the thickness of the outer inert layer, namely increasing the viscosity of the reaction 
solvent so as to slow the reactant’s diffusion into the activated support, and microwave heating 
immediately prior to adding the reactant to preferentially increase bromine’s reaction with 
anchored allyl functions over its diffusion into the allylated support. These two techniques are 




Fig. 2.3 Schematic illustrating the manufacture of functionalised, bi-layered beads using an AGE 
Activation/Partial Bromination technique (Reproduced courtesy of Prof. O.R.T. Thomas).  
There is an incentive to improve the fabrication process to create bilayered media with outer shells 
as thin, uniform and inert as possible, so that maximal functionalised core volume and therefore 
binding capacity for the smaller contaminants is achieved.  
Accordingly, the work described in this chapter builds on Karnchanasri’s (2013) studies on the 
manufacture of bi-layered SEC-IEC supports by viscosity-enhanced (VE) and microwave-assisted 
(MW) reaction-diffusion (R-D) balancing approaches, with the aim of generating agarose-based 
SEC-IEC media with improved binding selectivity. Specifically, this involved replacing 
Karnchanasri’s chosen starting material, Sepharose CL6B, with three different matrices (Sepharose 
6 Fast Flow, Superose 6 Prep Grade, Superose 12 Prep Grade) differing with respect to particle 
size distribution, agarose content and pore size distribution, and cross-linker chemistry (Cao et al., 
2015), and screening four different reaction solvents (ethylene glycol, water, 64% w/v sucrose in 
water, 0.4% w/v Carbopol® 934 in water). The resulting supports were initially evaluated in static 
binding studies conducted with plasmid DNA and BSA as probes for surface and core binding 
respectively, and subsequently by fluorescent microscopy using the same probes tagged with 
fluorophores to localise binding to the chromatographic beads.   
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2.2 Materials & Methods 
2.2.1 Materials & Reagents  
Sepharose 6 Fast Flow, Superose 6 Prep Grade and Superose 12 Prep Grade and PD-10 desalting 
columns were purchased from GE Healthcare (Uppsala, Sweden).  
Bromine (99.9%), sodium hydroxide pellets (NaOH), trimethylamine chloride (Q), sodium 
borohydride (99%) (NaBH4), dimethyl sulphoxide (DMSO), ethylene glycol, allyl glycidyl ether 
(AGE), sodium chloride (NaCl), triaminomethane hydrochloride (100 X Concentrate), potassium 
bromate (0.1 M), methanol (99%), ethanol (99%), sucrose and bovine serum albumin (BSA) were 
obtained from Sigma-Aldrich (Poole, UK).  
Carbopol® 934 was procured from Lubrizol (Wickliffe, USA), whilst sulphuric acid (99%), Syto™ 
9 Green Fluorescent Nucleic Acid Stain, Texas Red-X succinimidyl ester and Bicinchoninic Acid 
assay Protein Kit (BCA) were obtained from Fisher Scientific (Loughborough, UK). Buffers and 
all aqueous solutions were prepared using electro-deioinised water (resistivity 5–15 MΩ-cm at 22ºC) 
purified by a Sartorius Arium® Advanced EDI Pure Water System (Sartorius AG, Göttingen, 
Germany). 
2.2.2 Allyl Glycidyl Ether Activation  
Ten millilitre (wet settled bed volume) portions of size exclusion matrix were washed copiously 
(300 ml) with deionised water under vacuum on a sintered glass filter funnel to remove traces of 
20% (v/v) ethanol storage buffer. The matrix was then transferred to a 100 ml conical flask 
containing 12.5 mg of NaBH4. Four millilitres of 50% (w/v) NaOH was then added before 
incubating at 50 °C in a reciprocating (170 rpm) water bath for 1 h. The supports were then suction 
dried under vacuum before being transferred back to the flask and adding 8.5 ml of AGE, sealing 
and placing in a reciprocating (170 rpm) water bath held at 40 °C for 16 h. Thereafter the AGE-
activated matrices were recovered from the reaction liquor on a sintered glass filter funnel, before 
washing sequentially with deionised water, 70% (v/v) ethanol and finally deionised water, and 
storing in 20% (v/v) ethanol at 4 °C in tightly sealed tubes.  
2.2.3 Partial Bromination  
Three millilitre aliquots of allylated chromatography matrices were recovered from storage solution 
by vacuum filtration and then equilibrated in either 64% (w/v) sucrose or 0.4% (w/v) Carbopol® 
for viscosity enhanced reaction-diffusion balancing, or 60% (v/v) ethylene glycol or water for 
microwave enhanced reaction-diffusion balancing reactions.  After equilibration the matrices were 
subsequently suction dried before slurrying with 2.4 ml of fresh solution (to yield 55% v/v slurries) 
and transferring to 100 ml conical flasks.  
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2.2.3.1 Viscosity Enhanced Partial Bromination 
Calculated amounts (based on a bromine assay) of pure liquid bromine were supplied to each 
conical flask to brominate 10% of the allyl groups present in each AGE-activated support (Table 
2.1). After addition of the bromine solution, the flasks were immediately sealed and shaken 
manually until the orange colour disappeared.   
Table 2.1 Allyl contents introduced into commercial agarose base matrices following reaction with 
AGE.  
Matrix Allyl content 
(μmol/ml) 
AGE-activated Sepharose 6 Fast 
Flow 
326.6 ± 26.5 
(n=9) 
AGE-activated Superose 6 Prep 
Grade 
348.4 ± 14.4 
(n=9) 
AGE-activated Superose 12 Prep 
Grade 
477.6 ± 20.5 
(n=9) 
AGE-activated Sepharose CL6B 315.7 ± 25.5 
(n=24) 
  
2.2.3.2 Microwave Assisted Partial Bromination 
A conical flask was placed into the cavity of a CEM Discover S Class mono-modal microwave 
reactor8 (CEM Corporation, NC, USA). A magnetic stirrer flea was placed inside the flask to allow 
for uniform mixing before the heating the vessel to a stable 83 °C. This was carried out at 60 W 
and under “dynamic” heating mode, where the target temperature can be maintained via a feedback 
loop. Importantly, the round bottom glass flask behaves as an insulator and is transparent to the 
microwaves. The buffers and chromatography beads both act as absorbers of microwave radiation 
(Jones et al., 2002).  
As with the viscosity enhanced protocol in Section 2.2.3.1, a calculated amount of bromine was 
added to achieve 10% bromination. The flask was immediately sealed and the temperature and 
                                                 
8 This microwave reactor has numerous benefits including accurate temperature and pressure control as well as 
magnetic stirring to facilitate a well-mixed suspension and avoidance of hot and cold spots in the vessel (Wiesbrock et 
al., 2004; Karnchanasri, 2013). 
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mixing held for a further 60 s and until the orange colour had disappeared, as per the set up 
described in Fig. 2.3.  
 
Fig. 2.3 Mode of operation of the CEM Microwave reactor with chromatography resin mixed with microwave 
assisting buffer to form a slurry. This is placed in the round bottom flask prior to heating (Reproduced from 
Karnchanasri, 2013).  
The supports were subsequently washed with copious amounts of deionised water under vacuum 
on a sintered glass filter funnel. A small aliquot (~20 µL) of each partially brominated sample was 
taken for a bromine assay to measure the actual level of bromination achieved.  
2.2.4 Hydrolysis  
Portions (2.9 ml) of partially brominated supports were then transferred to a conical flask 
containing 11.2 mg of NaBH4 and subsequently 314 µL of 50% (w/v) NaOH and 1 ml of deionised 
water were added before sealing and placing the flask in a 40 °C water bath agitating at 170 rpm 
for 18 h.  
After 18 h, matrices were washed with deionised water under vacuum on a sintered glass filter 
funnel in order to remove excess hydrolysing agents.  
2.2.5 Full Bromination & Q Coupling  
The entire portion of vacuum dried, hydrolysed support was aliquoted into a fresh conical flask 
containing 4 ml before steady drop-wise addition of bromine until a permanent orange colour was 
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observed. The matrix was then washed with deionised water under vacuum on a sintered glass 
filter funnel. 
The fully brominated supports were transferred to a fresh screw cap tube containing 11.2 mg of 
NaBH4, before adding 730 µL of 50% (w/v) NaOH and 1.22 ml of deionised water and gently 
mixing the suspension on a vortex mixer operated at low speed. Once mixed, 1.87 ml of 65% 
(w/v) trimethylamine chloride (a quaternary amine, strong anion exchange ligand) was added 
before immediately sealing and left to agitate end-over-end on an SB1 blood tube rotator (Stuart 
Scientific, Stone, UK) for 18 h.  
The modified supports were then thoroughly washed through two cycles of water and 1 M NaCl 
before being stored at 4°C in 20% (v/v) ethanol. Control supports were created by skipping the 
partial bromination and hydrolysis steps and performing full bromination and Q coupling directly 
after AGE activation.  
2.2.6 Particle Size Distribution  
The particle size distributions of the three base SEC matrices used to create the modified supports 
were measured using a Malvern Mastersizer 2000 (Malvern Instruments, Malvern, UK). Briefly, 
10% (v/v) matrix slurries were made up in deionised water before mixing and gradual addition 
into the unit’s dispersion tank. Addition of the support was terminated once laser obscuration had 
reached a pre-determined optimum of 12% (a background measurement is taken prior to addition 
of the sample). The Malvern Mastersizer 2000 software then generates a particle size distribution 
based on the scattering pattern of the sample.  
2.2.7 Viscosity Measurements  
The rheology of the viscosity enhancing solutions was measured using a Bohlin C-VOR 
Rheometer (Malvern Instruments, Malvern, UK), equipped with a 60 mm, 1° angle stainless steel 
cone geometry. Changes in viscosity were measured at a shear rate of 10 s-1.  
2.2.8 Temperature Stability  
The temperature stability of a variety of solvents and base size exclusion chromatography media, 
whilst in the microwave cavity, were assessed with respect to time. 3 ml of each solvent or 5.4 ml 
of chromatography resin slurry (55% v/v) were aliquoted into a round bottom flask with a 
magnetic stirrer before being placed into the microwave reactor, with a target temperature set at 
83 °C and held for a further minute once reached.  
2.2.9 Bromine Stability  
In order to assess the stability of the highly reactive bromine species in either the viscosity 
enhancing or microwave reaction solutions, a starting concentration of 200 mM bromine in each 
solution was made up to a volume of 3 ml. Loss of bromine in solution was assessed by measuring, 
in triplicate, the absorbance at 410 nm, at 3 min intervals over a time course of 21 min. For this, 
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an Evolution 300 UV-Vis Spectrophotometer (Thermo Scientific, Stafford, UK) and a High 
Precision Quartz Cell (Hellma Analytics, Müllheim, Switzerland), with each solution blanked 
against an identical solution without the added bromine.  
2.2.10 Plasmid Production 
Plasmid DNA material (used to characterise the chromatography resins) were generated in a 5 L 
batch Escherichia coli fermentation. Briefly, 10 ml aliquots of Luria Bertani (LB) broth supplemented 
with 50 µg/ml ampicillin were inoculated with a single fresh colony of Escherichia coli DH5α cells, 
contained within them the 26.7 kbp plasmid pIT14 (from pBR322-P170), kindly donated by Dr. 
Eirini Theodosiou, Aston University, Birmingham, UK. This inoculum culture was shaken 
overnight at 37 °C and 220 rpm before a 1 ml aliquot was added to a 250 ml shake flask containing 
80 ml of LB broth (containing 50 µg/ml ampicillin) and left to agitate on an orbital shaker at 37°C 
and 220 rpm.  
Once an optical density (OD600nm) of 0.6 was reached (measured on an Evolution 300 UV-Vis 
Spectrophotometer (Thermo Scientific, Stafford, UK)), the inoculum was transferred to a 5 L 
Fermac 310/60 fermenter (Electrolab, Tewkesbury, UK) with an impeller equipped with two six-
blade Rushton turbines for agitation. Growth media for the fermentation was an LB broth with a 
final volume of 4 L, with 30 g/L glucose, 100 µg/ml ampicillin and antifoam (polypropylene glycol) 
added as required.  
The batch fermentation employed starting conditions of 37°C, controlled by a cooling jacket, an 
agitator speed of 400 rpm and air–flow rate set at 1.0 VVM. The pH was maintained at 7.0 
throughout the fermentation by the automatic addition of 5 M NaOH. The dissolved oxygen 
tension (DOT) was controlled above 50% by adjusting either the aeration or agitation. After the 
cells reached late exponential phase, the fermentation was terminated and cells harvested.  
Plasmid DNA (pDNA) was isolated using a QIAGEN Plasmid Giga Kit (QIAGEN, Manchester, 
UK) with pDNA quality and concentrations measured using a UV Spectrophotometric assay (see 
Section 2.3.6 for more details).  
Cell harvest was achieved via centrifugation in a J2-21 centrifuge (Beckman, High Wycombe, UK) 
operated at 6,000 rpm (4°C) for 15 min. The cell paste weighed 24.5 g (wet cell weight), 1.17 g/L 
dry cell weight, generating a plasmid yield of 615 µg/g of wet cell weight; the paste and purified 
pDNA was stored at -20°C.  
2.2.11 Analysis  
2.2.11.1 Environmental Electron Scanning Electron Microscopy   
Chromatography resins were visualised via environmental electron scanning microscopy with the 
assistance of Paul Stanley and Theresa Morris, both from the School of Metallurgy & Materials, 
University of Birmingham. Chromatography resins were subjected to a methanol drying gradient; 
re-suspended firstly in a 50% methanol solution, before gently spinning down and re-buffering 
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(over 3 cycles) into consecutively increasing methanol concentrations until suspended in 100% dry 
methanol (100% methanol & molecular sieve).  
The beads were subsequently mounted onto aluminium stubs prior to critical point drying and 
sputter coating with a thin layer of platinum to minimise the effect of charging and improve image 
contrast. Imaging of the samples was on a Philips XL-30 FEG Environmental Scanning Electron 
Microscope (FEI Company, OR, USA).  
2.2.11.2 Bromine Assay 
Supports were quantified for the allyl groups generated during AGE activation and post-partial 
bromination by exposing 0.05 ml of vacuum dried resin to 1 ml of an acidified bromine solution 
(sulphuric acid 0.5 M, potassium bromate 0.1 M ratio, 2: 1). The acidified bromine solution was 
prepared by mixing the two reagents, then left for 10 min to develop a strong yellow colour, before 
mixing again by inversion then adding to the chromatographic supports.  
Once added, the suspension was mixed by vortex for 10 s and subsequently separated by a brief 
centrifugation spin (1000 rpm, 10 s) using a benchtop micro-centrifuge (VWR MiniStar Silverline, 
VWR International, Radnor, USA). Each supernatant was removed and measured for absorbance 
at 410 nm using an Evolution 300 UV-Vis Spectrophotometer (Thermo Scientific, Stafford, UK) 
and a High Precision Quartz Cell (Hellma Analytics, Müllheim, Switzerland).  
0.5 M sulphuric acid was utilised as a diluent and a blank and the original, underivatised size 
exclusion matrices used as controls. A bromine standard curve was constructed by measuring the 
absorbance at 410 nm of a range of bromine stock solutions ranging from 0 – 10 mM, made up in 
sulphuric acid. The moles of bromine disappearing from solution corresponds, in a 1 : 1 ratio, with 
the moles of allyl groups present on the chromatography supports, relative to the underivatised 
control supports. This assay is repeated after the partial bromination step on a small aliquot of 
sample to assess the level of partial bromination achieved. 
108 
 
2.2.11.3   Static Binding Studies 
Chromatography matrices were washed with deionised water before buffer exchanging and 
equilibrated 3 times in 1 ml of 0.05 M Tris-HCl (pH 8.0), such that the settled bed volume of the 
resin was 0.05 ml. Each chromatography matrix was then exposed to either a 5 mg/ml BSA or a 
15 µg/ml pIT14 plasmid solution and allowed to incubate for 2 h with end-over-end mixing on 
an SB1 blood tube rotator (Bibby Scientific Ltd., Stone, UK). Binding isotherms for plasmid DNA 
were generated for the control matrices by applying an identical methodology but by varying the 







Fig. 2.4 A general schematic of the methodology involved in a finite bath study starting from resin in a 20% 
Ethanol storage buffer through to isolation of the pelleted beads for microscopy and analysis of supernatant 
concentrations for mass balancing and calculations of static binding capacities.  
Each loading condition would be measured in triplicate to determine averages and standard 
deviations. Post-incubation, the chromatography matrices were pelleted via a brief 10 s pulse of 
500 rpm on a benchtop micro-centrifuge (VWR MiniStar Silverline, VWR International, Radnor, 
USA). The supernatants were carefully removed for quantification for either protein or pDNA 
concentration using a bicinchoninic acid (BCA) or ultraviolet (UV) spectrophotometric assay, 
respectively.  
2.2.11.4 Bicinchoninic Acid Assay for Protein  
For protein quantitation during the static binding studies, a Pierce® Bicinchoninic acid (BCA) 
assay kit was purchased from Thermo Fischer (Thermo Scientific, Stafford, UK). Working reagent 
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was prepared by mixing 50 parts reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic 
acid, sodium tartrate in 0.1 M sodium hydroxide) with 1 part reagent B (4% cupric sulphate). The 
microplate protocol was applied, whereby 0.2 ml of the working reagent was aliquoted into each 
well of a 96-well microplate (Thermo Scientific, Stafford, UK) before addition of a 0.025 ml 
protein sample to each individual well. Samples were aspirated three times to ensure uniform 
mixing in each well before the plate was sealed and placed in a microplate shaker-incubator for 30 
mins at 350 rpm at 37°C (Infors AG, Bottmingen, Switzerland).  
For each plate analysed, a BSA standard curve was generated by including standards in the 
(absorbance linear) range of 0.02 - 2 mg/ml and thus the concentration of the unknown protein 
sample on the plate can be ascertained based on the well’s absorbance reading. Absorbance values 
were read at 562 nm using a Synergy Neo2 HTS Multi-Mode Microplate Reader (BioTek, Vermont, 
USA).  
2.2.11.5 Ultraviolet Spectrophotometric Assay for pDNA  
Plasmid DNA (pDNA) was assessed for both quality and concentration using an Ultraviolet 
Spectrophotometric assay with the aid of a quartz cuvette; an Evolution 300 UV-Vis 
Spectrophotometer (Thermo Scientific, Stafford, UK) and a High Precision Quartz Cell (Hellma 
Analytics, Müllheim, Switzerland) were both used in this methodology. 
Plasmid DNA stocks and aliquots were assessed for concentration, purity and salt carryover by 
measuring absorbance values at four different wavelengths; 230, 260, 280 and 320 nm, each in 
triplicate. Samples were diluted to within the linear range of the instrument (absorbance values 
between 0.1-0.9) to allow for accurate determination of concentration.  
2.2.11.6 Confocal Laser Scanning Microscopy  
In order to compliment the static binding data for the two probes, BSA and pDNA, confocal laser 
scanning microscopy has been employed to provide images of the spatial location of the probes 
with respect to the optically transparent chromatography beads.  
To achieve this, the two probes need to be conjugated with fluorescent dyes prior to contact with 
the chromatography matrices. BSA was conjugated with Texas-Red X; briefly, 1 mg of Texas Red-
X dye was dissolved in 1 ml DMSO and incubated for one hour at room temperature on an SB1 
blood tube rotator.  
Using a molar dye/protein ratio of 1: 100 (Hubbuch and Kula, 2008), aliquots of BSA were tagged 
by incubating with the dye in a light-free environment (an Eppendorf wrapped in aluminium foil) 
for one hour with end-over-end mixing on an SB1 blood rotator. The dye/protein ratio was chosen 
to reduce the contribution of emitted fluorescence re-adsorption to light attenuation as well as to 
allow for efficient purification of conjugated protein-dye complexes.  
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Free, un-conjugated dye was separated from the bio-conjugated proteins using single-use PD-10 
desalting columns packed with Sephadex G-25 media (GE Healthcare, Uppsala, Sweden) operated 
in gravity flow mode.  
With respect to the pDNA, Syto™ 9 was utilised as a minor groove-binding fluorescent dye. Here 
the probe was added to a pDNA stock solution with a dye/DNA ratio of 1 dye molecule to 100 
DNA base pairs, as per the manufacturer recommendations. No purification was required in the 
case of pDNA-Syto™ 9 conjugates due to the fact that the intensity of fluorescence is much higher 
when the Syto™ 9 probe is conjugated to pDNA, than free, unconjugated Syto™ 9 in solution.  
Therefore, by adjusting fluorescent detection settings on the microscope, it is possible to threshold 
such that any fluorescence from the unconjugated dye is eliminated. Effects of dye labelling on 
protein surface characteristics (and therefore binding behaviour) were assessed using cation 
exchange chromatography and isoelectric focussing, as discussed in Chapter III. Dye labelling 
effects on pDNA were adjudged to be minimal as trials were conducted to assess differences 
between labelling of the pDNA pre- and post- binding to chromatography resin, for which little 
difference in fluorescent intensity was found.  
 
Fig. 2.5 Schematic illustrating how a three-dimensional image can be generated using a confocal microscope. The 
confocal pinhole facilitates focus on individual layers, as thin as 1 µm, and these slices can be scanned and 
subsequently re-stacked to construct a three dimensional image of a bead with a fluorescent probe bound (Hubbuch 
and Kula, 2008).  
Protein-dye and pDNA-dye conjugates were then diluted to the correct loading concentrations 
before being used in static binding studies as described in 2.2.11.3, running in parallel to the non-
fluorescent, quantitative static binding studies. As opposed to isolating the supernatant after 
centrifugation, the chromatography matrix pellet was washed three times in fresh TRIS-HCl buffer 
in order to remove non-specific bound and free BSA or pDNA in solution. For sample 
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preparation, resin, in 5 µL aliquots, were pipetted onto microscope slides, with a cover slip carefully 
placed on top to hold the samples in place. Precautions were taken to minimise fluorophore 
bleaching; the use of low laser powers, minimised exposure times and use of aluminium foil to 
cover all samples during conjugation, transition and storage. 
Image acquisition was conducted using a confocal laser scanning microscope (Leica TCS SPE 
102A, Leica Microsystems, GmbH, Mannheim, Germany) equipped with krypton/argon (λ = 488 
nm and λ = 568 nm) and helium/neon (λ = 633 nm) lasers. A 40x oil emersion objective was used 
to image the samples on a microscope slide with a cover slip. For the BSA experiments, samples 
were excited with the 568 laser to visualise the protein species labelled with Texas Red-X 
(excitation and emission maxima at λ = 596 and 615 nm, respectively).  For the pDNA 
experiments, the 488 nm was used for excitation as Syto™ 9 has excitation and emission maxima 
at λ = 485 and 498 nm, respectively.  
Images were captured and processed using the Leica Application Suite (LAS X) software (Version 
1.9) (Leica Microsystems, GmbH). Settings were optimised to ensure minimisation of auto-
fluorescence (see Fig. 2.17), including laser intensity, signal gain, offset and emission detection 
range. Control tests ensured that the detected emitted light intensity was within detection range 
and blank tests ensured no auto-fluorescence of untagged protein or the chromatography resin 
(Close et al., 2013). Emission detection ranges for the photomultiplier tube, gain, offset and 
thresholds were all optimised on the confocal microscopy software in order to enhance 
fluorescence detection and remained constant within a set method across all samples to allow for 
effective comparative across samples. For each sample type, five beads were imaged to confirm 
similar binding characteristics were taking place across the entire sample set. 
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2.3 Results & Discussion 
2.3.1 Particle Size Distribution  
In order to assess the distribution of bead sizes within each commercial resin suspension, a light 
scattering technique was employed using a Mastersizer 2000. This provided insight into both a 
distribution of size as well as an average particle diameter. This allowed a comparison to be made 
between the stated sizes from the manufacturer and the actual size characteristics of the batch used 
for the manufacturing of the bi-layered materials as well as a direct comparison between the bead 
types used in this study. 
 
Fig. 2.6 Particle size distribution data for a) the commercial multi-functional resin, Capto™ Core 700 and the 











Table 2.2 A comparison of the three chromatography resins used as base matrices in this study, compared with 
a), a commercial, bi-functional matrices currently on the market. Mean particle sizes of the experimental Mastersizer 
data are compared against the manufacturers stated values. Comparison of the relative pore sizes are also given, with 
molecular weight exclusion limits (kDa) and base pairs (bp) quoted for globular proteins and DNA, respectively 









   (kDa)          (nm)                (bp) 
a) Capto™ Core 700 85 90 700 35  - 
b) Superose 12 Prep 
Grade 
30 30 – 40 300 25 150 
c) Sepharose 6 Fast Flow 100 90 4, 000 50 165 
d) Superose 6 Prep Grade 35 30 - 40 5,000   40 450 
The mean particle size of the cumulative volume distribution corroborate with manufacturer’s 
specifications. 
The three size exclusion base matrices vary in terms of their average sizes and pore structure, with 
the Superose media tending to have much smaller average wet bead diameters than the Sepharose 
or Capto™ media. While information on the Capto™ media is currently proprietary, the Superose 
and Sepharose media are both beaded media formed by cooling aqueous agarose in a non-polar 
organic solvent and subsequently covalently cross-linking the repeating 1-3-linked β-D galactose 
and 1,4-linked 3,6-anhydro-α-L-galactose polymers to preserve the 3-D network fibre structure, as 
indicated in Fig. 2.7 (Nweke, McCartney and Bracewell, 2017).  
The percentage of agarose in the matrix gives rise to the nomenclature of the bead (e.g. Sepharose 
6 Fast Flow and Superose 6 PG are composed of 6% agarose, whereas Superose 12 has an agarose 
content of 12%) and this has an impact on the porosity of the media, allowing for varied selectivity 
and exclusion limits, as well as flow, hydrophilicity and rigidity properties. Thus the media have 
different applications, (Pääkkönen, Pursiainen and Lajunen, 2010). These characteristics will be 






Fig. 2.7 Molecular structure of cross-linked agarose which form the basic make up of all three starting matrices 
used in this study (Sigma Aldrich, 2018b).  
2.3.2 Viscosity Measurements 
As this methodology of viscosity enhanced reaction diffusion balancing had been the subject of a 
PhD thesis within the O.R.T Thomas Research Group prior to commencement of this work. The 
thesis titled “Bi-layered chromatography matrices for the purification of biological nanoplexes” 
(Karnchanasri, 2013) looked to optimise the conditions of viscosity enhanced- and microwave 
assisted- manufacture of bi-layered beads using the chromatography media Sepharose CL-6B. It is 
important to note at this stage that as Sepharose CL-6B was not available at the point of 
manufacture, Sepharose 6 Fast Flow was employed as a comparative point of reference; the two 
are similar though Sepharose 6 is mechanically stronger. They both have a similar average particle 
size and are both 6% cross-linked agarose particles, spherical in shape and employ the same cross-
linker, but only differ in the extent of cross-linking.   
Karnchanasri (2013) optimised the viscosity enhanced protocol, concluding that the optimal bi-
layered Sepharose CL-6B based matrix was achieved using a viscosity of 0.007 Pa.s at 25°C during 
the partial bromination step (corresponding to the use of 64% (w/v) sucrose in water). This work 
looks to build upon this, replicating these viscosity conditions with both sucrose and a new 
viscosity enhancer, Carbopol® 934, employed at a concentration of 0.4% (w/v) in water to give a 
viscosity (0.006 Pa.s, 25 °C) close to Karnchanasri’s (2013) identified optimum. . Carbopol® 934 
is a poly-acrylic acid polymer cross-linked with allyl ethers of sucrose and was chosen as an 
alternative to sucrose to circumvent some of Karnachanasri’s observations of sucrose 
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consumption of bromine; it was hypothesised that Carbopol would be less reactive with bromine 
and therefore aid in the partial bromination of the resins.  
2.3.3 Viscosity Enhanced & Microwave Assisted Partial Bromination 
In order to achieve a thin outer shell and maximise the functionalised core within each bead, the 
partial bromination step can be improved by either viscosity enhancement or microwave assistance 
(Karncahnasri, 2013). The principles behind these techniques are based on the Arrhenius, 
Arrhenius-Guzman and Stokes-Einstein equations.  






Equation 2: Arrhenius-Guzman Equation 





Equation 3: Stokes-Einstein Equation 





 k is the rate constant (mol/L.s)  
 A is the frequency factor (the frequency of collisions between reactant molecules) (s-1) 
 Ea is the activation energy (~238.7 kJ/mol for the bromination of a double bond (Islam 
and Poirier, 2007)  
 R is the universal gas constant (8.314 J /K.mol) 
 T is the absolute temperature (K) 
 η is viscosity (kg/m.s) 
 B is an empirical constant dependent on the properties of the liquid (Morris, 1992) 
 D is the diffusion coefficient (m2 /s) 
 kB is the Boltzmann constant (1.381 x 10-23 J/K)(kB = R ÷ NA, where NA is the Avogadro 
constant, 6.022 x 10-23) (Reeks, 2011) 




Evidently, adjusting the viscosity of the reaction buffer will lower the diffusion coefficient, the 
magnitude of which is dependent on the empirical constant, B, of the experimental buffer chosen. 
Theoretically, the more viscous the solution, the slower the diffusion coefficient and thus diffusion 
into the chromatography resin is limited, allowing bromination of the carbon-carbon double bond 
to occur only at or near the surface of the matrix, given a finite amount of bromine is added.  
 
Fig. 2.8 a) Relationship between viscosity & temperature for deionised water. b) k/D – temperature profile for 
the bromination of a double bond (Gilbert and Martin, 2011).  
With regards to microwave assisted reaction-diffusion balancing, Equation 1 highlights an increase 
in the rate constant with increasing experimental temperature. This allows the bromination 
reaction to occur quicker and thus the loaded bromine is used up at a faster rate. Increasing 
temperature was conducted by microwave heating due to its multiple advantages over conventional 
heating. These include better energy transfer, faster heating and cooling rates, higher energy 
efficiency due to minimal heat loss and uniform sample heating, as well as minimal heat conduction 
within the vessel (Agrawal, 1998) and finally relatively lower capital costs (Pääkkönen, Pursiainen 
and Lajunen, 2010). 
The fundamentals of microwave heating are dependent on the interaction of the sample with an 
electromagnetic field, either by dipole rotation or ionic conduction. The former represents an 
interaction where heat is generated through polar molecules attempting to align in the alternating 
electrical field. Heat generation is strongly dependent on the dipole involved and the radiation 
frequency, in a range (usually 2.45 GHz) whereby the dipole can respond to the oscillating field 
but is not able to accurately align with it, causing a phase difference between the field orientation 
and the dipole orientation, resulting in a loss of energy from the dipole through molecular friction, 
collisions and dielectric heating (Kappe, Stadler and Dallinger, 2012).  
Heat generation can also occur through ionic conduction, whereby the electrical field generates 
ionic movement as dissolved charged particles oscillate and attempt to align to the oscillating field, 
causing increased molecular collisions with neighbouring atoms, resulting in agitation and 
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ultimately conversion of the electrical energy to heat. Of the two mechanisms, ionic conduction is 
the more prominent though both work in tandem to effect sample heating (Thostenson and Chou, 
1999; Lidström et al., 2001; Hayes, 2002; Kappe, Stadler and Dallinger, 2012; Karnchanasri, 2013).  
The efficiency of heating a material in an electromagnetic field is dependent on its dielectric loss 
tangent (tan δ), which is a measure of reactance (resistance in a capacitor), i.e. how well the material 
is able to absorb microwave radiation. The dielectric loss tangent is described with respect to two 
parameters, as per Equation 4.  
Equation 4: 





 ε” is the dielectric loss factor (imaginary permittivity) which indicates the efficiency of 
dissipation of electrical energy as heat within the bulk substance 
 ε’ is the dielectric constant (real permittivity) which illustrates how polarisable the 
molecules in the sample are and thus describes the proportion of microwave radiation 
reflected vs. the proportion absorbed 
To achieve an efficient conversion of microwave energy into thermal energy, a significant dielectric 
loss factor and low dielectric constant are required to achieve a high tan δ value, which would 
result in efficient absorption and rapid heating. Classification of materials, with respect to tan δ, 
are listed as follows: high (tan δ > 0.5), medium (0.5 > tan δ > 0.1) and low (0.1 > tan δ) (Kappe, 
Stadler and Dallinger, 2012).  
Table 2.2 illustrates some of the buffers available for microwave-assisted bi-layering and their 
respective tan δ values. Previous work by Karnchanasri (2013) looked to optimise the partial 
bromination step with microwave assistance using water as a buffer system. The work presented 
here expands on this by using different microwave-assisting buffers alongside water, as elaborated 
upon in section 2.3.3 and 2.3.5.  
However, a balance is required as, although increasing temperature increases the reaction rate, it 
also increases both the diffusion rate directly and also reduces the buffer’s viscosity (Fig. 2.8 a)) 
which will also increase the diffusion rate. Karnchanasri (2013) demonstrated that the relationship 
between reaction/diffusion rates (k/D) for the bromination reaction has a greater impact on the 
rate of reaction when the temperature is ramped to 60 °C or higher, whilst diffusion remains 
relatively constant above this temperature. Therefore operating above 60 °C for the microwave 
reactions should theoretically have a minimal impact on diffusion whilst greatly improving the rate 
of formation of bromo-alkyl groups on the surface of the beads, forming a thin and well defined 
shell on the surface.  
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Table 2.3 Comparison table of the loss tangents of a variety of potential microwave-assisted reaction buffers (2.45 
GHz, 20 °C) (Kappe, Stadler and Dallinger, 2012). 
Solvent tan δ Solvent tan δ 




DMSO 0.825 Water 0.123 
2-Propanol 0.799 Chlorobenzene 0.101 
Formic Acid 0.722 Chloroform 0.091 
Methanol 0.659 Acetonitrile 0.062 
Nitrobenzene 0.589 Ethyl Acetate 0.059 
1-Butanol 0.571 Acetone 0.054 
2-Butanol 0.447 Tetrahydrofuran 0.047 
1,2-Dichlorobenzene 0.280 Dichloromethane 0.042 
1-Methyl-2-
pyrrolidone 
0.275 Toluene 0.040 
Acetic Acid 0.174 Hexane 0.020 
 
It is important to note that the tan δ values for polysaccharides (i.e. chromatography matrices) are 
much higher than any of the solvent and under heating conditions the polar, hydroxyl-rich 
polysaccharides will interact directly with the microwaves, heating up much faster than the solvent. 
This will result in a tight banding effect as the bromine should, in theory, react instantly upon 
contact with the outer surface of the bead.  
2.3.4 Bromine Stability  
A point of concern during the partial and full bromination studies was the stability of the highly 
reactive bromine in its buffer prior to contact with the chromatography resins. For this reason, a 
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number of different solvents were assessed for their efficacy as a buffer system for the bromination 
reactions. The aim was to find a buffer that is minimally oxidised by bromine allowing more of the 
originally loaded bromine to interact with the chromatography media and not the buffer.  
 
Fig. 2.9 Bromine stability studies with respect to time on a) viscosity-enhanced; -□- 80% Sucrose, -■- 64% 
Sucrose, -○- 0.4% Carbopol 934 and b) microwave-assisted reaction buffers; -●- 85% Ethylene Glycol, -△- 
60% Ethylene Glycol, -▲- 50% Ethylene Glycol, -▽- 60% DMSO & -▼- Deionised Water.  
To this end, a range of concentrations of a variety of buffers were assessed for bromine loss with 
respect to time, as illustrated in Fig. 2.9, aiming to optimise buffer conditions for a) viscosity 
enhancement and b) microwave assisted partial bromination.  
Although bromine stability studies were conducted at room temperature (conditions for the 
viscosity enhanced reactions only), and assumption is made that the trends observed would be a 
useful indicator (and in fact be accelerated at the experimental 83 °C temperature) for the 
microwave reactions too. 
Equation 5: 
𝐵𝑟2 + 𝐻2𝑂 ⇌ 𝐻𝐵𝑟 + 𝐻𝑂𝐵𝑟  
 
Equation 6: 
𝐻𝐵𝑟 + 𝑅𝑂𝐻 ⇌ 𝑅𝐵𝑟 + 𝐻2𝑂 
Equation 7: 
𝐻𝐵𝑟 ⇌ 𝐻+ + 𝐵𝑟− 
With respect to the viscosity-enhanced buffers, it is evident that sucrose-based buffers are a better 
choice with respect to bromine loss, with 80% (w/v) sucrose performing the better of the two 
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over the time course. This can be attributed to the % water in the buffer causing increased loss of 
bromine, as shown in Equation 5 (Willett, 2009). The higher the percentage of water, the further 
the equilibrium will be pushed towards the formation of hydrogen bromide, ultimately limiting the 
reactivity of bromine with the allyl groups on the chromatographic supports. Carbopol® 934 in 
Fig. 2.9 a) and 50% ethylene glycol in b) performed comparatively poorly as the buffers are also 
aqueous and the water content is the main contributor responsible for the loss of bromine.  
Equation 5 goes some way to illustrating the performance of high percentage of sucrose and also 
ethylene glycol buffers, with respect to time (Gilbert and Martin, 2011). Not only is lack of water 
a factor here, but also the interaction with the additional hydroxyl residues of the sucrose and 
ethylene glycol molecules, whereby in aqueous solution, sucrose, Carbopol, ethylene glycol and 
DMSO are being oxidised by bromine.  
 
Fig. 2.10 The monomer molecular structure of Carbopol® 934(GenScript, 2018; Thermo Fisher Scientific, 
2018b). 
Equation 6 highlights the equilibrium between the dissociation of HBr in solution allowing Br- 
ions to carry out nucleophilic attacks of carbon-carbon double bonds, such as the carbonyl group 
in Carbopol® 934 and the sulfinyl group in DMSO, explaining why the two also performed poorly 
(Aida et al., 1976; Willett, 2009). To further confirm this, 85% (v/v) DMSO was also assessed for 
bromine stability, however within seconds the absorbance value dropped below the linear range 
of the instrument indicating a rapid and high loss of bromine in solution. Whilst ethylene glycol 
has two terminal hydroxyl groups which can also undergo nucleophilic attack from the bromine, 
Fig. 2.9 indicates that bromine’s reactivity is higher with DMSO’s sulfinyl double bond.  
What is also interesting to note is the peak and trough behaviour of some buffers with respect to 
time and it is hypothesised that this is as result of pre-equilibrium fluctuations as bromine dissolves 
in solution and fluctuates between HBr, HOBr and Br- and back to Br2 until equilibrium is reached.  
According to Karnchanasri (2013), bromine concentration would stabilise to ~ 50% of the original 
loaded concentration after between 5 – 50 min after point of addition, depending on the buffer 
system used. Identifying suitable buffer conditions which limit this bromine interaction and 
maintains bromine concentration in a stable fashion for an extended period of time is vital. This 
will facilitate the use of smaller volumes of pure bromine whilst improving the efficiency of the 
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partial bromination step by having more bromine in solution readily available to interact with the 
allyl groups on the surface of the resin rather than being used up by the buffer.  
Karnchanasri (2013) also determined 64% (w/v) sucrose as optimal for partial bromination, in 
essence demonstrating that a balance must be struck between viscosity enhancement of the 
layering action and bromine loss within the buffer.  In addition, the time from adding bromine to 
the slurry of beads and buffer is < 5 min until complete mixing occurs, whereby there is little 
oxidation of the buffer and bromine concentration is relatively constant for the two sucrose-based 
buffers. For these reasons, 64% (w/v) sucrose was carried forward for the bi-layering reactions. 
Similarly, for the microwave assisted reactions, 60% (v/v) ethylene glycol was found to hold 
bromine in the most stable fashion up to 5 min and therefore was also carried forward. This is 
further justified after testing various microwave assisting buffers for temperature ramp times and 
stability, as described in 2.3.5. 
Carbopol® 934 (at a concentration of 0.4% w/v in water), despite having a similar viscosity to 
64% (w/v) aqueous solution of sucrose, whilst envisaged to perform better with respect to 
bromine stability, was still carried forward as an alternative viscosity enhancing reaction buffer. Its 
high water content, carbonyl and hydroxyl groups are possible explanations for its high bromine 
reactivity. The rationale for including it in subsequent experiments derives from the idea that due 
to its highly aqueous composition, it would be easy to remove the viscosity enhancer from the 
chromatography beads after the viscosity enhancing step. This has been an issue in screening tests 
for other viscosity enhancers in the past, whereby washing of the beads would take hours and 
remnants of viscosity enhancing buffers would remain and thus influence subsequent probe 
binding experiments.  
2.3.5 Temperature Stability & Ramping Rates 
Karnchanasri demonstrated that the optimum condition for bi-layering via microwave assistance 
was 83°C, which would allow the bromination reaction to proceed at a quicker rate before the 
reagent diffuses into the core of the bead, thus creating a thin, outer shell.  
With this in mind, a variety of buffers were assessed in temperature ramping experiments. Figs 
2.11 and 2.12 highlight the performance of the various buffers and chromatography media, 
respectively. Varying concentrations of ethylene glycol and DMSO were assessed for ramp rates 
based on their high tan δ values, as detailed in Table 2.2. Deionised water has the lowest tangential 
loss factor and also the lowest dipole moment, compared to both ethylene glycol and DMSO (1.85, 





Fig. 2.11 Temperature ramps and stability assessment for microwave assisting buffers composed of varying 
percentages of a) Ethylene Glycol and b) DMSO. Symbols: -□- 50% Ethylene Glycol, -■- 60% Ethylene Glycol, 
-○- 85% Ethylene Glycol, -●- 100% Ethylene Glycol, -△- 50% DMSO, -▲- 60% DMSO, -▽- 100% 
DMSO & -▼- Deionised Water.  
It is important to note that, as per Equation 4, tan δ will decrease upon heating and has varying 
impacts dependent on the solvent; for instance at 25 °C, DMSO has the highest dielectric loss, 
however between 55 – 90 °C, ethylene glycol has a higher overall dielectric loss tangent. This is 
because the reduction in the dielectric loss factor (ε”), which occurs upon heating, is less for 
ethylene glycol compared to DMSO (Horikoshi and Serpone, 2013). This is likely due to the 
molecular composition of the two solvents, with the two hydroxyl groups present on an ethylene 
glycol molecule contributing heavily to its high heat capacity.  This explains the deceleration in 
ramping rate for all samples at ~ 55 °C and also the slow ramp rate for 100% DMSO, compared 
to its ethylene glycol equivalent.  
Hydrophobic interactions from the non-polar groups, the formation of cage structures by water 
molecules around these groups, as well as extensive hydrogen bonding and low entropy can 
increase the apparent heat capacity of the solution, facilitating rapid heat adsorption and rapid 
temperature ramps (Sturtevant, 1977). These interactions are all readily available in both ethylene 
glycol and DMSO, corroborating their accelerated heat adsorption characteristics.   
In the case of both Fig. 2.11 a) and b), however, a 60% concentration of the aqueous buffer reached 
the target temperature the quickest, indicating a balance is required between high tangential loss 
values and the aqueous nature of the buffer. It is likely that 60% provides an optimum compromise 
condition whereby the water content of the buffer allows sufficient formation of structural cages 
around the non-polar groups in the solvent whilst also providing a high enough dipole moment 





Fig. 2.12 Temperature ramps of the chromatography matrices in a) Deionised water and b) 60% ethylene glycol. 
Symbols: -□- Sepharose 6 Fast Flow, -■- Superose 6 Prep Grade, -○- Superose 12 Prep Grade.  
Another important experimental factor to take into consideration is the temperature ramp rates of 
the chromatography bead slurries in both deionised water and 60% ethylene glycol. Fig. 2.7 
indicates the general dipole-rich molecular structure of all of the cross-linked agarose 
chromatography beads and all of them had relatively similar temperature ramp profiles.  
The three supports heated in 60% ethylene glycol experienced the quickest temperature ramp, 
reaching target temperature between 66 – 71 s, compared to deionised water, which had resins 
reaching target temperature between 71 – 80 s. This trend was also observed previously when 
considering the heating profiles of the buffers on their own. The existence of the two terminal 
hydroxyl groups and high tan δ value of ethylene glycol relative to deionised water aids in 
explaining these observations.   
Despite their different size distributions, surface area: volume ratios and degrees of cross-linking, 
the temperature profiles for the three resins in each buffer were comparatively similar. Superose 
12 Prep Grade performing the best in deionised water and Sepharose 6 Fast Flow in 60% ethylene 
glycol, but with < 10 s to reach target temperature between each resin type for each buffer set.  
An ideal microwave assisting buffer would meet the criteria of balancing a rapid ramp rate whilst 
having low bromine interaction. For the microwave reaction buffers, ethylene glycol was carried 
forward for the partial bromination reactions alongside deionised water, whilst DMSO was 
discarded due to its strong interaction with bromine, as detailed in section 2.3.3. 60% ethylene 
glycol was selected due its ability to retain bromine in a stable fashion up to five minutes as well 
as its temperature stability and rapid ramp rate to 83 °C. This information becomes relevant when 
considering the process at a larger bioprocess scale, as a rapid temperature ramp can result in 
higher process throughput and ultimately a more economical bioprocess. In addition, limiting 
bromine interaction can save litres of buffer and limit the use of expensive and dangerous pure 
liquid bromine.  
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Table 2.4 The experimental design matrix. Summary table highlighting the sample types and treatment conditions 
carried forward for static binding assessment. 
Base Resins Bi-layering Technique Buffer 
 
Sepharose 6 Fast Flow 
Superose 6 Prep Grade 
Superose 12 Prep Grade 
 
Viscosity Enhanced 
64 % Sucrose 
0.4% Carbopol® 934 
 
Microwave Assisted 
60% Ethylene Glycol 
Deionised Water  
With all the above taken into consideration with regard to screening for bromine stability, 
temperature ramping and buffer characteristics, Table 2.3 details the partial bromination 
conditions selected to create the bi-layered matrices. All three resins undergo the same partial 
bromination step, aiming for 10% bromination based on allyl quantification from the bromine 
assay with only the technique (viscosity enhanced or microwave assisted) and buffer being varied 
as points of comparison.  
2.3.6 Plasmid Map & Quality Assessment  
In order to critically assess the binding performance of the bi-layered matrices, the manufactured 
chromatography beads were challenged with two biological probes. The first of these was bovine 
serum albumin, a negatively charged (at pH 7.2) protein capable of infiltrating the entirety of the 
porous structure of all three media and binding to the ligands present.  
The second is plasmid DNA, a much larger probe (see Fig. 2.14) which exceeds the exclusion limit 
of all three pores structures of the bi-layered resins (see Table 2.2).  However, plasmid DNA is 
also negatively charged and will therefore bind to conventional anion exchange matrices as well as 
any surface ligands that still exist due to an inefficient bi-layering step. Both probes are well 
characterised and commonly used as analytical tools in the field of purification (Janzen et al., 1990; 
Ljunglöf and Thömmes, 1998; Gustavsson et al., 2004a; Latulippe and Zydney, 2009; Arpanaei et 
al., 2010); bovine serum albumin is often used as a “model” protein while adsorption data 
concerning plasmid DNA is especially useful due to its use as a vector for gene therapy and DNA 
vaccines (Lara, Ramírez and Wunderlich, 2012; Scholz and Wagner, 2012).  
Whilst the protein probe can be purchased as a lyophilised powder, the plasmid DNA is generated 
through a recombinant Escherichia coli fermentation and purified after cell lysis using filtration and 





Fig. 2.13 Plasmid map of pBR322-P170 used as probe for assessing the chromatography media manufactured in-
house.   
Post-purification, it is important to determine the purity of the plasmid DNA sample and to ensure 
little co-purification of impurities such as cell debris, host cell proteins, RNA, organic compounds 
and chaotropic salts. This can be done using a spectrophotometric assay, across wavelengths 230, 
260, 280 and 320 nm and using Equations 8, 9 & 10 to determine concentration, purity and salt 
carryover, respectively.  
Equation 8: 
𝑝𝐷𝑁𝐴 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝜇𝑔/𝑚𝑙)  = (𝐴260 −  𝐴320) × 50 (𝜇𝑔/𝑚𝑙)  
Equation 9: 












The results of this assay are summarised in Table 2.5 and are a result of scanning a small aliquot 
of the plasmid DNA stock (1 ml of the 270 ml stock created). According to Promega (Madison, 
NI, USA), an acceptable value for purity will lie in the range of 1.7 – 2. A value of 1.84 indicates 
low to no levels of impurities in the purified stock; the low absorbance value at 320 nm also 
emphasises low turbidity and further reaffirms the lack of presence of impurities in solution. 
Furthermore, Promega also state that ratios of 1.5 and greater indicate low to no carryover of 
organic compounds or chaotropic salts from the purification process, thus a ratio of 2.27 is another 
confirmation of a pure sample with little contamination present.  
Table 2.5 Quality assessment of a sample of the master stock of purified plasmid DNA used 









56 1.84 2.27 0.02 
 
2.3.7 Static Chromatography  
Characterising and comparing the newly manufactured chromatography resins are carried out 
using static or “finite-bath” chromatography. In this methodology, chromatography beads are 
incubated with a solution containing a probe which interacts and binds to the matrix ligands under 
end-over-end mixing. A mass balance of the finite bath provides data on binding capacity and 
adsorption kinetics for each of the chromatography resins. These metrics are useful as points of 





Fig. 2.14 Comparison of the molecular weights and hydrodynamic radii of the two probes used in the 
chromatographic studies (GenScript, 2018; Thermo Fisher Scientific, 2018b). Probes with and without 
fluorescent dyes conjugated to the surface are contacted with the manufactured resins to assess their binding 
performance. 
The two probes used in this study are indicated in Fig. 2.14 and, whilst both being negatively 
charged at the operating pH of 7.2, their size difference is exploited to characterise how well the 
bi-layering of the beads has been carried out. Plasmid DNA is a much larger molecule, with a 
molecular weight of 16.5 x 106 Da compared to 6.64 x 104 Da for Bovine Serum Albumin 
(Erickson, 2009). It is therefore expected that pDNA should only be able to bind to ligands (if 
present) on the surface of the supports, as the exclusion limits of all the supports are too small for 
the probe to diffuse further than the shell (see Table 2.2 for more detail). Conversely, Bovine 
Serum Albumin is a much smaller, negatively charged (at pH 5 and above) probe, capable of 
passing the shell of the matrix and infiltrating the bead to its core, saturating the trimethylamine 
(Q) ligands throughout the porous structure of the bead. 
The relative degree of penetration explains why the plasmid DNA static binding capacity values 
are much lower than those obtained for Bovine Serum Albumin, as only the protein can diffuse 
throughout the bead and is thus are exposed to and can interact with a higher concentration of 
ligands. This is illustrated in the relative binding capacities in Fig. 2.16 and is further demonstrated 
in subsequent confocal images in Section 2.3.8, where binding localisation is clearly illustrated and 
thus justifies their use as useful tools in assessing the degree to which bi-layering has been achieved.  
The size and physiochemical properties of the probes are dependent on the environment that the 
probe is in, as the supercoiled plasmid DNA and quaternary structure of BSA will adopt varying 
conformations dependent on pH, temperature, ionic strength and polarity of the buffer that 
surrounds it (Damodaran and Kinsella, 1980; Takeda et al., 1989; Kongraksawech et al., 2006; 
Arkhangelsky et al., 2008; Li et al., 2008; Jiang et al., 2013; Pabbathi, Patra and Samanta, 2013).  
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These changes are due to the species adjusting size and shape to achieve the most 
thermodynamically stable conformation in response to its surroundings, with respect to both its 
hydrophobic and hydrophilic/polar residues/chains that make up its structure. Provided the 
experimental conditions remain constant throughout the static binding studies, accurate 
comparisons can be drawn from each of the finite bath studies.  
Finally, it is important to state that the two probes were challenged onto the beads in separate 
finite bath experiments. A “mixed-feed” study was avoided, to maintain clean binding to the resin 
for each individual probe and to prevent competitive binding and charge repulsion between the 
two species as well as complexes forming between the probes in solution due to hydrogen bonding 
(Seeman, Rosenberg and Rich, 1976); separating the probes into individual feeds would provide a 
more accurate indication of the performance of each of the manufactured chromatography media.  
2.3.7.1 Control Isotherm Analysis  
As a precursor to designing the static biding experiments, it is important to determine the 
maximum probe binding capacity for each fully functionalised resin type. This determines the 
highest amount a probe should bind to the resins with total functionalisation and provides a useful 
indication as to an appropriate loading concentration of the probe for static binding studies on the 
manufactured bi-layered matrices.  
Adsorption isotherms were constructed for each of the fully functionalised (i.e. not core-shell) 
control matrices for both BSA and plasmid DNA, as highlighted in Fig. 2.15. Here, an increase in 
challenge concentration of the probe is applied, measuring free probe concentration (C*) against 
mass of A bound to the supports (Q*). A Langmuir model was applied to the experimental data 
as per Equation 11, resulting in quantification of Qmax (the static binding capacity) and Kd (the 
adsorption coefficient - a measure of the rate of adsorption onto the chromatography beads). 




Fig. 2.15 Adsorption Isotherm data for BSA and plasmid DNA adsorption onto the fully functionalised supports 
which act as controls in this study. Plasmid DNA binding onto a) Superose 12 Prep Grade , b) Superose 6 Prep 
Grade and c) Sepharose 6 Fast Flow. d) BSA binding characteristics for all three resins as described above. 
Symbols: -□- Sepharose 6 Fast Flow, -■- Superose 6 Prep Grade, -○- Superose 12 Prep Grade.  A Langmuir 
model was fitted to each data set using Equation 11. Table 2.6 describes in detail the parameters derived from this 
set of curves.  







 Q* is the amount of pDNA or BSA bound to the support matrix  
 C* is the amount of free protein in solution  
 Qmax (µg pDNA or mg BSA / ml resin) is the static or equilibrium binding capacity  
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 Kd (µg or mg/ml) is the adsorption coefficient (given the method of addition of plasmid 
DNA to the same batch of media for each data point, K d is less valid and therefore not 
reported here). 
Table 2.6 Langmuir fitting parameters for each of the control samples for the plasmid DNA probe (mean ± SD, 
n = 3) as well as two commercial resins, Q-Sepharose Fast Flow (Anion Exchanger) and Capto™ Core 700 (Bi-
layered media  
  Sepharose 6  
Fast Flow 
Superose 6  
Prep Grade 













(µg / ml 
resin) 
 
161 ± 5 
 
929 ± 84 
 












74.92 ± 6.69 
 










(µg / ml 
resin) 
 
0.40 ± 0.06 
 
3.54 ± 0.65 
 






(mg / ml 
resin) 
 
0.03 ± 0.02 
 
0.06 ± 0.02 
 





The adsorption isotherm data reveal interesting characteristics about each of the respective resins. 
Both Superose 6 & 12 resins exhibited a significantly higher (~ 8 fold) binding capacity for plasmid 
DNA than the Sepharose 6 resin. This can be attributed to the smaller average bead size of the 
Superose media and thus higher surface area: volume ratio available for interaction with plasmid 
DNA. With respect to BSA, the maximum binding capacities are relatively similar, though as with 
plasmid DNA, Superose 12 has the highest binding capacity. As we will see later in later analysis 
of the bromine assay, Superose 12 samples generated the highest number of allyl groups of all 
three samples and thus a higher concentration of ligand can be conjugated onto the beads, resulting 
in larger binding capacities for both plasmid DNA and BSA.  
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Adsorption isotherm analysis was also carried out for two commercial resins as a point of 
comparison. The first was Q Sepharose Fast Flow; a strong anion-exchanger with a similar size 
distribution, pore size and cross-linking chemistry as Sepharose 6 Fast Flow, also functionalised 
with an identical trimethylamine chloride (Q) ligand used in this study. The second was Capto™ 
Core 700, a bi-layered media similar to those being manufactured in this study; both commercial 
resins are manufactured by GE Healthcare.  
For Q Sepharose Fast Flow, static binding capacities of 59 mg and 175 µg / ml resin were 
established experimentally for Bovine Serum Albumin and plasmid DNA, respectively. This data 
corroborates well with the Bovine Serum albumin binding data observed in other studies (in similar 
buffer conditions) (Liu et al., 2007) as well as the control binding data in Fig. 2.16. The 
functionalised Sepharose 6 Fast Flow control in Table 2.5 for plasmid DNA also corroborates well 
with this figure for plasmid DNA binding in Q Sepharose Fast Flow. For Capto™ Core 700, static 
binding capacities of 52 mg and 18 µg / ml resin were established for Bovine Serum Albumin and 
plasmid DNA, respectively. 
The data for the two probes on both types of resin were then utilised as decisional tools for 
informing an appropriate loading concentration in the subsequent static binding studies. The data 
provides an indication of suitable ranges for the loading concentration such that an appropriate 
challenge can be selected which will provide sufficient material to detect binding differences 
between samples whilst also avoiding over saturation of the chromatography media (and thus 
exaggerated aggregative pseudo-binding characteristics on the surface of the beads, especially for 
plasmid DNA). In addition, the load concentration also considers economical experimental design, 
preserving finite probe and chromatography resin material.  
Against this, a load of 5 mg of Bovine Serum Albumin and 15 µg of plasmid DNA were challenged 
onto 0.05 ml of the manufactured bi-layered resin to determine the matrices’ performance, as 
detailed in Section 2.2.11.3. In this way, a sufficient amount of probe material would remain in the 
bulk liquid phase to draw accurate comparisons between the matrices tested.   
2.3.7.2 Bi-layered Beads Performance Characterisation  
A facile method of comparing the various bi-layered matrices for their adsorption performance is 
via a selectivity index, as detailed in Equations 12 and 13. In essence, the selectivity index (SI) 
quantifies how well the bi-layered sample retains core-binding (Bovine Serum Albumin binding 
capacity) and how well it excludes shell-binding (plasmid DNA binding capacity) compared to the 
fully functionalised control made from the same base matrix. The lower the value of the selectivity 
index, the better performing the resin, as an ideal bi-layered matrix will maximise core BSA binding 
with minimal surface plasmid DNA binding. 
Equation 12:  
% 𝑅𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 𝑝𝑟𝑜𝑏𝑒 𝑆𝐵𝐶 =  





Equation 13:  
𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝐼𝑛𝑑𝑒𝑥 (µ𝑔 𝑝𝐷𝑁𝐴 / 𝑚𝑔 𝐵𝑆𝐴) =




 The probe refers to either plasmid DNA or BSA 
 SBC is the static binding capacity for a matrix (mg or µg / ml resin) 
 The control sample is one which has been fully functionalised without any bi-layering  
 Sample refers to any material which has been partially brominated to create a bi-layered 
matrix 
Table 2.7 Allyl contents introduced into commercial agarose base matrices following reaction with AGE.  
Matrix Allyl content (μmol/ml) 
AGE-activated Sepharose 6 Fast Flow 326.6 ± 26.5 (n=9) 
AGE-activated Superose 6 Prep Grade 348.4 ± 14.4 (n=9) 
AGE-activated Superose 12 Prep Grade 477.6 ± 20.5 (n=9) 
AGE-activated Sepharose CL6B 315.7 ± 25.5 (n=24) 
 
Table 2.7 shows the allyl contents of the various agarose based supports following full activation 
with AGE. Included for sake of comparison are values obtained by Karchanasi (2013) for the 
AGE activation of Sepharose CL6B. Allyl groups are generated by reacting allyl glycidyl ether with 
the hydroxyl residues present on the agarose matrix, as illustrated in Fig. 2.3. Not surprisingly, the 
allyl densities of AGE activated reflected their agarose contents. Allyl densities of the three 6% 
agarose base matrices were roughly similar while that of Superose 12 PG was ca. 50% higher. As 
noted earlier (2.2.3.1) the values in Table 2.7 were employed to calculate the amount of bromine 
required to react with 10% of the reactive allyl groups in each support type. 
The relative success of viscosity enhanced compared to microwave assisted appears dependent on 
the type of resin and buffer system, with no evident superior partial bromination technique based 
on the bromine assay. Fig. 2.16 summarises the reduction in static binding capacity and raw static 
binding data across all the samples, with controls included for reference. One would expect a high 
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level of partial bromination would result in a complete reduction in plasmid DNA binding and a 






Fig. 2.16 a) Percentage binding reduction for probes plasmid DNA & BSA for each base resin and 
manufacturing condition, relative to the fully functionalised control samples; selectivity indices (SI) are calculated via 
Equations 12 & 13. b) Original static binding capacity data for each sample type. H2O & EG refer to deionised 
water and Ethylene Glycol, respectively. 
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Comparing across the three resins, the Superose Prep Grade media displayed significantly higher 
selectivity indices, with all bar one eliminating ≥ 98% of plasmid DNA binding. Some of these 
were at the cost of a reduction BSA binding, for instance Superose 12 Prep Grade partially 
brominated with a 0.4% (w/v) Carbopol® viscosity enhancing buffer, which reduced the core 
binding by nearly 11%.  
Sepharose 6 Fast Flow was the poorest performing resin; although reduction in core binding 
capacity was generally low, the partial bromination failed to sufficiently eliminate surface plasmid 
DNA binding. Despite the high partial bromination percentages across the samples, the low 
selectivity indices can be attributed to the physical size of the beads, being much larger than the 
other two media can lead to mixing issues and lack of exposure of the entire surface of the beads 
to the brominating buffer. This can be observed in Section 2.3.8.3, with “patchy” plasmid DNA 
binding, which explains the limited 50 – 90% reduction in surface binding and thus the low 
selectivity indices.  
In evaluating the partial bromination techniques across the Superose media, for the microwave 
assisting buffers, deionised water performed consistently better than 60% ethylene glycol, 
predominantly due to the incomplete elimination of surface binding. In the case of Superose 6 
Prep Grade, both conditions achieved similar selectivity indices but for opposing reasons. With 
deionised water, a more significant proportion of core binding is lost but a higher degree of shell 
binding is eliminated. The reverse is true for 60% (v/v) ethylene glycol, where core binding is 
preserved at the expense of a small proportion of shell binding.  
This trend is strongly apparent in the Superose 12 Prep Grade media; where a high proportion of 
allyl groups are generated and the bromine that has been added is either insufficient in quantity 
and/or is reacting too quickly (with the supports and the buffer) to cover the entire surface of the 
resin. The rapid reaction time can be attributed to the high tan δ value of 60% (v/v) ethylene glycol 
relative to deionised water. This can result, again, in “patchy” surface binding, as is evident in the 
fluorescent images in Fig. 2.1.8.  
This hypothesis is further supported in that very little core binding of the protein is compromised 
in the 60% Ethylene Glycol samples compared to the deionised water sample (which should 
theoretically react slower due to a lower tangential loss factor). This gives the bromine molecules 
sufficient time to diffuse around the surface of the beads as well as into the porous support before 
the bromine reaction can take place, resulting in more complete elimination of surface binding, 
but at the cost of some loss of core binding, as is reflected in Fig. 2.16.  
The 64% Sucrose technique produced the highest selectivity indices for a viscosity enhancer and 
as a technique overall, eliminating 99% of plasmid DNA at the expense of only 4% and 5% 
compromise in core Bovine Serum Albumin binding for Superose 12 and 6 Prep Grade samples, 
respectively. Compared to the 64% Sucrose samples, surface binding of the plasmid DNA was 




Interestingly, the Carbopol® samples had inferior selectivity indices mainly as a result of significant 
core binding loss (compared to the 64% Sucrose samples) indicating that the buffer facilitates 
better mass transport of bromine molecules into the core of the porous support rather than 
reacting with the surface of the beads, even at lower partial bromination percentages.  As these are 
highly porous resins, with an intra-particle porosity in the range of 85% (Carta and Jungbauer, 
2010), the buffer the beads are suspended in (and “filled” with) will have an impact on both the 
experimental pore size and mass transfer characteristics within the resin.   
Although both buffers have similar viscosities, the high percentage of sucrose can both “close-
off” pores and hinder diffusion into the resin through molecular interactions, including hydrogen 
bonding, between the sucrose polymer and the agarose beads. This can lead to steric hindrance of 
the bromine molecules as they diffuse via the buffer into the porous supports. Conversely, the 
highly aqueous nature of the Carbopol® buffer can aid mass transfer of the bromine into the 
porous support. This benefits the sucrose buffers in that bromination is limited mainly to the 
surface and thus preserves core binding, consequentially leading to better selectivity indices.  
2.3.8 Confocal Laser Scanning Microscopy  
Whilst the static binding data provides a solid foundation for a comparative assessment of the 
chromatography samples, a useful corroborative study was run in parallel using fluorescent probes. 
Bovine Serum Albumin was labelled with Texas-Red X, attaching covalently to the abundant lysine 
residues on the protein via a succinimidyl ester on the dye whilst plasmid DNA was labelled with 
Syto™ 9, a minor-groove binding dye.  Both labelling reactions were carried out in a controlled 
fashion to ensure an appropriate probe: dye ratio was attained (see Section 2.2.11.6 for more 
details) as well as any un-conjugated dye either removed or accounted for.  
The fluorescent studies were run as identical experiments to the original static binding capacity 
studies utilising the same load concentrations for the probes and settled bed volumes for the 
chromatographic media.  
2.3.8.1 Correcting for Auto-Fluorescence  
It is important to optimise microscope and image acquisition settings prior to excitation of the 
sample, imaging and interpretation of the images. Fig. 2.17 highlights the importance of 
correcting for auto-fluorescence which can occur when the sample is excited by a photon source. 
In this case, no auto-fluorescence was observed when the beads were excited with a 568 nm 




Fig. 2.17 Illustration of auto-fluorescence of the base and functionalised matrices and thresholding to eliminate the 
effect; a) Sepharose 6 Fast Flow, b) Sepharose 6 Fast Flow fully functionalised with the anion exchange ligand Q, 
c) sample B incubated with fluorescent plasmid DNA (pDNA-Syto™ 9) & d) sample C post-thresholding to 
remove auto-fluorescence from the chromatography bead. Note that the value in the bottom left corner corresponds to 
the gain value for each image.  
However, for the plasmid DNA, which is excited by a 488 nm laser, a small degree of auto-
fluorescence can be observed from the agarose base matrix and a slightly higher degree with the 
anion-exchange ligand functionalised to the matrix (Fig. 2.17  a) and b), respectively). 
Interestingly, this indicates that some emission is being detected from both the agarose backbone 
and from the trimethylamine (Q) ligand.  
Control samples were run loading the beads with solely un-labelled plasmid DNA to assess auto-
fluorescence of the probe itself. Similar studies were run for Syto™ 9 label without DNA (at 
equivalent concentrations to the original samples), to trial levels of fluorescence of the Syto™ 9 
dye binding to the anion-exchange ligands on the beads. The images attained for both control 
tests were qualitatively similar to Image B in Fig. 2.17, indicating little additional fluorescence for 
both.  
Without correction, as seen in Image C, one could interpret this result as ingress of plasmid 
DNA into the core of the media, which, by reasonable size-exclusion principles, is not possible. 
In reality, this interior fluorescence is as a result of either un-conjugated dye binding to the core 
anion-exchange ligands (due to the relatively small size of the Syto-9 label) or auto-fluorescence 
of the beads themselves (likely a combination of both). This can be corrected when you consider 
that the Syto-9 stain “exhibits enhanced fluorescence upon binding (to plasmid DNA)” (Thermo 
Fisher Scientific, 2018c).  
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By evaluating the level of auto-fluorescence in Image B, it is possible to correct Image C by 
either adjusting the gain value, lowering the laser intensity, or in this case, a method known as 
thresholding. The former two require adjustments needed to be carried out prior to image 
acquisition, whereas image thresholding can be carried out post-acquisition. For the sake of 
comparison, the laser intensity and gain were kept constant across all samples unless otherwise 
stated. On occasion, the gain will be adjusted in order to pick up sufficient signal to generate a 
comprehensible image; corresponding values for each sample are stipulated in each individual 
image shown. 
The gain value corresponds to the sensitivity of the photomultiplier tube, which collects the 
electronic signal from the sample after it has been excited with the laser. This data is processed 
and digitised by the computer and each pixel has an associated intensity value assigned (grey 
levels) for 8-bit storage, ranging from 0 – 255 (Nikon, 2018). This range of grey levels can be 
thresholded to remove any noise or, in this case, background auto-fluorescence. The result of 
this thresholding can be seen in Image D, where only plasmid DNA-Syto™ 9 probe binding can 
be observed.  
2.3.8.2 Control Samples 
A natural starting point for the confocal laser scanning microscopy studies was to assess the 
functionalised control samples; these are the samples that have undergone complete saturation 
with bromine and subsequently hydrolysed and coupled with trimethylamine chloride (Q). These 
samples exhibit no bi-layering and are used as yardsticks to compare the bi-layered matrices against. 
Fig. 2.18 illustrates the light microscopy and corresponding florescent microscopy for each sample.  
The disparity in fluorescence visualised in the samples is a useful insight into the importance of 
time in fluorescence work and how the age of samples and fluorophore conjugates has an impact 
on the quality of the image attained.  
The brighter images (Sepharose 6 Fast Flow – Plasmid DNA, Superose 6 – Bovine Serum 
Albumin & Superose 6 – Plasmid DNA) were all imaged within min of completing the 
incubation time; however the other samples in the set were inhibited by a time delay of up to one 
day. Fluorescence can be lost with respect to time, usually by a photo-bleaching mechanism 
where the fluorophore is destroyed via exposure to excitation light, or by a quenching 
mechanism due to short-range interactions between the fluorophore and the local molecular 




Fig. 2.18 Light Microscopy (LM) & Confocal Laser Scanning Fluorescent Microscopy (CLSM) images for the 
fully functionalised samples and bi-layered materials challenged with BSA and plasmid DNA.  
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In addition to fluorescent degradation by either bleaching or quenching, a second reason of matrix 
age may aid in rationalising the contrasting fluorescent intensities. An example of this is Superose 
6 Prep Grade – BSA; as a result of a damaged original batch, the sample was manufactured and 
incubated with its respective probe within one day, thus giving it a different “age” to the other 
samples. The particularly striking fluorescence (even at a lowered gain value) may point to some 
degree of probe loss, or “ligand leakage” with respect to time; a phenomenon common in both 
ion-exchange and especially affinity chromatography (Gribnau and Tesser, 1974; Johansson, 
Hellberg and Wennberg, 1987; Levison and Pathirana, 1996). Importantly, for the quantitative 
static binding studies, all three resins were from their original batches and thus challenged with 
probes at the same matrix age.  
All three resin types had similar BSA static binding capacities (~ 68 mg / ml resin) and quite varied 
plasmid DNA static binding capacities, ranging from 161 – 1332 µg / ml resin). The fluorescence 
in the images does not equate perfectly with the static binding data and emphasises the need to 
have static binding data as a quantitative measure of comparison between the manufactured resins. 
However, the confocal microscopic data can be a useful tool if used qualitatively to corroborate 
trends illustrated in the finite bath studies and identify potential inconsistencies in binding, such 
as “patchy” binding, as observed in Section 2.3.8.3. 
2.3.8.3 Bi-Layered Samples  
Fig. 2.18 also summarises the bi-layered samples by light microscopy and confocal laser scanning 
microscopy images, grouping them by base matrix and type of bi-layering technique. The light 
microscopy images are useful as they provide supporting evidence that the bead(s) being imaged 
are in the correct focal plane, even if a fluorescent image is not visible (in the case of some of the 
high SI matrices incubated with plasmid DNA).  
On the whole, the image panels marry well across to the static binding studies results. For instance, 
the poor selectivity indices for the Sepharose 6 Prep Grade bi-layered materials is clearly due to 
incomplete elimination of plasmid DNA binding on the surface of the beads. 
This is likely a direct result of both bromine reactivity with the buffer and inefficient mixing during 
the partial bromination step, especially for the microwave samples, where the increased in 
temperature has accelerated reaction rates with both the buffer and supports. This has resulted in 
the remaining limited bromine molecules to react rapidly and only on a limited surface area of the 
beads, leaving allyl groups exposed on the surface to allow for Q-coupling. This ultimately leads 
to “patchy” binding of plasmid DNA, clearly evident in multiple bi-layered samples manufactured 
from Sepharose 6 Fast Flow.  
Additionally, the degree to which the plasmid DNA binding capacity has been reduced is also 
evident in the Sepharose 6 Fast Flow fluorescent images, with the two microwave samples (60% 
v/v ethylene glycol - 50% reduction in plasmid DNA binding and Deionised water - 60% 
reduction in plasmid DNA binding) showing high amounts of fluorescent plasmid DNA around 
the surface of the beads whilst 0.4% Carbopol® (90% reduction in plasmid DNA binding) exhibits 
no visible plasmid DNA fluorescence around the beads and 64% Sucrose (86% reduction in 
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plasmid DNA binding) exhibiting some patches of plasmid DNA binding but significantly less 
than the microwave assisted samples.  
With respect to the two Superose Prep Grade media, the percentages of plasmid DNA binding 
reduction are ≥ 98%, barring the Superose 12 Prep Grade microwave assisted sample with 60% 
Ethylene Glycol (82% reduction), which again exhibits some patchy binding of plasmid DNA to 
the surface of the beads. 
 
2.3.8.4 Commercial Resin Comparison  
Naturally it makes sense to draw comparisons between the commercially available Capto™ Core 
700 bi-layered material and the resins manufactured in house. Importantly, Capto™ Core 700 is 
functionalised with a different ligand, octylamine, as opposed to trimethylamine chloride (Q); due 
to its different structure, octylamine has both anion-exchange and hydrophobic interaction 
capabilities. 
 
Fig 2.19 Light Microscopy (LM) & Confocal Laser Scanning Fluorescent Microscopy (FM) images comparing 
the commercial Capto™ Core 700 resin against the worst & best performing resins.  
Here we compare the commercial resin against the best and worst performing manufactured 
chromatography resins. As no commercial resin fully functionalised with octylamine exists as a 
control for Capto™ Core 700, static binding capacities are used as a point of comparison in lieu 
of selectivity indices.  
The bi-layering process has had little impact on the static binding capacities of the proteins for the 
two manufactured resins, with a comparable amount also bound to the commercial bead, despite 
the difference in ligand. Notably, some plasmid DNA binding is picked up for the Capto™ Core 
700 resin, supported by the spectrophotometric data indicating that the shell is not completely 
inert. This is likely due to ligands still present on the surface of the beads, with a more accentuated 
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effect seen with the Capto™ Core 700 due to its highly potent, bi-functional octylamine ligand. In 
the context of maximising plasmid DNA yield in a bioprocess, it is clear that the Superose 6 Prep 
Grade media performs the best of the three. 
2.3.9 Environmental Scanning Electron Microscopy  
Electron Microscopy facilitates high resolution visualisation of the surface of the chromatography 
beads and Fig. 2.21 highlights differences in the surface morphology of the base matrices and bi-
layered beads manufactured in this study. The rationale was to observe differences in bead 
morphology and surface porosity between the three starting matrices and any significant 
differences in surface configuration once the beads have been functionalised fully or in bi-layering.  
 
Fig. 2.20 Scanning electron micrographs of a number of commercial chromatography resins, taken at low and high 
magnifications (in purple text) to gauge bead size and surface morphology/porosity, respectively. a) Capto™ Core 
700, b) Q Sepharose Fast Flow, c) Sepharose 6 Fast Flow, d) Superose 6 Prep Grade, e) Superose 12 Prep 
Grade & f) Capto™ Q. Wherever possible, images were taken which were representative of the entire sample, i.e. 
significantly damaged/difficult to image beads were avoided.  
The micrographs reveal interesting differences between the various commercial resins; purely in 
terms of size the sizes corroborate well with sizing data illustrated in Fig. 2.6, with the Capto™ 
and Sepharose media much larger compared with the two Superose media. The composition and 




Fig. 2.20 also highlights how the degree of cross-linking affects the porosity of the media that can 
be seen on the surface of the media. At 10,000 X magnification, the Sepharose 6 and Superose 6 
media appear to be much more porous than the Superose 12 surface, appearing to have clusters 
with nanometre scale spaces in between them. The Superose 12 surface, at the same magnification, 
has no such apparent gaps, with a smoother, sheet-like surface. 
 
Fig. 2.21 Scanning electron micrographs of the functionalised control chromatography resins and bi-layered matrices, 
organised by method and type of starting matrix. Images were taken at high magnification only as, at lower 
magnifications, the resins were qualitatively similar to the original starting matrices.  
The micrographs for the treated samples reveal intriguing differences between the bead types and 
partial bromination routes. The fully functionalised control beads bear a great deal of resemblance 
to their base matrices illustrated in Fig. 2.21. For Sepharose 6 Fast Flow, the most striking 
difference is the sample partially brominated with 0.4% Carbopol® 934, which appears much 
rougher with much taller peaks and deeper crevices than the other samples of its type, which 
exhibit a pockmark effect on the surface. This deep crevice effect can also be seen to some degree 
with the Superose 6 media, though not at all with the Superose 12 media, perhaps due to its close 
knit cross-linking structure.  
This surface effect may be due to an interaction between the polymer and the matrix, effectively 
leading to a thin coating/film of Carbopol® 934 forming over the surface of the bead, even after 
multiple washes of the bead.  The effect seems to be more prominent in the 6% cross-linked 
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matrices, perhaps due to the larger porosity providing more surface area for the polymer to interact 
with.  
This corroborates well with the static binding data, as this thin film can improve selectivity indices 
in two ways, either by restricting bromine diffusion into the bead and thus forcing bromination 
solely on the surface, or by “sealing off” both the pores and the ligands on the surface to limit 
plasmid DNA binding. This is further emphasised in that, compared with 64% Sucrose, and for 
all three media, the partial bromination route with 0.4% Carbopol® 934 has a higher percentage 
reduction in binding in BSA, indicating that a 0.4% Carbopol® 934 film is restricting access to 
both probes. From an experimental front, it was noticed during washing steps that the Carbopol® 
934 samples took abnormally long to vacuum dry, which is a further inference that the Carbopol® 
934 is hindering mass transfer within the beads.  
Another interesting featured highlighted by the electron micrograph images is the presence of 
round holes in the media, most predominantly in the Superose 12 matrices. The worst of the 
samples was that of the microwave assisted 60% Ethylene Glycol, which marries up well with the 
static binding data, with this sample binding the highest proportion of plasmid DNA for the bead 
type. Depending on when and how these holes formed, these structural defects could have an 
impact on the partial bromination step as well as the probe binding experiments. The holes could 
aid diffusion of bromine into the core of the bead, which supports the relatively high loss of BSA 
binding and low reduction in plasmid DNA binding for the Superose 12 samples.  
With respect to the probe binding experiments, the holes could either be providing additional 
surface area on the exterior of the bead for the plasmid DNA to bind, or, given the size of some 
of holes, providing channels into the core of the bead, providing access to the abundance of 
functionalised ligands present in the interior of the bead. It seems more likely that the holes, much 
like the roughed surfaces of the beads, provide additional surface area for the plasmid DNA to 
interact with thus diminishing the selectivity indices of these particular beads.  
It is important to consider at this point that these features, including the pockmarking, deep 
crevices and holes, could potentially stem from the bead’s manufacturing process. Multiple cycles 
of washing, scraping the beads off vacuum filters, centrifugation and re-suspension during their 
manufacture may have caused shear damage to the bead’s surface, resulting in a much rougher 
exterior.   
Alternatively, the method of dehydration required for electron microscopy may be the underlying 
cause for the diverse surface appearances. It could be envisaged that, as the beads are highly porous 
and principally composed of (and thus structurally supported by) an aqueous buffer, removing this 
water could have a detrimental impact on the structure and morphology of the beads. Curiously, 
the beads that have the highest percentage of cross-linking (and theoretically the most rigid 
structure) have the highest degree of damage. This may be due to adverse effects of dehydration 
on the cross-linker itself, causing disruption in the agarose backbone chains, leading to holes 
forming in the surface of the beads.  
145 
 
Environmental Scanning Electron Microscopy – Energy Dispersive X-Ray (E-SEM/EDX) 
analysis was attempted on the samples shown in this section in an attempt to pick up changes in 
elemental composition on the surface of the resins. Unfortunately, the resolution of this technique 
is not high enough to observe incremental changes in the surface composition of the beads, i.e. 
changes in concentration of nitrogen from the Q ligand. It is suggested that either Cryo-SEM is 
utilised, whereby the samples are slices using a microtome, revealing interior sections of the bead 
which can be scanned for elemental composition.  
Conversely, the signal from EDX can be enhanced by using a heavier element probe, which would 
need to be designed to bind to the anion-exchange ligand prior to imaging (e.g. Au nanoparticles 
covalently linked to a protein which could bind to the ligands and highlight, albeit indirectly, the 
spatial distribution of the ligand within the bead using E-SEM/EDX).  
2.4 Conclusions 
This study demonstrates the manufacture of chromatography resins with a bi-layered architecture, 
formulated under varying conditions and subsequently tested to determine binding performance 
using both quantitative colorimetric assays and qualitative microscopic imaging.  
The results from this study highlight that bi-layering is achievable will all three matrices tested, 
with varying degrees of success. Both viscosity enhanced and microwave assisted partial 
bromination proved to be viable techniques, though with variable performances, depending on 
the type of buffer and starting resin used. The most effective of the three resins was Superose 6 
Prep Grade, partially brominated with 64% Sucrose, with a selectivity index of 370, mainly due to 
its smaller bead volume and comparatively larger pore sizes, which aid mass transfer mechanisms 
during the partial bromination step. Superose 12 also achieved notably high selectivity indices for 
both 64% Sucrose as a viscosity enhancer and deionised water as a microwave assisting buffer.  
The confocal laser scanning images corroborated well with the quantification data and illustrates 
its use as a powerful tool for assessing and troubleshooting chromatography resins in both 
analytical and process purification contexts. It is hoped that the data attained from the screening 
studies, static binding quantification and microscopy can be used as tools for informing the 
development of an even better generation of chromatography materials which can ultimately be 
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MANUFACTURE & CHARACTERISATION OF PROTEIN 
NANOPARTICLES AS SURROGATE VIRUS MIMICS 
Abstract 
Biological nanoplexes are a fast growing and diverse product group in the current 
biopharmaceutical environment, particularly for gene therapy and vaccine treatments. They 
generally consist of plasmid DNA, viral vectors, virus-like particles (VLPs), mega-molecular 
vaccines, mega protein complexes and IgMs. They are characterised by their large physical size, 
fragility, complex surfaces and chemical similarity to smaller contaminating macromolecular 
components. 
The acquisition of representative virus feedstock, sufficient in quantity and particle concentration, 
as well as the methods for monitoring these species during purification, poses several practical 
issues in the realm of virus particle purification. We have developed a platform for the manufacture 
of protein nanoparticles as surrogate virus mimics. The nanoparticles can be manufactured cost 
effectively, in high volume and rapidly in the context of characterising viral chromatographic 
media. 
The reproducible manufacture of protein nanoparticles within a defined size range using varying 
ratios of organic solvent as desolvation agents is detailed herein. Tailoring bovine serum albumin 
to mimic adenovirus virus particles facilitates the creation of crude virus analogues with similar 
size and surface characteristics.  These characteristics are assayed using a number of techniques to 
determine efficiency of manufacture and demonstrate how well the nanoparticulate solutions 
represent their bone fide viral counterparts.  
This chapter will focus on the groundwork of manufacturing the protein nanoparticles and the 
concept of tailoring this process to target a specific virus, human adenovirus type 5. In order to 
produce adenoviral mimics, a 70:30 Methanol: Ethanol mix was employed to desolvate a 10% BSA 
solution under continuous stirring. In the long term, these sophisticated nanoparticles serve to 
broaden the scope of virus chromatography and enable the collection of effective and novel data 
to improve recovery and purification of viruses.  It is envisioned that the manufacture of 
reproducible, well characterised and multi-functional nanoparticles will provide a platform for 
assessment of established and novel viral purification media in the near future. The concept of 
characterising chromatography media with these viral mimics is taken forward in future chapters 






AdV: Adenovirus Type V 
As: Asymmetry Factor  
BCA: Bicinchoninic Acid  
BSA: Bovine Serum Albumin 
CCD: Charge-Coupled Device  
CD: Circular Dichroism  
CV: Column Volumes 
DLS: Dynamic Light Scattering 
 h: Theoretical Plate Height 
HCl: Hydrochloric Acid   
HSA: Human Serum Albumin 
NTA: Nano-tracking Analysis 
PDI: Polydispersity Indices 
PES: Polyethersulfone 
PSD: Particle Size Distribution  
PTFE: Polytetrafluoroethylene  
Tris: Tris(hydroxymethyl) aminomethane  
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List of Figures 
Fig. 3.1 Experimental set up for the formation or protein nanoparticles using a syringe pump (1) to control the 
rate of addition of organic solvent contained within the syringe (2) before it enters the glass beaker (3). Stirring is 
controlled using a magnetic stirrer plate (4) and prior to addition the solvent is filtered using a 0.22 µm syringe 
filtration unit (5). The solvent flows through a PTFE tube before making physical contact with the glass rod (6), 
allowing the solvent to flow down the rod and allow uniform droplets to fall into the centre of the protein solution (7) 
to initiate protein unfolding. 
Fig. 3.2 The process of desolvation (adapted from Paik et al. 2013); a thermodynamically driven, self-assembling 
process to produce protein nanoparticles from their respective monomeric form (Holban, Grumezescu and Giri, 
2016).  
Fig. 3.3 a) The result of harsh centrifugation conditions on a nanoparticle preparation, whereby the nanoparticles 
would aggregate heavily onto the interior surface of the Eppendorf™ tube and could not be effectively re-dispersed 
using an L&R T-9 ultrasonic bath (L&R Ultrasonics, NJ, USA). b) An improved purification method (as 
stipulated in Section 3.2.2) whereby a centrifuge concentrator is used to dialyse the crude nanoparticle preparation 
against a 300 kDa membrane, allowing for removal of unreacted reagents, diafiltration and re-constitution of the 
nanoparticles into fresh buffer (3 times)..  
Fig. 3.4 Crude protein nanoparticles sampled direct from manufacture (bars & ─) and purified nanoparticles 
after three cycles of dialysis against a 300,000 MWCO centrifugal concentrator membrane (bars & ─). a) Changes 
in average particle size pre- and post- purification for BSA nanoparticles with respect to increasing Ethanol 
concentration in the desolvating “cocktail”. b) Size exclusion chromatograms illustrating the efficacy of purification 
in removing residual protein species from final nanoparticle preparations;  
Fig. 3.5 NativePAGE™ Gel of Bovine Serum Albumin & Bovine Serum Albumin Nanoparticles of various 
sizes: (i) Invitrogen model protein ladder superimposed alongside the gel; (ii) NativeMark™ protein ladder utilised 
as a molecular weight standard; Nanoparticles of a variety of sizes:  (iii) 49 nm; (iv) 75 nm; (v) 113 nm; (vi) 
73 nm; (vii) 63 nm & (viii) Bovine Serum Albumin.  
Fig. 3.6 Bovine Serum Albumin nanoparticles manufactured using varying ratios of Ethanol & Methanol (mean 
± SD, n = 3); the line & scatter plot represents protein yield whilst the bars represent the average particle size for 
each preparation.  
Fig. 3.7 Theoretical determination of particle size distributions using DLS. a) Particles causing a scattering of 
light creating b) a resultant speckle pattern on a detector screen. c) The relationship between particle size and 
correlation function decay rate and d) the three types of distribution achievable using the Zetasizer Nano ZS 
(Malvern Instruments, 2004).  
156 
 
Fig. 3.8 Particle size distribution of a BSA nanoparticle preparation using DLS (- -) and NTA (─) analytical 
techniques.  
Fig. 3.9 Particle size -□- & polydispersity indices -■- for a) un-purified & b) purified nanoparticles as a function 
of nanoparticle concentration (mean ± SD, n = 3). The data illustrates the importance of a correct dilution factor 
prior to analysis via DLS, to avoid issues of noise and contaminants skewing the average particle size and PDI 
data.  
Fig. 3.10 The impact of variations in organic solvent on a) average BSA nanoparticle size and polydispersity 
index & b) the relationship between the dielectric constant of the organic solvent mixture and the eventual average 
particle size produced (mean ± SD, n = 3). Note that these protein solutions were initially dissolved in 10 mM 
NaCl, rather than in Deionised Water as with Fig. 3.4 & 3.6, though the trend holds true in both instances. See 
3.3.10 for further discussion into the importance of ionic concentration on nanoparticle formation.  
Fig. 3.11 The relationship between increasing Ethanol concentration (in an Ethanol-Methanol desolvating 
mixture) on the average particle size (grey columns) with respect to polydispersity indices -□- and ζ-potential (at pH 
8)  -■- of the BSA nanoparticles (mean ± SD, n = 3).  
Fig. 3.12 The impact of 10 mM NaCl (circles -○-/-●-) vs. deionised water (squares -■-/ -□-) on the average 
particle size (filled symbols) and polydispersity indices (open symbols) of the BSA nanoparticles, with respect to 
increasing Ethanol concentration (in an Ethanol / Methanol mixture (mean ± SD, n = 3)). 
Figure 3.13 a) An illustration of the electrical double layer that surrounds each protein nanoparticle in a 
suspension. A two-part liquid layer surrounds each particle, the inner layer is known as the Stern layer, where 
counter-ions are strongly attached and an outer, more diffuse layer where there is a significantly weaker interaction 
between the ions and the particle. A boundary exists within the diffuse layer where the ions and particle are stable, 
whereby when the particle moves the ions within the boundary move with the particle; this boundary is termed the 
slipping plane, or the surface of hydrodynamic shear. It is the potential at this boundary that is the zeta potential. 
b) The folded capillary cell used to carry out micro-electrophoresis to determine the electrophoretic mobility of the 
particles. c) Laser Doppler Velocimetry measuring fluctuations in intensity signals from scattered light to determine 
the velocity of the migrating particles. Images and theory courtesy of Malvern Instruments 2004.  
Figure 3.14 a) Isoelectric focussing curves of BSA & BSA Nanoparticles of various sizes and b) changes in ζ-
potential -■- and average particle size -□- of an 85 nm BSA nanoparticle as a function of varying pH. 
Fig. 3.15 Scale down approach for the manufacture of protein nanoparticles; a) large scale Simax 50 ml beaker 
utilising a 25 x 6 Spinbar® polygon stirrer, b) 2 ml Safe-Lock Eppendorf tube with a 5 x 2 Spinbar® micro-
flea for stirring.  Note that all dimensions are in mm and drawings are not to scale. c) key dimensions and metrics 
for both scales. The Reynolds number (Re) was calculated based on a 10% BSA solution desolvated by a 70: 30 
MeOH: EtOH solvent mixture at a volumetric ratio of 1: 4, resulting in ρ = 836.32 kg/m3 & µ = 0.000872 
N.sm-2 (Chick and Lubrzynska, 1913; Doran, 1995). This dimensionless value would increase proportionally 
with additional Methanol in the mixture.  d) The impact on scale down on average particle size over a range of 
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dielectric constants for 50 ml scale -■- and 0.5 ml scale -○-. The native protein was dissolved in 10 mM NaCl 
prior to desolvation, in order to stabilise the high concentrations of protein at lower working volumes. e) The effect 
of increasing stirring rate on a 10% BSA solution desolvated by a 70: 30 MeOH: EtOH solvent mixture at 0.5 
ml scale and the equivalent size for the same conditions at 50 ml scale (mean ± SD, n = 3).  
Fig. 3.16 The impact of a) the time of glutaraldehyde addition post-desolvation, b) addition rate of the organic 
solvent mixture, c) pre-treatment of the protein with heat and d) experimental temperature (inset:  4 ⁰ C & 21 
⁰ C) on the average particle size -■- and polydispersity index -□- of BSA nanoparticles (mean ± SD, n = 3) . 
Fig. 3.17 a) The batch-to-batch variance in mean particle size of protein nanoparticles manufactured under various 
organic solvent compositions. b) Average particle size and PDI of nanoparticle preparations manufactured under 
identical conditions (Methanol: Ethanol, 70: 30) with each colour representing a new 10% BSA stock (mean ± 
SD, n = 3).  
Fig. 3.18 a) CD spectra for BSA, Desolvated BSA and BSA Nanoparticles. b) The relative proportions of 
secondary structure for the protein in its native and desolvated states, as well as the conformational change once 
formed into nanoparticles.  
Fig. 3.19 BSA Nanoparticles images; a) A transmission electron micrograph imaged using a negative uranyl 
acetate stain and b) An atomic force microscopy image acquired via liquid tapping mode.  
Fig. 3.20 A comparative study of BSA nanoparticles and Adenovirus type V (AdV); a) Nano-tracking analysis 
of the BSA nanoparticles with an average particle size of 75 nm compared to b) DLS & ζ-potential analysis (pH 
8) of native AdV ((Weng et al., 2014). c) & d) Transmission electron micrographs of BSA nanoparticles and 
AdV. e) Circular dichroism spectra for both the 75 nm BSA nanoparticle and that of the AdV hexon capsid 
protein (Day et al., 1972). f) Summary table highlighting the similarities in physiochemical properties between the 







3.1.1 Viral Vectors  
As discussed in Chapter II, the advent of gene therapy has caused a re-think in the bioprocessing 
sector in order to generate sufficient volumes of large-titre, clinical grade viral vectors. Novel 
methods of purification are required to handle more complex feedstocks, higher titres and more 
labile products. This chapter will focus on the human adenovirus and its potential in gene therapy. 
This adaptable vector has  wide ranging applications, from tumour suppression using CRISPR-
Cas 9 (Takayama and Mizuguchi, 2018) to the  treatment of cystic fibrosis via transduction of 
airway basal cells (Cao et al., 2018). The adenovirus (Ad) species have shown great efficacy as a 
targeted drug delivery vehicle, with high applicability in gene therapy and vaccine treatments. Ad 
and Ad-associated viruses are now the most commonly used vehicle for gene therapy, with 547 
gene therapy clinical trials having been conducted to date (from 2600 globally), representing  20.5% 
of all vectors trialled (Ginn et al., 2018b). 
Whilst these vectors have huge implications for the bio-therapeutics market, issues often arise with 
their large scale manufacture, purification and quality/quantitation assays. Duffy et al. describe 
adenoviral production and purification as “labour intensive, costly and requiring specialised 
equipment” involving 120 hours of cell culture to observe cytopathic effects (CPE) and a further 
36 hours for caesium chloride (CsCl) gradient ultracentrifugation to purify the vector. The cell 
culture alone can cost in the region of $ 520 to produce a titre of ~2 x 1013 virus particles, with the 
risk of contamination and complications of safety, sampling and cell counting required, the process 
can be complex and costly to run (Isayeva et al. 2003; Duffy et al. 2005).  
There are further complications downstream, such as the separation of empty capsids which can 
compete for cell-surface receptors and elicit a heightened immune response (Urabe et al., 2006). 
Traditional methods of purification have an adverse effect on vector infectivity, variability and can 
lead to product aggregation (Fernandes et al., 2015). Purification processes also need to consider 
the maturation cycle of the virus, as well as issues with assaying the vectors accurately. 
The industry standard Maizel method (OD260) runs into issues when titres are particularly low or 
contaminants cause any degree of interference. Infectivity assays are traditionally carried out by 
plaque (PFU) or tissue culture infectious dose (TCID50) methods, which can take close to two 
weeks to observe any CPE traces. Reporter genes can also be used (GFP, Luciferase, β-
galactosidase etc.) to track transduction efficiency, though again these methods can be exhibit high 
variability, as well as being both labour and time consuming  (Segura et al., 2010).  
There are also safety implications and issues with handling and storage of viral vectors. The UK 
requires a Biosafety Level 2 (BSL-2) to handle the vector, with stringent precautions to limit any 
risk of inhalation. Handling of the vector requires specialised material, such as Lo-Bind Eppendorf 
tubes to prevent loss of material and storage requirements need to consider the propensity for the 
virus to aggregate at high particle concentrations (Trilisky and Lenhoff, 2007).  
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In this chapter we explore the potential of protein nanoparticles and their ability to mimic the 
characteristics of real viral vectors, whilst circumventing many of the issues discussed above. 
Whilst protein nanoparticles have a multitude of applications across numerous fields, this thesis 
focusses on their application as a screening tool for present-day and emergent purifications 
systems, without the hassle of live viral feedstocks.  
3.1.2 Virus Mimics 
The desire to create mimics of viruses stems from a number of different areas, including 
biosensors, drug delivery, vaccines and water treatment. The methods employed have utilised a 
number of different starting materials, including gold, silica and polymeric nanoparticles, as well 
as the use of virus-like particles (Liu and Han, 2005; Ghosh et al., 2008; Pang et al., 2014; Hyun et 
al., 2018).  
In the case of gold and silica nanoparticles, a protein coat is often required to better represent a 
viral capsid and thus elicit a cell interaction or immune response (Pang et al., 2014). Whilst gold 
nanoparticles have  advantages of facile assaying due to their distinctive surface plasmon resonance 
(SPR) band and ease of coating (Schäffler et al., 2014), there is a distinct issue with the high density 
of the nanoparticles and their propensity to aggregate, both as neat and coated nanoparticles 
(Zhao, Brook and Li, 2008; Meena Devi, 2014).  
Silica nanoparticles have shown much promise, due to their relatively porous nature and ease of 
functionalisation with high impact applications such as the successful delivery of anti-cancer drugs 
such as camptothecin (Liu and Han, 2005; Lu et al., 2007; Niu et al., 2013). One of the main issues 
with functionalised silica nanoparticles is the uncertainty of their cytotoxic effects in vivo, 
particularly due to variations in particle size, which would need to be addressed prior to their wide-
spread use as a drug delivery vector (DeForest, Polizzotti and Anseth, 2009; Nel et al., 2009; 
Napierska et al., 2010; Wu, Hung and Mou, 2011).  
Polymeric-based nanoparticles such as poly(lactic-co-glycolic acid) (PLGA) and poly(lactic acid) 
(PLA) have been formulated for drug delivery due to the starting materials being approved by the 
FDA as biocompatible and their ability to biodegrade in-vivo (Bala, Hariharan and Kumar, 2004; 
Kim and Martin, 2006). However, their oil-in-water emulsion/solvent manufacturing technique 
can cause issues in manufacture and with reproducibility and the final nanoparticles also have 
issues with water solubility (Govender et al., 1999).  
The most promising viral mimic to date has been the use of virus-like particles (VLPs) which are 
essentially empty capsids devoid of any genetic material responsible for the infectivity potential of 
the viral vector. This feature circumvents many safety concerns such as reverse mutations or 
reverting back to pathogenic form, two issues commonly associated with attenuated vectors. VLPs 
are composed of all or part of the viral capsid and thus provide a representative surface of for 
antigen recognition to stimulate an appropriate immune response (Fuenmayor, Gòdia and Cervera, 
2017).   
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One of the main disadvantages of VLPs is the arduous nature of manufacture, first requiring 
cloning of appropriate structural genes, followed by choice of a suitable expression system and 
finally purification and isolation of the vectors. The most common is E. coli, however many VLPs 
are insoluble in this expression system and require purification in the form of inclusion bodies, 
which require denaturing, re-folding and re-assembly (Zeltins  2013). In addition, E. coli culture 
requires monitoring and control systems and can take in excess of 48 hours, followed by cell lysis 
and capture steps which themselves are time consuming and require several man hours (Huo et al., 
2018). 
3.1.3 Protein Nanoparticles 
Rather than functionalise synthetic nanoparticles with proteins in order to mimic the 
physiochemical properties of viruses, there has been an alternative methodology of utilising 
protein(s) as starting materials for the formation of nanoparticles. There has been a lot of interest 
in protein nanoparticles, particularly for the purpose of drug delivery and vaccinations, due to their 
ease of manufacture, biocompatibility and low cytotoxicity (Lohcharoenkal et al., 2014).  
A significant advantage of using protein nanoparticles over synthetic particles is their ability to 
respond to environmental stimuli as a bona fide vector would, largely due to the fact that they are 
completely (and not partially) composed of similar polypeptide structures which make up the 
surface proteins of a typical viral capsid. This immediately puts them at an advantage as a surrogate 
virus mimic, whilst making their interaction behaviour (in vivo and in vitro) more predictable. This 
feature also allows proteins to self-assemble, changing confirmation and forming inter- and intra- 
molecular bonds in response to their surroundings.  
Another advantage of using protein nanoparticles is their strong avidity, possessing multiple 
potential binding sites for interaction as well as points for modification/conjugation to improve 
stability, biocompatibility and traceability. These include PEGylation to improve in vivo half-life of 
therapeutics, fluorescent functionalisation to aid in imaging and signalling peptides to facilitate 
cellular uptake and tumour targeting (Lin et al., 1997; Langer et al., 2000; Fahrländer et al., 2015; X. 
Yu et al., 2016).  
It is this approach of protein nanoparticles that has been adopted in the chapter, aiming to create 
a mimic of the human adenovirus type V vector using a commonly available protein, Bovine Serum 
Albumin. This chapter will cover the manufacturing and characterisation of the protein 
nanoparticles for Bovine Serum Albumin and identify key processing parameters that impact the 
integrity of the final product. Also detailed are the important physiochemical characteristics of 
both the live vector and the surrogate mimic and how the two compare, with reference to their 
purification requirements. Subsequent chapters will look at building on the process knowledge 
developed and adapting the technique to target other virus particles of gene therapy interest.  
It is envisaged that by optimising the manufacture and rigorous characterisation, the nanoparticles 
can be used for a novel application not yet applied in analytical chromatography; road testing 
purification media for their ability to isolate virus species, using sophisticated protein nanoparticles 
as surrogate virus mimics, thus removing the need for live viral feedstocks. 
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3.2 Materials & Methods 
3.2.1 Materials & Reagents  
Bovine Serum Albumin (fatty acid free, ≥ 96%), 8% Aqueous Glutaraldehyde, Methanol and 
Ethanol (both analytical grade, ≥ 99%), Sodium chloride (NaCl), Sodium phosphate monobasic 
(NaH2PO4) and dibasic (Na2HPO4), Sodium hydroxide (NaOH), Dimethyl Sulfoxide (DMSO) and 
all glassware and other reagents were obtained from Sigma Aldrich (Poole, Dorset) unless 
otherwise stated. Buffers and all aqueous solutions were based upon use of ultrapure water from 
a Sartorius Arium® Advanced EDI Pure Water System (Sartorius AG, Göttingen, Germany). 
Bicinchoninic Acid Assay Protein Kit (BCA) and Protein Concentrator Centrifugal Filters were 
obtained from Fisher Scientific (Loughborough, UK). Chromatography resins (Superdex 200 Prep 
Grade), PD-10 Desalting Columns and Tricorn empty glass columns were purchased from GE 
Healthcare (Uppsala, Sweden).  
3.2.2 Preparation of Bovine Serum Albumin Nanoparticles  
Protein Preparation Bovine Serum Albumin (BSA) nanoparticles were prepared using a 
desolvation technique as described by Weber et al. 2000; Jun et al. 2011 & von Storp et al. 2012. 
Briefly, a 10% BSA solution was prepared by dissolving lyophilised, lipid free Bovine Serum 
Albumin power in 10 mM NaCl (hereto referred to as aqueous solution, unless otherwise stated). 
The solution was then filtered through a 0.22 µm syringe filtration unit (Whatman, Maidstone,UK) 
to remove any aggregates or contaminants and subsequently adjusted to pH 8 using 1M NaOH 
and an Accumet® XL200 pH meter (Thermo Scientific, Stafford, UK).  
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Fig. 3.1 Experimental set up for the formation or protein nanoparticles using a syringe pump (1) to control the 
rate of addition of organic solvent contained within the syringe (2) before it enters the glass beaker (3). Stirring is 
controlled using a magnetic stirrer plate (4) and prior to addition the solvent is filtered using a 0.22 µm syringe 
filtration unit (5). The solvent flows through a PTFE tube before making physical contact with the glass rod (6), 
allowing the solvent to flow down the rod and allow uniform droplets to fall into the centre of the protein solution (7) 
to initiate protein unfolding.  
Desolvation Particle formation was achieved by controlled addition of an organic solvent 
mixture to 1 ml of protein solution aliquoted into a 50 ml beaker, diameter 35 mm (Simax 
Kavalierglass, Prague, Czech Republic) via a 0.22 µm syringe filtration unit connected with an 
adapter to a portion of PTFE tubing (VWR International, Radnor, PA, USA). Prior to addition of 
solvent, the beaker was placed on a magnetic stirrer plate (Corning PC-420D, Coring Inc., USA) 
with a rectangular Spinbar® magnetic flea (Sigma Aldrich, Poole, Dorset)  of 25 mm in length 
used to maintain continuous stirring.   
4 ml of desolvating organic solvent were added dropwise using a NE-1000 Programmable Syringe 
Pump (New Era Pump Systems, New York, USA) attached with either a 10 or 20 ml Luer-lock® 
syringe (BD, Franklin Lakes, USA) filled with the solvent mixture. A constant flow rate of 1.0 
ml/min was maintained, under continuous stirring (600 rpm) at room temperature and such the 
solution became visibly turbid (Weber et al., 2000) as the protein dehydrates and unfolds. Droplet 
size and placement was kept constant by placing the end of the syringe in direct contact with a 
glass rod held vertically above the centre of the glass beaker via a clamp stand. The organic solvent 
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would run axially down the glass rod and form droplets which fall from a set height into the centre 
of the glass beaker holding the protein solution. This is illustrated in the experimental set up in 
Fig. 3.1. 
Cross-Linking After 4 minutes, 8% aqueous glutaraldehyde solution was added to induce 
particle cross-linking (Habeeb and Hiramoto, 1968), in an aliquot representative of 100% of the 
theoretic amount necessary for quantitative cross-linking of the sixty lysine residues present on 
each BSA molecule particle matrix in the 10% protein solution (Patterson and Geller, 1977; Weber 
et al., 2000). The cross-linking process was left to complete under continuous stirring at 600 rpm 
for 12 hours at room temperature (von Storp et al., 2012). The beaker was sealed with a sheet of 
Parafilm® (Sigma Aldrich, Poole, Dorset) to prevent contamination from airborne particulates, 
except during addition of protein and organic solvent.  
Purification The nanoparticle suspension was purified from unused free protein and reagents 
by either three cycles of centrifugation and re-suspension in fresh buffer in 2 ml Eppendorfs at 
15,000 x g for 30 mins (Sigma 3K30 refrigerated centrifuge, SciQuip, Shropshire, UK) at a constant 
temperature of 4 ⁰ C or four cycles of dialysis against a 300 000 MWCO protein concentrator 
polyethersulfone (PES) centrifugal filter (Thermo™ Scientific, Loughborough, UK) in an 
Eppendorf 5810 centrifuge (Eppendorf, Hamburg, Germany) at 2,500 rpm for 20 minutes. The 
retentate was re-suspended three times in the same buffer the initial protein was dissolved in before 
aliquoting into 15 ml Falcon tubes (Thermo Scientific, Stafford, UK) for subsequent analytical 
testing or for refrigerated storage at 4 °C. 
3.2.3 Analysis  
3.2.3.1 Dynamic Light Scattering 
3.2.3.1.1 Particle Sizing   
Determining the particle size distributions (PSD), average particle size (Z-Average) and 
polydispersity indices (PDI) of the nanoparticles were carried out using a Zeta Sizer Nano ZS 
(Malvern Instruments, Malvern, UK). Nanoparticle preparations were diluted 200-fold in aqueous 
solution, corresponding to a final concentration of ~ 0.1 mg/ml, providing sufficient light scatter 
intensity for the detector and correlator to generate a digital signal to be processed by the Zetasizer 
Nano ZS software (Malvern Instruments, Malvern, UK). 
The diluted samples were then mixed by repeated gentle aspiration and then transferred, in aliquots 
of 0.8 ml, to disposable DTS0012 polystyrene semi-micro cuvettes (Thermo™ Scientific, 
Loughborough, UK) before placing into the cuvette chamber of the Zetasizer Nano ZS. The 
refractive indices for the sample were set at 1.45 and 1.33 for the sample (protein) and dispersant 
(aqueous solution), respectively (McMeekin, Groves and Hipp, 1964). Equilibration time was set 
to 120 seconds with conditions set at 25 °C, dispersant viscosity 0.8872 cp, with measurements 
performed at a backscattering angle of 173 °. This means that the detector is placed at an angle of 
173 ⁰  from the angle of incidence and is an example of a patented technique known as Non-
Invasive Back Scatter (NIBS). 
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The use of NIBS is advantageous as the incidence beam does not traverse the entire sample and 
thus limits the effect of multiple scattering (scattered light from one particle scattered by other 
particles multiple times), facilitating the measurement of higher sample concentrations. Larger 
contaminant particles (e.g. dust) usually scatter in the forward direction, thus the use of NIBS 
greatly reduces the impact of contaminant interference (Malvern Instruments, 2004). 
Data was evaluated for average particle diameter and polydispersity indices on the basis of 
scattering intensity data. Three separate measurements were then taken for each sample and 
subsequently averaged to determine a mean and standard deviation for each nanoparticle 
preparation. 
3.2.3.1.2 Zeta Potential & Isoelectric Focussing  
Zeta potential and isoelectric focussing measurements were both attained using the same Zetasizer 
Nano ZS.  Samples of protein and protein nanoparticle were prepared by diluting stocks 200-fold 
in aqueous solution, equating to a final concentration of ~ 0.1 mg/ml to facilitate sufficient light 
scattering for optimum measurement conditions.  
For single zeta potential measurements, samples were titrated to pH 8 by addition of small volumes 
of NaOH before transferring 1 ml aliquots into a re-useable DTS1061 folded capillary cell 
(Malvern Instruments, Malvern, UK). Isoelectric focussing data was accomplished with the aid of 
a MPT-2 auto-titrator and de-gasser connected to the Zetasizer Nano ZS (all Malvern Instruments, 
Malvern, UK). The refractive indices for the sample were set at 1.45 and 1.33 for the sample 
(protein) and dispersant (aqueous solution), respectively (McMeekin, Groves and Hipp, 1964). 
Equilibration time was set to 120 seconds with experimental temperature set at 25 ⁰ C, dispersant 
viscosity at 0.8872 cp and dielectric constant at 78.5.  
For isoelectric focussing, 15 ml of protein or protein nanoparticle sample, prepared to the same 
concentrations as stipulated for sizing and single zeta potential measurements, were utilised for 
each isoelectric focussing curve, with 0.1 M NaOH and 0.1 M HCl used as titrants for pH 
adjustment. Starting at pH 8 or 9, the samples were titrated to pH 1.8 in increments of 0.5, applying 
a target pH tolerance of ± 0.05. Three measurements were taken at each pH point with the sample 
re-circulated through the cuvette and magnetically stirred in the holding vessel between each 
measurement to ensure thorough mixing between samples and titrations of pH points.  
Titration curves were fitted with a sigmoidal curve plotted using the Origin 2017 graphing package 
(OriginLab, MA, USA), with an isoelectric point determined for each curve (y = 0), resulting in a 
mean and standard deviation from three values for each sample. 
3.2.3.2 Nano-Tracking Analysis  
As a complimentary assay to dynamic light scattering and as a methodology for ascertaining particle 
concentration, purified nanoparticle preparations were analysed using Nano-tracking analysis 
(NTA). For this, nanoparticles were purified and prepared as with DLS, though diluted to a 
concentration such that a clear image of the scattering volume is obtained (usually between 106 to 
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109 particles/ml). This involved an element of trial and error and was dependent on the sample 
type, though generally equated to a concentration of ~ 2 x 10-5 mg/ml of protein in the 
measurement sample.  
Samples were measured using a NanoSight LM10 (NanoSight, Wiltshire, UK). Diluted samples 
were injected into the sample inlet of the flow cell, housed in a metal LM10 unit which was 
mounted onto a conventional microscope with an X20 objective attached. Here a focussed 635 
nm laser passes through the LM10 unit into the 300 µL sample chamber, causing the nanoparticle 
preparations to scatter light. The particles passing through the laser beam act as point scatterers 
and their random paths under Brownian motion are dynamically tracked and recorded (as a video) 
by a Marlin CCD camera (Allied Vision Technologies, Germany) operating at 30 frames per second 
(fps), to be analysed and de-convoluted by the NTA Software v. 1.5 (NanoSight, Wiltshire, UK). 
Conditions were set and equilibrated at 25 °C, viscosity 0.8872 cp and gain and detection 
thresholds set at 1 and 10, respectively. The latter two are nominal values selected to increase signal 
below a certain limit and limit background noise, as well as removing any false centres where no 
clear particles were present and thus eliminate false positives. The first frame of the recorded video 
can be used to adjust parameters to remove blurring, threshold and smooth images. This ensures 
a better signal/noise ratio as well as tracking of appropriate particle size ranges for subsequent 
frames, facilitating better accuracy in generating a particle size distribution.  
3.2.3.3 Protein Nanoparticle Quantification 
3.2.3.3.1 Bicinchoninic Acid Assay  
Protein and protein nanoparticle preparations were quantified using a bicinchoninic acid (BCA) 
assay, as described in Section 2.2.11.4. In the case of protein nanoparticle samples, the 
methodology follows that stipulated by Arroyo-Maya et al. 2014, whereby the protein content 
within the nanoparticles are measured via the same principles of a conventional BCA assay. This 
concept was validated by conducting a BCA assay with a stock nanoparticle preparation, 
developing a standard curve by serial dilution (in parallel to the customary protein standard curve) 
and observing a linear correlation between nanoparticle concentration and absorbance at 562 nm. 
On this basis, it was possible to use the protein standard curve to ascertain the concentration of 
BSA in any nanoparticle preparation.  
3.2.3.3.2 Size Exclusion Chromatography  
Superdex 200 Prep Grade chromatography media was flow-packed in a 5/100 Tricorn column 
using an ÄKTA Explorer 100 system (both GE Healthcare, Uppsala, Sweden) and tested prior for 
packing quality via a 2% Acetone pulse (As and h values of 1.11 and 0.04 cm, respectively).  
The column was equilibrated with six column volumes (CV 3.54 ml) of phosphate buffered saline 
(20 mM phosphate, 150 mM NaCl, pH 8.0) before being subjected to a 0.1 ml isocratic load (via 
sample loop injection) of a crude nanoparticle preparation, previously diluted to a concentration 
of ~ 5 mg/ml. A variable wavelength UV-vis detector, set at 280 nm, alongside conductivity and 
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pH probes, were used to monitor species elution and buffer exchanges during packing and 
equilibration.  
3.2.3.3.3 Native Polyacrylamide Gel Electrophoresis  
Native Polyacrylamide Gel Electrophoresis (Native PAGE) was carried out on a range of un-
purified nanoparticle samples to assess quality of nanoparticle preparation and degree of 
incorporation of protein within the nanoparticles. A Novex® NativePAGE™ Bis-Tris (3 – 12%) 
gel, with a resolution of 15 to 10,000 kDa under non-denaturing conditions, was procured from 
Life Technologies (Thermo™ Scientific, Loughborough, UK).  
Sample Preparation Samples were prepared using the NativePAGE™ sample prep kit, diluting 
in sample buffer to yield a concentration of 0.1 mg/ml. Cathode (Bis-Tris 15 mM, Tricine 50 mM, 
Coomassie Brilliant Blue G-250 (0.002 %), pH 7) and anode (Bis-Tris 15 mM, pH 7) and sample 
(0.1 % PonceauS in 50% Glycerol) buffers were also prepared using the NativePAGE™ running 
buffer prep kit. 10 µL of sample were loaded into separate wells of the gel alongside a 10 µL aliquot 
of NativeMark™ unstained protein standard ladder.  
Gel Electrophoresis The gel was secured in an Invitrogen™ Mini Gel Tank with an electrical 
field applied to the gel using a PowerEase™ 90W power supply (both Life Technologies, 
Thermo™ Scientific, Loughborough, UK). A constant voltage of 150 V was applied to the gel for 
a total run time of 115 minutes.  
Gel Staining For enhanced visualisation of the protein bands, the gel was stained with 
Coomassie G-250; the gel was removed from the tank and submerged in a plastic container 
containing 100 ml of fixing solution (40% Methanol and 10% Acetic Acid) and microwaved at 900 
W for 45 seconds. The gel was subsequently agitated on an orbital shaker for 30 minutes at room 
temperature. The fixing solution was then replaced by 100 ml of staining solution (0.02 % 
Coomassie Brilliant Blue G-250, 30% Methanol and 10% Acetic Acid) and the same process 
repeated. Finally, the staining solution was replaced by a de-staining solution (8% Acetic Acid) and 
the process repeated, except held on the orbital shaker for 3 hours until visual inspection of the 
contrast of the protein bands was deemed acceptable. The gel was then carefully placed in a plastic 
wallet before scanning on a CanoScan 9000F Mark II Flat Bed Scanner (Canon, Ota, Japan). Image 
processing was conducted using the image manipulation software ImageJ (NIH, MD, USA).  
3.2.3.4 Circular Dichroism Spectroscopy 
To observe the structural changes of BSA through the nanoparticle formation process, samples of 
BSA monomer, desolvated monomer and cross-linked nanoparticles were analysed using circular 
dichroism (CD) spectroscopy via a Jasco J-1500 instrument (Jasco, Tokyo, Japan). Protein samples, 
at a concentration of 0.1 mg/ml, were analysed in a quartz cuvette of 0.1 cm optical path length at 
room temperature. CD spectra were obtained between 190 -350 nm and a scanning speed of 100 
nm/min was employed with four accumulations. Protein species were examined in the far UV 
range (190 – 250 nm) and de-convoluted using the SELCON3 algorithm (Sreerama and Woody, 
1993) to assess changes in protein secondary structure. 
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3.2.3.5 Transmission Electron Microscopy 
Investigation of the morphology of the nanoparticles was carried out through Transmission 
Electron Microscopy using a JEOL 1200EX (JEOL, Welwyn Garden City, UK). Briefly, a drop of 
nanoparticle sample, diluted 1: 100 in aqueous solution, was placed on a copper grid and 
subsequently dried in an exsiccator and a 1% uranyl acetate solution applied as a negative stain to 
enhance contrast before imaging.  
3.2.3.6 Atomic Force Microscopy  
To observe the nanoparticles in their aqueous state, Atomic Force Microscopy was employed. 
Sample preparation involved dropping a diluted sample of nanoparticle suspension onto a pre-
coated poly-L-lysine glass slide (Sigma Aldrich, Poole, Dorset), leaving to settle for 30 mins before 
placing on the imaging stand of the JPK NanoWizard® II (JPK Instruments, Berlin, Germany). 
Phase and topographical images were acquired by fluid intermittent contact mode at room 
temperature and ambient conditions at a scan rate of 0.45 Hz. Gold/chromium reflex coated 
silicon nitride cantilevers (Budget Sensors-SiNi, NanoScience Instruments, Pheonix, AZ) with a 
resonant frequency between 20 – 40 kHz, a tip radius less than 15 nm and a spring constant of 
0.27 N/m were used.  Images were processed using the JPKSPM Data Processing software (JPK 









3.3 Results & Discussion 
3.3.1 Desolvation  
 
 
Fig. 3.2 The process of desolvation (adapted from Paik et al. 2013); a thermodynamically driven, self-assembling 
process to produce protein nanoparticles from their respective monomeric form (Holban, Grumezescu and Giri, 
2016).  
The technique involves an organic solvent replacing the water molecules that form a solvating shell 
around a protein macromolecule. Water molecules aid in stabilisation of the protein in its folded, 
hydrated state, facilitating a stable secondary and tertiary structure supported by hydrogen bonding 
and hydrophobic interaction resulting in a confirmation where the Gibbs free energy is at its 
lowest; hydrophobic, non-polar amino acid residues are buried in the core, whilst polar, 
hydrophilic residues exposed on the surface, aiding in solubilising the protein in aqueous solution 
(Raschke, 2006; Bellissent-Funel et al., 2016). Consequently, addition of the organic solvent results in 
changes in the protein secondary structure (α-helices, β-sheets, turns and hairpins) as the protein 
begins to “re-shape” itself in response to its environment.  
The use of  Serum Albumin as a model protein for nanoparticulation has been widely documented 
in literature (Lin et al. 1997; Weber et al. 2000; Zhang et al. 2001; Jahanshahi & Najafpour 2006; 
Langer et al. 2008; Mehravar et al. 2009; Jun et al. 2011; von Storp et al. 2012; Yedomon et al. 2013; 
Yu et al. 2014; Galisteo-González & Molina-Bolívar 2014; Jahanban-Esfahlan et al. 2016; 
Deshapriya et al. 2015; Queiroz et al. 2016) for a variety of applications, including drug delivery and 
bio markers.  
Bovine serum albumin in particular has been widely used as a model protein in separation science. 
Its physiochemical characteristics are well understood including its molecular weight, isoelectric 
point, crystal structure and amino acid sequence; thus making this protein a suitable protein for 
targeting specific residues for desolvation and cross-linking (Majorek et al., 2012).  
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Desolvation, among other techniques, including emulsification, thermal gelation and nano-spray 
drying, have all been used to manufacture albumin nanoparticles (Elzoghby, Samy and Elgindy, 
2012; Jahanban-Esfahlan, Dastmalchi and Davaran, 2016). Desolvation followed by coacervation 
and cross-linking has proved to be one of the more established and well characterised techniques 
and one which could be optimised and controllably adjusted to produce nanoparticulates within 
controlled size ranges.  
As illustrated in Fig. 3.2, addition of organic solvent to a high concentration of an aqueous BSA 
solution results in unfolding of the quaternary, tertiary and secondary structure of the protein, 
which are held together by a balance of hydrophobic interactions, as well as hydrogen bonding, 
dipole-dipole interactions and van der Waals forces. This organic solvent-stimulated unfolding 
induces a conformational change whereby the polar and non-polar residues re-organise to its most 
thermodynamically favourable state, given its surrounding environment (Y. Yu et al., 2016). As the 
protein becomes less hydrated in situ, the molecules begin to self-assemble into clusters due to 
electrostatic, hydrophobic and dipole-dipole interactions between the exposed residues.  
3.3.2 Cross-Linking 
Post-desolvation, cross-linking of the exposed ε-amino groups was induced using a bi-functional 
cross-linker, glutaraldehyde, to “lock” the self-assembled nanoparticulate structures into place. The 
un-protonated lysine residues behave as nucleophiles and form amide bonds through the carbonyl 
functional groups of the glutaraldehyde cross-linker.  
The pH of the protein solution is adjusted to 8.0 as, despite glutaraldehyde being reactive with 
amines over pH ranges ≥ 3.0, the reaction becomes irreversible between pH 7.0 – 9.0. Under acidic 
conditions, the aldehyde forms unstable Schiff's bases when the cross-linker undergoes 
nucleophilic attack from the ε-amino lysine residues, however at pH ≥ 7.0, the reaction is shown 
to have exceptional stability (Migneault et al., 2004).  
3.3.3 Nanoparticle Purification  
BSA nanoparticles were purified away from un-utilised cross-linker and protein and desolvating 
solvents and reconstituted into aqueous buffers by two methods, as highlighted in Fig. 3.3. The 
photograph in a) highlights the methodology as per Weber et al., whereby the nanoparticles were 
centrifuged at high speed (≥ 20,000 g) directly onto the base of an Eppendorf tube, before 
removing the supernatant and re-suspending in deionised water via an ultrasonic bath.  
The centrifugal g force and the spin time would vary slightly depending on the size of the 
nanoparticle required, with smaller nanoparticles requiring longer periods of time and higher g 
forces to pellet down. The work by K. Langer and his group allude to this purification requirement 
(Weber et al., 2000) and this observation does fit with sedimentation rate theory; the sedimentation 
rate of a particle is proportional to the square of the particle radius, as determined by the Svedberg 










 ρP & ρM are the densities of the particle and liquid medium, respectively (kg/m3) 
 η is the viscosity of the liquid medium (kg/m.s) 
 r is the particle radius (m) 
Whilst this approach proved successful in some cases, it was often arduous to re-suspend the 
nanoparticles post centrifugation and the average particle size profile and polydispersity were not 
always preserved. 
 
Fig. 3.3 a) The result of harsh centrifugation conditions on a nanoparticle preparation, whereby the nanoparticles 
would aggregate heavily onto the interior surface of the Eppendorf™ tube and could not be effectively re-dispersed 
using an L&R T-9 ultrasonic bath (L&R Ultrasonics, NJ, USA). b) An improved purification method (as 
stipulated in Section 3.2.2) whereby a centrifuge concentrator is used to dialyse the crude nanoparticle preparation 
against a 300 kDa membrane, allowing for removal of unreacted reagents, diafiltration and re-constitution of the 
nanoparticles into fresh buffer (3 times).  
This technique does not require lengthy spells of incubation in an ultrasonic bath and avoids 
aggregation and adsorption of nanoparticles directly onto the polypropylene tube. The PES 
membrane filter is hydrophilic and commonly used for serum purification applications, resisting 
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the hydrophobic interaction driving forces which can contribute to protein adsorption onto filter 
surfaces (Goebel-Stengel et al., 2011; Murray et al., 2013).  
For applications that require highly pure, undiluted sample (e.g. for chromatographic application 
and for morphological analysis) a gentler purification technique of centrifugation filtration was 
employed to avoid aggregation at the base of the round-bottom Eppendorf™ centrifuge tubes 
(Eppendorf, Cambridge, UK) as can be visualised in Fig. 3.3b.  
In order to validate that the centrifugation filtration approach had removed any unincorporated 
BSA, samples were run on an SEC column pre- and post- centrifugation-filtration, as illustrated in 
Fig. 3.4. The figure illustrates the reproducibility of the purification technique across a variety of 
desolvating agent concentrations and average particle size ranges. Whilst the average particle size 
of the purified samples sees little compromise relative to its crude counterpart, interestingly 80% 
of the samples tested showed a slight decrease in size, post-purification.  
It is stipulated that this may be attributed to a layer of BSA bound via weak electrostatic or 
hydrogen bond interaction to the surface of the nanoparticles, which is subsequently removed 
during the three cycles of washing in the centrifuge concentrator.  
Fig. 3.4 Crude protein nanoparticles sampled direct from manufacture (bars & ─) and purified nanoparticles 
after three cycles of dialysis against a 300,000 MWCO centrifugal concentrator membrane (bars & ─). a) Changes 
in average particle size pre- and post- purification for BSA nanoparticles with respect to increasing Ethanol 
concentration in the desolvating “cocktail”. b) Size exclusion chromatograms illustrating the efficacy of purification 
in removing residual protein species from final nanoparticle preparations. 
Importantly, the nanoparticles are fractionated in the void volume of the column as the Superdex 
200 Prep Grade (fractionation range 10 kDa – 600 kDa for globular proteins) is unable to resolve 
particulates of this size (GE Life Sciences, 2000). Samples were run as an isocratic pulse with an 
injection volume of 100 µL at a flow rate of 0.1 ml/min. Purified nanoparticles were more dilute 
than the un-purified samples due to the nature of the filtration technique, which accounts for the 
variation in  peak absorbance between the two samples. Normalising (by nanoparticle peak height) 
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the spectra for the purified sample to the concentration of the un-purified sample illustrates that 
the protein impurities that elute later (32-40 minutes) still do not appear in the purified sample.  
3.3.4 Particle Yield Analysis 
In order to assess particle yield, a simple mass balance was applied and the protein content of the 
nanoparticles assayed after formation and purification using a BCA assay, with a standard curve of 
BSA used to determine concentration. It was found that, for a nanoparticle preparation with an 
average size of 73 nm, 76% of the original monomer solution was incorporated into the formed 
nanoparticles; a figure which corroborates well with similar yield quantitation (Arroyo-Maya et al., 
2014).  
 
Fig. 3.5 NativePAGE™ Gel of Bovine Serum Albumin & Bovine Serum Albumin Nanoparticles of various 
sizes: (i) Invitrogen model protein ladder superimposed alongside the gel; (ii) NativeMark™ protein ladder utilised 
as a molecular weight standard; Nanoparticles of a variety of sizes:  (iii) 49 nm; (iv) 75 nm; (v) 113 nm; (vi) 
73 nm; (vii) 63 nm & (viii) Bovine Serum Albumin.  
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In addition to colorimetric determination of yield, the NativePAGE™ gel illustrated in Fig. 3.5 
highlights migration of protein and nanoparticle species through a gel under non-denaturing 
conditions. The advantage of using a gel over the other respective orthogonal techniques is the 
increased sensitivity of the technique, as low as 30 ng of protein, compared to 20 µg for the BCA 
assay. The gel indicates that the bulk of the nanoparticle material experienced no migration through 
the gel and remained at the top. The smaller sized nanoparticle preparations ((iii) and (vii)) illustrate 
degrees of streaking which is indicative of a higher degree of polydispersity as the average size of 
the nanoparticle preparation decreases.  
Worthy of note is the upper band in lane (viii) (BSA protein) which is likely trimeric BSA, though 
the bulk of the sample is monomeric BSA. This phenomenon is observed in similar experiments 
involving gel electrophoresis of BSA (Wise, 2000) and confirmed by HPLC (Shodex, 2018). 
Interestingly, a faint band at 66 kDa is evident for the smallest nanoparticle preparation [(iii) 49 
nm], indicating the presence of some monomeric protein in the crude preparation. This evidence 
supports the fact that the yield is different depending on the organic solvent produced, which 
corroborates with the data in Fig. 3.6 and that smaller nanoparticles exhibit lower yields.   
 
Fig. 3.6 Bovine Serum Albumin nanoparticles manufactured using varying ratios of Ethanol & Methanol (mean 
± SD, n = 3); the line & scatter plot represents protein yield whilst the bars represent the average particle size for 
each preparation. There is a positive correlation between particle size and yield and this conclusion supports the 
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hypothesis that the larger the nanoparticle produced, the more protein is incorporated and thus the higher the yield. 
The organic solvent composition will also play a role here, with more Ethanol comes higher degrees of hydrophobic 
interaction, “opening up” the protein molecules to reveal more lysine residues for incorporation with other proteins 
and nanoparticle nucleation sites.  
This concept is discussed further in Section 3.3.8, but in essence the more polydisperse the 
preparation is, the more likely the inclusion of smaller mis-formed components existing in the 
crude nanoparticle preparation, as artefacts of the nanoparticle manufacturing methodology. These 
could be stray semi-cross linked polypeptide strands from the desolvated BSA, for instance, which 
could experience some, but limited migration into the gel.   
3.3.5 Molecular Weight Analysis 
Nanoparticle preparations were also analysed by size-exclusion chromatography using Sephacryl 
S-500 HR, a resin with a high MR fractionation resin (up to a maximum of 100 MDa) but also with 
a range broad enough to also resolve BSA.  In reality, for all nanoparticle preparations loaded onto 
the column, the nanoparticle fractions were isolated in the void volume of the column, illustrating 
that even the smallest nanoparticles formed were too large to be retained and fractionated by this 
matrix.  
Based on work by Erickson in 2009, who determines a physically intuitive parameter for the size 
of protein species and assuming a spherical nanoparticle shape, a density of 1.37 g/ cm3 and a 
partial specific volume of 0.73 cm3 /g (typical values for protein), the molecular weight can be 
derived using the following equations: 
Equation 1: 
𝑉 =  
(0.73 𝑐𝑚3/ 𝑔)  × (1021𝑛𝑚3/𝑐𝑚3) 












 V (nm3) is the volume occupied by a protein of mass M (Daltons) 
 Rmin is the minimal radius of a sphere that could contain the given mass of protein  
By rearranging Equation 2, it is possible to calculate the molecular weight of a given protein 
nanoparticle preparation. On this basis, the 75 nm nanoparticle preparation has a theoretical 
molecular weight of 147 MDa.  
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Nano-tracking analysis (further discussed in Section 3.3.6) reveals the concentration of 
nanoparticles per millilitre (~2.1 X 1014 nanoparticles/ml) produced for the 75 nm nanoparticle 
preparation. Knowing the original starting concentration of the protein stock (10% solution), 
accounting for a 76% yield (revealed through the BCA assay) of BSA particles incorporated into 
nanoparticles (moles of BSA multiplied by Avogadro’s constant) and the number of nanoparticles 
generated (through NTA analysis) the average molecular weight of the nanoparticle preparation is 
calculated to be ~ 218 MDa; a value in the same ball-park as the theoretical estimation as set out 
by Erickson. 
To put this into context, the target virus of this chapter, Adenovirus type 5, has a molecular weight 
of ~ 170 MDa and a hydrodynamic size of ~ 80 to 100 nm (Horwitz et al. 1986; Klyushnichenko 
et al. 2000; Trilisky & Lenhoff 2007).   
3.3.6 Dynamic Light Scattering vs. Nano-Tracking Analysis  
Both dynamic light scattering (DLS) and Nano-tracking Analysis (NTA) were utilised as 
orthogonal techniques to assay protein nanoparticle preparations for their size distribution 
profiles. The two methods both work on similar principles, in that size distributions can be derived 
from the diffusion coefficient of the Stokes-Einstein equation, however their methodology varies 
slightly, as will be explained in the following sub-sections.  
3.3.6.1 Dynamic Light Scattering 
DLS functions by illuminating a nanoparticle suspension with a 633 nm He-Ne laser and analysing 
the fluctuations in intensity to relate the Brownian motion (the random collision of particles with 
surrounding liquid molecules) of the particles to their size. The Stokes-Einstein equation (see 
Chapter II, Equation 3) highlights an inverse relationship between particle size and its diffusional 
coefficient, i.e. the smaller the particle, the quicker its speed due to Brownian motion. 
Note that this theory relies on a number of assumptions; the particles are perfectly or near-perfectly 
spherical in shape, monodisperse and homogeneous in solution (with equivalent density) and that 
the average particle size is significantly smaller than the wavelength of incidence light to avoid 
multiple scattering and such that the Rayleigh approximation remains valid.  
A speckle pattern (see Fig. 3.7 b)), consisting of bright and dark patches, is created by the scattered 
light of the nanoparticles on a detector screen. Bright areas are created by particles in the same 
phase, constructively interfering to form a well-lit patch, whereas darker patches are formed where 
the phase additions are mutually destructive, cancelling one another out. This pattern of light and 
dark will be constantly changing as the particles randomly move under Brownian motion and 
scatter light differently. This causes an overall fluctuation in intensity with time and it is this rate 
of change in intensity that is used to calculate the size distribution of particles.  
A digital correlator in the instrument measures the degree of similarity between the intensity signal 
of a spot on the speckle pattern a defined point in time (t) and a short (usually nanoseconds) time 
later (t + δt). As t → ∞, the correlation function decays from one (perfect correlation) to zero (no 
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correlation). This rate of decay is much faster for smaller particles than for larger particles and thus  
the Malvern Zetasizer software utilises its proprietary algorithm to extract decay rates for various 
size classes to create a particle size distribution.  
 
Fig. 3.7 Theoretical determination of particle size distributions using DLS. a) Particles causing a scattering of 
light creating b) a resultant speckle pattern on a detector screen. c) The relationship between particle size and 
correlation function decay rate and d) the three types of distribution achievable using the Zetasizer Nano ZS 
(Malvern Instruments, 2004).  
Fig. 3.7 d) is an example of a bi-modal sample containing equal numbers of 5 nm & 50 nm 
nanoparticles. The first output from the Zetasizer is that of an intensity distribution, which can be 
subsequently manipulated into volume and number distributions. For the intensity distribution, 
the area of the 50 nm peak is 106 times larger than the 5 nm class due to the fact that larger particles 
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 I is the intensity of light scattered  
 I0 is the intensity of the beam of unpolarised light from the laser and λ is its wavelength  
 R is the distance to the particle  
 θ is the scattering angle 
 d is the diameter of the theoretical sphere with a refractive index n  
According to Rayleigh’s approximation (above), the intensity of light scattered is proportional to 
a sixth of the power of its diameter (Seinfeld and Pandis, 2006).   
The volume distribution indicates a peak area 103 times larger for the 50 nm particle class, relative 
to the 5 nm one. This is due to the fact that the volume of a sphere is proportional to a third of 
its radius (Volume of a sphere =  
4
3
𝜋𝑟3). Finally the number distribution displays both peaks 
with equal areas as both populations have an identical number of particles (Malvern Instruments, 
2004).  
It is possible to convert the basic intensity distribution output from the software to a number 
distribution (and subsequently volume distribution) using the following simplified relationship:  
Equation 4:  
𝐼(𝑥) = 𝑁(𝑥)𝑀(𝑥, ñ𝐷,ñ𝑃) 
Where: 
 I(x) & N(x) represent the DLS intensity and number distributions, respectively  
 M(x, ñD, ñP) is the Mie Scattering formula with D and P representing the dispersant and 
particle characteristics 







It is important to note that the converted distributions are sensitive to minute errors in correlation 
function data collection, which can be multiplied multi-fold in the conversion from intensity to 
number and volume distributions (Nobbmann, 2016). For this reason, the DLS data displayed 
herein is that of the unedited and unconverted intensity data.  
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3.3.6.2 Nano-Tracking Analysis  
Although based on the principle of the Stokes-Einstein equation and deriving the diffusion 
coefficient, NTA mechanistically operates quite differently. The technique still requires 
illumination of the particles, this time housed in a metal flow cell, using a focussed 80 µm 635 nm 
red laser.  
Rather than interpreting their intensity fluctuations, the nanoparticles are visualised and tracked 
directly and in real time using NTA. The particles behave as Rayleigh scatterers which scatter light 
isotropically, provided they are ≤ 100 nm in size. Based on the Brownian motion of each particle 
and the path it takes, the NTA tracking analytical tool can determine the mean squared 
displacement (as well as predict statistically accurate trajectories of particles) and thus derive 
suitable displacement coefficients for each individual particle.  
Given the temperature and viscosity of the sample, as well as an estimation of the Boltzmann 
constant, the software uses the Stokes-Einstein principle to calculate a hydrodynamic radius for 
each particle that is tracked. A particle size distribution can be generated from this data and as each 
and every particle is tracked (in a given volume – 400 µL) the distribution units can be given as 
particles per ml (NanoSight Ltd., 2007).  
3.3.6.3 DLS vs. NTA 
In deciding the optimal technique to characterise the protein nanoparticle distributions, both DLS 
and NTA have a lot to offer whilst also having significant drawbacks which require consideration.  
Fig. 3.5 highlights some important distinction between DLS and NTA; firstly it is evident that, for 
the same nanoparticle preparation, NTA has a much higher peak resolution that DLS, as the 
particle tracking technique is able to distinguish two peaks within the population distribution at 62 
and 85 nm, which is not recognised by the DLS data, which presents a z-average particle mean 




Fig. 3.8 Particle size distribution of a BSA nanoparticle preparation using DLS (- -) and NTA (─) analytical 
techniques.  
A common issue encountered with DLS is that because all particles are assayed simultaneously, 
larger particles cause higher degrees of scattering and thus can skew the distribution, concealing 
the existence of smaller sub populations within the sample. This is a limitation of the intensity 
weighted z average correction factor used by DLS (Mehtala and Wei, 2014).  
Generally DLS analysis produces much broader peak distributions as compared to NTA (Mehtala 
and Wei, 2014) with a peak resolution > 3 fold difference in diameter compared to NTA’s < 0.5 
and suffers from large errors between measurements due to changes in shape and position between 
measurements. In addition, NTA has little sensitivity to large contaminants such as dust and 
microorganisms, whereas this can heavily skew the intensity weighted z-average of DLS.  (Filipe, 
Hawe and Jiskoot, 2010).  
This phenomenon has been encountered and reported on numerous occasions in analysis of 
nanoparticles using these two orthogonal techniques and conclude that NTA produces narrower 
distributions and a much higher, unbiased peak resolution for samples which are not perfectly 
mono-disperse (Carr and Malloy, 2007; Filipe, Hawe and Jiskoot, 2010; Gercel-Taylor et al., 2012; 
Mehtala and Wei, 2014; Nobbmann, 2016). 






















































One significant advantage of DLS over NTA is the simplicity of the approach. Preparation for 
analysis is straightforward and only requires aliquoting sample into a disposable polystyrene cuvette 
and placing into the holder ready for measurement. Data input into the software prior to analysis 
is minimal, only requiring the user to set the temperature and viscosity conditions, as well as the 
refractive index of the sample. The built-in attenuator within the DLS system adjusts laser 
exposure to the sample automatically, which is both time saving but also accommodates a wider 
range of sample concentrations; ~108-1012 particles/ml compared to NTA’s ~107-109 particles/ml 
(Filipe, Hawe and Jiskoot, 2010).  
An interesting disadvantage of the NTA system is the exposure of sample to aggregate inducing 
surfaces such as stainless steel, nylon tubing and rubber O-rings as well as shear force as the sample 
is injected into the sample chamber, though this becomes more relevant when dealing with protein 
aggregates and antibody products; rather than protein nanoparticles as viral mimics which tend to 
be more stable and aggregation resistant (Bee et al. 2009; Bee et al. 2010; Remmele et al. 2015).   
The NTA standard operating procedure is somewhat more complex, requiring a higher degree of 
operator skill and experience to be able to iteratively dilute the sample and judge the optimum 
conditions for video capture and analysis (e.g. low flaring, minimal blurring and appropriate 
thresholding) to achieve accurate PSDs. The dilution steps and temperature equilibration makes 
the NTA process much lengthier than DLS as well as having to ensure the sample chamber is 
clean before and after sampling. Filipe et al. 2010 estimate that NTA analysis can take up to 12 
times longer per measurement compared with DLS, an approximation that corroborates with the 
experience in collecting the experimental data for this particular chapter.  
The additional time consumed does derive benefits however, in that, as mentioned prior, the 
samples can be visualised and counted to give concentrations in particles/ml, which have 
facilitated molecular weight approximations as stipulated in Section 3.3.5. Furthermore, the peak 
resolutions are higher, distributions narrower and accuracy of the technique is much better for 
polydisperse samples. 
Given the methodology and appraisal of both the techniques above, the speed of analysis for DLS 
was highlighted as the main factor in choosing between the techniques moving forward. Given the 
multitude of nanoparticle preparations that are analysed in this chapter and subsequent chapters, 
analytical throughput is a key factor. DLS evaluates each preparation in ≤ 5 minutes and sample 
conditions and methods can be pre-programmed to facilitate rapid set-up. 
Whilst it was accepted that the technique displayed inferior peak resolution and was limited by 
intensity weighted averages, these factors were not deemed detrimental in identifying evident 
trends in our subsequent experimental analysis of nanoparticle preparations. A big contributor to 
this was the low polydispersity quotients that were achieved for the majority of the nanoparticle 
preparations made, which aided in reducing the errors caused by PSDs based on an intensity 
weighted average. Despite not being able to evaluate nanoparticle concentrations in particles/ml 
for all the preparations made, an alternative protein assay was utilised (see Section 3.2.3.3.1) to 
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provide quantitative data for the nanoparticles; an asset which was useful in both yield analysis and 
chromatographic media testing in Chapter V of this thesis.  
One final advantage is the convenience of being able to run both sizing and zeta-potential 
measurements using the same Zetasizer Nano ZS equipment, with the same software and sample 




















3.3.7  DLS Validation 
In evaluating nanoparticles by DLS, an appropriate degree of dilution is required in sample 
preparation to prevent excessive light scattering but also to achieve a sufficient level of laser 















Fig. 3.9 Particle size -□- & polydispersity indices -■- for a) un-purified & b) purified nanoparticles as a function 
of nanoparticle concentration (mean ± SD, n = 3). The data illustrates the importance of a correct dilution factor 
prior to analysis via DLS, to avoid issues of noise and contaminants skewing the average particle size and PDI 
data. At lower concentrations for both samples, insufficient levels of scattering occur and errors creep into the 
deconvolution of the speckle pattern to achieve a reliable PSD and PDI. This is further evidenced as, at lower 
nanoparticle concentrations, the Zetasizer attenuator index was set at value at 11, indicating no laser attenuation 
in an attempt to collect any available scattering signal. More pronounced increases in average particle size and 
polydispersity are observed at lower concentrations for un-purified samples, likely due to an increase in noise or 
contribution from contaminants in the sample. The lower the dilution, the higher the concentration of organic solvents 
in the sample, which can contribute to a change in the refractive index of the solution and again skew the particle 
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size distribution generated. In a similar vein, increased dilution improves the validity of the Smoluchowski 
approximation (aqueous solutions), thus improving the accuracy of the measurements; see Equation 6 for detail. For 
the purified samples in b), average particle size and PDI remain relatively constant across all dilutions greater than 
0.01 mg/ml, likely due to removal of contaminants during the centrifugation/filtration process. 
3.3.8 Impact of the Organic Solvent Composition on Nanoparticulation 
In order to effectively adjust the size of the nanoparticles produced, the composition of the organic 
solvent “cocktail” used in the desolvation step was adjusted. Fig. 3.10a illustrates the impact of 
variation of concentrations of Methanol and Ethanol, both as mixtures and in aqueous solution, 
on the average particle size and polydispersity indices of the nanoparticle preparations. With 
respect to polydispersity, the general trend observed was that smaller nanoparticle preparations 
exhibited larger PDIs; this is discussed further in Section 3.3.9.   
Observations from all nanoparticle preparations, both in method development and in producing 
nanoparticles for further characterisation, indicated that polydispersity varied batch to batch, 
dependent on a number of factors, including ambient conditions, stirrer speed, vessel size, flea size 
etc. and not just organic solvent-dependent. A polydispersity index < 0.2 was used as a general 
rule of thumb to categorise good nanoparticle preparations from poor ones. Once the method had 
been optimised, the majority of nanoparticles fell within these acceptability criteria.  
To mimic the adenovirus type 5 viral vectors, the preparation used was a 70 : 30 MeOH : EtOH 
organic solvent mixture, which provided a relatively monodisperse preparation with an average 
particle size of 100 nm, approximately the same size as the vector itself (Trilisky and Lenhoff, 
2007). 
Three batches, produced using varying organic solvent conditions, were purified and stored at 4 
⁰ C in deionised water and re-analysed after a time period > 100 days to assess stability. 
Promisingly, little deviation in size (≤ 9 nm) and PDI (≤ 0.03) was observed on the stored samples 
indicating that the samples are stable for prolonged periods of time. This provides a significant 
advantage of these nanoparticles over bona fide viral vectors, as the latter have maturation life-cycles 
and will thus change their capsid composition and potentially their stability in solution, with respect 




Fig. 3.10 The impact of variations in organic solvent on a) average BSA nanoparticle size and polydispersity 
index & b) the relationship between the dielectric constant of the organic solvent mixture and the eventual average 
particle size produced (mean ± SD, n = 3) with a non-linear regression polynomial inverse first-order fit curve. 
Note that these protein solutions were initially dissolved in 10 mM NaCl, rather than in Deionised Water as with 
Fig. 3.4 & 3.6, though the trend holds true in both instances. See 3.3.10 for further discussion into the importance 
of ionic concentration on nanoparticle formation.  
A trend was observed between particle size and an increase in the dielectric constant of the 
desolvating mixture, as per Fig. 3.9. b). As discussed in Chapter II, 2.3.3, the dielectric constant 
(or real permittivity) is a measure of the polarisablilty of the molecules in the sample and their 
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ability to store electrical energy. The dielectric constant of each organic solvent mixture is 
calculated by totalling the dielectric constants of each constituent component of the desolvating 
“cocktail”, as per the Silberstein Equation, below (Arnold et al., 1985): 
Equation 5: 
𝐷𝜀 =




 Dε is the dielectric constant of the mixture (kg m/ (V /s)) 
 P is the volume fraction for each solvent fraction, 1 to n 
 ε is the dielectric constant for each pure organic solvent (kg m/ (V /s)) (Ethanol: 24.6, 
Methanol: 32.6 & Deionised Water: 78.54) (Furniss et al., 1989) 
A solvent mixture with a higher dielectric constant creates a higher electrical flux and also better 
protein hydration in situ (von Storp et al., 2012; Mohammad-Beigi et al., 2016). Henry’s equation, 
below, describes the inversely proportional relationship between the zeta potential (ζ (V)) of the 







 Uε is the electrophoretic mobility of the protein (m2 /V.s) 
 η is the absolute zero-shear viscosity of the surrounding medium (kg/ m.s) 
 ε is the dielectric constant of the surrounding medium (kg m/ (V /s)) 
 f(κα) is the Henry function (dimensionless), the ratio of a particle’s radius (a) to its Debye 
length ((1/κ) - the radius of a spherical, charge-carrying particle and its net electrostatic 
effect). The Smoluchowski approximation states f(κα) = 1.5 for particles > 20 nm in 
diameter in aqueous (or ionic) media (Lowry et al., 2014).  
Thus at high dielectric constants, the protein molecules exhibit less charge repulsion and thus 
smaller, more compact and tightly-cross linked nanoparticles are formed. 
With respect to particle size, as evidenced in both Fig. 3.4 and Fig. 3.10 a), particle size is correlated 
to the composition of organic solvents used for desolvation. During desolvation, the aqueous 
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protein is thermodynamically destabilised upon addition of the organic solvents due to increase in 
the protein’s chemical potential and depending on the type of solvent. Depending on the solvent 
composition, varying degree of denaturation may occur due to hydrophobic interaction with non-
polar side chains, increasing the chemical state of the protein.  
Both solvents have the ability to behave as proton donors and can form strong intermolecular 
(hydrogen bonding, dipole-dipole, hydrophobic and van der Waals) interactions with the protein. 
This causes disruption to the protein’s alpha helical and beta sheet/turn/coil and un-ordered 2⁰ 
structures occur. This ultimately causes denaturation and the formation of un-ordered aggregates, 
which are subsequently cross linked into nanoparticles. 
The solvents themselves also play a role; a higher proportion of Ethanol in the purely organic 
solvent mixtures results in the average particle size increasing. This is due to the fact that Ethanol 
allows for better disruption of the protein’s hydrophilic layer, causing higher disruption to the 
protein’s 2⁰  structure, ultimately causing more pronounced denaturation and the formation of 
larger clusters or “building blocks”, which are ultimately cross linked into larger nanoparticles. 
Systematic studies on the denaturation transitions of proteins found that “the effectiveness of 
alcohols as protein denaturants increases with increasing chain length and hydrocarbon content, 
in conformance (with) the disorganisation of the hydrophobic interior of proteins revealed by 3D 
X-ray structures” (Herskovits, Gadegbeku and Jaillet, 1970).  
High Ethanol concentrations are better than Methanol-dominant “cocktails” at solubilising the 
non-polar residues that form the albumin core (mainly due to the additional methyl group), as 
confirmed by more drastic changes in secondary structure, seen through CD spectral data; see 
Section 0 and Mohammad-Beigi et al. 2016.  
This corroborates well with experimental observations, whereby desolvating cocktails high in 
Methanol took significantly longer to exhibit solution turbidity (compared to Ethanol), indicating 
that Methanol is less effective at disrupting the albumin’s structure.  
By applying a more water-miscible, protic, polar solvent (such as Methanol, rather than Ethanol)9 
to an aqueous protein solution, a retarded decrease of the mixture’s polarity occurs and the protein 
molecules experience a slower and more ordered dehydration. In addition to this, Methanol has a 
slightly lower high dipole moment, relative to Ethanol (1.6 and 1.7, respectively) which limit the 
formation of large hydrogen bond lattices and larger nanoparticulate structures (Pagni 2005, 
Mohammad-Beigi et al. 2016).  
As Methanol has a higher dielectric constant, higher addition volumes can have an impact on the 
interfacial tension and enthalpy of the proteins, creating a larger protein surface area to volume 
ratio for the zero-length glutaraldehyde cross-linker to interact with the exposed lysine residues 
which in turn forms tighter cross-linked and eventually smaller nanoparticles. This coupled with 
                                                 
9 The Hildebrand solubility parameters for Water, Ethanol and Methanol are 48, 26.2 and 26.9, respectively (von Storp 
et al., 2012; Mohammad-Beigi et al., 2016). The parameter is a numerical indication of solvency characteristics and can 
be used as a measure of interaction between molecules (Burke, 1984).  
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the fact that higher volumes of Methanol will reduce the overall viscosity of the solution 
(Methanol: 0.55, Ethanol 1.10 & Water 1.00, all centipoise) (Sigma Aldrich, 2018a) and thus 
promote better mixing and cross-linking reactivity due to elevated diffusion coefficients, as 




3.3.9 Relationship between Size & PDI  
Adjusting the composition of desolvating agent invariably causes changes in the particle size and 
polydispersity of the preparations. It was found that there is a distinct inverse relationship between 
increasing Ethanol concentration (and particle size) with the polydispersity indices of said 
preparations, as illustrated in Fig. 3.11.  
 
Fig. 3.11 The relationship between increasing Ethanol concentration (in an Ethanol-Methanol desolvating 
mixture) on the average particle size (grey columns) with respect to polydispersity indices -□- and ζ-potential (at pH 
8)  -■- of the BSA nanoparticles (mean ± SD, n = 3).  
The relationship between solvent ratios and size has been discussed earlier in the chapter; however, 
Fig. 3.11 highlights an important trend between solvent concentration and PDI. It is hypothesised 
that as the proportion of Ethanol decreases (and thus Methanol increases), the polar groups on 
the surface of the protein, as well as the solvation layer surrounding the protein, are more strongly 
disrupted when the organic solvent makes contact with the aqueous protein solution.  
Additionally, the lower hydrophobic potential that comes with higher Methanol concentrations 
may result in more disordered unfolding and aggregation mechanisms, disrupting the self-assembly 
process of the nanoparticles. This is further corroborated by the increased time span required to 
observe solution turbidity with desolvating cocktails of higher Methanol concentration, indicating 
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that the time window to form disordered aggregates is longer, which could lead to higher 
polydispersities for the nanoparticle preparation.  
A colloidal suspension with predominantly smaller nanoparticles will have stronger gap 
interactions due to an increased surface area: volume ratio, resulting in increased van der Waals 
and depletion interaction (and subsequent decrease in the height of the potential barrier), which 
can cause the nanoparticles to flocculate together; an entropic-driven process to reduce the surface 
energy of the particles (Kovalchuk and Starov, 2012). This effect may cause an increased deviation 
in average particle size due to the existence of multi-particle agglomerates in suspension, resulting 
in an apparent increase in polydispersity index for the preparation. This should be balanced against 
the increase in repulsive forces that should theoretically occur with smaller nanoparticles; though 
Fig. 3.11 suggests that there is no significant relationship between smaller particle sizes and ζ-
potential, rather that the surface charge is more a reflection of the re-ordering of amino acids on 
the surface of the nanoparticles during desolvation. This further supports the hypothesis of more 
significant attractive forces contributing to higher polydispersities.  
It should also be mentioned that the degree of impact on PDI could be a result of the impact of a 
few large particles in a suspension of smaller nanoparticles, as discussed prior in Section 3.3.6.3. 
Common contaminants, such as gas bubbles, can appear as artefacts in light scattering 
measurements and will scatter more intensely than smaller particles. This will cause a higher degree 
of polydispersity in smaller nanoparticle preparations relative to larger nanoparticles, where the 
contaminants will fit closer to the mean of the particle size distribution (~ 100 nm).  
3.3.10 Relationship between Size & Ionic Strength 
An important factor which plays an influential role in the average particle size of the nanoparticles 
is the ionic concentration of the starting 10% protein solution. Based on previous work, Langer et 
al. in 2003 stated the requirement of a small amount of NaCl in order to reliably adjust the pH of 
the solution, especially at high protein concentrations, as per Westcott 1978 & Salis et al. 2006, 
who conclude that  a background electrolyte is required to improve the reliability of a pH reading 
using a glass electrode.  
A buffered solution was also attempted by Langer et al., however these experiments were thwarted 
due to interference with the desolvation, resulting in large aggregates, salt precipitation and non-
uniform nanoparticles. The cross-linking process was also affected, particularly with TRIS buffer 
due to its primary amino group competing for substrate with the lysyl residues on the protein 
(Langer et al., 2003).  For this reason, 10 mM NaCl was adopted as a background electrolyte for 
accurate pH readings, achieving predictable and reproducible nanoparticle characteristics.  
However, it was found that the presence of 10 mM NaCl had an impact on the average particle 
size produced after cross-linking, as illustrated in Fig. 3.12. Despite the issue of pH measurement 
reliability, consistent nanoparticles were produced using deionised water as a diluent which 
followed the same trend as with 10 mM NaCl over a range of desolvating conditions, with a 50 – 
70% reduction in average particle size.  
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It is hypothesised that the salt behaves as a surfactant and the Na+ ions shield charges on the 
protein / nanoparticle surface (see Fig. 3.13a)), thus reducing protein charge repulsion and 
enhancing hydrophobic interaction mechanisms between protein molecules and intermediate 
nanoparticulate structures, causing them to flocculate and increase the overall average particle size, 
for a given desolvating condition.  These findings corroborate well with those of other research 
groups, namely Jun et al. 2011 and Galisteo-González & Molina-Bolívar 2014, who also indicate a 
drop in the zeta potential with increasing ionic strength.  
Fig. 3.12 The impact of 10 mM NaCl (circles -○-/-●-) vs. deionised water (squares -■-/ -□-) on the average 
particle size (filled symbols) and polydispersity indices (open symbols) of the BSA nanoparticles, with respect to 
increasing Ethanol concentration (in an Ethanol / Methanol mixture (mean ± SD, n = 3)).  
Interestingly, the polydispersity indices are overall slightly better for the 10 mM NaCl samples 
compared to those produced in water, though this may more likely be due to the relationship 
between size and PDI, as discussed in 3.3.9. 
3.3.11 Zeta Potential & Isoelectric Focussing 
In order to evaluate the surface charge of the nanoparticles produced under various manufacturing 
conditions (as illustrated in Fig. 3.11), zeta potential analysis was employed. With the dielectric 
constant and viscosity of the suspending medium is known and by using the Smoluchowski 
approximation it is possible to measure the electrophoretic mobility of the nanoparticle suspension 
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and thus derive the zeta potential using the Henry Equation (Equation 6). The zeta potential of a 
colloid in suspension is explained in more detail in Fig. 3.13a.  
The sample is placed in a micro-electrophoresis cell with +ve and –ve charged electrodes at either 
end (see Fig. 3.13b) and electric field is applied across the electrolyte solution, causing migration 
of the particles towards the electrode with opposing charge. Equilibrium is reached between this 
attractive force and resistive viscous forces in the medium, such that the particles then move with 
constant velocity which is measured and termed the particle’s electrophoretic mobility.  
In order to calculate the zeta potential for a nanoparticle preparation, the velocity of the particles 
is measured using Laser Doppler Velocimetry (see Fig. 3.13c). Here an incident beam is applied to 
the capillary cell and the scattered light from the migrating particles are collected. Nanoparticles 
that move through the measurement volume will result in fluctuations in the intensity of light with 
a frequency which is proportional to the velocity of the particles.  
The beam is first run through compensation optics, to correct for cell wall thickness and dispersant 
refraction as well as to maintain alignment, and combining optics, to relate and combine the 
received beam to a reference beam from the laser source (via a beam splitter placed behind the 
measurement cell). An optical modulator with an oscillating mirror is also used to determine the 
positive or negative sign of the zeta potential. The combined beam is then run through a digital 
signal processor to determine the signature frequencies from the scattered light and translated via 
the Malvern Zetasizer Nano ZS software; here a frequency spectrum is generated and the rate of 
fluctuation used to calculate the velocity of the migrating nanoparticles and thus the 




Fig. 3.13 a) An illustration of the electrical double layer that surrounds each protein nanoparticle in a suspension. 
A two-part liquid layer surrounds each particle, the inner layer is known as the Stern layer, where counter-ions are 
strongly attached and an outer, more diffuse layer where there is a significantly weaker interaction between the ions 
and the particle. A boundary exists within the diffuse layer where the ions and particle are stable, whereby when the 
particle moves the ions within the boundary move with the particle; this boundary is termed the slipping plane, or the 
surface of hydrodynamic shear. It is the potential at this boundary that is the zeta potential. b) The folded capillary 
cell used to carry out micro-electrophoresis to determine the electrophoretic mobility of the particles. c) Laser Doppler 
Velocimetry measuring fluctuations in intensity signals from scattered light to determine the velocity of the migrating 
particles. Images and theory courtesy of Malvern Instruments 2004.  
An important characteristic to determine is how the surface charge of a species changes in different 
pH environments, especially in the context of purification systems, which is discussed in 
subsequent chapters. In order to assess this, isoelectric focussing was carried out whereby the zeta 
potential of the BSA nanoparticles was measured through incremental changes in pH buffer 
conditions. Using this technique it is also possible to determine the isoelectric point of the 
nanoparticles, which has significance both for colloidal stability and in tailoring its purification 
strategy.  
Figure 3.14 highlights changes in the isoelectric point dependent on the size of the nanoparticles 
(a), as well as how the size of the nanoparticle changes as the pH of the suspension approaches 
and diverges from the isoelectric point (b). Interestingly, the larger nanoparticle preparations 
present an IEF curve shape and pI similar to that of the native protein, whilst the smaller 
nanoparticles have more acidic pI values, with less overall charge at both extremes of the curve.   
With respect to isoelectric point deviations, as discussed in 3.3.8, increased Methanol 
concentrations have the potential to increase the efficiency of cross-linking reactions by “opening 
up” the protein structure, creating a larger surface area for cross linking of the lysine residues, 
producing smaller, tighter cross-linked nanoparticles. As lysine is a basic residue, with a pI of 9.7 
(Carey, 2000), logically a higher level of cross-linking would result in more lysine residues being 
used for cross-linking and thus an acidic shift in the pI, compared to larger nanoparticles 


















Fig. 3.14 a) Isoelectric focussing curves of BSA & BSA Nanoparticles of various sizes and b) changes in ζ-
potential -■- and average particle size -□- of an 85 nm BSA nanoparticle as a function of varying pH. 
Referring to Fig. 3.6, the yield (and thus, degree of incorporation of starting protein) increases as 
a function of average particle size. As more BSA molecules are incorporated into each nanoparticle 
(for a constant cross-linker concentration), the efficiency of glutaraldehyde in cross-linking 
proteins drops, resulting in larger, more loosely bonded nanoparticulates. It is therefore reasonable 
to assume that the larger nanoparticles experience less amino acid structural change as a result of 
cross linking and so will exhibit a similar isoelectric point to that of the native protein. 
When considering the magnitude of ζ-potential at pH’s away from the pI, the IEF curves suggest 
that the smaller nanoparticles internalise their polar residues (and present hydrophobic patches 
onto the surface of the nanoparticle) to a higher degree than the larger nanoparticles. It is 
hypothesised that this may be due to the method of manufacture of the nanoparticles, as the higher 
methanol concentrations required in the desolvation process to create smaller nanoparticles cause 
a higher degree of disruption to the solvation layer around the protein, allowing for better exposure 
and re-ordering of hydrophobic residues on the surface of the particles.   
Considering that lysine is a charged, basic residue, one would expect that better cross-linked, 
smaller nanoparticles would have a more acidic pI and lower magnitudes of charge away from the 
pI compared to larger nanoparticles and native BSA. This is largely down to more efficient cross-
linking removing free positively charged amino groups, thus whilst titrating toward basic 
conditions, fewer hydroxyl ions are required to reduce the colloidal surface charge to zero (or to 
reach pI), as confirmed by the work of Weber et al. in 2000 and Langer et al. in 2003.  
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It should also be mentioned that, as indicated by Fig. 3.14, the ζ-potential of the colloids at 
operating pH is independent of size or solvent preparation. BSA has 26 arginine (pKa = 12.48), 
17 histidine (pKa = 6.04) and 60 lysine (pKa = 10.75) (all positively charged at pH 8.0) and 59 
glutamic acid (pKa = 4.10) and 40 aspartic acid (pKa = 3.66) (both negatively charged at pH 8.0) 
residues (Henchoz et al., 2007). It is the ordering of these respective residues at the surface of the 
nanoparticle which will ultimately determine the nanoparticle species’ overall surface charge.  
When considering Fig. 3.14 b), as the suspending medium experiences a basic-shift away from the 
colloidal pI, for instance at pH 8.0, the solution counter-ions, in this case Na+, develop a stable 
coating around the colloid; the Stern layer, as illustrated in Fig. 3.14 a). In these conditions, charge 
repulsion prevents any flocculation of the nanoparticles together and keeps the colloids in 
suspension, with a stable particle size of ~ 80 nm.   
Moving towards the isoelectric point through hydrochloric acid titration, the diffuse layer is built 
up with Cl- ions, causing charge neutralisation at the surface of hydrodynamic shear, or the slipping 
plane.  In this scenario, the charge repulsion effect is lost, causing the nanoparticles to aggregate 
together and eventually crash out of solution; this can be seen as at ~ pH 5, the average particle 
size is at its highest (421 nm – a 5 fold increase) with the nanoparticles visually aggregating and 
falling out of solution in the capillary cell. As the suspension transitions to acidic pHs beyond the 
pI of the nanoparticles, the effect is reversed and charge repulsion is restored (with opposite 
charges), preventing aggregation and a restoration of the average particle size.  
3.3.11 Scale Down of Nanoparticle Fabrication 
An ultra-scale down (USD) approach was adopted to facilitate the expeditious screening of 
multiple process parameters in order to determine the key variables which affect the quality of the 
nanoparticles produced. In addition to this, this approach allowed for lower volumes of expensive 
materials (solvent and protein) to be used as well as adopting a single-use approach of disposable 
Eppendorf tubes rather than having to clean 50 ml glass beakers; this would also reduce the risk 
of cross-contamination across batches as well as improve the batch-to-batch reproducibility whilst 
also saving time that would otherwise go into cleaning the glass vessels.  
Figure 3.15 describes how this scale down was carried out and the associated key geometric 
parameters.  The scale down was based on a 10 fold volumetric reduction in working volume, 
adding  100 µL of 10% protein and 400 µL of desolvating agent, before addition of 6 µL of cross-
linker. An important parameter to maintain was the stirrer: vessel diameter ratio, within 
commercially available constraints, thus a micro-flea was used and placed within an Eppendorf 
clamped directly above a magnetic stirrer plate.  
To assess the efficacy and reproducibility of the scale down approach, a direct comparison was 
carried out at both scales under the same desolvating conditions, as illustrated in Fig. 3.14 d). It 
became apparent that although the overall trend in the reduction of particle size with increasing 
dielectric constant was preserved, the average particle size was on average 20-30% larger at the 0.1 





Fig. 3.15 Scale down approach for the manufacture of protein nanoparticles; a) large scale Simax 50 ml beaker 
utilising a 25 x 6 Spinbar® polygon stirrer, b) 2 ml Safe-Lock Eppendorf tube with a 5 x 2 Spinbar® micro-
flea for stirring.  Note that all dimensions are in mm and drawings are not to scale. c) key dimensions and metrics 
for both scales. The Reynolds number (Re) was calculated based on a 10% BSA solution desolvated by a 70: 30 
MeOH: EtOH solvent mixture at a volumetric ratio of 1: 4, resulting in ρ = 836.32 kg/m3 & µ = 0.000872 
N.sm-2 (Chick and Lubrzynska, 1913; Doran, 1995). This dimensionless value would increase proportionally 
with additional Methanol in the mixture.  d) The impact on scale down on average particle size over a range of 
dielectric constants for 50 ml scale -■- and 0.5 ml scale -○-. The native protein was dissolved in 10 mM NaCl 
prior to desolvation, in order to stabilise the high concentrations of protein at lower working volumes. e) The effect 
of increasing stirring rate on a 10% BSA solution desolvated by a 70: 30 MeOH: EtOH solvent mixture at 0.5 
ml scale and the equivalent size for the same conditions at 50 ml scale (mean ± SD, n = 3).  
The disparity in particle size as shown in Fig. 3.15 d) can be attributed to a number of factors and 
is likely a consequence of poor mixing patterns within the Eppendorf. Naturally poorer mixing 
conditions would limit the cross-linking reaction and result in looser, more open-structured and 
ultimately larger nanoparticles forming. In addition, the larger the stirrer: vessel diameter for a 
given power input or rpm, the lower the mixing time and thus the quicker the suspension reaches 
homogeneity and thus at smaller scale (for the same rotational speed) the mixing will be poorer 
(Nienow, 1997).  
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Furthermore, the aspect ratio of the vessel plays a very important role in mixing conditions; the 
ratio is 6 times larger at smaller scale and thus with a single agitator system, mixing is worse and 
time to homogeneity is longer (Afshar-Ghotli et al. 2013).  This is due to the fact that the liquid 
level is much higher above the moving mixer component in the vessel and as such axial mixing 
becomes more difficult to achieve.  
Calculation of tip speed, Reynolds number (Re) and mixing time (Tm) are shown below:  
Equation 7: 
𝑇𝑖𝑝 𝑆𝑝𝑒𝑒𝑑 =  𝜋 . 𝐷𝑠 . 𝑁𝑖 
Where:  
Ds is the diameter of the stirrer (m) 











ρ is the density of the liquid (kg/m3) 
u is the velocity of the solution, in this case the tip speed of the stirrer (m/s) 
D is the characteristic length of flow, in this case the internal diameter of the vessel (m) 
µ is the dynamic viscosity of the liquid (N.sm-2) 










V is the volume of the liquid (m3) 
Ds is the diameter of the stirrer (m) 
Ni is the rotational speed of the stirrer (s
-1) 
Note that the approximation is determined for a Rushton turbine, however this is deemed to be 
the closest estimation available and is kept constant across both scales for the sake of comparison 
(Doran, 1995).  
A further characteristic which is disparate between the two scales is that of the tip speed of the 
stirrer. Fig. 3.14 c) highlights that the tip speed is four times lower at small scale (for the same rpm) 
and thus mixing at the edge of the stirrer is severely limited. In addition to this, the power input 
per unit volume is much lower at the smaller scale (P/V ∝ u2) and thus mixing and circulation 
time will be lengthier, resulting in poorer cross-linking.  
The Reynolds number (Re), which is the relationship between inertial and viscous forces in the 
solution and describes the fluid flow and thus the mixing conditions within the vessel, is used here 
to describe the degree of turbulence in the two systems (Doran, 1995). There is a stark difference 
in the flow patterns; at large scale the flow is turbulent and thus good mixing is achieved, whilst in 
the Eppendorf the mixing is much poorer, characterised by a laminar flow, with smoother fluid 
paths and low momentum convection.  
The final parameter to calculate is, of course, the mixing time, which is based on a relationship 
between the system volume and the diameter of the stirrer (Equation 9). Evidently, the mixing 
time is significantly (12.5 times) longer at small scale indicating that it takes much longer for the 
suspension to reach homogeneity. This can result in an inefficient desolvation and will severely 
limit cross-linking reaction times, resulting in larger nanoparticles forming, as seen in Fig. 3.15 d).  
In order to remediate the inconsistencies in particle size at smaller scale, the stirrer speed was 
systematically increased and average particle size recorded, as illustrated in Fig. 3.15 e). 
Theoretically, to reach the tip speed and mixing time needed to match large scale would require 
rotational speeds of 3000 rpm and 7000 rpm, respectively, which would be experimentally 
unfeasible.  
However, by increasing the rotational speed above 1500 rpm in the Eppendorf vessels, the average 
particle size of the nanoparticles matched that of the 50 ml scale, for the same desolvating 
conditions. For these specific conditions, the tip speed and mixing time are 0.42 m/s and 230 
milliseconds, respectively; not quite the same conditions but a significant improvement. The crucial 
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parameter here is the Re, which for these conditions is 3535, which represents a change from 
laminar flow to transient, verging on turbulent. This indicates that the fluid flow in the vessel has 
changed significantly, resulting in better mixing.  
The justification for not requiring rotational speeds as dictated by identical tip speeds or mixing 
times may be down to the geometry of the vessel; the Eppendorf is round bottomed and thus 
there is less chance of mixing dead-spots due to improved radial mixing and circulation fluid 
dynamics, relative to a rectangular-bottomed vessel like the 50 ml glass beaker. For subsequent 
screening of process conditions, a stirrer speed of 1500-1600 rpm was adopted.  
3.3.12 Influence of Process Parameters 
In order to produce nanoparticles reproducibly and within a controlled size range, it is important 
to understand the impact of variations in manufacturing parameters and how this affects the 
characteristics of the nanoparticle suspension formed. Being able to predict and adjust these 
parameters to target specific sized nanoparticles becomes relevant when attempting to 
manufacture nanoparticles as surrogates of viral vectors. A summary of the experimental factors 
tested are detailed in Fig. 3.16. 
Fig. 3.16 The impact of a) the time of glutaraldehyde addition post-desolvation, b) addition rate of the organic 
solvent mixture, c) pre-treatment of the protein with heat and d) experimental temperature (inset:  4 ⁰ C & 
21 ⁰C) on the average particle size -■- and polydispersity index -□- of BSA nanoparticles (mean ± SD, n = 3). 
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It is important to note here that some operating parameters were not considered for assessment 
based on prior optimisation detailed in literature; the fact that stirring rate should be ≥ 500 rpm in 
order to preserve both particle size and low polydispersity was demonstrated by von Storp et al. in 
2012. The use of 60 µL of cross-linker is to theoretically cross-linker 100% of the available lysyl 
groups on BSA, though cross-linker amount was systematically varied and found to have little 
impact on particle size ranging from 40% to 200% of the theoretical required amount (Langer et 
al., 2003).  
The same group varied the concentration of serum albumin from 2.5% to 10%; the increase to 
10%, whilst causing a slight increase in the eventual particle size, derived the lowest polydispersity, 
relative to lower starting concentrations of protein. These findings were confirmed by both 
Mehravar et al. in 2009 and Galisteo-González & Molina-Bolívar in 2014; the latter related the 


















J is the nucleation rate (per unit volume & unit time 
c is a constant of proportionality  
B is the free energy at the pinnacle of the nucleation barrier  
S is the degree of supersaturation (S = C/C0; Solute concentration (C), Equilibrium solute solubility 
(C0)) 
σ is the interfacial tension at the solid-liquid interface  
Vs is the solute molecule volume 
kB is the Boltzmann constant (1.381 x 10
-23 J/K)(kB = R ÷ NA, where NA is the Avogadro constant, 
6.022 x 10-23) (Reeks, 2011) 
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T is the absolute temperature (K) 
(Genck, 1969) 
A higher concentration of starting BSA results in higher viscosities, which limits the frequency of 
molecular transport of protein from the aqueous solution to organic solvent (as well as the rate of 
cross-linking), slowing the nucleation rate, allowing fewer and larger nucleation sites to form, 
facilitating the self-assembly of larger nanoparticles in more ordered structures, reducing the 
polydispersity too. However, higher protein concentrations also improve the degree of 
supersaturation (S), increasing the rate of nucleation , which could result in smaller nanoparticles 
forming (Langer et al., 2003; Galisteo-González and Molina-Bolívar, 2014). These counter-acting 
influences may account for the only slight increase in particle size.  
A protein: solvent ratio of 1: 4 was chosen based on literature and experimental observation. In all 
desolvating conditions, 4 ml of organic solvent was sufficient to observe turbidity in the solution, 
indicating appropriate unfolding of the protein and the beginning of the self-assembly process. 
These observations were confirmed by Weber et al., who found little compromise to particle size 
also assessed the yield of protein and found that the degree of incorporation into the nanoparticles 
drastically improved as the ratio increased from 1: 0.5 to 1: 4 (Weber et al. 2000). 
With respect to cross-linking incubation time, once again both literature and experimental trial and 
error were used to inform a reliable protocol. A number of groups (Weber et al. 2000; von Storp 
et al. 2012; Galisteo-González & Molina-Bolívar 2014; Jahanban-Esfahlan et al. 2016) quote  
overnight, 18 or 12 hours as appropriate time for cross-linking, however running sacrificial batches 
and sampling at 12, 18, 24, and 48 hours revealed little differences in the average particle size and 
polydispersity of the nanoparticles. For this reason, we have adopted a protocol of 12 hours to 
improve the throughput of our screening tests.  
Finally, both Mehravar et al. and Galisteo-González & Molina-Bolívar optimised the pH of the 
protein solution, finding that titrating the pH of the solution above pH 8 resulted in consistent 
average particle sizes and low polydispersity of the nanoparticles (Mehravar, Jahanshahi and 
Saghatoleslami, 2009; Galisteo-González and Molina-Bolívar, 2014). Although glutaraldehyde can 
react with amino residues over a broad pH range (≥ pH 3) (Migneault et al., 2004), this reaction is 
irreversible only between pH 7 to 9 (Okuda et al., 1991) and thus sheds some light on optimal 
nanoparticles being formed at pH 8. Furthermore, at this pH, the protein and intermediate 
nanoparticles possess a strong net negative charge (see Fig. 3.14) and thus will exhibit strong 
electrostatic repulsion which limits coagulation of proteins during the cross-linking process and 
aids in keeping polydispersity down.  
3.3.12.1 Cross-linker Addition 
As detailed in Fig. 3.2, the process of re-folding of BSA post-desolvation into nanoclusters is one 
of self-assembly. The cross-linker is subsequently used to “lock” the structures into place via 
covalent cross-linkages and to maintain rigidity and stability.  
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In order to optimise the manufacturing process it is important to define an appropriate addition 
point to add the cross-linker and this was assessed systematically, as described in Fig. 3.16. It was 
promising to see that average particle size and polydispersity remain relatively constant after a delay 
of five minutes, which appears to be sufficient time for the nanoparticles to self-assemble into 
stable nanoparticles.  
There does appear to be a window between instantaneous addition and five minutes where a 
polydispersity < 0.1 can be attained, without compromising the average particle size, which should 
be ~70 nm given the 70:30 Ethanol : Methanol desolvating ratio used. If this window is missed, 
the PDI appears to increase and then stabilise to ~ 0.2 (which is still acceptable) indicating that 
given more than five minutes, the self-assembly process becomes more disordered as the 
nanoparticles already formed have more time to interact and are subsequently cross-linked into di, 
tri or even poly-clusters, increasing the value of the polydispersity index.  
3.3.12.2 Addition Rate of Organic Solvent 
Whilst the majority of protocols opt for the use of a 1 ml / min addition rate of organic solvent 
(Weber et al. 2000; Langer et al. 2003; Langer et al. 2008; von Storp et al. 2012), an investigation into 
the rate of addition was carried out. The work by Langer et al. in 2003, Meharavar et al. and 
Galisteo-González & Molina-Bolívar, detail a decrease in particle diameter with increasing addition 
rate and conflicting results with respect to PDI (some proportonal and others inversely 
proportional to addition rate). This data was collected over a broad range of addition rates, 
extending up to 10 ml/min in some cases.  
These optimisation experiments were aimed at investigating the effects on particle size at much 
lower addition rates and in this range (0.1 – 1 ml /min) a similar trend was found, with deceeasing 
particle sizes and improvement in PDI at higher rates. Interestingly, at very low rates of addition 
(0.1 ml / min) the average particle size doesn’t fit the trend and is much lower than expected; the 
desolvating conditions were 80: 20, Ethanol : Water in this scenario (BSA in water), with an 
expected size of ~ 55-60 nm at an addition rate of 1 ml/min.  
It is hypothesised that this phenomenon can be explained by a change in the organic solvent 
mixture with respect to time. Despite stringent attempts to maintain a closed system, there is a 
portion of the manufacturing process where the system is open; the solvent runs along a glass rod 
to form uniform droplets into the protein solution and there is headspace in the vessel once the 
organic solvent has dropped into solution. Both aspects provide room for evaporation of solvent, 
especially at a flow rate of 0.1 ml /min, where it takes 40 minutes to complete the desolvation step. 
In this time, the composition of the organic solvent mixture is changing due to the higher volatility 
of Ethanol, relative to water, at room temperature (Pagni, 2005). As the Ethanol evaporates, the 
ratio is driven in favour of water, thus increasing the dielectric constant of the solution and, as per 
Fig. 3.10, the average particle size is reduced.  
The polydispersity follows a similar trend to average particle size, with better preparations being 
formed with higher addition rates. This is likely due to more rapid desolvation taking place, with 
the protein in solution unfolding simultaneously leaving little solvated protein left in solution to 
202 
 
disrupt   the self-assembly process of nanoparticles, helping to improve the polydispersiy index. 
These findings justify the use of a 1 ml/min addition rate are in good agreement with similar work, 
especially that of Mehravar et al. who demonstrate a parabolic relationship between addition rate 
and PDI, with a minima at 1 ml/min (Mehravar, Jahanshahi and Saghatoleslami, 2009).  
3.3.12.3 Temperature  
Another important factor to take into account is the influence of temperature, which can have a 
profound effect both on the structure of the protein, but also on the rate of reaction of unfolding 
and cross-linking. It was therefore important to investigate the impact of temperature on the 
formation of nanoparticles; first through heat pre-treatment of the monomer and secondly 
adjusting the temperature of the coacervation reaction. 
3.3.12.3.1 Pre-heat Treatment  
A systematic heat treatment study was carried out on the 10% BSA solution prior to desolvation. 
The solution was heated to a set temperature and held for five minutes under identical mixing 
conditions as the desolvation/cross-linking process. The solution and apparatus were subsequently 
allowed to cool to room temperature; all temperatures were checked with aid of an infrared 
thermometer (Extech IR400, Extech Instruments, NH, USA).  
The study highlights little change between 0 ⁰ C (protein solution stored in an ice bath) to room 
temperature through to 45 ⁰ C. Beyond this temperature, an evident decrease in size is observed. 
This can be attributed to a permanent change in the secondary structure of the protein. Takeda et 
al. looked at the conformational changes of BSA during thermal denaturation and found that the 
ratio of α-helices to β-sheets decreased (characteristic of mild aggregation) with increasing 
temperature, though this conformational change was reversible below 45 ⁰ C., with some partial 
reversibility even up to 65 ⁰ C (Takeda et al., 1989).  
Whilst theoretically BSA has 59 lysyl groups available for cross-linking, Weber et al. demonstrate 
that in reality only ~ 9 amino groups per serum albumin molecules (HSA) are available for cross-
linking. This is largely due to the secondary structure of BSA, ~ 55-60% alpha-helical (Baler et al., 
2014) stabilised by 17 disulphide linkages (Wang and Chen, 2010), most of which are buried within 
the core of the protein and inaccessible to the surrounding solution (Carter and Ho, 1994).   
Weber et al. illustrated an increase in available amino groups upon heating serum albumin to 70 
⁰ C, rising from 9 to 14; this was strongly supported by the work of Rombouts et al., who 
demonstrated a re-ordering of the disulphide linkages upon heating BSA to 90 ⁰ C (Weber et al. 
2000 and Rombouts et al. 2015).  Their findings corroborate well with the concept that the native 
BSA confirmation becomes more flexible (Borzova et al., 2016) and the secondary structure 
distorts to various degrees under heat, unravelling to reveal more lysyl sites for potential cross-
linking, facilitating stronger, tighter nanoparticle formation and a smaller average particle size.  
A competing hypothesis is that the heat treatment, particularly at higher temperatures, leads to the 
formation of small, stable aggregates, which are subsequently cross-linked and fixed and thus 
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contribute to driving the average particle size down. No observable trend could be determined for 
PDI with respect to temperature increase (range between 0.18-0.22) however similar work by 
Borzova et al. document the precipitation of small particulates (~ 10-30 nm) upon heating of BSA 
above 70 ⁰ C (Borzova et al., 2016), which support this hypothesis.  
Heating beyond 75 ⁰ C led to visible aggregation of the protein in solution, even after cooling to 
room temperature, thus nanoparticles could not be formed. A study by Murayama et al. found that 
above 74 ⁰ C, the FTIR amide I band fingerprint at 1645 cm-1 for BSA broadens significantly as 
well as the appearance of strong bands at 1615 cm-1 and 1685 cm-1 , illustrating a disintegration of 
secondary disordered moieties and formation of strongly hydrogen-bonded β-sheet structures, 
respectively. Both indicate significant loss of native structure and for the latter, irreversible 
aggregation of the protein (Murayama and Tomida, 2004).  
3.3.12.3.2 Experimental Temperature 
Temperature also plays a role on the formation of nanoparticles during desolvation and cross-
linking and impacts the process in a number of ways. The trend in Fig. 3.16d suggests a 
proportional relationship between temperature and average particle size, with a dip between 30-40 
⁰ C and polydispersities generally constant with a small dip over the same temperature range. The 
column graph, inset, illustrates the reduction in particle size at lower temperatures is reflected 
across a range of desolvating conditions.  
The general trend of increasing temperature and average particle size is supported by both 
Rahimnejad et al. in 2002 and Galisteo-González et al. in 2014, who also demonstrate larger sized 
protein nanoparticles with respect to increasing temperatures. Initially, an increase in temperature 
will have an impact on the native protein, as discussed in the previous section, though in this 
scenario the protein is held at set temperature for a significant time period (12 hours) which can 
impact the intermolecular electrostatic, hydrophobic interactions and particularly the hydrogen 
bonding, all of which aid in stabilising the protein in its native state.  
As we have seen with pre-treatment, higher temperatures (≥ 45 ⁰ C) lead to decreases in particle 
size, however the inverse is true in this instance. This suggests that, whilst protein structural change 
is integral here, the impact of temperature on other factors during desolvation/cross-linking are 
playing a more influential role on the overall trend here.   
Temperature plays a pivotal role in the nucleation rate (Equations 10 & 11) and thus the final 
particle size; a slower nucleation rate creates fewer nuclei per unit volume, which will promote 
growth of the nanoparticles and lead to a larger average particle size (Zhang et al., 2006; Park and 
Yeo, 2010; Galisteo-González and Molina-Bolívar, 2014). Equations 10 & 11 highlight the fact 
that an increase in temperature (T) reduces the free energy for the formation of a nucleus (B), thus 
subsequently reducing the rate of nucleation (J). To support this theory, the equations to derive 
the frequency factor (A), which describes the regularity of particle collisions, from the Arrhenius 




𝐴 =  𝑁0𝜐 
Equation 13: 





N0 is the initial number of molecules per unit volume 
𝜐 is the frequency of molecular transport to the solid-liquid interface  
α is the mean effective diameter of the solute (m) 
η is the viscosity of the suspending liquid viscosity (kg/m.s) 
kB is the Boltzmann constant (1.381 x 10
-23 J/K)(kB = R ÷ NA, where NA is the Avogadro constant, 
6.022 x 10-23) (Reeks, 2011) 
T is the absolute temperature (K) 
(Cao, 2004) 
As temperature increases, the supersaturation reduces by enhancing the solubility of protein in the 
desolvating solvent, which reduces the rate of nucleation, creating fewer and larger nucleation sites, 
increasing the average particle size (see Equation 10). In addition, an increased temperature will 
lower the viscosity of the solution (see the Arrhenius-Guzman equation, Chapter II, Equation 2), 
and so the frequency of molecular transport and consequently the frequency of collisions will 
increase, facilitating an agglomeration effect in creating larger nanoparticles. Furthermore, the 
diffusional coefficient (Stokes-Einstein equation) will increase at higher temperatures (see Chapter 
II, Equation 3) which will again improve the accumulation of unfolded protein at nucleation sites, 
further contributing to the creation of larger particle sizes.   
Considering the decrease in average particle size at ~ 30-40 ⁰ C, there are two possible hypotheses 
as to why this phenomenon occurs. The first is that globular proteins exhibit a parabolic 
temperature profile with respect to the free energy of stabilisation, with a minimum at ~ 20 ⁰ C 
(for the protein chymotrypsinogen) (Jaenicke, 1990); it is feasible that BSA would have a similar 
profile with a minimum shift to higher temperatures due to its larger molecular weight.  This 
parabolic relationship indicates the protein structure (and the intermolecular forces holding it 
together) is sensitive to disruption at both high and low temperatures.  
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At low temperatures, hydrogen bonding improves due to low bond energy requirements whilst 
concurrently the entropic-favoured hydrophobic interactions within the protein are weakened 
(Jaenicke, 1990). Thus smaller nanoparticles may be formed at low extremes of temperature due 
to a higher susceptibility of disruption from the organic solvent during desolvation and thus better 
exposure of buried lysine residues. The change in balance between these interactions during the 
transition from each extreme of temperature may contribute to changes in protein structure and 
the eventual formation of nanoparticles post-desolvation and cross-linking.  
Alternatively, the decrease in particle size in this range may be due to a change in desolvating agent 
composition (Ethanol / Water mixture) as discussed in 3.3.12.2, with evaporation of the Ethanol 
accelerated at higher temperatures (the flash point of absolute Ethanol is 17 ⁰ C (Pagni, 2005)), 
thus increasing the dielectric constant of the solution and driving the average particle size further 
down. The fact that the trend does not continue at higher temperatures may be due to competing 
impacts of temperature superseding that of higher rates of evaporating solvent and impacts on 
protein structure. 
3.3.13 Nanoparticle Reproducibility  
In order to optimise the manufacture of protein nanoparticles, production needs to be both 
reproducible and robust such that a defined experimental set up will produce predictable results. 
Fig. 3.17 demonstrates variance between batches and from different protein stocks.  
Fig. 3.17 a) The batch-to-batch variance in mean particle size of protein nanoparticles manufactured under various 
organic solvent compositions. b) Average particle size and PDI of nanoparticle preparations manufactured under 
identical conditions (Methanol: Ethanol, 70: 30) with each colour representing a new 10% BSA stock (mean ± 
SD, n = 3).  
Equation 14: 






Methanolic desolvating agents appear to produce nanoparticles with the highest batch-to-batch 
variance. This may be attributed to the smaller average particle size produced using Methanol; its 
absolute size deviation appearing more significant when compared relatively to the other 
conditions. On the other hand, the solvent itself may play a role in the batch variance; absolute 
Methanol has the highest volatility of the three organic solvent conditions tested, thus will be the 
most susceptible to evaporation during manufacture. It is feasible that variations in room 
temperature on any given day could contribute to the rate of evaporation of the solvent and thus 
result in disparities in average particle size from batch-to-batch.  
Mixtures of ethanol/methanol appear to show the least variation, likely due to the influence of 
both solvents limiting evaporation through inter-molecular forces such as hydrophobic interaction 
and hydrogen bonding, which aid in keeping the Methanol in solution.    
Fig. 3.17b highlights the importance of the starting BSA stock solution used to manufacture the 
nanoparticles. Lyophilised BSA powder dissolved in aqueous solution can contain a mixture of 
monomeric, dimeric and trimeric BSA in varying ratios. In order to maintain reproducibility in the 
manufacturing process, the monomeric protein should be purified via size-exclusion 
chromatography step prior to protein nanoparticle manufacture (Murayama and Tomida, 2004).  
3.3.14 Protein 2⁰ Structure Analysis 
In order to probe the secondary structure characteristics of the various protein species and track 
changes through the nanoparticle manufacturing process, a circular dichroism approach was 
adopted. The spectral data was analysed for structural composition using a self-consistent method, 
whereby the secondary structure of the protein species is estimated via a deconvolution algorithm, 
SELCON3 (Sreerama and Woody, 1993).  
Inspection of the raw spectra indicates secondary structural changes do occur upon desolvation. 
BSA is predominantly α-helical, with classical minima at both 208 and 222 nm, with a maximum 
at 190 nm. The spectra also highlight very little change in the 250-300 nm region, which suggests 
a preservation of the protein tertiary structure and the environment surrounding phenylalanine, 
tyrosine, cysteine and tryptophan residues (Greenfield, 2006).   
During unfolding and re-folding, increases in β-sheet/turn formation and subsequent reduction in 
α-helical structure, with little change to the unordered secondary structures occur. This is 
symptomatic of protein aggregation, where the formation of β-sheet fibres occurs. These findings 
correlate well with that of the coacervation of α-lactalbumin nanoparticles (Arroyo-Maya et al., 
2014). This fibrillation/amyloidation process derives stability for partially folded or unfolded states 
as the protein residues re-orientate to the new organic solvent conditions (Holm et al., 2007). Upon 
addition of a cross-linker, it appears this conformational change is locked in place, coinciding with 










Fig. 3.18 a) CD spectra for BSA, Desolvated BSA and BSA Nanoparticles. b) The relative proportions of 
secondary structure for the protein in its native and desolvated states, as well as the conformational change once 















3.3.15 Nanoparticle Morphology 
Two orthogonal techniques were utilised to image the protein nanoparticles to assess their 
morphology and homogeneity, as demonstrated in Fig. 3.19.  
 
 
Fig. 3.19 BSA Nanoparticles images; a) A transmission electron micrograph imaged using a negative uranyl 
acetate stain and b) An atomic force microscopy image acquired via liquid tapping mode.  
3.3.15.1 Transmission Electron Microscopy  
Transmission Emission Microscopy images illustrate the formation of nanoparticle aggregates, 
pertinent to the sample preparation involved in BIO-TEM. The sample is critical point dried, 
removing, to trace, water, before being negatively stained with uranyl acetate, in order to enhance 
imaging contrast. Images reveal smooth, rounded nanoparticles aggregated in clumps during 
dehydration. The comparative sizes of the nanoparticles from the TEM images, as processed by 
ImageJ, were approximately 50% smaller than the Stokes diameter indicated by DLS. This is as a 




3.3.15.2 Atomic Force Microscopy  
Atomic Force Microscopy facilitated the imaging of the nanoparticle species in their hydrated state, 
immersed in an aqueous-based buffer. The phase image illustrates relatively monodisperse, 
uniform nanoparticles anchored onto the poly-L-lysine slide, with a size distribution corroborating 
well to the 80 nm average size attained from DLS analysis.   
3.3.16 Adenovirus Type V Mimic 
In order to create suitable viral mimics which are applicable to the characterisation of 
chromatography media, the protein nanoparticles should exhibit similar physiochemical properties 
such that they interact with the purification resin in an analogous fashion. Given the optimisation 
of manufacture of nanoparticles, it is possible to target specific nanoparticle sizes within narrow 
distribution ranges, in order to mimic viral particles. Fig 3.20 illustrates the similarity in average 
particle size, whilst the TEM images reveal similarities in the morphology of both species.  
The CD spectra demonstrate that both species have α-helical character; the hexon protein is mostly 
random coil, with close to equal amounts of both α-helical (27%) and β-sheet/turn (26%) 
structure. Important to note here is that the AdV capsid is composed of multiple proteins; mostly 
hexon proteins (60%), followed by varying amounts of minor proteins (IIIa, VI, VIII & IX), 
penton bases and fibres (Rexroad et al., 2003). This is therefore a rudimentary estimation of the 
composition of the viral capsid, but nonetheless a good starting point for comparison. Crucially, 
ζ-potential values for both species (and the isoelectric point) are similar, indicating they will behave 





Fig. 3.20 A comparative study of BSA nanoparticles and Adenovirus type V (AdV); a) Nano-tracking analysis 
of the BSA nanoparticles with an average particle size of 75 nm compared to b) DLS & ζ-potential analysis (pH 
8) of native AdV ((Weng et al., 2014). c) & d) Transmission electron micrographs of BSA nanoparticles and 
AdV10. e) Circular dichroism spectra for both the 75 nm BSA nanoparticle and that of the AdV hexon capsid 
protein (Day et al., 1972). f) Summary table highlighting the similarities in physiochemical properties between the 
protein nanoparticle mimic and that of the bona fide virus particle (Trilisky and Lenhoff, 2007).  
3.4 Conclusions 
This chapter demonstrates the reproducible and robust manufacture of Bovine Serum Albumin 
nanoparticles from native protein using a desolvation and cross-linking technique. The work 
details both the influence of a variety of process parameters as well as the effective scale down of 
the technique to improve throughput of analytical testing.  
Characterisation of the nanoparticles has also been described herein, using numerous 
complimentary techniques to understand the physiochemical properties of the nanoparticles 
produced. The work highlights the ability to create protein nanoparticles as appropriate surrogate 
mimics of a virus species with gene therapy applicability. 
The ability to generate these synthetic protein nanoparticles in high volume and in a relatively short 
time span has the potential to create a pathway for screening and characterising new and already 
commercial chromatography and alternative purification media via the analytical tools shown 
                                                 
10 Image sourced from http://www.virology.net/Big_Virology/EM/Adeno-FD.jpg 
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herein. This holds promise for rapid development and optimisation of the downstream process 
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BUILDING & CHARACTERISING A LIBRARY OF VIRAL MIMICS 
VIA A TOOLBOX APPROACH 
Abstract 
The utility of viral vectors in the application of gene therapy and vaccine treatments has been a 
topic of great interest in the bioprocessing industry. However, their labour intensive and 
downstream processing complications have posited new challenges to process development 
scientists in optimising the throughput of viral vectors to clinic.  
The previous chapter demonstrated the potential of protein nanoparticles as promising surrogates 
of viruses, particularly Bovine Serum Albumin nanoparticles as surrogates of the adenoviral vector. 
This work will detail how we have incorporated the process knowledge surrounding this technique 
into a “toolbox approach” for targeting other virus types which have relevance in the gene therapy 
field. These include adeno-associated, human papilloma and polio viruses, transitioning towards 
nanoparticles which mimic the physiochemical characteristics of these bona fide vectors without the 
cost and safety implications of the true viral vectors.  
The chapter also explores the use of different cross-linking mechanisms and targeting different 
functional groups to create multi-component, “2nd generation” nanoparticles to move towards the 
creation of more accurate viral mimics. The aspiration is that this approach will facilitate the 




AdV: Adenovirus Type V  
AEX: Anion Exchange 
Chromatography 
Arg: Arginine  
Asp: Aspartic Acid 
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Haemoglobin  
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Cys: Cysteine  








Glu: Glutamic Acid 
HCl: Hydrochloric Acid 
His: Histidine 
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4.1.1 Viral Vectors in Gene Therapy 
Viral vectors represent a promising vehicle for delivery of therapeutic payloads to treat genetic 
disorders and in the implementation of DNA vaccines. There are a number of viral vectors which 
are suitable for this application, depending on their individual features and requirements of the 
therapy. These include retroviral and adenoviral vectors, two of the most common genetic vehicles 




Fig. 4.1 The proportions of viral vectors used in gene therapy to date (Ginn et al., 2018b).  
As discussed in Chapter III, one of the main aims of the work is to demonstrate the use of protein 
nanoparticles as mimics of viral vectors, aiming to imitate the surface characteristics of viral 
capsids. In this way, it is hoped that the virus analogues interact with purification media as a virus 
would and thus provide a useful simulation tool for optimisation of purification unit operations, 
without the hassle of working with infectious, expensive viral material.   
Naturally, in attempting to mimic protein capsids, enveloped vectors were not considered for 
mimicking, as the lipid envelope that surrounds vectors such as the retroviridae, poxviridae and 
herpesviridae families will play an important role in their surface interactions and physiochemical 
properties. This can complicate their purification strategies, as the biophysical properties of this 
envelope are not completely known (Steppert et al., 2016) and thus hard to re-create within a mimic.  
For this reason, the library of viral mimics developed in this chapter is restricted to non-enveloped 
viruses, which are highlighted in Fig. 4.2. Whilst the applicability of the adenoviral vector has been 
detailed in Chapter III, there have also been strong cases made for the use of alternative viral 
vectors, including the human papilloma virus (HPV) (Storey et al., 1991; Chen et al., 1995, 1996; 
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Hung et al., 2012), polio virus (Morrow, Ansardi and Porter, 1997; Mandl et al., 1998; van 
Kuppeveld et al., 2002; Ylä-Pelto, Tripathi and Susi, 2016) and adeno-associated virus (AAV) 
(Flotte and Carter, 1995; Gao et al., 2002; Hauswirth et al., 2008; Konishi et al., 2008; Naso et al., 







Fig. 4.2 The physiochemical characteristics of common non-enveloped viral vectors employed in gene therapy 
applications (Wu, Asokan and Samulski, 2006; Arbyn et al., 2007; Regenmortel, 2009; Michen and 
Graule, 2010; Thomassen et al., 2013; Zhou, 2013; Ghebremedhin, 2014; Potter et al., 2014). 
As such, it becomes important to develop “second generation” protein nanoparticles which can 
mimic the characteristics of these vectors. Each viral vector has its own distinct features and thus 
the conventional approach of forming nanoparticles using serum albumin will have to be modified 
(via a “toolbox approach”) in order to successfully represent these species with respect to their 
size and surface characteristics.  
4.1.2 Protein Characteristics 
The first strategy will be replacing the starting protein molecule and observing how different 
proteins perform under coacervation and cross-linking manufacture. Fig. 4.3 demonstrates a range 
of commonly available, relatively inexpensive proteins which have potential use as starter building 




Fig. 4.3 Characteristics of common proteins as potential building blocks of protein nanoparticles (Stein et al., 
1991; Shoichet et al., 1995; Aranda et al., 2008; Majorek et al., 2012).  
Evidently, each protein has its own individual characteristics and thus will respond differently 
when manipulated to form nanoparticles, partially due to their molecular weights, hydrodynamic 
radius, surface charge and hydrophobicity index. It is therefore hypothesised that these proteins 
could have potential in developing protein nanoparticles that mimic the characteristics of the gene 
therapy vectors illustrated in Fig. 4.2.  
4.1.3 Functional Groups & Cross-Linkers 
With the single protein experiments, glutaraldehyde was maintained as the cross-linker of choice 
such that the only influential variable was the characteristics of the protein. As lysine residues are 
present on all four of the proteins under experimentation, glutaraldehyde should theoretically be 
able to stabilise the formed nanoparticles via the formation of imines (or Schiff bases) through 
nucleophilic attack from the ε-amino group of the lysine residue.   
With respect to the second generation nanoparticles, more sophisticated cross-linking approaches 
were adopted to capitalise upon the availability of available reactive residues on the proteins. These 




Fig. 4.4 Mechanisms for cross-linking amino acid residues (1 & 2) via the a) EDC or b) DTME route. Note 
that the reduction of the disulphide bonds is required prior to cross-linking using DTME to liberate the thiol groups 
for reaction with DTME. Schematics were adapted from the ThermoFisher Scientific cross-linker selection guide.  
4.1.3.1 EDC Cross-Linking 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) is a water soluble, heterobifunctional 
cross-linker that achieves cross-linking via a two-step process. Initially, the carbodiimide group 
within the cross-linker reacts with an available carboxyl residue on the protein to create an o-
acylisourea ester intermediate, followed by a substitution reaction with a primary amine from a 
second amino acid residue to form a peptide bond, with urea as a bi-product. One advantage of 
EDC is that it is, by definition, zero length as it does not remain within the final cross-linked 
product (Nakajima and Ikada, 1995).  
4.1.3.2 DTME Cross-Linking  
Dithio-bis-maleimidoethane (DTME) is a water soluble, homobifunctional cross-linker that reacts 
with sulfhydryl reactive groups on cysteine residues of proteins. A significant advantage of DTME 
is that the cross-linking process is reversible due to a disulphide group in the middle of the 
molecule, which can be cleaved under reducing conditions (Green, Reisler and Houk, 2008). A 




4.2 Materials & Methods 
4.2.1 Materials & Reagents  
Bovine Serum Albumin (fatty acid free, ≥ 96%), Albumin from chicken egg white (Ovalbumin) 
(≥ 98%), Haemoglobin from bovine blood, Lysozyme from chicken egg white (≥ 90%),  N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), dithio-bis-maleimidoethane 
(DTME), Fluorescamine,  8% Aqueous Glutaraldehyde, Methanol and Ethanol (both analytical 
grade, ≥ 99%), Sodium chloride (NaCl), Sodium phosphate monobasic (NaH2PO4) and dibasic 
(Na2HPO4), Sodium hydroxide (NaOH), Dimethyl sulfoxide (DMSO) and all glassware and other 
reagents were obtained from Sigma Aldrich (Poole, Dorset) unless otherwise stated.  
Texas Red-X Succinimidyl Ester and Cyanine 5 Succinimidyl Ester (Cy5™) were obtained from 
Fisher Scientific (Loughborough, UK). Buffers and all aqueous solutions were based upon use of 
ultrapure water from a Sartorius Arium® Advanced EDI Pure Water System (Sartorius AG, 
Göttingen, Germany). Chromatography resins (Q-Sepharose Fast Flow & Sepharose 6 Fast Flow) 
and PD-10 Desalting columns were purchased from GE Healthcare (Uppsala, Sweden).  
4.2.2 Preparation of Protein Nanoparticles  
Protein nanoparticles were prepared using the desolvation technique as described in Chapter III 
(3.2.2). Slight deviations are reported to accommodate for different protein characteristics or cross-
linking strategies, which are detailed on a case by case basis in the discussion.   
Various cross-linking strategies were employed in the work detailed in this chapter. With respect 
to Ovalbumin (OVA), Bovine Haemoglobin (BHB) and the initial Lysozyme (LYS) nanoparticle 
formation experiments, the 8% glutaraldehyde protocol used for conventional BSA nanoparticles 
was conducted, as detailed in Chapter III. In the development of 2nd generation nanoparticles, two 
novel strategies were employed.  
4.2.2.1 Blended Nanoparticles 
BSA-LYS blended nanoparticles were manufactured in a similar fashion to that of conventional 
BSA nanoparticles. 10% BSA and 10% LYS solutions were prepared separately in ultrapure water, 
before mixing a working solution of varying ratios of BSA: LYS to a total volume of 1 ml. This 
solution was then used for desolvation, cross-linking and subsequent purification, as detailed 
previously.   
4.2.2.2 Core-Shell Nanoparticles 
BSA nanoparticles were initially formulated, purified and analysed via DLS to determine particle 
size and polydispersity characteristics. These preparations were subsequently used as scaffolds for 
the preparation of core-shell nanoparticles, using LYS as a coating protein.  
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4.2.2.2.1 EDC Cross-Linking 
A 10% LYS aqueous solution was prepared and aliquots were added to 1 ml of purified BSA 
nanoparticles (~ 14 mg/ml) in molar ratios of 1: 2, 1: 5 and 1:10, LYS: BSA (194 µL, 78 µL and 
39 µL of LYS starting solution, respectively). The native LYS in solution was desolvated using 1 
ml of organic solvent (identical conditions to that of the original BSA nanoparticles) and allowed 
to self-assemble in-situ around the BSA nanoparticles.  
After five minutes, aqueous EDC was added in a 10 fold molar excess (relative to total protein 
content in solution) and left for three hours to complete the cross-linking reaction (Jahanban-
Esfahlan, Dastmalchi and Davaran, 2016).  
4.2.2.2.2 DTME Cross-Linking 
A 0.2 ml working solution of aqueous LYS was prepared to a concentration of 1.475 mg/ml before 
being aliquoted into 1 ml of a purified BSA-NP solution at an approximate concentration of 14 
mg/ml (representing a 1 : 10 molar ratio LYS : BSA). As with EDC cross-linking, 1 ml of 
desolvating agent (identical ratios used in the formation of the BSA-NP scaffold) was added at a 
controlled addition rate of 1 ml/min under continuous stirring to induce unfolding of the added 
LYS. 
To initiate reduction of the disulphide bonds in both protein species, a molar excess of (74 µg) 
NaBH4 (4: 1 molar ratio NaBH4: LYS) was dissolved in 80 µL of 0.6 M NaOH before being 
aliquoted into the desolvating mix (Ashraf et al., 2014). The NaOH in this case is required to create 
a basic environment to stabilise the intermediate thiolate which forms prior to cross-linking 
(Duane Brown, 1960). After ten minutes, a molar excess of DTME cross-linker (1.22 mg dissolved 
in 60 µL DMSO) was added (2: 1 DTME: NaBH4) to favour the formation of covalent cross-
linkages and limit interference from un-reacted NaBH4. The cross-linking process was left in an 
oxygen-free environment for three hours under continuous stirring to run to completion.  
Purification of all the formed nanoparticles was carried out either by size-exclusion 
chromatography using disposable PD-10 Desalting Columns or via six wash cycles of 
centrifugation/filtration (2,500 x g, 20 minutes), with re-dispersion in 1 M NaCl (3X) and 
subsequently in aqueous buffer (3X) using a 300 000 MWCO protein concentrator 
polyethersulfone (PES) centrifugal filter (Thermo™ Scientific, Loughborough, UK), prior to 
storing at 4 ⁰ C, as detailed in Chapter III (3.2.2). The high salt washes were required to eliminate 





4.2.3 Analysis  
4.2.3.1 Dynamic Light Scattering, Zeta Potential & Isoelectric Focussing  
Determination of particle size, ζ-potential and isoelectric focussing studies were carried out as 
described in Chapter III, 3.2.3.1.1 & 3.2.3.1.2.  
4.2.3.2 Protein Nanoparticle Quantification 
Protein and protein nanoparticle preparations were quantified using a bicinchoninic acid (BCA) 
assay, as described in Chapter III, 3.2.3.3.  
4.2.3.3 Static Binding Studies 
Nanoparticle challenges onto anion-exchange (Q-Sepharose Fast Flow) & control size-exclusion 
matrices (Sepharose 6 Fast Flow) were conducted as described in Chapter II, 2.2.11.3. The buffer 
system in this instance was 0.01 M Tris-HCl (pH 8.0) and the settled bed volume 20 µL.   
4.2.3.4 Confocal Laser Scanning Microscopy  
CLSM analysis of the beads conjugated with protein nanoparticles (through static binding studies) 
were conducted via the same methodology as detailed in Chapter II 2.2.11.6. In these experiments, 
LYS was tagged with Cy5 (λEXC=646 nm, λEMI=666 nm) and purified via gel filtration prior to 
coating BSA nanoparticles (for both EDC and DTME approaches). BSA Nanoparticles were 
conjugated with either Texas Red-X (λEXC=596 nm, λEMI=615 nm) or Fluorescamine (λEXC=390 
nm, λEMI=465 nm) prior to coating with LYS (Life Technologies, 1996). The only deviation from 
the original protocol is that Fluorescamine was incubated with the protein species for 10 minutes 




4.3 Results & Discussion 
The approach adopted was to target specific viral vectors based on their size and surface 
characteristics using different starting proteins with varying proportions of amino acids and thus 
surface properties and isoelectric points. In the first instance, proteins were substituted in for BSA 
and carried through the original desolvation/cross-linking process to observe how the new 
proteins responded and the characteristics of the nanoparticles that formed as a result. Similar 
systematic variations in organic solvent ratios were also assessed to determine if trends could be 
observed independent of starting protein.  
4.3.1 Protein Building Blocks 
 Two proteins, Ovalbumin (OVA) & Bovine Haemoglobin (BHB), were initially assessed for their 
feasibility as starting materials in the formation of self-assembling nanoparticles, as per BSA as 
previously outlined. Fig. 4.5a) illustrates that both proteins are amenable to the desolvation/cross-
linking method and formed nanoparticles with a relatively tight size distribution.  
Fig. 4.5 Nanoparticle formation characteristics from novel protein building blocks; a) Particle Size Distributions 
& b) Isoelectric focussing curves for Ovalbumin (- / -■- ) and Bovine Haemoglobin (- - / -□-) formed using a 90 
: 10 Methanol : Water desolvating mixture. The isoelectric points for Ovalbumin & Bovine Haemoglobin were 
4.41 and 6.61, respectively and each fitted with a sigmoidal fit curve.  
Rationally, this result is plausible given that both proteins have a significant amount of lysine 
residues available for cross-linking and will unfold when exposed to organic solvent and 
hydrophobic environments. Indeed, there have been numerous accounts of the formation of 
protein nanoparticles (including ovalbumin and haemoglobin) using a plethora of starting proteins 
including α-lactalbumin, β-lactoglobulin and gelatin (Gunasekaran, Ko and Xiao, 2006; Arroyo-
Maya et al., 2014; Wang et al., 2015; Etorki et al., 2016; Ahsan and Rao, 2017).   
As the ultimate aim of the work is to create protein nanoparticles with a more basic isoelectric 
point (to target and mimic a wider range of viral vectors), BHB was carried forward for more 
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systematic assessment. One adjustment was made to the manufacturing process and that was the 
titration of dissolved BHB to pH 9.0 (rather than 8.0 for BSA); thus the surface charge of BHB is 
as close as possible to that of BSA in the original experiments detailed in Chapter III, though still 
within the pH range in which glutaraldehyde cross-links irreversibly.  
4.3.2 Bovine Haemoglobin Nanoparticles 
As with BSA, BHB was methodically evaluated to identify possible trends in nanoparticle 
formation such that specific sizes could be targeted where relevant. Fig. 4.6 demonstrates a 
comparative study between the two proteins and the resultant nanoparticle characteristics as the 
organic solvent ratios are varied. 
 
Fig. 4.6 The impact of variations in organic solvent on a) average BSA (filled) and BHB (gradient filled) 
nanoparticle size and polydispersity index (dashed fill). The relationship between the dielectric constant of the organic 
solvent mixture and the eventual average particle size for b) BSA & c) BHB nanoparticles  produced (mean ± 
SD, n = 3) with non-linear regression polynomial inverse first-order fit curves. 
Generally, BHB nanoparticles could be formed across a range of organic solvent conditions, 
though in most cases producing nanoparticles of larger sizes than BSA. A second important 
characteristic of BHB nanoparticle formation was the increased batch-to-batch variation, reflected 
in higher standard deviations for BHB nanoparticle samples.  
These differences may be attributed to the structure of BHB; a largely spherical protein, built on 
four subunits (2 identical α & β globin chains, each) ordered as a tetrahedral with non-polar 
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residues buried to facilitate water solubility. Each subunit houses a porphyrin ring coordinated 
around a ferrous atom (known as a haem molecule) within a hydrophobic cleft creviced between 
two helices (the haem pocket) to protect the Fe atom against oxidation (Dickerson and Geis, 1983; 
Perutz et al., 1993).  
As with BSA, the mechanisms of unfolding are governed by the disruption of the inter- and intra-
molecular interactions which give BHB its native conformation; these are composed of hydrogen 
bonding, van der Waals, ionic and hydrophobic interactions which stabilise the polypeptides chains 
to maintain the secondary, tertiary and quaternary tetra sub-unit structure (Dickerson and Geis, 
1983).    
It is a combination of solvent-protein side chain hydrophobic interaction and disruption of inter-
chain hydrogen bonding which cause BHB to dissociate into its subunits and subsequently un-fold 
into its secondary structure (Herskovits, Gadegbeku and Jaillet, 1970; Asakura, Adachi and 
Schwartz, 1978; Frantzen et al., 1997; Wang, Wang and Li, 2000). 
An important observation was a greater deal of aggregation within the glass vessel after the cross-
linking reaction (compared to BSA desolvations) and this is reflected in the elevated 
polydispersities for BHB as the formed aggregates are cross-linked together to form larger 
complexes. This may be attributed to incomplete unfolding of protein and potential cross-linking 
of either whole tetrameric structures or α & β subunits to form un-ordered nanoparticulate 
assemblies.  This is corroborated by the work of MacDonald & Pepper, who studied the 
stabilisation of native haemoglobin through inter- and intra- molecular cross-linkages using 
glutaraldehyde and found a heterogeneous mixture of products was formed including cross-linked 
tetramers, oligomers and “a wide range of higher molecular weight species” (MacDonald and 
Pepper, 1994).  
This hypothesis can be supported by a second experimental observation; that desolvating mixtures 
with higher percentages of water (relative to organic solvent) could not form measurable 
nanoparticles due to a high degree of aggregation occurred in the vessel. This indicates that higher 
percentages of solvent are required to completely unfold BHB subunits in order to form uniform 
nanoparticles and that lower concentrations of solvent can in fact have a stabilising effect on BHB, 
as demonstrated by Asakura et al. in 1978.  
To support this further, the surface charge of BHB also needs to be taken into account. Despite 
titrating to pH 9.0, BHB has a ζ-potential of -14.7 mV whereas at pH 8.0 BSA has a surface charge 
of -24.0 mV. This difference may contribute to the aggregation observed in the formation of BHB 
nanoparticles due to lower surface charge repulsion and thus less resistance to inter-particle 
aggregation.   
A third observation was a distinct change in colour prior to and post-addition of solvent, with the 
10% protein solution presenting as a dark red and upon addition of organic solvent, the mixture 
transitioned to a dark brown. This colour change indicates oxidation of the ferrous haem (Fe2+ to 
Fe3+) to produce haematin and thus a conversion of BHB to methaemoglobin, which is 
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symptomatic of a change in the hydrophobic environment of the prosthetic group and potential 
disruption of structure due to the organic solvent addition (Blanco and Blanco, 2017).  
Circular dichroism studies have shown tertiary structural disruption of haemoglobin to release the 
prosthetic haem group when exposed to only 30% Methanol (Wang et al., 2010); a completely 
dissociated free haem group can instigate protein aggregation through catalysis of oxidation and 
cross-linking reactions between peptides (Kumar and Bandyopadhyay, 2005) which may be a 
contributing factor to both batch-to-batch variation through random aggregation and higher 
polydispersities within batches.   
Work by Asakura et al. has also revealed the shear sensitivity of haemoglobin and observed that 
under mechanical shaking the protein denatures and irreversible precipitation occurs rapidly 
(Asakura et al., 1974, 1977; Ohnishi and Asakura, 1976). Given the high rotational speeds used to 
form nanoparticles in this set up, it is feasible that BHB also undergoes shear stress and denatures 
to form irreversible aggregates, contributing to the variations illustrated in Fig. 4.6.  
Percentage incorporation of BHB into BHB nanoparticles ranged between 80 – 90% and increased 
with increasing Ethanol concentration, as with BSA nanoparticles (see Chapter III, Fig 3.6) (3 
samples, n = 1). The reason for the low sample number was a significant issue with purifying BHB 
nanoparticles to determine yield and for subsequent analytical studies. The crude nanoparticles 
were purified using centrifugal concentrators but for most manufacturing conditions the 
nanoparticles would aggregate on the surface of the membrane and blind the pores of the filter 
rendering them impossible to be re-solubilised and diafiltered into fresh buffer.  
This observation corroborates with adsorption studies carried out between BHB and BSA onto 
hydrophilic and hydrophobic polymer surfaces, whereby at pH 8.0 a higher mass of BHB adsorbed 
onto the surface of both surface types, relative to BSA.  This is likely due to hydrophobic patches 
on the surface of BHB providing hydrophobic interaction sites with the concentrator membrane 
(Shirahama, Suzuki and Suzawa, 1989). These issues with purification prevented subsequent 
analytical methods such as isoelectric focussing studies to be carried out on the BHB nanoparticles.  
4.3.3 Lysozyme Nanoparticles 
Whilst BHB nanoparticles could be formed with some degree of predictability, issues with 
purification for further characterisation justified investigation of a new protein; in this case, 
lysozyme. A much smaller protein with a far more basic pI (11) , it was hypothesised that lysozyme 
would be a suitable candidate as a starting “building block” protein to form nanoparticles which 




Fig. 4.7 a) DLS size distribution for LYS nanoparticles formed using the conventional desolvation/cross-linking 
manufacturing strategy as used for BSA & b) Isoelectric focussing curve for native LYS with non-linear regression 
polynomial inverse fifth-order fit curve. 
LYS desolvation & cross-linking was attempted at pH 8.0 and the resultant PSD is shown in Fig. 
4.7. Evidently, little-to-no nanoparticles were formed using this technique, with a high percentage 
of monomeric LYS dominating the distribution with a peak at 5 nm. Visually, aggregates formed 
at the base of the vessel almost instantaneously as the organic solvent was added. This is likely due 
to a very weak positive surface charge (10.2 mV) on LYS which would do little to prevent 
aggregation between the lysozyme molecules in solution. Indeed, prior work on human serum 
albumin nanoparticles recommends a surface charge of ±20 mV to successfully produce protein 
nanoparticles (Langer et al., 2003).  
With this in mind, identical desolvations were carried out at pH 3.2 (ζ-potential = 22.8 mV) and 
pH 13.5 (ζ-potential = -23.8 mV) in order to replicate the required surface charge as defined by 
Langer et al. However, PSD data similar to that of Fig. 4.7a) were produced, with the same 
aggregation visible and no nanoparticles formed. This is likely due to the inefficiency of 
glutaraldehyde at these two extremes of pH conditions, thus the nanoparticles could not be 
stabilised through covalent cross-linkage (Migneault et al., 2004). 
4.3.4 Multi-Component 2nd Generation Nanoparticles 
Given the issues documented with BHB and LYS nanoparticles, a multi-component approach was 
adopted, whereby the well characterised BSA nanoparticle manufacture would be utilised and then 
spiked with a second protein, LYS, in order to elevate the resulting isoelectric point of the 
nanoparticle preparation and begin to move towards the surface characteristics of different viral 
vectors. As most viral capsids are composed of multiple protein subunits(Stewart and Burnett, 
1995; Wu, Asokan and Samulski, 2006; Glasgow and Tullman-Ercek, 2014), which contribute to 
its overall surface charge, it is plausible that a multifarious protein approach would represent a 
more accurate nanoparticle mimic.  
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4.3.4.1 Blended Nanoparticles 
The first approach was to “blend in” varying molar ratios of LYS into the starting BSA solution 
(to a final concentration of 10%) such that LYS could be cross-linked with BSA through available 
amino groups on both proteins and form structured and stable nanoparticles.   
 
Fig. 4.8 a) Average particle size (columns) & polydispersity indices (line & scatter) of purified, blended BSA-
LYS with respect to increasing LYS dosing concentrations by percentage volume. Inset data values above the bars 
indicate the molar percentage of LYS relative to BSA.  b) Isoelectric focussing curve for native BSA (-) and LYS 
(- -) with non-linear regression sigmoidal and polynomial inverse fifth-order fit curves, respectively. The isoelectric 
points of BSA & LYS are 4.78 & 11.12, respectively.  
Fig 4.8a) illustrates the resultant nanoparticle characteristics with respect to the volume proportion 
of LYS included in the initial 10% protein mixture. Interestingly, even as low as a 9%  molar 
percentage inclusion of LYS resulted in an ~ 5-fold increase in average particle size, relative to just 
BSA prepared under the same desolvating conditions (70 : 30, Methanol : Ethanol), though the 
polydispersity indices remained at ~ 0.2, indicating a relatively homogenous nanoparticle 
suspension had formed.  
As the percentage of LYS increases, so too does the average particle size and polydispersity of the 
produced nanoparticles, whereby when the two proteins are in equal volume proportion, the 
average particle size and polydispersity of the resultant nanoparticles are  10-fold and 4-fold larger, 
respectively, relative to just BSA under the same conditions.  
The increase in particle size with increasing starting LYS concentration may suggest incorporation 
of LYS into the nanoparticle structures, though during the manufacture, aggregation of protein 
was visible and became more extreme as the percentage of LYS increased. This is not particularly 
surprising given that, at pH 8.0, BSA has a net negative charge of -24.0 mV and LYS has a net 




Similar work on albumin-lysozyme mixtures have indicated the formation of structure-less 
aggregates or precipitates (Yu et al., 2006) as well as hetero-protein complexes in the order of 
micrometres in diameter (Diarrassouba et al., 2015; Santos, de Carvalho and Garcia-Rojas, 2018). 
One would expect this effect to be exacerbated further when both proteins are desolvated and 
thus also prone to hydrophobic interaction-led aggregation.  
Importantly, as the volume percentage of LYS in the mixture increases, so too do the total moles 
of protein in the 1 ml starting mixture, whist the number of available lysine residues available for 
cross-linking decreases. Thus the number of available sites for cross-linking per unit protein 
molecule diminishes with increasing LYS %, so the potential to create smaller, tightly cross-linked 
nanoparticles via numerous covalent intermolecular linkages is significantly reduced.  
4.3.4.2 Core-Shell Nanoparticles  
As with BHB, the blended nanoparticles were particularly difficult to purify, largely due to their 
large particle sizes and being interspersed in a polydisperse solution of aggregates of various sizes. 
For this reason, an alternative core-shell approach was adopted to incorporate LYS onto the 
surface of pre-fabricated BSA nanoparticles.  
This methodology was based on the creation of a suspension of core BSA nanoparticles, exploiting 
the well characterised manufacturing technique documented in Chapter III and subsequently 
coating them with a shell of LYS to achieve a core-shell nanoparticle architecture. The technique 
plays on the concept of electrostatic attraction between the BSA nanoparticles, which display a 
strong negative charge at pH 8.0 (ζ-potential = -43.9 mV), and LYS, which exhibits a mild positive 
charge (ζ-potential = 10.2 mV) and to subsequently cross-link the two proteins to form the desired 
core-shell structure.  
Furthermore, it was hypothesised that a core-shell approach would improve the issues of excessive 
particle size and aggregation during manufacture. Firstly, the core BSA nanoparticle can be tightly 
controlled and unlike with the blending approach using native BSA, the BSA nanoparticles are 
structured and highly ordered and would provide a rigid scaffold for the coat LYS to envelope and 
interlock around.  
In order to maximise the number of cross-linking sites available on LYS, the protein is desolvated 
with the nanoparticles in situ, prior to addition of an appropriate cross-linker depending on the 




Fig. 4.9 Scouting studies to optimise the coating method for formation of core-shell nanoparticles. a) SEC 
purification chromatograms for LYS-coated BSA nanoparticles of different starting scaffold sizes (with identical 
starting concentrations of both protein species); 65.18 nm (-) & 44.92 nm (- -). b) Photograph of centrifugal 
concentrators used to purify LYS-coated (EDC) BSA nanoparticles with varying molar ratios of nanoparticle to 
coat protein. The average particle size for the scaffold nanoparticle was 41 nm in each case and the centrifugal filters 
were run under identical conditions (2,500 x g for 20 minutes).  
Initial scouting experiments were carried out to determine the optimal starting BSA nanoparticle 
scaffold size as well as an appropriate concentration of LYS to spike into the nanoparticle solution. 
From a logical perspective, starting with smaller nanoparticles would provide a higher surface area 
to volume ratio to maximise LYS surface attachment. Indeed, Fig. 4.9a) corroborates with this 
reasoning; given an identical starting concentration of LYS and scaffold NP, the second free 
protein peak is lower for the smaller nanoparticle scaffold, indicating a higher percentage of LYS 
has been incorporated onto the surface of the nanoparticles.  
An important side note here; the nanoparticle peak does not directly relate to concentration (as 
you would otherwise expect the nanoparticle peak for the 45 nm sample to be higher). This is as a 
result of a distortion of the UV absorbance reading due to scattering by the nanoparticles and as 
such determination of concentration cannot be ascertained by direct UV measurement (Mamane, 
Ducoste and Linden, 2006; Porterfield and Zlotnick, 2010).  
A second important factor to consider is the concentration of the coat protein to spike into 
scaffold nanoparticle solution. As with blended nanoparticles, lower molar ratios of LYS proved 
to be the most effective for coating. Ratios greater than 10: 1 of NP: LYS produced a 
heterogeneous population of nanoparticles dispersed between aggregates, which formed a thick 
cake on the surface of the centrifugal filters, rendering purification unviable, as illustrated in Fig. 
4.9b).   
Whilst glutaraldehyde has proven to be an effective cross-linker for the formation of nanoparticles 
thus far, its reactivity is limited to coupling primary amine groups and as such can only target lysine 
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residues on each respective protein species. As per Fig. 4.3, LYS has only 11 lysine residues 
available for coupling and one would expect that the lysine content for the glutaraldehyde cross-
linked BSA nanoparticles scaffolds would be significantly exhausted.   
For this reason, novel cross-linking strategies were employed to capitalise on other available amino 
acid residues on both BSA and LYS (see Fig. 4.3), thus boosting the probability that LYS could 
successfully assimilate into the scaffold particles.  
4.3.4.2.1  EDC Coupling  
The first approach was to use N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) as a 
cross-linker to couple available primary amines (lysine) to carboxyl groups (glutamate & aspartate), 
forming stable amide bonds between both LYS and the scaffold BSA nanoparticles (Nakajima and 
Ikada, 1995).  
Given the particle sizes of the bona fide virus species this methodology aims to mimic, EDC as a 
zero-length cross-linker should facilitate a thin coat of LYS on the surface of the nanoparticles. As 
such, a 10 fold molar excess of EDC to total protein concentration was added to maximise the 
opportunity for LYS incorporation. The only by-product, urea (see Fig. 4.4), can subsequently be 
removed via the centrifugal-filter purification step.   
4.3.4.2.2 DTME Coupling 
The second approach was to exploit the availability of reactive thiol groups on both BSA 
nanoparticles and free LYS cysteine residues using dithio-bis-maleimidoethane (DTME) as a 
coupling agent.  As the functional groups form disulphide bonds in both native species, which are 
integral to the structure of both proteins, a reduction step (using NaBH4) is required to liberate 
free thiol groups prior to cross-linking (Guez et al., 2002; Rombouts et al., 2015).  
As such, the DTME coupling approach is a little more complex and time consuming than 
glutaraldehyde and EDC as pre-treatment of the protein species is required, as well as the 
requirement of a vacuum to prevent oxidation of the free sulfhydryls and re-formation of 
disulphide bonds, prior to the cross-linking reaction taking place (Brinkley, 1992).  
The core-shell nanoparticles were characterised with respect to their particle size and isoelectric 
point, as well as how they interact with size-exclusion and anion exchange chromatography media, 
the results of which are illustrated in Fig. 4.10.  
The starting BSA nanoparticle scaffold control provides a point of comparison to observe the 
impact of a LYS coat on the surface of the nanoparticles. It should be stated here that any 
electrostatically, non-covalently attached LYS is assumed to be removed by three high salt wash 
steps prior to characterisation.  
The first indication of LYS incorporation is the increase in average particle size relative to the 
control (12% and 49% increase for EDC and DTME cross-linked strategies, respectively). When 
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incubated with the SEC media Sepharose 6 Fast Flow (pore size of 50 nm) in a finite bath 
experiment, an initial mass balance of the supernatant revealed a correlation between the average 
particle size and a decrease in the species lost within the porous structure of the beads. This 
indicates that a lower percentage of the coated nanoparticles were able to penetrate into the porous 
structure of the beads and confirms an increase in size, relative to the control.  
 
Fig. 4.10 a) Isoelectric focussing curves for native BSA (-) & LYS (- -) alongside a control BSA nanoparticle 
sample and LYS-coated BSA nanoparticles via two cross-linking methods. Non-linear regression sigmoidal and 
polynomial inverse fifth-order (LYS only) fit curves were used to create the IEF curves respectively. b) Changes in 
average particle size upon coating of LYS onto the BSA nanoparticle scaffold (columns) as well as modification of 
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isoelectric point (-■-) & % loss of nanoparticulate bulk when incubated with a Sepharose 6 Fast Flow SEC 
matrix (-□-). Isoelectric points for BSA-NPs, EDC LYS-BSA NPs & DTME LYS-BSA NPs were 4.61, 
5.07 & 4.82, respectively.  
Interestingly, despite the limited number of available cysteine residues available for cross-linking 
on both species, DTME coated nanoparticles exhibited the larger increase in average particle size. 
This may potentially be due to the relatively long 13.3 A⁰  spacer arm within the DTME molecule 
(Green, Reisler and Houk, 2008) which will contribute to an extended hydrodynamic radius.  
A second plausible explanation is that the presence of NaOH in creating a basic environment for 
stabilising the reduced intermediate thiolate would adjust the electrostatic interaction dynamic 
between the desolvated LYS on the surface of the nanoparticles. In these basic conditions (pH of 
13.5) LYS and BSA nanoparticles have a net negative surface charge of -23.8 mV and -45.33 mV, 
respectively and as such one would expect a degree of electrostatic repulsion between amino acid 
residues on both species.  It is therefore hypothesised that this effect would change the orientation 
of the desolvated LYS on the surface of the nanoparticles and as such limited cross-linking could 
take place to form a strongly interlocked, tight shell around the scaffold BSA nanoparticle.  
The amino acid residues which contribute to the overall charge of the protein species are arginine 
(Arg), histidine (His), lysine (Lys) (all positively charged at pH 8.0) and glutamic (Glu) and aspartic 
(Asp) acid (both negatively charged at pH 8.0). Simple BSA nanoparticles are likely to exhibit a 
stronger negative charge at pH 8.0 than native BSA due to positively charged lysine residues being 
exhausted through the glutaraldehyde cross-linkages and as such the proportion of negatively 
charged amino acids increases. This does vary, likely due to the orientation of the other charged 
residues when the nanoparticle forms and is independent of the size of the nanoparticles formed 
(see Chapter III, Section 3.3.1.1).  
Both coated nanoparticles exhibit a basic shift in isoelectric point due to the additional arginine, 
histidine and lysine residues introduced through the LYS coat. EDC cross-linked nanoparticles 
exhibit a more exaggerated shift due to a significant change in the ratio of positive and negatively 
charged amino acids on both proteins during the coating. There is a significantly higher availability 
of carboxyl functional groups for cross-linking via EDC on both BSA (59 Glu, 40 Asp) and LYS 
(8 Glu, 7 Asp) and 11 lysine residues on LYS to contribute reactive amino groups. Compare this 
to the DTME approach; 35 and 4 cysteine residues on each BSA and LYS molecule, respectively, 
are available for thiol cross-linking and as such LYS incorporation is relatively limited.  
Glu and Asp residues are negatively charged and are depleted during EDC cross-linking, increasing 
the proportion of positively charged residues within the nanoparticle species. Titrating towards 
acidic conditions with HCl, fewer H+ ions are required to reduce the colloid surface charge to zero 
(i.e. reach the isoelectric point) due to a lower proportion of negatively charged amino acid residues 
on the nanoparticle surface. As such, the isoelectric point shifts to the right and is more basic, 
compared to the BSA NP control sample.  
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In a similar vein, the surface charge of the EDC coated nanoparticles is less negative at pH 8.0 and 
more positive at pH 3.0, relative to the control BSA NP scaffold. Occupying the acidic residues 
via EDC cross-linking allows a greater contribution to the overall net colloid surface charge from 
the basic, positively charged Arg, His and Lys side chains from both BSA and the introduced LYS 
at both extremes of pH.  
Conversely, the surface charge for the DTME cross-linked nanoparticles are similar to the BSA 
nanoparticle control at pH 3.0, as cysteine has a limited contribution to the overall protein charge. 
As Glu and Asp residues remain un-conjugated in both the DTME and BSA NP control samples 
and as both residues have a pKa ~ 4.0, at pH conditions of 4.0 and above, the side chains become 
deprotonated and increasingly negatively charged. This drives the surface charge down and causes 
the sharp declining slope in ζ-potential observed at this point in Fig. 4.10a).  
This same  decline is shallower and begins at more basic pH conditions for the EDC sample due 
to a lower net negative charge contribution stemming from Glu and Asp residues utilised for cross-
linking. At pH 8.0, DTME samples are significantly less negative than the BSA NP control; as with 
EDC this likely due to the contribution of the additional positively charged Arg, His and (limited) 
Lys residues from a successfully integrated LYS shell.   
The isoelectric point shift and the shape of the isoelectric focussing curves for the respective 
nanoparticle species provide interesting insights into the degree of LYS incorporation. For both 
coated nanoparticle preparations, the isoelectric point shifted to a more basic pI (4% increase for 
DTME & 9% for EDC), relative to the scaffold; a strong indication that whilst the entire scaffold 
nanoparticle has not been coated, an appreciable amount of the surface has been enriched with 
LYS protein.  
4.3.4.3 Finite Bath & CLSM Analysis 
As an orthogonal characterisation study, finite bath studies were carried out to assess the binding 
characteristics of the two nanoparticle samples and the control BSA NP scaffolds on the anion 
exchange chromatography resin, Q-Sepharose Fast Flow. As all three species exhibit some degree 
of negative charge at pH 8.0, this buffer condition was employed when challenging the resin with 
the three sample types, with each nanoparticle suspension loaded at the same concentration. 
EDC cross-linked LYS coated samples demonstrated a 51.3% reduction in anion-exchange 
binding, relative to the scaffold control. This is indicative of both a shielding effect of the coat 
LYS, limiting electrostatic interaction between the predominantly negatively charged surface 
residues on the original BSA nanoparticle structure and the anion exchanger surface. The removal 
of Glu and Asp residues for cross-linking will also contribute to this effect. This reduction in 
binding capacity corroborates well with the isoelectric focussing data and indicates the surface 
charge of the species plays an important part in its binding characteristics to ion exchangers.  
 Interestingly, DTME cross-linked core-shell nanoparticles finite bath mass balance data did not 
corroborate with its isoelectric focussing, as the binding capacity to the anion-exchanger in fact 
increased by 22.8%, relative to the scaffold control. Despite the apparent increase (less negative) 
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in ζ-potential for the DTME sample, the significantly large size of the formed nanoparticles may 
play a role in the elevated binding capacity.  
 
 
Fig. 4.11 Relative binding capacities for the BSA nanoparticle scaffold and the two cross-linking strategies when 
challenged at the same starting concentration onto a strong anion-exchange resin (Q-Sepharose Fast Flow) and the 
binding capacity determined through colorimetric assay of the supernatant and subsequent mass balance.  
Due to a limited number of available functional cysteine residues to cross-link on both protein 
species, it was hypothesised that the alteration to the surface chemistry of the BSA nanoparticles 
through DTME would be less significant than EDC. As DTME has a relatively long spacer arm 
and the conditions for cross-linking could impact the intra-particle electrostatic environment, it 
could be envisaged that a tentacular-type nanoparticle morphology is achieved; whilst the LYS is 
locked through covalent linkages between the sulfhydryl groups at specific points on the 
nanoparticle surface, the bulk of the coat LYS extends away from the nanoparticle scaffold.  
This can create a higher surface area for electrostatic interaction between the anion-exchange 
ligand and the negatively charged residues on the nanoparticle species. It appears that this affect 
supersedes the impact of coating the nanoparticles with a basic protein and the apparent 




Fig. 4.12 Confocal Laser Scanning Micrographs of fluorescent core-shell LYS-coated BSA nanoparticles bound 
to the surface of the anion exchanger Q-Sepharose Fast Flow. a) BSA nanoparticles tagged with Texas-Red X. 
Lysozyme, pre-tagged with Cy5, coated onto un-tagged BSA nanoparticles via b) EDC cross-linking & c) 
DTME cross-linking. BSA NPs and Lysozyme, both pre-tagged separately with Fluorescamine & Cy5, 
respectively, then formed into core-shell nanoparticles; d) Detecting BSA NPs: sample excited with a 405 nm 
laser and detected at 465 nm (λEXC= 390 nm, λEmi= 465 nm for fluorescamine), e) Detecting incorporated 
LYS: sample excited with a 635 nm laser and detected at 666 nm (λEXC= 646 nm, λEmi= 666 nm for Cy5). f) 
Laser lines from d) & e) run sequentially over the same focal plane suggesting co-localisation of both BSA-NPs 
& Lysozyme in the same locality.  
Fluorescent tags were conjugated onto each respective protein species to facilitate visual 
confirmation of LYS integration into the nanoparticles, as illustrated in Fig. 4.12. The fluorescent 
micrographs reveal interaction of the nanoparticles solely on the surface of the resin, forming a 
bright fluorescent corona around the beads. This is due to a size-exclusion effect as the size of the 
nanoparticles are too large to penetrate into the porous structure and can only interact with the 
anion-exchange ligands on the surface of the beads. Fig. 4.12b) and c) reveal the presence of LYS 
as native LYS was pre-tagged prior to coating on the surface of the nanoparticles. The lack of 
interaction with the centre of the bead suggests that the LYS is localised to the nanoparticulate 
species, with  a similar corona formed to that of the control BSA NP scaffolds highlighted in a).  
To confirm the assimilation of LYS within the BSA nanoparticles, the scaffold nanoparticles and 
LYS were separately pre-tagged with fluorescent dyes (with no overlap of emission spectra) that 
could be excited with two separate laser lines. The DTME cross-linking strategy was employed 
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rather than EDC to avoid interference of the amine reactive fluorescent probe limiting any 
potential sites for cross-linking (see Chapter V for further discussion on impact of labelling). 
Fig 4.12d) and e) highlight the existence of both fluorescent species on the same bead through 
excitation with each separate laser line and finally f) confirms co-localisation of the two protein 
species by exciting both fluorescent species sequentially. As both protein species were conjugated 
using the same dye: protein molar ratio when tagged, the intensity provides some indication as to 
the degree of incorporation of the coat protein. The fluorescent intensity is significantly higher for 
the BSA NP with a rather weaker signal for LYS; indicative of some degree of integration of LYS, 
though not a complete envelopment over the scaffold, understandable given the molar ratio of 





The work detailed in this chapter has detailed the development of novel approaches to forming 
more sophisticated protein nanoparticles based on the platform established manufacturing BSA 
nanoparticles detailed in the previous chapter. The main aim of this chapter has been to adopt a 
“tool-box approach” whereby the knowledge ascertained from previous work can be used to 
inform the development of better viral mimics. A key example of this is the manufacture of very 
small BSA nanoparticles as a starting scaffold structure to incorporate a significant amount of LYS 
onto the surface without causing significant aggregation. Through an understanding of dielectric 
constants of the desolvating agents and its impact on the average nanoparticle size, this was made 
possible.  
Pleasingly, the work carried out on BHB revealed similar trends with respect to dielectric constant 
and particle size, though the complexity of the starting protein led to batch to batch variability and 
significantly high polydispersities. As such, despite its relatively high isoelectric point, the 
difficulties in purification and its lack of sufficient reproducibility made further characterisation 
impractical.  
Whilst other proteins were also tested for formation of protein nanoparticles, the most promising 
and arguably most interesting aspect of the work is the formation of multi-component 
nanoparticles with a core-shell architecture. Whilst EDC appeared to be the more successful cross-
linker with respect to LYS incorporation, DTME provides a useful alternative approach as the 
cross-linker is “reversible” i.e. it contains a disulphide in the spacer arm that can be disrupted by a 
reducing agent such as DTT or β-mercaptoethanol. This would allow quantitative assessment of 
the degree of incorporation of LYS onto the scaffold nanoparticles by a cleaving reaction and 
quantitative analysis of free LYS produced; thus providing a useful tool in optimising the 
manufacturing technique further.  
Whilst the technique requires further optimisation to better replicate the surface characteristics of 
a bona fide virus such as Polio or AAV, the work illustrates the potential to tailor specific loading 
concentrations of a coat protein to “titrate” onto the surface of a scaffold, dependent on the mimic 
requirements. There is even scope to titrate specific amino acid residues or oligopeptides onto the 
surface for more specific modification of the colloid’s surface properties.  
As an aside, work by Yu et al. report a technique for the formation of stable OVA-LYS “nanogels” 
with particle sizes < 100 nm, PDI values < 0.2 and an isoelectric point of approximately 7.0. The 
technique involves careful addition and titration of both proteins (in equal molar ratios) to 
modulate surface charge and prevent aggregation. The mixture is then heated  to 80 ⁰ C to achieve 
thermal stabilisation through inter-protein hydrogen bonding, disulphide linkages and 
hydrophobic interaction (Yu et al., 2006). It is important to note that the total protein concentration 
used to form the nanogels was significantly lower (86 µM, compared to 1.5 mM for these 
experiments) which aids in limiting aggregation during the manufacture of the nanogels, though 
may impact the concentration of protein nanoparticles produced.  
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This electrostatically-driven self-assembly of two proteins with opposite charge into a nanogels 
may be an alternative avenue to explore in the future in the creation of accurate viral mimics, 
though due consideration should be given to particle stability and response to environmental 
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SYNTHETIC PROTEIN NANOPARTICLES AS TOOLS INFORMING THE 
CHROMATOGRAPHY OF VIRUS PARTICLE PRODUCTS 
Abstract 
The acquisition of representative virus feedstock, sufficient in quantity and particle concentration, 
as well as the methods for monitoring these species during chromatography, poses several practical 
issues in the realm of virus particle purification. This chapter follows on from that described in 
Chapter II and aims to characterise the bi-functional materials, as well as two commercial resins, 
using the BSA nanoparticles described in Chapter III. Specific modifications, including 
conjugation with fluorophores, allow for the nanoparticles to be tracked in both the mobile and 
porous stationary phases of chromatographic media to facilitate an in-depth study of protein 
species/matrix interaction. To optimise chromatography performance and assess binding kinetics, 
the use of protein assays and confocal laser scanning microscopy have been employed. 
Using monomer and nanoparticles to mimic a crude virus feedstock has enabled the 
characterisation and optimisation of both commercial chromatography media and resins 
manufactured in-house. The results highlight the utility of both commercial resins, Q-Sepharose 
Fast Flow and Capto™ Core 700, in purifying the surrogate mimics. Of the bi-layered materials, 
Superose 6 Prep Grade generally outperformed both Sepharose 6 Fast Flow and Superose 12 Prep 
Grade, revealing differences between the media not shown by the plasmid DNA binding studies. 
This was generally supported by the complimentary confocal data, which provided an insight into 
the spatial location and binding kinetics when challenged onto the beads.   
This information can be used to inform scale-up of viral purification columns in a cost-effective 
and efficient manner, excluding the need for contact with real virus species and their associated 
complications. These sophisticated nanoparticles serve to broaden the scope of virus 
chromatography and enable the collection of effective and novel data to improve recovery and 
purification of viruses, tailoring the selection of media and operating conditions to a specific target 
nanoplex.  It is envisioned that the manufacture of reproducible, well characterised and multi-
functional nanoparticles will provide a platform for assessment of established and novel viral 









Ad: Adenovirus  
AU: Absorbance Units 
BCA: Bicinchoninic Acid  
BSA NP: Bovine Serum Albumin 
Nanoparticles  
BSA: Bovine Serum Albumin  
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Biological nanoplexes are a fast growing and diverse product group in the current 
biopharmaceutical environment. They generally consist of plasmid DNA, viral vectors, virus-like 
particles (VLPs), mega-molecular vaccines, mega protein complexes and IgMs. They are 
characterised by their large physical size, fragility, complex surfaces and chemical similarity to 
smaller contaminating macromolecular components (Arpanaei et al., 2010; Olszewski et al., 2013). 
The adenovirus (Ad) species have shown great efficacy as a targeted drug delivery vehicle, with 
high applicability in gene therapy and vaccine treatments. Ad and Ad-associated viruses are now 
the most commonly used vehicle for gene therapy, with > 500 gene therapy clinical trials having 
been conducted to date, representing 20.5% of all vectors trialled (Ginn et al., 2018a). Despite its 
potential, the current purification of nanoplexes (such as Ad) for clinical work leaves much room 
for improvement. Routine purification of therapeutic Ad products rely on sucrose, iodixanol or 
caesium chloride density gradients, in combination with ultracentrifugation, with vector yields 
typically in the order of 70% (Blom et al., 2014). 
Although conferring an efficient separation of recombinant viral particles from cell debris and 
defective virions, there has been a recent trend in using chromatography for purification of such 
nanoplexes (Burova and Ioffe, 2005). As opposed to density based separation, which present 
labour and time intensive issues as well as limited scalability, chromatographic purification exploits 
retention and affinity characteristics to isolate viral units, whilst also providing a gentler method 
of purification; appropriate for a shear-sensitive product of interest.  
Higher throughput times in chromatography are also beneficial in safeguarding the lability and 
infectivity of the virus particles, whilst also boasting better selectivity, facilitating purer isolation of 
particles of interest from physically similar contaminants such as host cell proteins and DNA 
(Morenweiser, 2005 & McGrath et al., 1978).  
Chromatography based techniques have also displayed comparable yields when processing crude 
viral feedstocks, reaching yields of 80% and purities as high as 99% when using two-step 
chromatography purification trains (Blanche et al., 2000). These figures are based on the use of Q-
Sepharose XL media, a chromatography resin traditionally associated with purification of much 
smaller protein products; a resin, one could argue, that is not suited to purifying large 
macromolecules such as Ads. 
This has fuelled a trend in the production of chromatography media more suited to large nanoplex 
purification. An example of this is the multifunctional matrix, Capto™ Core 700, a product of GE 
Healthcare released in 2012. Purification works in flow-through mode, where the large targets of 
interest are excluded by a size-exclusion matrix shell, whilst the core, functionalised with a potent 
octylamine ligand, binds target-similar yet smaller protein impurities through anion and 




In this study we develop a platform for assessing chromatography resins such as these by 
manufacturing protein nanoparticles which, from the perspective of downstream purification, 
mimic bona fide viruses of therapeutic interest. The nanoparticles are first characterised using 
dynamic light scattering for their size distributions and polydispersity. Isoelectric focussing & 
circular dichroism spectroscopy are employed to assess surface characteristics and 2º structure, 
whilst atomic force and transmission electron microscopy are utilised to visualise surface shape 
and morphology.  
In this study, we employ two commercial chromatography media; Q-Sepharose Fast Flow and 
Capto™ Core 700 to compare performance in purifying nanoparticle and protein solutions, as 
well as the bi-layered materials manufactured and detailed in Chapter II, to demonstrate the value 




5.2 Materials & Methods 
5.2.1 Materials & Reagents  
Bovine Serum Albumin (fatty acid free, ≥ 96%), 8% Aqueous Glutaraldehyde, Methanol and 
Ethanol (both analytical grade, ≥ 99%), Sodium chloride, Sodium phosphate monobasic and 
dibasic, Sodium hydroxide, Dimethyl sulfoxide and all glassware and other reagents were obtained 
from Sigma Aldrich (Poole, Dorset) unless otherwise stated. Buffers and all aqueous solutions 
were based upon use of ultrapure water from a Sartorius Arium® Advanced EDI Pure Water 
System (Sartorius AG, Göttingen, Germany).  
Chromatography equipment and media; Q-Sepharose Fast Flow, Sepharose 6 Fast Flow, Capto™ 
Core 700 and PD-10 pre-packed columns, as well as 5/50 Tricorn columns were obtained from 
GE Healthcare Life Sciences (Uppsala, Sweden). Texas Red-X succinimidyl ester for tagging of 
the protein was purchased from Thermo™ Scientific (Loughborough, UK). 
5.2.2 Preparation of Bovine Serum Albumin Nanoparticles  
Bovine serum albumin nanoparticles were prepared as described in Chapter III, Section 3.2.2, with 
specific average nanoparticle sizes targeted by modulating the organic solvent composition during 
desolvation. The nanoparticles were prepared, purified and re-buffered into sodium phosphate 
buffer (20 mM, pH 8.0, 150 mM NaCl) prior to contact with the chromatography resins.  
5.2.3 Analysis  
5.2.3.1 Dynamic Light Scattering, ζ-potential & IEF  
BSA nanoparticle preparations were characterised with for average particle size and surface charge 
using dynamic light scattering and ζ-potential analysis, as described in Chapter III, Section 3.3.2.  
5.2.3.2 Protein Quantification 
Quantification of protein content for BSA and BSA nanoparticle samples was carried out via BCA 
assay as detailed in Chapter II, Section 2.2.11.4.  
5.2.3.3 Cation Exchange Chromatography  
Effects of dye labelling on protein retention behaviour were assessed using cation exchange 
chromatography. SP Sepharose Fast Flow (GE Healthcare, Uppsala, Sweden) media was manually 
packed into a 5/100 Tricorn column. 1: 100 dilutions in a running buffer containing 0.2 M NaCl 
was carried out before sample injection via sample loop under isocratic conditions using an ÄKTA 




5.2.3.4 Circular Dichroism Spectroscopy 
Secondary structural analysis was carried out using CD spectroscopy as detailed in Chapter III, 
Section 3.2.3.4.  
5.2.3.5 Static Binding Studies 
Commercial Resins: For analysis on commercial resins, 10% slurry of each chromatography resin 
was prepared by gravity settling before buffer exchange from storage buffer with sodium 
phosphate buffer (20 mM, pH 7.8, 0.15 M NaCl). The settled bed volume was set at 100 µL and 
aliquoted into 2 ml Eppendorf tubes (Eppendorf, Cambridge, UK). Adsorption was initiated by 
addition of 2 ml of either BSA nanoparticles or BSA (protein concentrations of 2.5 mg/ml and 10 
mg/ml respectively). Finite baths were carried out in triplicate to assess binding kinetics whilst a 
fourth vessel used tagged protein species for subsequent confocal analysis. 
Bi-layered Resins: For analysis of bi-layered beads, a weaker ionic concentration buffer system 
was chosen (10 mM Tris-HCl, pH 8.0) to highlight any small binding differences between samples 
which could be masked by salt shielding effects, as well as to mirror the conditions run for the bi-
layered samples in Chapter II. The settled bed volume chosen was 20 µL (due to scarcity of 
manufactured matrix material) and a nanoparticle load of 0.4 mg/ml for each nanoparticle size (38 
nm & 94 nm) was chosen; this was based on the static binding capacities of all three control resins 
(see Figs. 5.6 & 5.7) being between 5 – 10 mg / ml resin, thus a load of 0.4 mg on 20 µL of beads 
was deemed sufficient to observe binding behaviour, if any.  
A Stuart Scientific SB1 rotator carousel mixer (Bibby Scientific, Stone, United Kingdom) was used 
to maintain end-over-end agitation, except before sampling, where the Eppendorf tube was briefly 
centrifuged using a micro-centrifuge (VWR MiniStar Silverline, VWR International, Radnor, USA) 
for 20 seconds at 2000 g before a 20 µL sample was taken from the supernatant for subsequent 
BCA analysis to determine protein concentration. The resin particles were re-suspended by 
inversion and confirmed by visual inspection, before resumption of carousel mixing. This was 
repeated for time points from one minute through to two hours. 
5.2.3.6 Commercial Resin Column Studies 
Capto™ Core 700 and Q-Sepharose Fast Flow resins were manually flow-packed into separate 
5/100 Tricorn columns (GE Healthcare, Uppsala, Sweden) using an ÄKTA Explorer 100 system 
and tested prior for packing quality (As values of 1.04 and 1.19 and h values of 0.07 and 0.06 for 
Capto™ Core 700 and Q-Sepharose Fast Flow, respectively) .  
The columns were subjected to sample loop loading of BSA at concentrations of 10 mg/ml and 
35 mg/ml for Capto™ Core 700 and Q-Sepharose Fast Flow respectively and also 80 nm BSA 
nanoparticles at a concentration of 2 mg/ml for both resins. Sodium phosphate (20 mM, pH 7.8, 
0.15 M NaCl) was used as a running buffer and gradient elution was carried out using a buffer of 




5.2.3.7 Confocal Laser Scanning Microscopy  
In order to measure batch uptake with respect to time, a similar approach to Linden et al., 1999’s 
finite bath experiments was adopted. The samples from the timed finite bath experiments were 
washed and re-suspended in sodium phosphate buffer and after brief mixing and subsequent 
centrifugation under the same conditions, fixed volumes of the washed adsorbent particles were 
prepared as samples for CLSM. 
For sample preparation, resin, in 5 µL aliquots, were pipetted onto microscope slides, with a cover 
slip carefully placed on top to hold the samples in place. Precautions were taken to minimise 
fluorophore bleaching; the use of low laser powers, minimised exposure times and use of 

















5.3 Results & Discussion 
5.3.1 Fluorophore Conjugation  
5.3.1.1 Physiochemical Characteristics  
 
Fig. 5.1 a) Isoelectric focussing curves for blank and fluorescent protein and protein nanoparticles, with species 
tagged prior to and post formation. b) Summary table detailing the particle size distribution (PSD) average particle 
size and the isoelectric point (IEP) of each species. c) The particle size distribution of the blank adenovirus mimic. 
d)  Chromatogram illustrating the retention times of blank (-) & fluorescently conjugated (-) BSA on a cation 
exchange resin. 11 
To observe spatial adsorption of protein species within specific chromatography resins using 
confocal laser scanning microscopy, detection requires BSA to be labelled by a suitable fluorescent 
dye molecule (Ljunglöf and Hjorth, 1996; Ljunglöf and Thömmes, 1998; Hubbuch et al., 2002). It 
was imperative that the attachment of the dye molecule was carried out in a controlled fashion and 
the impact of labelling on the protein species assessed.  
Selection of appropriate dye molecules was based on the works of Teske, Hubbuch and Susanto, 
who have shown that dye molecule attachment changes the adsorption behaviour of proteins. 
                                                 





Their work demonstrated that screening tests on Texas Red-X-conjugated BSA created the least 
effect on retention behaviour and therefore it was chosen to tag both free BSA and BSA 
nanoparticles. The fluorophore was coupled to protein using Texas Red-X succinimidyl ester 
which conjugates to available lysine residues on the protein species, via a simple click-chemistry 
conjugation reaction (Life Technologies, 1996; Ljunglöf and Thömmes, 1998; Teske et al., 2007; 
Hubbuch and Kula, 2008)To confirm the effect, if any, of fluorophore conjugation on the surface 
characteristics of the free protein and protein nanoparticles, two complimentary analytical 
techniques were employed. Initially, comparisons were drawn between BSA, BSA-NPs and Texas-
Red (TRX) BSA-NPs using DLS and isoelectric focussing to determine changes in zeta potential 
and isoelectric points of the species, respectively. 
In addition, species of tagged and untagged protein were run as an isocratic pulse on an SP 
Sepharose cation exchange column to observe changes in retention time. It was observed that 
retention time varied negligibly, indicating little change to the overall binding characteristics of 
BSA, confirming the work of previous authors. It was, therefore, with a degree of confidence that 
we could assess locational and kinetic binding of fluorescent BSA and BSA nanoparticles on 
chromatography resins. 
 
Fig. 5.2 a) CD spectra of BSA in native, tagged, unfolded and nanoparticulate forms. b) Changes in the secondary 
structure of BSA upon conjugation of the fluorophore, in its unfolded state and finally once cross-linked into 
nanoparticles.  
It is important, however to determine any changes or impact the conjugated fluorophore has on 
the physiochemical properties of the protein species, such that its binding properties to 
chromatography media are not compromised. The isoelectric point of the free protein and 
nanoparticle species, both tagged and untagged, had little variance.  
A more negative zeta potential for the bare nanoparticle relative to the monomer is suggestive of 
an internalisation of the hydrophobic residues of the protein monomers within the nanoparticle 
and therefore a presentation of more negatively charged residues on the surface. An interesting 




tag the monomer (pre-assembly) and the second to conjugate a fluorophore after nanoparticulation 
(post-assembly).  
Pre-assembly formed larger nanoparticles under identical desolvating conditions as the 
fluorophore conjugates to lysine residues that would have been used up in the cross-linking process 
used in nanoparticulation. This leads to a drop in cross-linking efficiency, leading to a looser, more 
open nanoparticle structure with a greater Stokes’ diameter. 
5.3.1.2 2⁰ Structural Analysis  
In order to probe the secondary structure characteristics of the various protein species and track 
changes through the nanoparticle manufacturing process, a circular dichroism approach was 
adopted. The spectral data was deconvoluted using Sreerama & Woody’s self-consistent method, 
whereby the secondary structure of the protein species is estimated (Sreerama and Woody, 1993). 
Inspection of the raw spectra indicates secondary structural changes do occur upon unfolding. 
Promisingly, little change is observed upon conjugation of the fluorophore to the protein 
monomer, further fortifying the argument that Texas Red-X addition has little impact to the 
protein’s overall characteristics.  
During unfolding and re-folding, increases in β-sheet/turn formation and subsequent reduction in 
α-helical structure, with little change to the unordered secondary structures occur. This is 
symptomatic of protein aggregation, where the formation of β-sheet fibres occurs. This 
fibrillation/amyloidation process derives stability for partially folded or unfolded states as the 
protein residues re-orientate to the new organic solvent conditions (Holm et al., 2007). Upon 
addition of a cross-linker, it appears this conformational change is locked in place, coinciding with 




5.3.2 Challenging Nanoparticles on Commercial Resins 
5.3.2.1 Finite Bath Experiments 
 
Fig. 5.3 Timed finite bath binding characteristics for BSA and BSA Nanoparticles (80 nm) on the commercial 






Fig. 5.4 Timed finite bath binding characteristics for BSA and BSA Nanoparticles(80 nm) on the commercial 
bi-layered media Capto™ Core 700 (GE Healthcare) supplemented with the associated fluorescent images below 
and inset.  
BCA analysis of supernatant concentrations from finite bath studies revealed varied adsorption 
kinetics for the two protein species challenged to the bi-layered and conventional anion-exchange 
matrices. Q Sepharose Fast Flow demonstrated a relatively rapid uptake of bovine serum albumin 
with a higher equilibrium static binding capacity than the Capto™ Core 700 media. The shrinking 
core effect of BSA uptake into the a bead can be visualised in the Capto™  Core 700 bead, however 
the effect is too rapid in the instance of Q Sepharose Fast Flow. This can be attributed to the ionic 
capacities of the two media, 0.21 and 0.066 mmol Cl-/ml resin, respectively (GE Healthcare, 2018).  
Despite Capto™ Core 700 being functionalised with a more potent octylamine ligand, which 
posits both anion and hydrophobic interaction with the protein challenge, the concentration of 
the ligand, as well as reduction in capacity due to the bi-layering architecture (for a similar bead 
size), contribute to the disparities in binding kinetics and overall static binding capacity.  
Adsorption of the nanoparticle species also followed similar binding, with Qmax plateauing over 
time, though the time to reach equilibrium is longer and the static binding capacity an order of 
magnitude lower. The assay for measuring protein nanoparticle concentration is based on the 




standard curve. In reality, the technique measures the amount of BSA protein in the nanoparticles 
as a method of quantification as it remains linear across a range of nanoparticle solution 
concentrations and can therefore be applied to the finite bath studies.  
The 80 nm nanoparticle species can only access and interact with the surface ligands of the Q 
Sepharose Fast Flow support due to their inability to penetrate the small pore openings, unlike the 
~ 6 nm BSA. This rationalises the lower rate of binding and equilibrium binding capacity for the 
nanoparticle species relative to the protein monomer. The static binding capacity of Capto™ Core 
700 is similar to that of a size exclusion matrix with a similar pore size (Sepharose 6 Fast Flow), as 
shown in Table 5.1. Confocal laser scanning microscopy imaging captures some interaction 
between the viral mimics at the surface, perhaps due to a low concentration of octylamine ligands 
on the surface of the beads, non-specific interaction between the nanoparticles and the agarose-
backbone of the matrix or precipitation of the nanoparticle species on the surface of the beads.  
Table 5.1 Comparison of equilibrium binding capacities across the two purification resins and challenge species. All values 
are quoted as mg of species / ml of chromatographic resin. 
Capto™ Core 700 Q-Sepharose Fast Flow Sepharose 6 Fast Flow 
BSA Nanoparticles BSA Nanoparticles BSA Nanoparticles 
33.8 0.15 43.9 2.8 2.4 0.11 
Despite this interaction, the static binding capacity is comparatively low and the majority of the 
nanoparticle load remains in the supernatant. As Capto™ Core 700’s derives its value from being 
an isolation-by-flow-through matrix, the low static binding capacity for the virus mimic 
corroborates well with a high level of purification. This, in combination with a competitive binding 
capacity for smaller protein contaminants (simulated by BSA in this instance), makes it a highly 
effective purification tool for crude viral feedstocks.  
In order to supplement the colorimetric assays from the finite bath studies, parallel studies using 
fluorescent protein species were provided as a challenge to the functionalised matrices. The time 
series’ images provide qualitative support to the colorimetric assay data with the shrinking core 
clearly visible for the Capto™ Core 700 media. In the case of Q Sepharose Fast Flow, the 
shrinking-core effect is not visible; the lack of this phenomenon could be attributed to rapid 
adsorption of the protein species, as corroborated by the BCA assay data, such that the effect’s 
window cannot be captured in the initial 60 seconds. Due to pore size restriction, the nanoparticle 
species is only able to interact with the exterior ligands of the Q Sepharose matrices, with an 
observed increase in intensity from the corona with respect to time. This fits with the adsorption 
kinetics observed for the nanoparticle challenge on Q Sepharose, with a relatively low 




5.3.2.2 On-Column Analysis  
Scaling up the finite bath studies to column scale under similar, yet dynamic, adsorption conditions 
reveal similar trends in mobile/stationary phase interaction. Comparing absorbance values at 280 
nm for BSA challenged to the two media, it would appear that Q-Sepharose Fast Flow has a 
significantly higher dynamic binding capacity, though this would need to be confirmed via 
systematic breakthrough studies.   
It is interesting to note that a small amount of nanoparticle material binds and is subsequently 
eluted from the Capto™ Core 700 column. As demonstrated in the finite bath studies, there is a 
small amount of the mimic material interacting with the media. Confocal imaging from the finite 
bath studies confirms there is a weak interaction on the resin surface as well as a downward flux 
through the porous media, potentially facilitating bead-nanoparticle interaction. Absorbance at 280 
nm, along with assay data and normalised intensity values from the radial plots confirm that a very 
low amount of nanoparticle material does interact, with the majority (~ 90%) of the target viral 
mimic isolated in the flow-through fraction.  
 
Fig. 5.5 Small scale column runs for BSA and BSA Nanoparticles on a) Q-Sepharose Fast Flow and b) 
Capto™ Core 700. All four runs underwent gradient elution using 1 M NaCl, 1 M NaOH and 30% 




5.3.3 Challenging Nanoparticles on Resins Manufactured In-House 
5.3.3.1 Binding Data  
Using a similar methodology as applied to the commercial resins, two nanoparticle preparations 
with average particle sizes of 38 nm and 94 nm were challenged onto the bi-layered media. As in 
Chapter II, a selectivity index was used to characterise the media in this instance, as described by 
Equations 1 & 2.  
In essence, the selectivity index (SI) quantifies how well the bi-layered sample retains core-binding 
(Bovine Serum Albumin binding capacity) and how well it excludes shell-binding (BSA 
nanoparticles binding capacity) compared to the fully functionalised control made from the same 
base matrix. The lower the value of the selectivity index, the better performing the resin, as the 
ratio → 0 as the core binding is maximised to the level of the control and the shell binding reduces 
to zero. It should be noted here that for direct comparison of performance between probes (i.e. 
pDNA & BSA nanoparticles), % reductions against a control should be used rather than 
comparing absolute SI values.   
Equation 1:  
% 𝑅𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 𝑝𝑟𝑜𝑏𝑒 𝑆𝐵𝐶 =  
𝑃𝑟𝑜𝑏𝑒 𝑆𝐵𝐶𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑃𝑟𝑜𝑏𝑒 𝑆𝐵𝐶𝑆𝑎𝑚𝑝𝑙𝑒
𝑃𝑟𝑜𝑏𝑒 𝑆𝐵𝐶𝐶𝑜𝑛𝑡𝑟𝑜𝑙
 
Equation 2:  
𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝐼𝑛𝑑𝑒𝑥 (𝑚𝑔 𝐵𝑆𝐴 𝑁𝑃𝑠 / 𝑚𝑔 𝐵𝑆𝐴) =




 The probe refers to either BSA or BSA Nanoparticles 
 SBC is the static binding capacity for a matrix (mg species / ml resin) 
 The control sample is one which has been fully functionalised without any bi-layering  
 Sample refers to any material which has been partially brominated to create a bi-layered 
matrix 
Addressing the control samples first (i.e. no bi-layering, behaving as conventional anion 
exchangers), Superose 6 PG exhibited the highest binding capacity for the smaller nanoparticle 
preparation, whilst for the 94 nm challenge, Superose 12 PG displayed the highest binding capacity. 
The latter follows the same pattern as observed for pDNA in Chapter II, which follows given both 
are relatively large colloidal species and as such will have more sites for interaction, particularly 




Interestingly, the 6% cross-linked agarose exhibited a higher static binding capacity for the smaller 
nanoparticle preparation; one would posit that this may be due the nanoparticles accessing a higher 
percentage of the bead volume (due to further pore penetration) as 39 nm is below the exclusion 
limit for both resins (see Chapter II Table 2.1).  However, the confocal images in Figs 5.8 and 5.9 
reveal this binding to be solely on the surface of the resin, with a corona forming around the beads, 
as seen with Q-Sepharose Fast Flow.  
Despite a lack of deep pore access, it may be hypothesised that the smaller nanoparticles have a 
higher degree of access to the immediate surface pores of Sepharose and Superose 6 media which 
are of course “wider” than their Superose 12 counterparts. As the nanoparticles are smaller, there 
is less steric hindrance and thus access to available Q ligands within these pores is more readily 
available, though outside the resolution capabilities of confocal microscopy for this phenomenon 
to be observed. As discussed previously, Superose 6 resins are markedly smaller in size than 
Sepharose 6 and so have a larger surface area to volume ratio available for nanoparticle interaction. 
With respect to the bi-layered binding data, the first observation to note is that the binding 
reductions are not as marked for the BSA nanoparticles as they were for the plasmid DNA, with 
maximum reductions capping out at ~ 75%, compared to close to 100% for plasmid DNA.  One 
possible explanation for this is that the surface charge of the protein nanoparticles (~ - 30 mV) is 
somewhat more strongly negative than plasmid DNA (-17.6 mV) and although plasmid DNA may 
be larger in terms of hydrodynamic diameter (~ 200 – 400 nm) (Liaw, Chang and Hsiao, 2001), a 
lower nanoplex surface charge may account for an “easier” reduction in binding.   
Whilst the Superose 6 media performed well for both plasmid DNA and BSA nanoparticle 
challenges, the Superose 12 performed unexpectedly poorly when incubated with both 
nanoparticle preparations. As stipulated prior, the stronger negative charger of the nanoparticles 
and the higher percentage of cross-linked agarose of Superose 12 (and thus more available sites 
for ligand conjugation) gives the nanoplex more opportunity to interact with any residual surface 
ligands. Sepharose 6 samples generally performed better with the larger nanoparticle challenge, 
partially due to a lower surface area to volume ratio on account of the larger bead size but perhaps 






Fig. 5.6 a) Static binding capacities for the three bi-layered materials with respect to challenges of BSA and BSA 
Nanoparticles of 38 nm average size with selectivity indices detailed on the lower x-axis. b) Reduction in binding 





Fig. 5.7 a) Static binding capacities for the three bi-layered materials with respect to challenges of BSA and BSA 
Nanoparticles of 94 nm average size with selectivity indices detailed on the lower x-axis. b) Reduction in binding 




5.3.3.2 Fluorescent Imaging  
 
Fig. 5.8 Light microscopy (LM) and confocal laser scanning (CLSM) images of fluorescent BSA and BSA 





Fig. 5.9 Light microscopy (LM) and confocal laser scanning (CLSM) images of fluorescent BSA and BSA 




The confocal images tend to agree well with the binding data, for instance one of the worst 
performing samples, Superose 12 bi-layered manufactured using 60% ethylene glycol (microwave), 
exhibits clear rings of BSA nanoparticle binding when challenged with both 38 nm (SI 0.058) and 
94 nm (SI 0.052) nanoparticles.  
Interestingly, worse performing beads tended to be completely coated by a corona of 
nanoparticles, rather than patches as observed with plasmid DNA binding images. This may point 
to a nanoparticle-nanoparticle interaction, perhaps driven by hydrophobic interactions of amino 
acid residue forming non-polar patches on the surface of the nanoparticles, or perhaps a non-
specific interaction whereby nanoparticles nucleate at an interface (i.e. the surface of a 
chromatography bead) and begin to aggregate with each other, resulting in a pseudo-binding effect.  
5.4 Conclusions 
In summary, the research here continues from that illustrated in Chapter II and reinforces the 
promise of the bi-layered resins in purifying not only plasmid DNA, but an array of gene therapy-
relevant nanoplexes. Interestingly, the data highlights that resins perform with varying degrees of 
success depending on the size and type of vector being purified and as such small scale 
optimisation studies are required to identify the best resin for the target species.  
The work also demonstrates the utility of protein nanoparticles as informative tools for the 
chromatography of virus particle products. Behaving as virus surrogates, these nanoparticles offer 
a safer and cheaper method of screening purification media and can be produced in large volume 
in a relatively short period of time. This methodology holds promise as a useful tool in the rapid 
development and optimisation of the downstream process chain of high value gene therapy 
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Abbreviations 
AFM: Atomic Force Microscopy  
AGE: Allyl Glycidyl Ether  
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HIC: Hydrophobic Interaction Chromatography  
pDNA: Plasmid DNA 
Q ligand: Trimethylamine Chloride 





6.1 Bi-Layered Chromatography Materials  
The manufacture of bi-layered materials was based on an AGE activation / partial bromination 
functionalisation technique on blank size exclusion media. I chose Sepharose 6 Fast Flow, 
Superose 6 and Superose 12 Prep Grade to vary the starting bead size and porosity and to observe 
the impact this would have when applied under the same manufacturing technique and the 
eventual binding characteristics.  
One important factor moving forward would be to use a wider selection of media, with different 
cross-linking chemistries and structural components; it would be interesting to see how different 
cross-linkers impact the AGE activation step. In a similar vein, assaying a wider range of viscosity 
enhancing and/or microwave-assisting buffers, depending on their bromine stability data could 
perhaps yield better results. One of the fundamental experimental points is to ensure that the resin 
suspension is well mixed upon addition of the bromine solution during the partial bromination 
step; this may avoid the patchy binding visualised in the pDNA static binding studies.  
Future work would certainly consist of scaling up the manufacturing process (~ 5 fold) such that 
the bi-layered resins can be packed into columns for dynamic assessment, which will provide a real 
insight into how the resins perform under flow.  
With respect to the Arrhenius-Stokes equation, it would also be interesting to see if lowering 
temperature significantly below ambient would limit the rate of diffusion such that the bromine 
only reacts with the initial surface layer of the support, to create a thin shell. In this case, a suitable 
buffer would need to be selected to avoid loss of bromine through side-reactions.  
Orthogonal analytical techniques may be applied to the manufactured chromatography resins in 
the future to assess how successful the layering reaction was. I attempted to use Confocal Raman 
microscopy to map the location of Q ligand during this work, however ran into resolution issues 
in locating a definitive bi-layered structure. The technique has been used with success for other 
chromatographic adsorbents (Ljunglöf et al., 2000; Larsson and Lindgren, 2005) and consequently 
would need some optimisation to have utility in this application too.  
6.2 BSA Nanoparticles  
The BSA nanoparticles were systematically assessed across a range of operating parameters to a 
point that a specific average target size (within ~ 10 nm) could be manufactured through prior 
knowledge of the conditions required, whether that be organic solvent conditions, temperature, 
pH, ionic strength etc.  
In terms of characterisation, it would be interesting to have done more morphological analysis on 
the nanoparticles; perhaps looking at how different mixing patterns impacted the shape of the 
nanoparticles as well as how nanoparticles composed of different starting proteins / mixtures 
eventually looked under a TEM or AFM microscope. I believe it would also be important to carry 




secondary structural changes in the protein, which would cement our understanding of the 
unfolding characteristics of the protein and hopefully corroborate with the findings in Chapter III.  
During this research project, I managed to acquire a small aliquot of un-purified adenoviral vector 
material from our collaborators at UCL.  However, during my experimental design, I found that 
to properly purify and to yield sufficient viral particles, as well as the specialist equipment required 
to handle and assay the material, would cost in excess of £2000. In a sense, this justifies the 
rationale for creating surrogates for virus material in order to assay chromatography materials, 
however real adenovirus is the gold standard for comparison and future work would certainly 
entail a head-to-head binding assay between the adenovirus mimic and the true bona fide virus.  
6.3 Viral Mimic Library 
The viral mimic library is a concept that is in its infancy; the idea being that given the process 
knowledge gained from systematically testing BSA in forming nanoparticles, a “toolbox approach” 
could be applied to other proteins and protein mixtures to custom build virus mimics according 
to the basic physiochemical properties. The bovine haemoglobin work was promising as it took a 
non-albumin based protein and showed it was possible to form nanoparticles and pleasingly, some 
of the trend observed, such as the influence of dielectric constant on particle size, was similar to 
BSA.  
Future studies would encompass a range of proteins with different initial starting properties; one 
of the main reasons for doing the scale down work was to facilitate low volume screening tests to 
be carried out on more expensive proteins with attractive characteristics for virus mimics, such as 
conalbumin (pI 6.6, MW: 77 kDa).  
Going forward, I believe it would be important to include an assay for hydrophobicity into the 
suite of analytics for the nanoparticles as this will also play an important role in virus mimic 
customisation. I did purchase a HIC 1 ml Hi-Trap Selection Kit (GE Healthcare, Uppsala, Sweden) 
with the intention of running this assay, which would have involved looking at the retention / 
elution profiles of the nanoparticles and native protein species through various HIC columns as a 
measure of their surface hydrophobicity. Crucially, this would also provide an insight into the 
ordering of amino acid residues on the surface of the nanoparticle upon formation.  
With regard to the multi-component nanoparticle work, both blending and core-shell 
nanoparticles have potential to form interesting virus surrogates. Future work would look to make 
this approach more systematic and to use SDS-PAGE gels, ion-exchange chromatography and 
reducing conditions to reverse the thiol cross-linkage to quantify the amount of incorporated 
second protein. It may also be worth considering other scaffold/coat protein combinations, 
depending on the type of virus being targeted. Finally, it may also be interesting to conjugated 
single amino acid residues or short peptide sequences (Look et al., 2015) to the surface of the 
nanoparticles as opposed to whole, globular proteins such as lysozyme. This may remove some of 
the steric and electrostatic interferences from other amino acids within the protein and allow for 




6.4 Nanoparticles Informing Viral Purification  
The utility of these virus surrogates is not limited to the chromatography materials tested here, but 
could also be applied to a range of chromatography resins and purification methods such as 
filtration, centrifugation and ATPS. As the nanoparticles can be easily assayed using colorimetric 
methods, quantitative data can easily be attained to inform optimised protocols for each of these 
units operations too. Much of their promise stems from their ability to be functionalised with 
fluorophores, as well as the ability to tailor their manufacture to mimic a range of different viral 
vectors.   
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7.1 The Art of Bioprocessing 
Since Genentech & Eli Lilly developed the first Food & Drug Agency (FDA) approved 
biotherapeutic product, Humulin® (insulin), in 1982, the biopharmaceutical industry has 
progressed significantly to sustain a plethora of therapeutic products ranging in size, complexity 
and culture platforms (Cooke 2001). It was the development of recombinant-DNA and hybridoma 
technologies that acted as a springboard for the development of an array of different 
biotherapeutic products. Humulin was the first recombinant plasmid DNA therapeutic approved, 
though the door has since been opened for a host of new biotherapeutic product types, including 
recombinant proteins, nucleic acids, vaccines and antibody based therapies.  
In the 18 years since the launch of Humulin to the turn of millennium, 84 biotherapeutics had 
been approved in Europe and the USA, treating a variety of indications including autoimmune 
disorders, cancers, blood disorders and heart disease (Walsh, 2003). To date, more than 200 
biopharmaceutical products have been approved for therapeutic use (Pohlscheidt, Kiss and 
Gottschalk, 2018) and the market is expected to grow in value to $213.97 billion by 2021 
(Challener, 2018).  
 
Fig. 7.1 The rise of therapeutic protein-based therapeutics to *August 31st 2016 and the distribution of therapeutic 
classes which make up the total protein therapeutics market (Lagassé et al., 2017).  
Monoclonal antibodies (mAbs) dominate the biopharmaceutical market with approximately 1500 
potential drugs in the pipeline in 2016 (Sun Hong et al., 2017). This is somewhat unsurprising due 




amenable to a wide range of clinical applications. Emerging onto the market in 1986 with 
Orthoclone OKT3 (muromonab) to prevent kidney transplant rejection, mAb-based therapeutics 
have since developed to treat a range of disorders including macular degeneration, asthma and 
multiple sclerosis (Kennedy et al., 2018). There are currently ~ 300 mAb products in the pipeline 
and with an approval rate of ~ 4 products/ year and a projected 70 mAb products by 2020, there 
is little to suggest that the growth in the mAb market will be kerbed in the mid-to-long term (Ecker, 
Jones and Levine, 2015).  
There are, of course, a multitude of other protein therapeutic classes on the market, including but 
not limited to growth and blood factors, receptor proteins, cytokines, enzymes and hormones. A 
high proportion of these are recombinant products, produced in expression systems including 
bacteria (Baneyx, 1999; Sørensen and Mortensen, 2005), yeast (Sanchis et al., 1998; Cregg et al., 
2000; Cereghino et al., 2002), insect (Maiorella et al., 1988; Altmann et al., 1999), mammalian (Wurm 
and Bernard, 1999; Wurm, 2004; Geisse and Henke, 2005) and even transgenic plant systems 
(Kusnadi, Nikolov and Howard, 1997; Ma, Drake and Christou, 2003).  
















































































































































































Bacterial expression systems offer numerous advantages for recombinant protein expression, 
largely due to their well characterised genetic manipulation strategies and established and 
comparatively low cost and scalable culture platforms. However, bacterial expression systems 
often fall short in the folding and secretion of eukaryotic proteins, particularly those rich in cysteine 
residues which form disulphide linkages. The proteins are often expressed as insoluble inclusion 
bodies which require a re-folding step which can complicate the downstream processing train 
whilst also compromising the yield of active protein (Verma, Boleti and George, 1998).  
As a result, immunoglobulins are usually expressed in mammalian systems, which facilitate 
appropriate folding and glycosylation patterns to form through the sophisticated endoplasmic 
reticulum available in mammalian cells. With the rise of antibody-based products, mammalian 
expression systems have come to the fore as the most popular expression system in the 




There are a number of popular mammalian cell lines used for recombinant protein production, 
including Chinese Hamster Ovary (CHO), Mouse Myeloma (NSO, SP2/0), Mouse Kidney (COS), 
Human Embryonic Kidney (HEK) and Baby Hamster Kidney (BHK), which are utilised for their 
stable expression systems and high specific production rate. In addition to this, their glycosylation 
patterns are close to that of human and some are amenable to amplification systems such as 
glutamine synthetase (GS) which facilitates stable and high-yielding cell lines (Brown et al., 1992; 
Barnes, Bentley and Dickson, 2000; Dempsey et al., 2003; Yu, Lee and Lee, 2018).   
 
Fig. 7.2 The increasing popularity of mammalian cell culture platforms for the production of biopharmaceutical 
products a) from 1989 – 2014 and b) with respect to competing cell culture systems (Walsh, 2014).  
There are, however, a number of issues associated mammalian cell cultures which need to be 
addressed, namely scalability, low product titres, process complexity (including shear sensitivity, 
high media/serum complexity, oxygenation requirements and costs and also the need for viral 
inactivation/removal (Palomares, Estrada-Mondaca and Ramírez, 2004).   
In light of this, there have been significant improvements in recombinant protein production over 
the last twenty years through significant research and development (e.g. host cell line engineering 
and clone development), process control including, but not limited to; metabolic engineering, 
process analytical technology, improvement in on-line, offline sensors and improvements in media 
composition. There has also been a drive to integrate product quality by process design to facilitate 
better product characterisation, monitoring tools and ease of validation to ensure regulatory 
requirements are met.  This has been supplemented by more focussed process intensification, 
including better bioreactor design (e.g. to improve dissolved oxygen content, mixing patterns etc.) 
and operation (such as perfusion reactors, micro-carriers etc.) (O’Callaghan et al., 2010; Butler and 
Meneses-Acosta, 2012; Gronemeyer, Ditz and Strube, 2014).  
Since the 1980s, recombinant protein productivity in mammalian cells has increased 100-fold with 
specific cell productivities of ~ 90 pg/cell/day and product titres in excess of 10 g/L when run in 
fed-batch operation; mAb titres can be as high as 25 g/L in some perfusion systems, whilst 




20, 000 L and thus yields of 15 – 100 kg of mAb /batch   (Wurm, 2004; Sommerfeld and Strube, 
2005; Kelley, 2009; F. Li et al., 2010; Gronemeyer, Ditz and Strube, 2014; Legastelois et al., 2017).  
Other expression systems have also seen growing popularity in recent times, including yeast, insect 
and plants which exploit their ease of manipulation (particularly yeast) whilst also being scalable, 
having a high throughput and are relatively inexpensive (especially insect and plant systems) 
compared to mammalian expression (Verma, Boleti and George, 1998; Dingermann, 2008; Walsh, 
2014).  
There is no “one-size-fits-all” for protein expression systems and as such one platform will never 
become the gold standard for all future therapeutic protein manufacture. As each protein has its 
own unique amino acid sequence, it will be more amenable to one expression system over another 
as well as a number of other factors. These include post-translational modification requirements 
(including but not restricted to glycosylation patterns), expression pathway, protein sequence, 
immunogenicity, viral and endotoxin considerations as well as bioprocess considerations including 
scale of production (quantity and purity of product) , throughput requirement and also the 
associated cost of capital, ancillary and support systems (Verma, Boleti and George, 1998; Leader, 
Baca and Golan, 2008).  
Whilst antibody-based therapeutics in mammalian cell culture systems have been the staple of 
therapeutic production in recent times, there have been a number of other interesting trends 
developing the field of biotherapeutics. New, experimental therapies are being developed, 
transitioning away from the au fait antibody therapeutics and adopting novel approaches such as 
regenerative medicine, including tissue engineering and/or complimentary gene therapy. This 
opens the door for the treatment of a wide range of patient issues, including inherited diseases, 
infections, autoimmune diseases and certain cancer types (Cotrim and Baum, 2008; Muñoz Ruiz 


















Fig. 7.3 Four mechanisms of gene editing (Image & detail were sourced from Delhove & Qasim 2017) 
Gene editing is based on the concept of introducing a double-stranded break into a sequence of 
genomic DNA, resulting in a knockout of gene function. Four main approaches currently exist, 
acting as “molecular scissors” to achieve gene editing: 
1. Meganucleases are essentially molecular scissors with adjustable recognition sequences to allow 
modification of a variety of target sequences. 
2. TALENs are engineered restriction enzymes which contain 34 amino acid repeat sequences in 
the DNA binding domain with two divergent amino acids, termed the repeat variable diresidue 
(RVD), which have a high specificity for nucleotide recognition and can target a single base on 
the target sequence.  
3. ZFNs are also engineered restriction enzymes made up of a zinc finger binding domain with 
three nucleotides of the target sequence and a DNA cleavage domain which requires 
dimerization of two FokI domains for cleavage to occur. 
4. CRISPR-Cas9 uses the endonuclease enzyme Cas9 and requires RNA guidance to achieve 
cleavage of the target sequence. A protospacer adjacent motif (PAM) sequence flanks the target 
site three bases downstream to ensure successful cleavage.  
 
